General Information of Drug Transporter (DT)
DT ID	DTD0003 Transporter Info
Gene Name	ABCB1
Protein Name	P-glycoprotein 1
Gene ID	5243
UniProt ID	P08183
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs1045642
Site of GPD	chr7:87509329 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G / A>T
Minor Allele Frequency	A=0.3952/1979 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:       410 Drugs in Total
Methadone	Drug Info	Opioid-Related Disorders	Correlated with the decreased drug concentrations in patients (compare with allele G)		[ 1]
Vincristine	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased likelihood of event-free survival in patients (compare with allele G)		[ 2]
Simvastatin	Drug Info	Hypercholesterolemia	Correlated with the decreased myalgia risk in patients (compare with allele G)		[ 3]
Nelfinavir	Drug Info	HIV Infection	Correlated with the decreased toxic liver disease risk in patient (compare with allele G); Correlated with the increased likelihood of toxicity-related treatment failure in patients (compare with allele G)		[ 4], [ 5]
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the increased adverse drug event risk in patients (compare with allele G); Irrelevant to the drug discontinuation in patients (compare with allele G); Irrelevant to the drug response in patients (compare with Allele G)		[ 6], [ 7], [ 8]
Clopidogrel	Drug Info	Hemorrhage	Correlated with the increased disease risk in patients (compare with allele G)		[ 9]
Clopidogrel	Drug Info	Acute Coronary Syndrome	Correlated with the increased disease risk in patients (compare with allele G); Irrelevant to the drug exposure in patients (compare with allele G); Irrelevant to the the drug antiplatelet effect or clinical outcomes in patients (compare with Allele G)		[ 10], [ 11], [ 12]
Digoxin	Drug Info	Congestive Cardiac Insufficiency; Arrhythmias; Heart Failure	Correlated with the increased drug serum concentrations in patients (compare with allele G)		[ 13]
Codeine	Drug Info	CNS Depression	Correlated with the increased likelihood of disease in patients (compare with allele G)		[ 14]
Carbamazepine	Drug Info	Epilepsy	Correlated with the increased likelihood of drug resistance in patients (compare with allele G); Irrelevant to the drug concentrations in patients (compare with allele G); Irrelevant to the drug metabolism in patients (compare with Allele G); Irrelevant to the increased drug response in patients (compare with Allele G)		[ 15], [ 16], [ 17], [ 18]
Everolimus	Drug Info	Breast Neoplasm	Correlated with the increased likelihood of mucositis in patients (compare with allele G)		[ 19]
Atorvastatin	Drug Info	Coronary Artery Disease	Correlated with the increased likelihood of myalgia in patients (compare with allele G)		[ 20]
Phenytoin	Drug Info	Healthy Individuals	Correlated with the increased plasma drug levels in healthy individuals (compare with genotype GG)		[ 21]
Olanzapine	Drug Info	Psychotic Disorders	Correlated with the positive relationship between drug plasma levels and positive symptom reduction in patients (compare genotype GG)		[ 22]
Tacrolimus	Drug Info	Kidney Transplantation	Irrelevant to the acute cellular rejection in patients (compare with allele G); Irrelevant to the dose-adjusted trough concentrations in patients (compare with allele G); Irrelevant to the drug bioavailability in patients (compare with allele G); Irrelevant to the drug clearance in patients (compare with Allele G); Irrelevant to the drug clearance in patients (compare with allele G); Irrelevant to the drug metabolism in patients (compare with Allele G); Irrelevant to the drug trough concentrations in patients (compare with Allele G); Irrelevant to the likelihood of achieving target concentrations of drug in patients (compare with Allele G)		[ 23], [ 24], [ 25], [ 26], [ 27], [ 28], [ 29], [ 30], [ 31], [ 32]
Paliperidone	Drug Info	Bipolar Disorder	Irrelevant to the drug clearance in patients (compare with Allele A)		[ 33]
Paliperidone	Drug Info	Psychotic Disorders	Irrelevant to the drug clearance in patients (compare with Allele A)		[ 34]
Risperidone	Drug Info	Bipolar Disorder	Irrelevant to the drug clearance in patients (compare with Allele A)		[ 33]
Risperidone	Drug Info	Psychotic Disorders	Irrelevant to the drug clearance in patients (compare with Allele A)		[ 34]
Tacrolimus	Drug Info	Hemopoietic Stem Cell Transplant	Irrelevant to the drug clearance in patients (compare with Allele G)		[ 35]
Tacrolimus	Drug Info	Liver Transplantation	Irrelevant to the drug clearance in patients (compare with Allele G)		[ 36]
Cyclosporine	Drug Info	Kidney Transplantation	Irrelevant to the drug clearance in patients (compare with allele G)		[ 23]
Sirolimus	Drug Info	Kidney Transplantation	Irrelevant to the drug metabolism in patients (compare with Allele G)		[ 24]
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Irrelevant to the drug response in patients (compare with Allele G)		[ 37]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Irrelevant to the drug response in patients (compare with Allele G)		[ 38]
Clopidogrel	Drug Info	Angina Pectoris	Irrelevant to the drug response in patients (compare with Allele G)		[ 39]
Clopidogrel	Drug Info	Platelet Reactivity	Irrelevant to the drug response in patients (compare with Allele G); Irrelevant to the the antiplatelet effect or drug clinical outcomes in patients (compare with Allele G)		[ 12], [ 40]
Sunitinib	Drug Info	Renal Cell Carcinoma	Irrelevant to the drug toxicity in patients (compare with allele G)		[ 41]
Clopidogrel	Drug Info	St-Segment Elevation Myocardial Infarction	Irrelevant to the increased disease risk in patients (compare with allele G)		[ 42]
Valproic acid	Drug Info	Epilepsy	Irrelevant to the increased drug response in patients (compare with Allele G)		[ 15]
Phenytoin	Drug Info	Epilepsy	Irrelevant to the increased drug response in patients (compare with Allele G)		[ 15]
Phenobarbital	Drug Info	Epilepsy	Irrelevant to the increased drug response in patients (compare with Allele G)		[ 15]
Clopidogrel	Drug Info	Coronary Artery Disease	Irrelevant to the increased high on-treatment platelet reactivity risk in patients (compare with Allele G); Irrelevant to the increased myocardial infarction (mI) or composite outcome of non-fatal mI, all cause death and stent thrombosis risk in patients (compare with Allele G); Irrelevant to the major adverse cardiac risk in patients (compare with Allele G)		[ 43], [ 44], [ 45]
Clopidogrel	Drug Info	Percutaneous Coronary Intervention	Irrelevant to the increased high post-treatment platelet reactivity risk in patients (compare with Allele G)		[ 46]
Clopidogrel	Drug Info	Myocardial Infarction	Irrelevant to the increased mortality risk in patients (compare with Allele G)		[ 47]
Clopidogrel	Drug Info	Coronary Disease	Irrelevant to the increased on-treatment platelet activity risk in patients (compare with Allele G)		[ 48]
Ritonavir	Drug Info	HIV Infection	Irrelevant to the likelihood of treatment failure in patients (compare with Allele G)		[ 49]
Ranitidine	Drug Info	Breast Neoplasm	Irrelevant to the overall survival in patients (compare with Allele G)		[ 50]
Dexamethasone	Drug Info	Breast Neoplasm	Irrelevant to the overall survival in patients (compare with Allele G)		[ 50]
Paclitaxel	Drug Info	Breast Neoplasm	Irrelevant to the overall survival in patients (compare with Allele G)		[ 50]
Oxcarbazepine	Drug Info	Epilepsy	Correlated with the decreased drug response in patients (compare with allele G)		[ 51]
Nevirapine	Drug Info	HIV Infection	Correlated with the decreased toxic liver disease risk in patients (compare with allele G); Correlated with the decreased toxic liver disease risk in patients (compare with allele G)		[ 5], [ 52], [ 53]
Isoniazid	Drug Info	Tuberculosis	Irrelevant to the drug-induced liver injury risk in patients (compare with Allele G)		[ 54]
Atazanavir	Drug Info	HIV Infection	Irrelevant to the likelihood of treatment failure in patients (compare with Allele G)		[ 49]
Efavirenz	Drug Info	HIV Infection	Correlated with the decreased toxic liver disease risk in patient (compare with allele G); Correlated with the decreased toxic liver disease risk in patients (compare with allele G); Correlated with the increased likelihood of toxicity-related treatment failure in patients (compare with allele G)		[ 4], [ 5]
Oxycodone	Drug Info	Postoperative Pain	Irrelevant to the severity of pain in patients (compare with Allele G)		[ 55]
Diphenhydramine	Drug Info	Breast Neoplasm	Irrelevant to the overall survival in patients (compare with Allele G)		[ 50]
Imatinib	N.A.	Myelosuppression	Allele A is associated with increased severity of Myelosuppression when treated with imatinib in people with Chronic myelomonocytic leukemia as compared to allele G.		[ 56]
Tacrolimus	N.A.	Drug Toxicity	Allele A is not associated with risk of adverse events when treated with tacrolimus in children with Kidney Transplantation as compared to allele G.		[ 32]
Rhodamine 123	N.A.	Drug Toxicity	Allele A is not associated with transport of rhodamine 123 CD56+ NK cells and CD4+ T-helper cells as compared to allele G.		[ 57]
Clopidogrel	N.A.	Platelet Reactivity	Allele A is not associated with platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to allele G.		[ 9]
Clopidogrel	N.A.	Hemorrhage	Allele A is not associated with risk of Hemorrhage, major adverse cardiac events (mace) and Thrombosis when treated with clopidogrel in people with Coronary Disease as compared to allele G.		[ 9]
Clopidogrel	N.A.	Major Adverse Cardiac Events (mace)	Allele A is not associated with risk of Hemorrhage, major adverse cardiac events (mace) and Thrombosis when treated with clopidogrel in people with Coronary Disease as compared to allele G.		[ 9]
Clopidogrel	N.A.	Thrombotic Disease	Allele A is not associated with risk of Hemorrhage, major adverse cardiac events (mace) and Thrombosis when treated with clopidogrel in people with Coronary Disease as compared to allele G.		[ 9]
Carbamazepine	N.A.	Toxic Liver Disease	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.		[ 58]
Phenytoin	N.A.	Toxic Liver Disease	Allele A is not associated with increased dose of phenytoin in people with Epilepsy as compared to allele G.		[ 58]
Digoxin	N.A.	Hemorrhage	Allele A is not associated with a functional effect on the P-gp-mediated transport rate of digoxin or imatinib in a X. laevis oocyte expression system as compared to allele G.		[ 59]
Imatinib	N.A.	Hemorrhage	Allele A is not associated with a functional effect on the P-gp-mediated transport rate of digoxin or imatinib in a X. laevis oocyte expression system as compared to allele G.		[ 59]
Tacrolimus	N.A.	Arthralgia	Allele A is not associated with clearance of tacrolimus in people with liver transplantation as compared to allele G.		[ 36]
Imatinib	N.A.	Arthralgia	Allele A is associated with increased clinical benefit to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.		[ 60]
Carbamazepine	N.A.	Neurotoxicity Syndromes	Allele A is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.		[ 61]
Phenytoin	N.A.	Neurotoxicity Syndromes	Allele A is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.		[ 61]
Valproic Acid	N.A.	Neurotoxicity Syndromes	Allele A is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.		[ 61]
Nevirapine	N.A.	Neurotoxicity Syndromes	Allele A is not associated with increased risk of toxicity when treated with nevirapine in people with HIV Infections as compared to allele G.		[ 62]
Oxycodone	N.A.	Pain	Allele A is not associated with severity of Pain when treated with oxycodone in people with Pain, Postoperative as compared to allele G.		[ 55]
Paroxetine	N.A.	Pain	Allele A is not associated with response to paroxetine in people with Depressive Disorder, Major as compared to allele G.		[ 63]
Tacrolimus	N.A.	Platelet Reactivity	Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 64]
Morphine	N.A.	Adverse Events	Allele A is not associated with likelihood of adverse events due to morphine in people with Pain, Postoperative as compared to allele G.		[ 65]
Codeine	N.A.	Adverse Events	Allele A is not associated with concentrations of codeine or morphine as compared to allele G.		[ 66]
Morphine	N.A.	Adverse Events	Allele A is not associated with concentrations of codeine or morphine as compared to allele G.		[ 66]
Morphine	N.A.	Neutropenia	Allele A is not associated with concentrations of morphine in people with Pain, Postoperative as compared to allele G.		[ 65]
Apixaban	N.A.	Hemorrhage	Allele A is not associated with increased likelihood of Hemorrhage when treated with apixaban in people with Atrial Fibrillation as compared to allele G.		[ 67]
Aspirin	N.A.	Adverse Events	Allele A is not associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to allele G.		[ 42]
Clopidogrel	N.A.	Adverse Events	Allele A is not associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to allele G.		[ 42]
Nimodipine	N.A.	Hemorrhage	Allele A is not associated with exposure to nimodipine in healthy individuals as compared to allele G.		[ 68]
Antiepileptics	N.A.	Drug Resistance	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.		[ 69]
Codeine	N.A.	Hemorrhage	Allele A is associated with increased likelihood of CNS depression in breast-feeding infants when treated with codeine in women with Pain as compared to allele G.		[ 14]
Nevirapine	N.A.	Toxic Liver Disease	Allele A is associated with decreased risk of Toxic liver disease when treated with nevirapine in people with HIV Infections.		[ 52]
Tacrolimus	N.A.	Toxic Liver Disease	Allele A is not associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 30]
Buprenorphine	N.A.	Thrombotic Disease	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Dihydrocodeine	N.A.	Thrombotic Disease	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Fentanyl	N.A.	Thrombotic Disease	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Hydromorphone	N.A.	Thrombotic Disease	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Methadone	N.A.	Thrombotic Disease	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Morphine	N.A.	Thrombotic Disease	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Oxycodone	N.A.	Thrombotic Disease	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Piritramide	N.A.	Thrombotic Disease	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Tilidine	N.A.	Thrombotic Disease	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Tramadol	N.A.	Thrombotic Disease	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Paclitaxel	N.A.	Adverse Events	Allele A is not associated with metabolism of paclitaxel in people with Neoplasms as compared to allele G.		[ 71]
Labetalol	N.A.	Exanthema	Allele A is not associated with decreased metabolism of labetalol in healthy individuals as compared to allele G.		[ 72]
Tacrolimus	N.A.	Diarrhea	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 28]
Antiepileptics	N.A.	Diarrhea	Allele A is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to allele G.		[ 16]
Carbamazepine	N.A.	Diarrhea	Allele A is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to allele G.		[ 16]
Antiepileptics	N.A.	Diarrhea	Allele A is not associated with likelihood of drug resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.		[ 73]
Axitinib	N.A.	Drug Resistance	Allele A is associated with concentrations of axitinib in people with Carcinoma, Renal Cell as compared to allele G.		[ 74]
Efavirenz	N.A.	Platelet Reactivity	Allele A is not associated with decreased response to efavirenz in people with Acquired Immunodeficiency Syndrome.		[ 75]
Mycophenolate Mofetil	N.A.	Prolonged Qtc Interval	Allele A is not associated with increased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.		[ 76]
Paroxetine	N.A.	Vomiting	Allele A is not associated with plasma concentrations when treated with paroxetine in people with Depressive Disorder, Major as compared to allele G.		[ 77]
Aspirin	N.A.	Colorectal Neoplasms	Allele A is not associated with risk of Colorectal Neoplasms in people not taking aspirin as compared to allele G.		[ 78]
Atazanavir	N.A.	Nephrolithiasis	Allele A is not associated with risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele G.		[ 79]
Ritonavir	N.A.	Nephrolithiasis	Allele A is not associated with risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele G.		[ 79]
Methotrexate	N.A.	Gastrointestinal Toxicity	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.		[ 80]
Dexamethasone	N.A.	Overall Survival	Allele A is not associated with likelihood of overall survival or progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Dexamethasone	N.A.	Progression-free Survival	Allele A is not associated with likelihood of overall survival or progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Lenalidomide	N.A.	Overall Survival	Allele A is not associated with likelihood of overall survival or progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Lenalidomide	N.A.	Progression-free Survival	Allele A is not associated with likelihood of overall survival or progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Dexamethasone	N.A.	Anemia	Allele A is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Dexamethasone	N.A.	Neutropenia	Allele A is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Dexamethasone	N.A.	Thrombocytopenia	Allele A is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Lenalidomide	N.A.	Anemia	Allele A is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Lenalidomide	N.A.	Neutropenia	Allele A is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Lenalidomide	N.A.	Thrombocytopenia	Allele A is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Antiepileptics	N.A.	Thrombocytopenia	Allele A is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele G.		[ 82]
Digoxin	N.A.	Neutropenia	Allele A is associated with increased serum concentrations of digoxin as compared to allele G.		[ 13]
Phenytoin	N.A.	Death	Allele A is associated with increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG.		[ 21]
Abemaciclib	N.A.	Exanthema	Allele A is associated with decreased dose of abemaciclib, palbociclib or ribociclib in women with Breast Neoplasms as compared to allele G.		[ 83]
Palbociclib	N.A.	Exanthema	Allele A is associated with decreased dose of abemaciclib, palbociclib or ribociclib in women with Breast Neoplasms as compared to allele G.		[ 83]
Ribociclib	N.A.	Exanthema	Allele A is associated with decreased dose of abemaciclib, palbociclib or ribociclib in women with Breast Neoplasms as compared to allele G.		[ 83]
Nevirapine	N.A.	Epistaxis	Allele A is not associated with increased risk of Stevens-Johnson Syndrome/Epidermal Necrolysis, Toxic when treated with nevirapine in people with HIV Infections as compared to allele G.		[ 84]
Methotrexate	N.A.	Mucositis	Allele A is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 38]
Aspirin	N.A.	Major Adverse Cardiac Events (mace)	Allele A is not associated with risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele G.		[ 85]
Clopidogrel	N.A.	Major Adverse Cardiac Events (mace)	Allele A is not associated with risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele G.		[ 85]
Atorvastatin	N.A.	Drug Toxicity	Allele A is associated with increased likelihood of myalgia when treated with atorvastatin in people with Coronary Artery Disease as compared to allele G.		[ 20]
Docetaxel	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele G.		[ 86]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele G.		[ 86]
Tacrolimus	N.A.	Transplant Rejection	Allele A is not associated with increased risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 87]
Sunitinib	N.A.	Drug Toxicity	Allele A is not associated with Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G.		[ 41]
Tramadol	N.A.	Opioid-related Disorders	Allele A is not associated with severity of Opioid-Related Disorders due to tramadol as compared to allele G.		[ 88]
Clopidogrel	N.A.	Adverse Events	Allele A is not associated with exposure to clopidogrel or clopidogrel thiol metabolite H4 as compared to allele G.		[ 11]
Clopidogrel Thiol Metabolite H4	N.A.	Adverse Events	Allele A is not associated with exposure to clopidogrel or clopidogrel thiol metabolite H4 as compared to allele G.		[ 11]
Dabigatran	N.A.	Transplant Rejection	Allele A is not associated with decreased dose-adjusted trough concentrations of dabigatran in people with Atrial Fibrillation as compared to allele G.		[ 89]
Raltegravir	N.A.	Hyperbilirubinemia	Allele A is not associated with concentration of raltegravir in people with HIV Infections as compared to allele G.		[ 90]
Methotrexate	N.A.	Progression-free Survival	Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.		[ 6]
Dexamethasone	N.A.	Drug Toxicity	Allele A is not associated with overall survival when treated with dexamethasone, diphenhydramine, paclitaxel and ranitidine in people with Head and Neck Neoplasms as compared to allele G.		[ 50]
Diphenhydramine	N.A.	Drug Toxicity	Allele A is not associated with overall survival when treated with dexamethasone, diphenhydramine, paclitaxel and ranitidine in people with Head and Neck Neoplasms as compared to allele G.		[ 50]
Paclitaxel	N.A.	Drug Toxicity	Allele A is not associated with overall survival when treated with dexamethasone, diphenhydramine, paclitaxel and ranitidine in people with Head and Neck Neoplasms as compared to allele G.		[ 50]
Ranitidine	N.A.	Drug Toxicity	Allele A is not associated with overall survival when treated with dexamethasone, diphenhydramine, paclitaxel and ranitidine in people with Head and Neck Neoplasms as compared to allele G.		[ 50]
Irinotecan	N.A.	Diarrhea	Allele A is not associated with risk of Diarrhea or Neutropenia when treated with irinotecan in people with Neoplasms as compared to allele G.		[ 91]
Irinotecan	N.A.	Neutropenia	Allele A is not associated with risk of Diarrhea or Neutropenia when treated with irinotecan in people with Neoplasms as compared to allele G.		[ 91]
Methotrexate	N.A.	Mucositis	Allele A is associated with increased risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 92]
Clopidogrel	N.A.	Adverse Events	Allele A is not associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.		[ 47]
Dexlansoprazole	N.A.	Adverse Events	Allele A is not associated with metabolism of dexlansoprazole in healthy individuals as compared to allele G.		[ 93]
Imatinib	N.A.	Event-free Survival	Allele A is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.		[ 37]
Lopinavir	N.A.	Event-free Survival	Allele A is not associated with an influence on plasma levels of lopinavir and efavirenz when treated with lopinavir in people with HIV Infections as compared to allele G.		[ 94]
Simvastatin	N.A.	Event-free Survival	Allele A is associated with decreased risk of Myalgia when treated with simvastatin in people with Hypercholesterolemia as compared to allele G.		[ 3]
Morphine	N.A.	Asthenia	Allele A is not associated with dose of morphine in people with Neoplasms as compared to allele G.		[ 95]
Dicloxacillin	N.A.	Asthenia	Allele A is not associated with pharmacokinetics of dicloxacillin.		[ 96]
Olanzapine	N.A.	Asthenia	Allele A is associated with positive relationship between olanzapine plasma levels and positive symptom reduction compared to subjects with the GG genotype when treated with olanzapine.		[ 22]
Methadone	N.A.	Asthenia	Allele A is associated with decreased concentrations of methadone in people with Opioid-Related Disorders as compared to allele G.		[ 1]
Carbamazepine	N.A.	Asthenia	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.		[ 15]
Phenobarbital	N.A.	Asthenia	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.		[ 15]
Phenytoin	N.A.	Asthenia	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.		[ 15]
Valproic Acid	N.A.	Asthenia	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.		[ 15]
Ritonavir	N.A.	Death	Allele A is not associated with phase 1 or phase 2 viral decay, changes in lymphocyte subsets over time, or plasma trough ritonavir concentrations when treated with ritonavir in people with HIV Infections as compared to allele G.		[ 97]
Tacrolimus	N.A.	Acute Cellular Rejection	Allele A is not associated with acute cellular rejection when treated with tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 25]
Clopidogrel	N.A.	Acute Cellular Rejection	Allele A is associated with increased response to clopidogrel in people with Acute coronary syndrome as compared to allele G.		[ 98]
Clopidogrel	N.A.	Diarrhea	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele G.		[ 10]
Sirolimus	N.A.	Diarrhea	Allele A is not associated with metabolism of sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 24]
Tacrolimus	N.A.	Diarrhea	Allele A is not associated with metabolism of sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 24]
Clopidogrel	N.A.	Neutropenia	Allele A is not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.		[ 43]
Ceftriaxone	N.A.	Drug Toxicity	Allele A is not associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to allele G.		[ 99]
Tacrolimus	N.A.	Drug Toxicity	Allele A is not associated with adverse events when treated with tacrolimus in children with hematopoietic stem cell transplant as compared to allele G.		[ 35]
Clopidogrel	N.A.	Drug Toxicity	Allele A is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to allele G.		[ 100]
Clopidogrel	N.A.	Drug Toxicity	Allele A is not associated with response to clopidogrel as compared to allele G.		[ 40]
Acenocoumarol	N.A.	Drug Toxicity	Allele A is not associated with dose of acenocoumarol or warfarin in people with venous thromboembolism as compared to allele G.		[ 101]
Warfarin	N.A.	Drug Toxicity	Allele A is not associated with dose of acenocoumarol or warfarin in people with venous thromboembolism as compared to allele G.		[ 101]
Atazanavir	N.A.	Hyperbilirubinemia	Allele A is not associated with risk of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections.		[ 102]
Efavirenz	N.A.	Cryoglobulinemia	Allele A is not associated with concentrations of efavirenz in children with HIV Infections as compared to allele G.		[ 103]
Lamivudine	N.A.	Neutropenia	Allele A is associated with response to lamivudine or nevirapine in people with HIV Infections as compared to allele G.		[ 104]
Nevirapine	N.A.	Neutropenia	Allele A is associated with response to lamivudine or nevirapine in people with HIV Infections as compared to allele G.		[ 104]
Quetiapine	N.A.	Transplant Rejection	Allele A is not associated with differences pharmacokinetic parameters when treated with quetiapine in healthy individuals as compared to allele G.		[ 105]
Sufentanil	N.A.	Adverse Events	Allele A is not associated with likelihood of adverse events due to sufentanil in people with Pain, Postoperative as compared to allele G.		[ 106]
Dolutegravir	N.A.	Overall Survival	Allele A is not associated with concentrations of dolutegravir in people with HIV Infections as compared to allele G.		[ 107]
Risperidone	N.A.	Central Nervous System Disorder	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele G.		[ 34]
Clopidogrel	N.A.	Diarrhea	Allele A is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.		[ 45]
Carbamazepine	N.A.	Diarrhea	Allele A is associated with increased clearance of carbamazepine in children with Epilepsy as compared to allele G.		[ 108]
Opioids	N.A.	Neurotoxicity Syndromes	Allele A is not associated with dose of opioids in people with Pain as compared to allele G.		[ 109]
Sirolimus	N.A.	Gingival Overgrowth	Allele A is not associated with dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to allele G.		[ 110]
Doxorubicin	N.A.	Cardiotoxicity	Allele A is associated with decreased likelihood of cardiotoxicity when treated with doxorubicin in women with Breast Neoplasms as compared to allele G.		[ 111]
Tenofovir	N.A.	Hemorrhage	Allele A is not associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G.		[ 112]
Efavirenz	N.A.	Hemorrhage	Allele A is not associated with exposure to efavirenz in healthy individuals as compared to allele G.		[ 113]
Vincristine	N.A.	Event-free Survival	Allele A is associated with decreased likelihood of event-free survival when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 2]
Sufentanil	N.A.	Hypoventilation	Allele A is not associated with dose of sufentanil in people with Pain, Postoperative as compared to allele G.		[ 106]
Amitriptyline	N.A.	Hypersensitivity	Allele A is not associated with response to amitriptyline, propranolol or valproic acid in people with Migraine without Aura or Migraine with Aura as compared to allele G.		[ 114]
Propranolol	N.A.	Hypersensitivity	Allele A is not associated with response to amitriptyline, propranolol or valproic acid in people with Migraine without Aura or Migraine with Aura as compared to allele G.		[ 114]
Valproic Acid	N.A.	Hypersensitivity	Allele A is not associated with response to amitriptyline, propranolol or valproic acid in people with Migraine without Aura or Migraine with Aura as compared to allele G.		[ 114]
Tacrolimus	N.A.	Transplant Rejection	Allele A is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 25]
Platinum Compounds	N.A.	Drug Toxicity	Allele A is not associated with severity of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.		[ 115]
Fentanyl	N.A.	Hypertension	Allele A is not associated with exposure to fentanyl in healthy individuals as compared to allele G.		[ 116]
Oxcarbazepine	N.A.	Hypertension	Allele A is associated with decreased response to oxcarbazepine in people with Epilepsy as compared to allele G.		[ 51]
Sufentanil	N.A.	Hypertension	Allele A is not associated with dose of sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to allele G.		[ 117]
Cyclosporine	N.A.	Hypertension	Allele A is associated with decreased response to cyclosporine in people with Psoriasis as compared to allele G.		[ 118]
Clopidogrel	N.A.	Hypersensitivity	Allele A is not associated with the antiplatelet effect or clinical outcomes of clopidogrel when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to allele G.		[ 12]
Dactinomycin	N.A.	Hypersensitivity	Allele A is not associated with clearance of dactinomycin in children with Neoplasms as compared to allele G.		[ 119]
O-desmethyltramadol	N.A.	Hypersensitivity	Allele A is not associated with concentrations of o-desmethyltramadol in healthy individuals as compared to allele G.		[ 120]
Tramadol	N.A.	Hypersensitivity	Allele A is associated with increased concentrations of tramadol in healthy individuals as compared to allele G.		[ 120]
Morphine	N.A.	Hypersensitivity	Allele A is not associated with concentrations of morphine in women with Pain, Postoperative as compared to allele G.		[ 121]
Antipsychotics	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with drug response when exposed to antipsychotics in people with Psychotic Disorders as compared to allele G.		[ 122]
Clopidogrel	N.A.	Transient Ischemic Attack	Allele A is not associated with risk of Transient Ischemic Attack and Stroke when treated with clopidogrel in people with Cerebrovascular Disorders as compared to allele G.		[ 123]
Clopidogrel	N.A.	Stroke	Allele A is not associated with risk of Transient Ischemic Attack and Stroke when treated with clopidogrel in people with Cerebrovascular Disorders as compared to allele G.		[ 123]
Tacrolimus	N.A.	Drug Toxicity	Allele A is not associated with increased dose-adjusted trough concentrations of tacrolimus in children with Nephrotic Syndrome as compared to allele G.		[ 124]
Rivaroxaban	N.A.	Hyperprolactinemia	Allele A is not associated with increased dose-adjusted trough concentrations of rivaroxaban in people with Atrial Fibrillation as compared to allele C.		[ 125]
Temozolomide	N.A.	Urinary Retention	Allele A is not associated with response to temozolomide in people with Glioma as compared to allele G.		[ 126]
Clopidogrel	N.A.	High On-treatment Platelet Reactivity	Allele A is not associated with increased risk of on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to allele G.		[ 48]
Pantoprazole	N.A.	High On-treatment Platelet Reactivity	Allele A (assigned as poor metabolizer phenotype) is not associated with response to pantoprazole in people with Helicobacter Infections as compared to allele G.		[ 127]
Clopidogrel	N.A.	High On-treatment Platelet Reactivity	Allele A is not associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.		[ 128]
Clopidogrel	N.A.	High On-treatment Platelet Reactivity	Allele A is not associated with differences in platelet reactivity and high on-treatment platelet reactivity when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to allele G.		[ 129]
Clopidogrel	N.A.	Major Adverse Cardiac Events (mace)	Allele A is not associated with risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.		[ 128]
Methadone	N.A.	Weight Gain	Allele A is not associated with response to methadone in people with Heroin Dependence as compared to allele G.		[ 130]
Cabazitaxel	N.A.	Gastrointestinal Toxicity	Allele A is associated with decreased likelihood of gastrointestinal toxicity when treated with cabazitaxel in people with Carcinoma, Transitional Cell as compared to allele G.		[ 131]
Clopidogrel	N.A.	Drug Toxicity	Allele A is not associated with increased risk of myocardial infarction (MI) or composite outcome of non-fatal MI, all cause death and stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.		[ 44]
Risperidone	N.A.	Mucositis	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.		[ 33]
Carbamazepine	N.A.	Kidney Disorder	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele G.		[ 18]
Mycophenolate Mofetil	N.A.	Leukopenia	Allele A is not associated with increased risk of Leukopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.		[ 132]
Mycophenolate Mofetil	N.A.	Diarrhea	Allele A is not associated with increased risk of Diarrhea when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.		[ 132]
Atazanavir	N.A.	Treatment Failure	Allele A is not associated with likelihood of treatment failure when treated with atazanavir in people with HIV Infections as compared to allele G.		[ 49]
Nevirapine	N.A.	Treatment Failure	Allele A is not associated with increased plasma level when treated with nevirapine in people with HIV Infections as compared to allele G.		[ 133]
Clopidogrel	N.A.	Eye Diseases	Allele A is not associated with metabolism of clopidogrel in men with Coronary Artery Disease as compared to allele G.		[ 134]
Morphine	N.A.	Hypoventilation	Allele A is associated with Hypoventilation when treated with morphine in women.		[ 135]
Nevirapine	N.A.	Toxic Liver Disease	Allele A is associated with decreased risk of Toxic liver disease when treated with nevirapine in people with HIV Infections as compared to allele G.		[ 53]
Efavirenz	N.A.	Toxic Liver Disease	Allele A is associated with decreased risk of Toxic liver disease when treated with efavirenz and nevirapine in people with HIV Infections as compared to allele G.		[ 5]
Nevirapine	N.A.	Toxic Liver Disease	Allele A is associated with decreased risk of Toxic liver disease when treated with efavirenz and nevirapine in people with HIV Infections as compared to allele G.		[ 5]
Warfarin	N.A.	Statin-related Myopathy	Allele A is not associated with increased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to allele G.		[ 136]
Lopinavir	N.A.	Statin-related Myopathy	Allele A is not associated with exposure to lopinavir or ritonavir in children with HIV Infections as compared to allele G.		[ 137]
Ritonavir	N.A.	Statin-related Myopathy	Allele A is not associated with exposure to lopinavir or ritonavir in children with HIV Infections as compared to allele G.		[ 137]
Clopidogrel	N.A.	Statin-related Myopathy	Allele A is not associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to allele G.		[ 46]
Tacrolimus	N.A.	Hypercholesterolemia	Allele A is not associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 138]
Isoniazid	N.A.	Drug-induced Liver Injury	Allele A is not associated with risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele G.		[ 54]
Midazolam	N.A.	Leukopenia	Allele A is not associated with increased clearance of midazolam in people with Carcinoma, Renal Cell as compared to allele G.		[ 139]
Carbamazepine	N.A.	Adverse Events	Allele A is not associated with increased resistance to carbamazepine in people with Epilepsy as compared to allele G.		[ 140]
Antiepileptics	N.A.	Adverse Events	Allele A is not associated with response to antiepileptics in people with Epilepsy as compared to allele G.		[ 141]
Nevirapine	N.A.	Adverse Events	Allele A is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele G.		[ 142]
Warfarin	N.A.	Dose Reduction	Allele A is associated with increased dose of warfarin as compared to allele G.		[ 143]
Antineoplastic Agents	N.A.	Dose Reduction	Allele A is not associated with survival when treated with antineoplastic agents in women with Ovarian Neoplasms as compared to allele G.		[ 144]
Tenofovir	N.A.	Dose Reduction	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections.		[ 145]
Tenofovir Disoproxil Fumarate	N.A.	Nephrotoxicity	Allele A is not associated with severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to allele G.		[ 146]
Tacrolimus	N.A.	Nephrotoxicity	Allele A is not associated with trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 31]
Vincristine	N.A.	Nephrotoxicity	Allele A is not associated with impaired motor performance when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 147]
Cyclosporine	N.A.	Nephrotoxicity	Allele A is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 23]
Tacrolimus	N.A.	Nephrotoxicity	Allele A is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 23]
Clopidogrel	N.A.	Toxic Liver Disease	Allele A is not associated with response to clopidogrel in people with Angina Pectoris as compared to allele G.		[ 39]
Folic Acid	N.A.	Mucositis	Allele A is associated with increased risk of adverse drug event when treated with folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to allele G.		[ 8]
Methotrexate	N.A.	Mucositis	Allele A is associated with increased risk of adverse drug event when treated with folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to allele G.		[ 8]
Lamotrigine	N.A.	Mucositis	Allele A is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele G.		[ 148]
Everolimus	N.A.	Mucositis	Allele A is associated with increased likelihood of mucositis when treated with everolimus in women with Breast Neoplasms as compared to allele G.		[ 19]
Carbamazepine	N.A.	Adverse Events	Allele A is not associated with increased response to carbamazepine in people with Epilepsy as compared to allele G.		[ 149]
Sunitinib	N.A.	Adverse Events	Allele A is not associated with concentrations of sunitinib in people with Carcinoma, Renal Cell as compared to allele G.		[ 150]
Efavirenz	N.A.	Chronic Kidney Failure	Allele A is associated with increased likelihood of toxicity-related treatment failure when treated with efavirenz in people with HIV Infections as compared to allele G.		[ 4]
Methadone	N.A.	Hemorrhage	Allele A is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele G.		[ 151]
Antiepileptics	N.A.	Hemorrhage	Allele A is associated with increased risk of drug resistance when treated with antiepileptics in men with Epilepsy.		[ 17]
Sufentanil	N.A.	Adverse Events	Allele A is not associated with likelihood of adverse events due to sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to allele G.		[ 117]
Risperidone	N.A.	Weight Gain	Allele A is associated with increased Weight gain when treated with risperidone in women with Schizophrenia as compared to allele G.		[ 152]
Fentanyl	N.A.	Adverse Events	Allele A is not associated with risk of adverse events when treated with fentanyl in people with Neoplasms as compared to allele G.		[ 153]
Fentanyl	N.A.	Adverse Events	Allele A is not associated with likelihood of adverse events due to fentanyl in healthy individuals as compared to allele G.		[ 116]
Cyclosporine	N.A.	Adverse Events	Allele A is not associated with resistance when treated with cyclosporine in people with Colitis, Ulcerative as compared to allele G.		[ 154]
Bleomycin	N.A.	Leukopenia	Allele A is not associated with risk of Leukopenia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to allele G.		[ 155]
Cisplatin	N.A.	Leukopenia	Allele A is not associated with risk of Leukopenia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to allele G.		[ 155]
Etoposide	N.A.	Leukopenia	Allele A is not associated with risk of Leukopenia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to allele G.		[ 155]
Methotrexate	N.A.	Neurotoxicity Syndromes	Allele A is associated with decreased likelihood of Neurotoxicity Syndromes when treated with methotrexate in children with Acute lymphoblastic leukemia as compared to allele G.		[ 156]
Tramadol	N.A.	Neurotoxicity Syndromes	Allele A is associated with increased likelihood of a decrease in visual analog scale >30mm within 6 hours when treated with tramadol in people with Fractures, Bone as compared to allele G.		[ 157]
Fentanyl	N.A.	Pain	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Fentanyl	N.A.	Pain, Postoperative	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Nevirapine	N.A.	HIV Infectious Disease	Allele A is associated with decreased risk of Toxic liver disease when treated with nevirapine in people with HIV Infections.		[ 52]
Nevirapine	N.A.	HIV Infectious Disease	Allele A is associated with decreased risk of Toxic liver disease when treated with efavirenz and nevirapine in people with HIV Infections as compared to allele G.		[ 5]
Nevirapine	N.A.	HIV Infectious Disease	Allele A is associated with decreased risk of Toxic liver disease when treated with nevirapine in people with HIV Infections as compared to allele G.		[ 53]
Antiepileptics	N.A.	Epilepsies, Partial	Allele A is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele G.		[ 82]
Antiepileptics	N.A.	Epilepsy	Allele A is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele G.		[ 82]
Antiepileptics	N.A.	Epilepsy, Idiopathic Generalized	Allele A is not associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele G.		[ 82]
Antiepileptics	N.A.	Epilepsies, Partial	Allele A is not associated with response to antiepileptics in people with Epilepsy as compared to allele G.		[ 158]
Antiepileptics	N.A.	Epilepsy	Allele A is not associated with response to antiepileptics in people with Epilepsy as compared to allele G.		[ 158]
Antiepileptics	N.A.	Epilepsy, Idiopathic Generalized	Allele A is not associated with response to antiepileptics in people with Epilepsy as compared to allele G.		[ 158]
Antiepileptics	N.A.	Epilepsies, Partial	Allele A is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to allele G.		[ 16]
Antiepileptics	N.A.	Epilepsy	Allele A is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to allele G.		[ 16]
Antiepileptics	N.A.	Epilepsy, Idiopathic Generalized	Allele A is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to allele G.		[ 16]
Antiepileptics	N.A.	Epilepsies, Partial	Allele A is not associated with likelihood of drug resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.		[ 73]
Antiepileptics	N.A.	Epilepsy	Allele A is not associated with likelihood of drug resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.		[ 73]
Antiepileptics	N.A.	Epilepsy, Idiopathic Generalized	Allele A is not associated with likelihood of drug resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.		[ 73]
Antiepileptics	N.A.	Epilepsies, Partial	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.		[ 69]
Antiepileptics	N.A.	Epilepsy	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.		[ 69]
Antiepileptics	N.A.	Epilepsy, Idiopathic Generalized	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.		[ 69]
Antiepileptics	N.A.	Epilepsies, Partial	Allele A is associated with increased risk of drug resistance when treated with antiepileptics in men with Epilepsy.		[ 17]
Antiepileptics	N.A.	Epilepsy	Allele A is associated with increased risk of drug resistance when treated with antiepileptics in men with Epilepsy.		[ 17]
Antiepileptics	N.A.	Epilepsy, Idiopathic Generalized	Allele A is associated with increased risk of drug resistance when treated with antiepileptics in men with Epilepsy.		[ 17]
Methadone	N.A.	Heroin Dependence	Allele A is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele G.		[ 151]
Methadone	N.A.	Opioid-related Disorders	Allele A is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele G.		[ 151]
Oxycodone	N.A.	Pain	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Methadone	N.A.	Pain	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Allele A is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.		[ 37]
Simvastatin	N.A.	Hypercholesterolemia	Allele A is associated with decreased risk of Myalgia when treated with simvastatin in people with Hypercholesterolemia as compared to allele G.		[ 3]
Simvastatin	N.A.	Myalgia	Allele A is associated with decreased risk of Myalgia when treated with simvastatin in people with Hypercholesterolemia as compared to allele G.		[ 3]
Clopidogrel	N.A.	Acute Coronary Syndrome	Allele A is not associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to allele G.		[ 42]
Clopidogrel	N.A.	Myocardial Infarction	Allele A is not associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to allele G.		[ 42]
Clopidogrel	N.A.	Acute Coronary Syndrome	Allele A is not associated with the antiplatelet effect or clinical outcomes of clopidogrel when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to allele G.		[ 12]
Clopidogrel	N.A.	Myocardial Infarction	Allele A is not associated with the antiplatelet effect or clinical outcomes of clopidogrel when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to allele G.		[ 12]
Clopidogrel	N.A.	Acute Coronary Syndrome	Allele A is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to allele G.		[ 100]
Clopidogrel	N.A.	Myocardial Infarction	Allele A is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to allele G.		[ 100]
Clopidogrel	N.A.	Acute Coronary Syndrome	Allele A is not associated with increased risk of myocardial infarction (MI) or composite outcome of non-fatal MI, all cause death and stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.		[ 44]
Clopidogrel	N.A.	Myocardial Infarction	Allele A is not associated with increased risk of myocardial infarction (MI) or composite outcome of non-fatal MI, all cause death and stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.		[ 44]
Clopidogrel	N.A.	Acute Coronary Syndrome	Allele A is not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.		[ 43]
Clopidogrel	N.A.	Myocardial Infarction	Allele A is not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.		[ 43]
Clopidogrel	N.A.	Acute Coronary Syndrome	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele G.		[ 10]
Clopidogrel	N.A.	Myocardial Infarction	Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele G.		[ 10]
Clopidogrel	N.A.	Acute Coronary Syndrome	Allele A is not associated with differences in platelet reactivity and high on-treatment platelet reactivity when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to allele G.		[ 129]
Clopidogrel	N.A.	Myocardial Infarction	Allele A is not associated with differences in platelet reactivity and high on-treatment platelet reactivity when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to allele G.		[ 129]
Clopidogrel	N.A.	Acute Coronary Syndrome	Allele A is not associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to allele G.		[ 46]
Clopidogrel	N.A.	Myocardial Infarction	Allele A is not associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to allele G.		[ 46]
Clopidogrel	N.A.	Acute Coronary Syndrome	Allele A is not associated with response to clopidogrel in people with Angina Pectoris as compared to allele G.		[ 39]
Clopidogrel	N.A.	Myocardial Infarction	Allele A is not associated with response to clopidogrel in people with Angina Pectoris as compared to allele G.		[ 39]
Clopidogrel	N.A.	Acute Coronary Syndrome	Allele A is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.		[ 45]
Clopidogrel	N.A.	Myocardial Infarction	Allele A is not associated with risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.		[ 45]
Clopidogrel	N.A.	Acute Coronary Syndrome	Allele A is not associated with increased risk of on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to allele G.		[ 48]
Clopidogrel	N.A.	Myocardial Infarction	Allele A is not associated with increased risk of on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to allele G.		[ 48]
Clopidogrel	N.A.	Acute Coronary Syndrome	Allele A is not associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.		[ 47]
Clopidogrel	N.A.	Myocardial Infarction	Allele A is not associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.		[ 47]
Clopidogrel	N.A.	Acute Coronary Syndrome	Allele A is not associated with exposure to clopidogrel or clopidogrel thiol metabolite H4 as compared to allele G.		[ 11]
Clopidogrel	N.A.	Myocardial Infarction	Allele A is not associated with exposure to clopidogrel or clopidogrel thiol metabolite H4 as compared to allele G.		[ 11]
Methadone	N.A.	Opioid-related Disorders	Allele A is associated with decreased concentrations of methadone in people with Opioid-Related Disorders as compared to allele G.		[ 1]
Olanzapine	N.A.	Psychotic Disorder	Allele A is associated with positive relationship between olanzapine plasma levels and positive symptom reduction compared to subjects with the GG genotype when treated with olanzapine.		[ 22]
Everolimus	N.A.	Breast Neoplasms	Allele A is associated with increased likelihood of mucositis when treated with everolimus in women with Breast Neoplasms as compared to allele G.		[ 19]
Carbamazepine	N.A.	Epilepsy	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.		[ 159]
Carbamazepine	N.A.	Epilepsy	Allele A is not associated with metabolism of carbamazepine in people with Epilepsy as compared to allele G.		[ 16]
Carbamazepine	N.A.	Epilepsy	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele G.		[ 18]
Atorvastatin	N.A.	Coronary Artery Disease	Allele A is associated with increased likelihood of myalgia when treated with atorvastatin in people with Coronary Artery Disease as compared to allele G.		[ 20]
Atorvastatin	N.A.	Myalgia	Allele A is associated with increased likelihood of myalgia when treated with atorvastatin in people with Coronary Artery Disease as compared to allele G.		[ 20]
Tacrolimus	N.A.	Kidney Transplantation	Allele A is not associated with acute cellular rejection when treated with tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 25]
Tacrolimus	N.A.	Kidney Transplantation	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 26]
Tramadol	N.A.	Fractures, Bone	Allele A is associated with increased likelihood of a decrease in visual analog scale >30mm within 6 hours when treated with tramadol in people with Fractures, Bone as compared to allele G.		[ 157]
Tramadol	N.A.	Pain	Allele A is associated with increased likelihood of a decrease in visual analog scale >30mm within 6 hours when treated with tramadol in people with Fractures, Bone as compared to allele G.		[ 157]
Tramadol	N.A.	Pain, Postoperative	Allele A is associated with increased likelihood of a decrease in visual analog scale >30mm within 6 hours when treated with tramadol in people with Fractures, Bone as compared to allele G.		[ 157]
Efavirenz	N.A.	HIV Infectious Disease	Allele A is associated with increased likelihood of toxicity-related treatment failure when treated with efavirenz in people with HIV Infections as compared to allele G.		[ 4]
Nelfinavir	N.A.	HIV Infectious Disease	Allele A is associated with increased likelihood of toxicity-related treatment failure when treated with efavirenz in people with HIV Infections as compared to allele G.		[ 4]
Efavirenz	N.A.	HIV Infectious Disease	Allele A is not associated with decreased response to efavirenz in people with Acquired Immunodeficiency Syndrome.		[ 75]
Nelfinavir	N.A.	HIV Infectious Disease	Allele A is not associated with decreased response to efavirenz in people with Acquired Immunodeficiency Syndrome.		[ 75]
Efavirenz	N.A.	HIV Infectious Disease	Allele A is associated with decreased risk of Toxic liver disease when treated with efavirenz and nevirapine in people with HIV Infections as compared to allele G.		[ 5]
Nelfinavir	N.A.	HIV Infectious Disease	Allele A is associated with decreased risk of Toxic liver disease when treated with efavirenz and nevirapine in people with HIV Infections as compared to allele G.		[ 5]
Cyclosporine	N.A.	Transplantation	Allele A is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 23]
Pantoprazole	N.A.	Helicobacter Infections	Allele A (assigned as poor metabolizer phenotype) is not associated with response to pantoprazole in people with Helicobacter Infections as compared to allele G.		[ 127]
Atazanavir	N.A.	HIV Infectious Disease	Allele A is not associated with risk of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections.		[ 102]
Ritonavir	N.A.	HIV Infectious Disease	Allele A is not associated with risk of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections.		[ 102]
Atazanavir	N.A.	HIV Infectious Disease	Allele A is not associated with risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele G.		[ 79]
Ritonavir	N.A.	HIV Infectious Disease	Allele A is not associated with risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele G.		[ 79]
Atazanavir	N.A.	HIV Infectious Disease	Allele A is not associated with likelihood of treatment failure when treated with atazanavir in people with HIV Infections as compared to allele G.		[ 49]
Ritonavir	N.A.	HIV Infectious Disease	Allele A is not associated with likelihood of treatment failure when treated with atazanavir in people with HIV Infections as compared to allele G.		[ 49]
Sunitinib	N.A.	Renal Cell Carcinoma	Allele A is not associated with Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G.		[ 41]
Drugs For Treatment Of Tuberculosis	N.A.	Tuberculosis	Allele A is not associated with risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele G.		[ 54]
Isoniazid	N.A.	Tuberculosis	Allele A is not associated with risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele G.		[ 54]
Opioids	N.A.	Pain	Allele A is not associated with dose of opioids in people with Pain as compared to allele G.		[ 109]
Opioids	N.A.	Pain, Postoperative	Allele A is not associated with dose of opioids in people with Pain as compared to allele G.		[ 109]
Opioids	N.A.	Pain	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Opioids	N.A.	Pain, Postoperative	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Morphine	N.A.	Pain	Allele A is not associated with dose of morphine in people with Neoplasms as compared to allele G.		[ 95]
Morphine	N.A.	Pain, Postoperative	Allele A is not associated with dose of morphine in people with Neoplasms as compared to allele G.		[ 95]
Morphine	N.A.	Pain	Allele A is not associated with dose of morphine in women with Pain, Postoperative as compared to allele G.		[ 121]
Morphine	N.A.	Pain, Postoperative	Allele A is not associated with dose of morphine in women with Pain, Postoperative as compared to allele G.		[ 121]
Morphine	N.A.	Pain	Allele A is not associated with dose of morphine in people with Pain, Postoperative as compared to allele G.		[ 65]
Morphine	N.A.	Pain, Postoperative	Allele A is not associated with dose of morphine in people with Pain, Postoperative as compared to allele G.		[ 65]
Morphine	N.A.	Pain	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Morphine	N.A.	Pain, Postoperative	Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.		[ 70]
Oxcarbazepine	N.A.	Epilepsy	Allele A is associated with decreased response to oxcarbazepine in people with Epilepsy as compared to allele G.		[ 51]
Carbamazepine	N.A.	Epilepsy	Allele A is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.		[ 61]
Carbamazepine	N.A.	Epilepsy	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.		[ 15]
Paclitaxel	N.A.	Breast Neoplasms	Allele A is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele G.		[ 86]
Paclitaxel	N.A.	Neoplasms	Allele A is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele G.		[ 86]
Docetaxel	N.A.	Breast Neoplasms	Allele A is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele G.		[ 86]
Docetaxel	N.A.	Neoplasms	Allele A is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele G.		[ 86]
Vincristine	N.A.	Acute Lymphoblastic Leukemia	Allele A is associated with decreased likelihood of event-free survival when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 2]
Risperidone	N.A.	Bipolar Disorder	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele G.		[ 34]
Risperidone	N.A.	Depression	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele G.		[ 34]
Risperidone	N.A.	Psychotic Disorder	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele G.		[ 34]
Risperidone	N.A.	Schizophrenia	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele G.		[ 34]
Risperidone	N.A.	Substance-related Disorders	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele G.		[ 34]
Risperidone	N.A.	Bipolar Disorder	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.		[ 33]
Risperidone	N.A.	Depression	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.		[ 33]
Risperidone	N.A.	Psychotic Disorder	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.		[ 33]
Risperidone	N.A.	Schizophrenia	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.		[ 33]
Risperidone	N.A.	Substance-related Disorders	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.		[ 33]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele A is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 38]
Clopidogrel	N.A.	Coronary Disease	Allele A is associated with increased risk of Hemorrhage when treated with clopidogrel in people with Coronary Disease as compared to allele G.		[ 9]
Clopidogrel	N.A.	Platelet Reactivity	Allele A is not associated with the antiplatelet effect or clinical outcomes of clopidogrel when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to allele G.		[ 12]
Clopidogrel	N.A.	Platelet Reactivity	Allele A is not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.		[ 43]
Clopidogrel	N.A.	Platelet Reactivity	Allele A is not associated with differences in platelet reactivity and high on-treatment platelet reactivity when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to allele G.		[ 129]
Clopidogrel	N.A.	Platelet Reactivity	Allele A is not associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to allele G.		[ 46]
Clopidogrel	N.A.	Platelet Reactivity	Allele A is not associated with increased risk of on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to allele G.		[ 48]
Clopidogrel	N.A.	Platelet Reactivity	Allele A is not associated with response to clopidogrel as compared to allele G.		[ 40]
Clopidogrel	N.A.	Platelet Reactivity	Allele A is not associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.		[ 128]
Methotrexate	N.A.	Burkitt Lymphoma	Allele A is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 38]
Methotrexate	N.A.	Drug Toxicity	Allele A is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 38]
Methotrexate	N.A.	Lymphoma, T-cell	Allele A is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 38]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele A is associated with increased risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 92]
Methotrexate	N.A.	Burkitt Lymphoma	Allele A is associated with increased risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 92]
Methotrexate	N.A.	Drug Toxicity	Allele A is associated with increased risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 92]
Methotrexate	N.A.	Lymphoma, T-cell	Allele A is associated with increased risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 92]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele A is associated with increased risk of adverse drug event when treated with folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to allele G.		[ 8]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.		[ 6]
Methotrexate	N.A.	Juvenile Rheumatoid Arthritis	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.		[ 80]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele A is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.		[ 80]
Efavirenz	N.A.	HIV Infectious Disease	Allele A is not associated with exposure to efavirenz in healthy individuals as compared to allele G.		[ 113]
Efavirenz	N.A.	HIV Infectious Disease	Allele A is not associated with concentrations of efavirenz in children with HIV Infections as compared to allele G.		[ 103]
Phenytoin	N.A.	Epilepsy	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.		[ 15]
Tacrolimus	N.A.	Organ Transplantation	Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 160]
Tacrolimus	N.A.	Organ Transplantation	Allele A is not associated with trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 31]
Tacrolimus	N.A.	Organ Transplantation	Allele A is not associated with clearance of tacrolimus in people with liver transplantation as compared to allele G.		[ 36]
Tacrolimus	N.A.	Organ Transplantation	Allele A is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 25]
Tacrolimus	N.A.	Organ Transplantation	Allele A is not associated with dose of tacrolimus in children with hemopoietic stem cell transplant as compared to allele G.		[ 35]
Tacrolimus	N.A.	Organ Transplantation	Allele A is not associated with likelihood of achieving target concentrations of tacrolimus in children with Kidney Transplantation as compared to allele G.		[ 32]
Tacrolimus	N.A.	Organ Transplantation	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 28]
Tacrolimus	N.A.	Organ Transplantation	Allele A is not associated with increased dose-adjusted trough concentrations of tacrolimus in children with Nephrotic Syndrome as compared to allele G.		[ 124]
Tacrolimus	N.A.	Organ Transplantation	Allele A is not associated with metabolism of sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 24]
Tacrolimus	N.A.	Organ Transplantation	Allele A is not associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 30]
Allele G	Click to Show/Hide the Full List of Affected Drugs:       182 Drugs in Total
Phenytoin	Drug Info	Epilepsy	Correlated with the increased likelihood of drug resistance in patients (compare with Allele A); Irrelevant to the drug response in patients (compare with allele A)		[ 161], [ 162]
Atorvastatin	Drug Info	Coronary Artery Disease	Irrelevant to the dose decrease or drug switching risk (compare with allele A)		[ 163]
Atorvastatin	Drug Info	Hypercholesterolemia	Irrelevant to the dose decrease or drug switching risk (compare with allele A)		[ 163]
Simvastatin	Drug Info	Coronary Artery Disease	Irrelevant to the dose decrease or drug switching risk (compare with allele A)		[ 163]
Simvastatin	Drug Info	Hypercholesterolemia	Irrelevant to the dose decrease or drug switching risk (compare with allele A)		[ 163]
Tacrolimus	Drug Info	Organ Transplantation	Irrelevant to the drug concentrations in patients (compare with Allele A)		[ 164]
Tacrolimus	Drug Info	Kidney Transplantation	Irrelevant to the drug metabolism in patients (compare with allele A)		[ 165]
Methotrexate	Drug Info	Rheumatoid Arthritis	Irrelevant to the drug response in patients (compare with allele A)		[ 166]
Fluorouracil	Drug Info	Esophageal Neoplasm	Irrelevant to the drug response in patients (compare with allele A)		[ 167]
Clopidogrel	Drug Info	Acute Coronary Syndrome	Irrelevant to the drug response in patients (compare with allele A)		[ 168]
Clopidogrel	Drug Info	Myocardial Infarction	Irrelevant to the drug response in patients (compare with allele A)		[ 169]
Cisplatin	Drug Info	Esophageal Neoplasm	Irrelevant to the drug response in patients (compare with allele A)		[ 167]
Carbamazepine	Drug Info	Epilepsy	Irrelevant to the drug response in patients (compare with allele A)		[ 161]
Valproic acid	Drug Info	Epilepsy	Irrelevant to the drug response in patients (compare with allele A)		[ 161]
Phenobarbital	Drug Info	Epilepsy	Irrelevant to the drug response in patients (compare with allele A)		[ 161]
Ritonavir	Drug Info	HIV Infection	Irrelevant to the hyperbilirubinemia risk in patients (compare with allele A); Irrelevant to the severity of hyperbilirubinemia in patients (compare with allele A); Irrelevant to the trough concentration of drug in patients (compare with allele A)		[ 170], [ 171], [ 172]
Paliperidone	Drug Info	Schizophrenia	Irrelevant to the increased drug metabolism in patients (compare with Allele A)		[ 173]
Risperidone	Drug Info	Schizophrenia	Irrelevant to the increased drug metabolism in patients (compare with Allele A)		[ 173]
Fluorouracil	Drug Info	Breast Neoplasm	Irrelevant to the likelihood of drug toxicity in patients (compare with allele A)		[ 174]
Cyclophosphamide	Drug Info	Breast Neoplasm	Irrelevant to the likelihood of drug toxicity in patients (compare with allele A)		[ 174]
Atazanavir	Drug Info	HIV Infection	Irrelevant to the drug concentrations in patients (compare with Allele A); Irrelevant to the hyperbilirubinemia risk in patients (compare with allele A); Irrelevant to the likelihood of hyperbilirubinemia in patients (compare with allele A); Irrelevant to the severity of hyperbilirubinemia in patients (compare with allele A); Irrelevant to the trough concentration of drug in patients (compare with allele A)		[ 170], [ 171], [ 172], [ 175]
Efavirenz	Drug Info	HIV Infection	Irrelevant to the neurotoxicity syndromes in patients (compare with allele A)		[ 176]
Methadone	N.A.	Discontinuation	Allele G is not associated with increased likelihood of Discontinuation when treated with methadone in people with Opioid-Related Disorders as compared to allele A.		[ 177]
Atazanavir	N.A.	Drug Toxicity	Allele G is not associated with concentrations of atazanavir in people with HIV Infections as compared to allele A.		[ 175]
Fluoxetine	N.A.	Asthenia	Allele G is not associated with increased fluoxetine/(S)-norfluoxetine ratio when treated with fluoxetine in children with Depressive Disorder as compared to allele A.		[ 178]
Methotrexate	N.A.	Hemorrhage	Allele G is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.		[ 166]
Risperidone	N.A.	Hemorrhage	Allele G is not associated with increased metabolism of risperidone in people with Schizophrenia as compared to allele A.		[ 173]
Atazanavir	N.A.	Hyperbilirubinemia	Allele G is not associated with likelihood of Hyperbilirubinemia when treated with atazanavir in people with as compared to allele A.		[ 175]
Clopidogrel	N.A.	Diarrhea	Allele G is not associated with response to clopidogrel in people with Myocardial Infarction as compared to allele A.		[ 169]
Cyclophosphamide	N.A.	Drug Toxicity	Allele G is not associated with likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele A.		[ 174]
Fluorouracil	N.A.	Drug Toxicity	Allele G is not associated with likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele A.		[ 174]
Temsirolimus	N.A.	Adverse Events	Allele G is not associated with likelihood of adverse events when treated with temsirolimus in people with Urinary Bladder Neoplasms as compared to allele A.		[ 179]
Clopidogrel	N.A.	Major Adverse Cardiac Events (mace)	Allele G is associated with increased likelihood of major adverse cardiac events (mace) when treated with clopidogrel in people with Cardiovascular Diseases as compared to allele A.		[ 180]
Lopinavir	N.A.	Toxic Liver Disease	Allele G is not associated with trough concentration of lopinavir in people with HIV Infections as compared to allele A.		[ 172]
Atazanavir	N.A.	Toxic Liver Disease	Allele G is not associated with trough concentration of atazanavir in people with HIV Infections as compared to allele A.		[ 172]
Atazanavir	N.A.	Hyperbilirubinemia	Allele G is not associated with severity of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections as compared to allele A.		[ 170]
Tramadol	N.A.	Hyperbilirubinemia	Allele G is not associated with response to tramadol in people with Pain, Postoperative as compared to allele A.		[ 181]
Olanzapine	N.A.	Neurotoxicity Syndromes	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele A.		[ 182]
Antiepileptics	N.A.	Diarrhea	Allele G is associated with increased likelihood of non-response when treated with antiepileptics in people with Epilepsy.		[ 183]
Citalopram	N.A.	Drug Resistance	Allele G is not associated with differences in remission or tolerance when treated with citalopram in people with Depressive Disorder, Major as compared to allele A.		[ 184]
Morphine	N.A.	Adverse Events	Allele G is not associated with risk of adverse events due to morphine and nortriptyline in people with Pain as compared to allele A.		[ 185]
Nortriptyline	N.A.	Adverse Events	Allele G is not associated with risk of adverse events due to morphine and nortriptyline in people with Pain as compared to allele A.		[ 185]
Clopidogrel	N.A.	Neutropenia	Allele G is associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele A.		[ 186]
Antipsychotics	N.A.	Vomiting	Allele G is associated with increased response to antipsychotics in people with Schizophrenia.		[ 187]
Atazanavir	N.A.	Hyperbilirubinemia	Allele G is not associated with risk of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele A.		[ 171]
Ritonavir	N.A.	Hyperbilirubinemia	Allele G is not associated with risk of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele A.		[ 171]
Methadone	N.A.	Thrombocytopenia	Allele G is not associated with metabolism of methadone in men with Heroin Dependence as compared to allele A.		[ 188]
Phenytoin	N.A.	Neutropenia	Allele G is associated with increased likelihood of drug resistance when treated with phenytoin in people with Epilepsy as compared to allele A.		[ 162]
Clozapine	N.A.	Neutropenia	Allele G is not associated with concentrations of clozapine in people with Schizophrenia as compared to allele A.		[ 189]
Cisplatin	N.A.	Death	Allele G is not associated with response to cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to allele A.		[ 167]
Fluorouracil	N.A.	Death	Allele G is not associated with response to cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to allele A.		[ 167]
Opioids	N.A.	Death	Allele G is not associated with risk of Death due to opioids in people with Opioid-Related Disorders as compared to allele A.		[ 190]
Propofol	N.A.	Adverse Events	Allele G is not associated with risk of adverse events due to propofol and remifentanil in children as compared to allele G.		[ 191]
Remifentanil	N.A.	Adverse Events	Allele G is not associated with risk of adverse events due to propofol and remifentanil in children as compared to allele G.		[ 191]
Aripiprazole	N.A.	Adverse Events	Allele G is not associated with concentrations of aripiprazole in healthy individuals as compared to allele A.		[ 192]
Vincristine	N.A.	Peripheral Nervous System Diseases	Allele G is not associated with increased risk of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 193]
Methotrexate	N.A.	Adverse Events	Allele G is not associated with risk of adverse events due to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.		[ 80]
Tacrolimus	N.A.	Adverse Events	Allele G is not associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to allele A.		[ 195]
Cyclosporine	N.A.	Adverse Events	Allele G is not associated with increased dose of cyclosporine in people with Kidney Transplantation as compared to allele A.		[ 195]
Atorvastatin	N.A.	Event-free Survival	Allele G is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele A.		[ 163]
Simvastatin	N.A.	Event-free Survival	Allele G is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele A.		[ 163]
Clopidogrel	N.A.	Asthenia	Allele G is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele A.		[ 168]
Fentanyl	N.A.	Acute Cellular Rejection	Allele G is not associated with concentrations of fentanyl in people with Neoplasms and Pain as compared to allele A.		[ 196]
Opioids	N.A.	Nausea	Allele G is associated with increased likelihood of Nausea due to opioids in people with Low Back Pain as compared to allele A.		[ 197]
Tacrolimus	N.A.	Transplant Rejection	Allele G is associated with increased likelihood of transplant rejection when treated with tacrolimus in children with Kidney Transplantation as compared to allele A.		[ 198]
Fentanyl	N.A.	Central Nervous System Disorder	Allele G is not associated with dose of fentanyl in women with Pain, Postoperative as compared to allele A.		[ 199]
Methotrexate	N.A.	Nephrotoxicity	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 200]
Antiepileptics	N.A.	Neurotoxicity Syndromes	Allele G is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.		[ 201]
Celiprolol	N.A.	Cardiotoxicity	Allele G is associated with decreased concentrations of Celiprolol in healthy individuals as compared to allele A.		[ 202]
Tacrolimus	N.A.	Cardiotoxicity	Allele G is not associated with concentrations of tacrolimus as compared to allele A.		[ 164]
Cisplatin	N.A.	Mucositis	Allele G is associated with decreased likelihood of mucositis when treated with cisplatin and doxorubicin in children with Osteosarcoma as compared to allele A.		[ 203]
Doxorubicin	N.A.	Mucositis	Allele G is associated with decreased likelihood of mucositis when treated with cisplatin and doxorubicin in children with Osteosarcoma as compared to allele A.		[ 203]
Tipifarnib	N.A.	Hemorrhage	Allele G is not associated with decreased metabolism of tipifarnib.		[ 204]
Imatinib	N.A.	Hypersensitivity	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A.		[ 205]
Methadone	N.A.	Drug-induced Liver Injury	Allele G is not associated with response to methadone in people with Opioid-Related Disorders as compared to allele A.		[ 206]
Remifentanil	N.A.	Adverse Events	Allele G is not associated with likelihood of adverse events due to remifentanil as compared to allele A.		[ 207]
Tacrolimus	N.A.	Drug Toxicity	Allele G is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to allele A.		[ 165]
Antiepileptics	N.A.	Hyperprolactinemia	Allele G is not associated with resistance to antiepileptics in people with Epilepsy, Temporal Lobe as compared to allele A.		[ 208]
Methadone	N.A.	Hyperprolactinemia	Allele G is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele A.		[ 209]
Pravastatin	N.A.	High On-treatment Platelet Reactivity	Allele G is not associated with metabolism of pravastatin in children with Hyperlipoproteinemia Type II as compared to allele A.		[ 210]
Imatinib	N.A.	Mucositis	Allele G is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A.		[ 211]
Imatinib	N.A.	Drug Toxicity	Allele G is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A.		[ 205]
Imatinib	N.A.	Discontinuation	Allele G is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A.		[ 205]
Carbamazepine	N.A.	Treatment Failure	Allele G is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele A.		[ 161]
Phenobarbital	N.A.	Treatment Failure	Allele G is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele A.		[ 161]
Phenytoin	N.A.	Treatment Failure	Allele G is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele A.		[ 161]
Valproic Acid	N.A.	Treatment Failure	Allele G is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele A.		[ 161]
Cyclophosphamide	N.A.	Peripheral Nervous System Diseases	Allele G is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele A.		[ 212]
Epirubicin	N.A.	Peripheral Nervous System Diseases	Allele G is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele A.		[ 212]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Allele G is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele A.		[ 212]
Propofol	N.A.	Exanthema	Allele G is not associated with response to propofol and remifentanil in children as compared to allele A.		[ 191]
Remifentanil	N.A.	Exanthema	Allele G is not associated with response to propofol and remifentanil in children as compared to allele A.		[ 191]
Lansoprazole	N.A.	Drug-induced Liver Injury	Allele G is associated with increased metabolism of lansoprazole as compared to genotype AA.		[ 213]
Methadone	N.A.	Mucositis	Allele G is not associated with response to methadone in people with Neoplasms and Pain as compared to allele A.		[ 214]
Methotrexate	N.A.	Drug Toxicity	Allele G is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele A.		[ 215]
Methotrexate	N.A.	Nausea	Allele G is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele A.		[ 215]
Fentanyl	N.A.	Neurotoxicity Syndromes	Allele G is not associated with clearance of fentanyl in children as compared to allele A (assigned as normal metabolizer phenotype) .		[ 216]
Efavirenz	N.A.	Neurotoxicity Syndromes	Allele G is not associated with Neurotoxicity Syndromes when treated with efavirenz in people with HIV Infections as compared to allele A.		[ 176]
Buprenorphine	N.A.	Adverse Events	Allele G is not associated with risk of adverse events when treated with buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele A.		[ 70]
Dihydrocodeine	N.A.	Adverse Events	Allele G is not associated with risk of adverse events when treated with buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele A.		[ 70]
Fentanyl	N.A.	Adverse Events	Allele G is not associated with risk of adverse events when treated with buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele A.		[ 70]
Hydromorphone	N.A.	Adverse Events	Allele G is not associated with risk of adverse events when treated with buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele A.		[ 70]
Methadone	N.A.	Adverse Events	Allele G is not associated with risk of adverse events when treated with buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele A.		[ 70]
Oxycodone	N.A.	Adverse Events	Allele G is not associated with risk of adverse events when treated with buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele A.		[ 70]
Piritramide	N.A.	Adverse Events	Allele G is not associated with risk of adverse events when treated with buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele A.		[ 70]
Tilidine	N.A.	Adverse Events	Allele G is not associated with risk of adverse events when treated with buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele A.		[ 70]
Tramadol	N.A.	Adverse Events	Allele G is not associated with risk of adverse events when treated with buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele A.		[ 70]
Morphine	N.A.	Pain	Allele G is not associated with exposure to morphine in healthy individuals as compared to allele A.		[ 218]
Phenytoin	N.A.	Postoperative Nausea And Vomiting	Allele G is not associated with resistance to phenytoin in people with Epilepsy as compared to allele A.		[ 219]
Methadone	N.A.	Infectious Disease	Allele G is not associated with dose of methadone in people with Heroin Dependence as compared to allele A.		[ 220]
Methotrexate	N.A.	Drug Toxicity	Allele G is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 221]
Methadone	N.A.	Pain	Allele G is not associated with severity of Pain when treated with methadone in people with Opioid-Related Disorders as compared to allele A.		[ 222]
Cisplatin	N.A.	Neoplasm Of Esophagus	Allele G is not associated with response to cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to allele A.		[ 167]
Fluorouracil	N.A.	Neoplasm Of Esophagus	Allele G is not associated with response to cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to allele A.		[ 167]
Fluorouracil	N.A.	Colorectal Neoplasms	Allele G is not associated with likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele A.		[ 174]
Fentanyl	N.A.	Pain	Allele G is not associated with dose of fentanyl in women with Pain, Postoperative as compared to allele A.		[ 199]
Fentanyl	N.A.	Pain, Postoperative	Allele G is not associated with dose of fentanyl in women with Pain, Postoperative as compared to allele A.		[ 199]
Opioids	N.A.	Low Back Pain	Allele G is associated with increased likelihood of Nausea due to opioids in people with Low Back Pain as compared to allele A.		[ 197]
Antiepileptics	N.A.	Epilepsies, Partial	Allele G is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.		[ 201]
Antiepileptics	N.A.	Epilepsy	Allele G is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.		[ 201]
Antiepileptics	N.A.	Epilepsy, Idiopathic Generalized	Allele G is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.		[ 201]
Antiepileptics	N.A.	Epilepsies, Partial	Allele G is not associated with resistance to antiepileptics in people with Epilepsy, Temporal Lobe as compared to allele A.		[ 208]
Antiepileptics	N.A.	Epilepsy	Allele G is not associated with resistance to antiepileptics in people with Epilepsy, Temporal Lobe as compared to allele A.		[ 208]
Antiepileptics	N.A.	Epilepsy, Idiopathic Generalized	Allele G is not associated with resistance to antiepileptics in people with Epilepsy, Temporal Lobe as compared to allele A.		[ 208]
Antiepileptics	N.A.	Epilepsies, Partial	Allele G is associated with increased likelihood of non-response when treated with antiepileptics in people with Epilepsy.		[ 183]
Antiepileptics	N.A.	Epilepsy	Allele G is associated with increased likelihood of non-response when treated with antiepileptics in people with Epilepsy.		[ 183]
Antiepileptics	N.A.	Epilepsy, Idiopathic Generalized	Allele G is associated with increased likelihood of non-response when treated with antiepileptics in people with Epilepsy.		[ 183]
Methadone	N.A.	Heroin Dependence	Allele G is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele A.		[ 209]
Methadone	N.A.	Opioid-related Disorders	Allele G is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele A.		[ 209]
Methadone	N.A.	Heroin Dependence	Allele G is not associated with dose of methadone in people with Heroin Dependence as compared to allele A.		[ 220]
Methadone	N.A.	Opioid-related Disorders	Allele G is not associated with dose of methadone in people with Heroin Dependence as compared to allele A.		[ 220]
Methadone	N.A.	Pain	Allele G is not associated with dose of methadone in people with Neoplasms and Pain as compared to allele A.		[ 214]
Simvastatin	N.A.	Hypercholesterolemia	Allele G is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele A.		[ 163]
Simvastatin	N.A.	Myalgia	Allele G is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele A.		[ 163]
Clopidogrel	N.A.	Acute Coronary Syndrome	Allele G is not associated with response to clopidogrel in people with Myocardial Infarction as compared to allele A.		[ 169]
Clopidogrel	N.A.	Myocardial Infarction	Allele G is not associated with response to clopidogrel in people with Myocardial Infarction as compared to allele A.		[ 169]
Clopidogrel	N.A.	Acute Coronary Syndrome	Allele G is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele A.		[ 168]
Clopidogrel	N.A.	Myocardial Infarction	Allele G is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele A.		[ 168]
Lansoprazole	N.A.	Gastroesophageal Reflux	Allele G is associated with increased metabolism of lansoprazole as compared to genotype AA.		[ 213]
Lansoprazole	N.A.	Transplantation	Allele G is associated with increased metabolism of lansoprazole as compared to genotype AA.		[ 213]
Tacrolimus	N.A.	Gastroesophageal Reflux	Allele G is associated with increased metabolism of lansoprazole as compared to genotype AA.		[ 213]
Tacrolimus	N.A.	Transplantation	Allele G is associated with increased metabolism of lansoprazole as compared to genotype AA.		[ 213]
Atorvastatin	N.A.	Coronary Artery Disease	Allele G is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele A.		[ 163]
Atorvastatin	N.A.	Myalgia	Allele G is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele A.		[ 163]
Tramadol	N.A.	Fractures, Bone	Allele G is not associated with response to tramadol in people with Pain, Postoperative as compared to allele A.		[ 223]
Tramadol	N.A.	Pain	Allele G is not associated with response to tramadol in people with Pain, Postoperative as compared to allele A.		[ 223]
Tramadol	N.A.	Pain, Postoperative	Allele G is not associated with response to tramadol in people with Pain, Postoperative as compared to allele A.		[ 223]
Efavirenz	N.A.	HIV Infectious Disease	Allele G is not associated with Neurotoxicity Syndromes when treated with efavirenz in people with HIV Infections as compared to allele A.		[ 176]
Nelfinavir	N.A.	HIV Infectious Disease	Allele G is not associated with Neurotoxicity Syndromes when treated with efavirenz in people with HIV Infections as compared to allele A.		[ 176]
Cyclosporine	N.A.	Transplantation	Allele G is not associated with increased dose of cyclosporine in people with Kidney Transplantation as compared to allele A.		[ 195]
Atazanavir	N.A.	HIV Infectious Disease	Allele G is not associated with risk of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele A.		[ 171]
Ritonavir	N.A.	HIV Infectious Disease	Allele G is not associated with risk of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele A.		[ 171]
Atazanavir	N.A.	HIV Infectious Disease	Allele G is not associated with trough concentration of atazanavir in people with HIV Infections as compared to allele A.		[ 172]
Ritonavir	N.A.	HIV Infectious Disease	Allele G is not associated with trough concentration of atazanavir in people with HIV Infections as compared to allele A.		[ 172]
Atazanavir	N.A.	HIV Infectious Disease	Allele G is not associated with concentrations of atazanavir in people with HIV Infections as compared to allele A.		[ 175]
Ritonavir	N.A.	HIV Infectious Disease	Allele G is not associated with concentrations of atazanavir in people with HIV Infections as compared to allele A.		[ 175]
Atazanavir	N.A.	HIV Infectious Disease	Allele G is not associated with severity of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections as compared to allele A.		[ 170]
Ritonavir	N.A.	HIV Infectious Disease	Allele G is not associated with severity of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections as compared to allele A.		[ 170]
Carbamazepine	N.A.	Epilepsy	Allele G is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele A.		[ 161]
Risperidone	N.A.	Bipolar Disorder	Allele G is not associated with increased metabolism of risperidone in people with Schizophrenia as compared to allele A.		[ 173]
Risperidone	N.A.	Depression	Allele G is not associated with increased metabolism of risperidone in people with Schizophrenia as compared to allele A.		[ 173]
Risperidone	N.A.	Psychotic Disorder	Allele G is not associated with increased metabolism of risperidone in people with Schizophrenia as compared to allele A.		[ 173]
Risperidone	N.A.	Schizophrenia	Allele G is not associated with increased metabolism of risperidone in people with Schizophrenia as compared to allele A.		[ 173]
Risperidone	N.A.	Substance-related Disorders	Allele G is not associated with increased metabolism of risperidone in people with Schizophrenia as compared to allele A.		[ 173]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele G is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 221]
Clopidogrel	N.A.	Platelet Reactivity	Allele G is not associated with response to clopidogrel in people with Myocardial Infarction as compared to allele A.		[ 169]
Clopidogrel	N.A.	Platelet Reactivity	Allele G is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele A.		[ 168]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 200]
Methotrexate	N.A.	Burkitt Lymphoma	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 200]
Methotrexate	N.A.	Lymphoma, T-cell	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 200]
Methotrexate	N.A.	Burkitt Lymphoma	Allele G is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 221]
Methotrexate	N.A.	Lymphoma, T-cell	Allele G is not associated with risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 221]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele G is not associated with risk of adverse events due to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.		[ 80]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele G is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele A.		[ 215]
Methotrexate	N.A.	Juvenile Rheumatoid Arthritis	Allele G is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.		[ 166]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele G is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.		[ 166]
Phenytoin	N.A.	Epilepsy	Allele G is associated with increased likelihood of drug resistance when treated with phenytoin in people with Epilepsy as compared to allele A.		[ 162]
Phenytoin	N.A.	Epilepsy	Allele G is not associated with resistance to phenytoin in people with Epilepsy as compared to allele A.		[ 219]
Tacrolimus	N.A.	Organ Transplantation	Allele G is not associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to allele A.		[ 195]
Tacrolimus	N.A.	Organ Transplantation	Allele G is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to allele A.		[ 165]
Tacrolimus	N.A.	Organ Transplantation	Allele G is not associated with concentrations of tacrolimus as compared to allele A.		[ 164]
Antiepileptics	N.A.	Epilepsy	Irrelevant to the drug resistance in patients (compare with allele A); Irrelevant to the drug response in patients (compare with allele A)		[ 201], [ 208], [ 224], [ 225]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:       441 Drugs in Total
Clopidogrel	Drug Info	Coronary Artery Disease	Correlated with the decreased bleeding events in patients (compare with genotype GG); Correlated with the decreased drug exposure in patients (compare with genotypes AG + GG); Correlated with the decreased drug peak plasma concentration (Cmax) and the total area under the plasma concentration-time curve (AUC) in patients (compare with genotypes GG + AG); Correlated with the decreased drug response in patients (compare with genotypes AG + GG); Correlated with the increase early major adverse cardiovascular events (mACE) risk in patients (compare with genotype GG)		[ 224], [ 225], [ 226], [ 227]
Tacrolimus	Drug Info	Kidney Transplantation	Correlated with the decreased drug clearance in patients (compare with genotypes AG + GG); Correlated with the decreased drug metabolism in patients (compare with genotype GG); Correlated with the increased drug dose in patients (compare with genotype AG)		[ 228], [ 229], [ 230]
Digoxin	Drug Info	Congestive Cardiac Insufficiency; Arrhythmias; Heart Failure	Correlated with the decreased drug metabolism (compare with genotype GG)		[ 231]
Fexofenadine	Drug Info	Healthy Individuals	Correlated with the decreased drug plasma concentration in healthy individuals (compare with genotypes GG + AG)		[ 232]
Fentanyl	Drug Info	Neoplasm	Correlated with the decreased drug response in patients (compare with Genotype AA + AG)		[ 195]
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the decreased drug response in patients (compare with genotypes AG + GG)		[ 234]
Anastrozole	Drug Info	Breast Neoplasm	Correlated with the decreased likelihood of Arthralgia in patients (compare with genotypes AG + GG)		[ 235]
Pantoprazole	Drug Info	Helicobacter Infections	Correlated with the decreased likelihood of Postoperative nausea and Vomiting in patients (compare with genotypes AG + GG); Correlated with the increased drug response in patients (compare with genotypes AG + GG)		[ 236], [ 237]
Sunitinib	Drug Info	Renal Cell Carcinoma	Correlated with the decreased neutropenia risk in patients (compare with genotypes AG + GG)		[ 238]
Methylprednisolone	Drug Info	Kidney Transplantation	Correlated with the decreased osteonecrosis risk in patients (compare with genotypes GG + AG)		[ 228]
Prednisolone	Drug Info	Kidney Transplantation	Correlated with the decreased osteonecrosis risk in patients (compare with genotypes GG + AG)		[ 228]
Clozapine	Drug Info	Schizophrenia	Correlated with the increased agranulocytosis and neutropenia risk in patients (compare with genotypes AG + GG); Correlated with the increased drug plasma concentrations in patients (compare with genotype GG)		[ 239], [ 240]
Vincristine	Drug Info	Lymphoma	Correlated with the increased anemia and thrombocytopenia risk in patients (compare with genotypes AG + GG)		[ 241]
Doxorubicin	Drug Info	Lymphoma	Correlated with the increased anemia and thrombocytopenia risk in patients (compare with genotypes AG + GG)		[ 241]
Prednisolone	Drug Info	Lymphoma	Correlated with the increased anemia and thrombocytopenia risk in patients (compare with genotypes AG + GG)		[ 241]
Methotrexate	Drug Info	Lymphoma	Correlated with the increased anemia and thrombocytopenia risk in patients (compare with genotypes AG + GG); Correlated with the increased drug concentrations in patients (compare with genotype GG); Correlated with the increased toxic liver disease risk in patients (compare with genotype GG)		[ 241], [ 242]
Clopidogrel	Drug Info	Acute Coronary Syndrome	Correlated with the increased cardiovascular death, myocardial infarction, or stroke risk in patients (compare with genotypes GG + AG); Correlated with the increased thrombosis risk in pstients(compare with genotypes AG + GG)		[ 243], [ 244]
Clopidogrel	Drug Info	Myocardial Infarction	Correlated with the increased cardiovascular events risk in patients (compare with genotype GG); Correlated with the increased platelet reactivity in patients (compare with genotypes AG + GG)		[ 245], [ 246]
Nelfinavir	Drug Info	HIV Infection	Correlated with the increased CD4 t cell count in patients (compare with genotype AG + GG)		[ 247]
Tacrolimus	Drug Info	Rheumatoid Arthritis	Correlated with the increased dose-adjusted trough concentrations in patients (compare with genotype GG)		[ 248]
Talinolol	Drug Info	Healthy Individuals	Correlated with the increased drug clearance in healthy individuals (compare with genotypes AG + GG)		[ 249]
Methadone	Drug Info	Opioid-Related Disorders	Correlated with the increased drug clearance in patients (compare with genotypes AG + GG)		[ 250]
Methadone	Drug Info	Heroin Dependence	Correlated with the increased drug dose in patients (compare with genotype GG)		[ 251]
Tramadol	Drug Info	Pain	Correlated with the increased drug exposure (compare with genotype GG)		[ 252]
Morphine	Drug Info	Pain	Correlated with the increased drug metabolism in patients (compare with genotypes AG + GG)		[ 253]
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased drug response in patients (compare with genotypes AG + GG)		[ 254]
Fentanyl	Drug Info	Postoperative Pain	Correlated with the increased likelihood of respiratory insufficiency in patients (compare with Genotype AA + AG)		[ 255]
Morphine	Drug Info	Neoplasm	Correlated with the increased reduction in pain in patients (compare with genotypes AG + GG)		[ 256]
Simvastatin	Drug Info	Coronary Artery Disease	Correlated with the increased reduction in total cholesterol in patients (compare with genotype GG)		[ 257]
Tacrolimus	Drug Info	Liver Transplantation	Irrelevant to the drug concentrations in patients (compare with genotypes AG + GG)		[ 258]
Daunorubicin	Drug Info	Acute Myeloid Leukemia	Irrelevant to the drug response in patients (compare with genotypes AG + GG)		[ 259]
Cytarabine	Drug Info	Acute Myeloid Leukemia	Irrelevant to the drug response in patients (compare with genotypes AG + GG)		[ 259]
Methotrexate	Drug Info	Hematologic Neoplasm	Irrelevant to the neurotoxicity syndromes risk in patients (compare with genotypes AG + GG)		[ 260]
Voriconazole	Drug Info	Healthy Individuals	Correlated with the decreased drug metabolism in healthy individuals (compare with genotype GG)		[ 261]
Granisetron	Drug Info	Nausea; Vomiting	Correlated with the increased drug response in patients (compare with genotypes AG + GG)		[ 262]
Dexrazoxane	Drug Info	Acute Myeloid Leukemia	Irrelevant to the drug response in patients (compare with genotypes AG + GG)		[ 259]
Efavirenz	Drug Info	HIV Infection	Correlated with the decreased drug concentrations in patients (compare with genotypes AG + GG); Correlated with the increased CD4 t cell count in patients (compare with genotype AG + GG); Correlated with the increased CD4 t cell count in patients (compare with genotype GG); Correlated with the increased drug clearance in patients (compare with genotype AG); Correlated with the increased likelihood of drug responses in patients (compare with genotypes GG + Gt); Irrelevant to increased likelihood of drug plasma exposure in patients (compare with genotypes AG + GG)		[ 4], [ 247], [ 263], [ 265]
Daptomycin	Drug Info	Bacterial infections	Correlated with the decreased drug clearance in patients (compare with genotypes AG + GG); Correlated with the increased drug concentrations in patients (compare with genotypes AG + GG)		[ 266]
Nortriptyline	Drug Info	Major Depressive Disorder	Correlated with the increased likelihood of hypotension, orthostatic in patients (compare with genotypes AG + GG)		[ 267]
Palonosetron	Drug Info	Nausea; Vomiting	Irrelevant to the drug response in patients (compare with genotypes AG + GG)		[ 268]
Omeprazole	Drug Info	Helicobacter Infections	Correlated with the decreased likelihood of postoperative nausea and vomiting in patients (compare with genotypes AG + GG); Correlated with the increased drug response in patients (compare with genotypes AG + GG)		[ 236], [ 237]
Rivaroxaban	N.A.	Thromboembolism	Genotype AA is associated with increased risk of Thromboembolism when treated with rivaroxaban in people with Atrial Fibrillation as compared to genotype GG.		[ 269]
Voriconazole	N.A.	Thrombotic Disease	Genotype AA is associated with decreased metabolism of voriconazole in healthy individuals as compared to genotype GG.		[ 261]
Digoxin	N.A.	Sudden Cardiac Death	Genotype AA is associated with increased likelihood of Death, Sudden, Cardiac when treated with digoxin as compared to genotypes AG + GG.		[ 270]
Voriconazole	N.A.	Hemorrhage	Genotype AA is associated with decreased trough concentration of voriconazole in children as compared to genotypes AG + GG.		[ 271]
Anastrozole	N.A.	Arthralgia	Genotype AA is associated with decreased likelihood of Arthralgia when exposed to anastrozole in women with Breast Neoplasms as compared to genotypes AG + GG.		[ 235]
Tacrolimus	N.A.	Arthralgia	Genotype AA is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 272]
Methotrexate	N.A.	Neurotoxicity Syndromes	Genotype AA is not associated with risk of Neurotoxicity Syndromes when treated with methotrexate in children with Hematologic Neoplasms as compared to genotypes AG + GG.		[ 260]
Aripiprazole	N.A.	Platelet Reactivity	Genotype AA is not associated with exposure to aripiprazole or dehydroaripiprazole in healthy individuals as compared to genotypes AG + GG.		[ 273]
Dehydroaripiprazole	N.A.	Platelet Reactivity	Genotype AA is not associated with exposure to aripiprazole or dehydroaripiprazole in healthy individuals as compared to genotypes AG + GG.		[ 273]
Citalopram	N.A.	Adverse Events	Genotype AA is not associated with exposure to citalopram in healthy individuals as compared to genotypes AG + GG.		[ 273]
Olanzapine	N.A.	Adverse Events	Genotype AA is not associated with exposure to olanzapine in healthy individuals as compared to genotypes AG + GG.		[ 273]
Quetiapine	N.A.	Adverse Events	Genotype AA is not associated with exposure to quetiapine in healthy individuals as compared to genotypes AG + GG.		[ 273]
Trazodone	N.A.	Adverse Events	Genotype AA is not associated with exposure to trazodone in healthy individuals as compared to genotypes AG + GG.		[ 273]
Agomelatine	N.A.	Adverse Events	Genotype AA is not associated with exposure to agomelatine in healthy individuals as compared to genotypes AG + GG.		[ 273]
Sertraline	N.A.	Adverse Events	Genotype AA is not associated with exposure to sertraline in healthy individuals as compared to genotypes AG + GG.		[ 273]
Clopidogrel	N.A.	Adverse Events	Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.		[ 245]
Tacrolimus	N.A.	Adverse Events	Genotype AA is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 274]
Tacrolimus	N.A.	Adverse Events	Genotype AA is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 230]
Valganciclovir	N.A.	Neutropenia	Genotype AA is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype GG.		[ 275]
Methadone	N.A.	Adverse Events	Genotype AA is associated with increased concentrations of methadone as compared to genotypes AG + GG.		[ 276]
Hydrochlorothiazide	N.A.	Dizziness	Genotype AA is associated with increased likelihood of Dizziness when treated with hydrochlorothiazide in healthy individuals as compared to genotypes AG + GG.		[ 277]
Warfarin	N.A.	Exanthema	Genotype AA is not associated with decreased dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism or Venous Thrombosis.		[ 278]
Gefitinib	N.A.	Diarrhea	Genotype AA is associated with increased likelihood of Diarrhea when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 279]
Methadone	N.A.	Diarrhea	Genotype AA is not associated with dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.		[ 280]
Antiepileptics	N.A.	Diarrhea	Genotype AA is associated with increased likelihood of drug-resistance when treated with antiepileptics in people with Epilepsy.		[ 281]
Methotrexate	N.A.	Drug Resistance	Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.		[ 234]
Trazodone	N.A.	Prolonged Qtc Interval	Genotype AA is associated with increased likelihood of electrocardiogram qt prolonged when treated with trazodone in healthy individuals as compared to genotypes AG + GG.		[ 282]
Atorvastatin	N.A.	Prolonged Qtc Interval	Genotype AA is associated with increased clinical benefit to atorvastatin in people with Coronary Artery Disease as compared to genotypes AG + GG.		[ 283]
Lamotrigine	N.A.	Prolonged Qtc Interval	Genotype AA are not associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype GG.		[ 284]
Aspirin	N.A.	Thrombotic Disease	Genotype AA is associated with increased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotypes AG + GG.		[ 244]
Clopidogrel	N.A.	Thrombotic Disease	Genotype AA is associated with increased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotypes AG + GG.		[ 244]
Aripiprazole	N.A.	Hyperbilirubinemia	Genotype AA is associated with decreased dose-adjusted trough concentrations of aripiprazole in children as compared to genotypes AG + GG.		[ 285]
Morphine	N.A.	Neutropenia	Genotype AA is associated with increased reduction in pain when treated with morphine in people with Neoplasms as compared to genotypes AG + GG.		[ 256]
Loperamide	N.A.	Neutropenia	Genotype AA is not associated with metabolism of loperamide as compared to genotype GG.		[ 286]
Tacrolimus	N.A.	Adverse Events	Genotype AA is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 228]
Digoxin	N.A.	Adverse Events	Genotype AA is associated with decreased metabolism of digoxin as compared to genotype GG.		[ 231]
Cyclosporine	N.A.	Adverse Events	Genotype AA is associated with increased risk of nephrotoxicity when treated with cyclosporine in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 287]
Docetaxel	N.A.	Peripheral Nervous System Diseases	Genotype AA is associated with increased risk of Peripheral Nervous System Diseases when treated with docetaxel and paclitaxel in women with Breast Neoplasms as compared to genotypes AG + GG.		[ 288]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Genotype AA is associated with increased risk of Peripheral Nervous System Diseases when treated with docetaxel and paclitaxel in women with Breast Neoplasms as compared to genotypes AG + GG.		[ 288]
Clozapine	N.A.	Agranulocytosis	Genotype AA is associated with increased risk of Agranulocytosis and Neutropenia when treated with clozapine as compared to genotypes AG + GG.		[ 239]
Clozapine	N.A.	Neutropenia	Genotype AA is associated with increased risk of Agranulocytosis and Neutropenia when treated with clozapine as compared to genotypes AG + GG.		[ 239]
Digoxin	N.A.	Neutropenia	Genotype AA is associated with decreased clearance of digoxin in healthy individuals as compared to genotypes AG + GG.		[ 289]
Simvastatin	N.A.	Hemorrhage	Genotype AA is associated with increased reduction in total cholesterol when treated with simvastatin as compared to genotype GG.		[ 257]
Atorvastatin	N.A.	Hemorrhage	Genotype AA is associated with increased AUC of atorvastatin in healthy individuals as compared to genotype GG.		[ 290]
Irinotecan	N.A.	Drug Toxicity	Genotype AA is not associated with Drug Toxicity when treated with irinotecan in people with Colonic Neoplasms as compared to genotype GG.		[ 291]
Irinotecan	N.A.	Neutropenia	Genotype AA is not associated with Neutropenia when treated with irinotecan in people with Colonic Neoplasms as compared to genotype GG.		[ 291]
Clozapine	N.A.	Drug-induced Liver Injury	Genotype AA is associated with increased plasma concentrations of clozapine as compared to genotype GG.		[ 240]
Methotrexate	N.A.	Transplant Rejection	Genotype AA is associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 242]
Simvastatin	N.A.	Transplant Rejection	Genotype AA is associated with increased AUC simvastatin acid when treated with simvastatin in healthy individuals as compared to genotype GG.		[ 290]
Tramadol	N.A.	Opioid-related Disorders	Genotype AA is associated with decreased risk of Opioid-Related Disorders due to tramadol as compared to genotypes AG + GG.		[ 88]
Tacrolimus	N.A.	Osteonecrosis	Genotype AA is not associated with dose of tacrolimus in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.		[ 248]
Atazanavir	N.A.	Hyperbilirubinemia	Genotype AA is associated with increased risk of Hyperbilirubinemia when exposed to atazanavir in healthy individuals as compared to genotypes AG + GG.		[ 293]
Clopidogrel	N.A.	Hyperbilirubinemia	Genotype AA is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to genotypes AG + GG.		[ 294]
Opioids	N.A.	Drug Toxicity	Genotype AA is associated with decreased dose of opioids in people with Pain, Postoperative as compared to genotypes AG + GG.		[ 295]
Methotrexate	N.A.	Adverse Events	Genotype AA is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 296]
Tacrolimus	N.A.	Adverse Events	Genotype AA is not associated with concentrations of tacrolimus in children with Kidney Transplantation as compared to genotypes AG + GG.		[ 297]
Tacrolimus	N.A.	Peripheral Nervous System Diseases	Genotype AA is not associated with dose of tacrolimus in children with Kidney Transplantation as compared to genotypes AG + GG.		[ 298]
Methotrexate	N.A.	Peripheral Nervous System Diseases	Genotype AA is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotypes AG + GG.		[ 299]
Granisetron	N.A.	Mucositis	Genotype AA is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AG + GG.		[ 268]
Palonosetron	N.A.	Mucositis	Genotype AA is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AG + GG.		[ 268]
Morphine	N.A.	Vomiting	Genotype AA is associated with increased metabolism of morphine in children as compared to genotypes AG + GG.		[ 253]
Clopidogrel	N.A.	Platelet Aggregation	Genotype AA is not associated with platelet aggregation when treated with clopidogrel as compared to genotypes AG + GG.		[ 226]
Talinolol	N.A.	Adverse Events	Genotype AA is associated with increased clearance of talinolol in healthy individuals as compared to genotypes AG + GG.		[ 249]
Lamotrigine	N.A.	Event-free Survival	Genotype AA is not associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotypes AG + GG.		[ 300]
Efavirenz	N.A.	Event-free Survival	Genotype AA is associated with increased CD4 T cell count when treated with efavirenz in people with HIV Infections as compared to genotype GG.		[ 4]
Efavirenz	N.A.	Event-free Survival	Genotype AA is associated with increased rise in CD4-cell count when treated with efavirenz or nelfinavir in people with HIV Infections as compared to genotypes AG + GG.		[ 247]
Nelfinavir	N.A.	Event-free Survival	Genotype AA is associated with increased rise in CD4-cell count when treated with efavirenz or nelfinavir in people with HIV Infections as compared to genotypes AG + GG.		[ 247]
Carboplatin	N.A.	Event-free Survival	Genotype AA is not associated with increased risk of sensoric neuropathy or neutropenia when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to genotypes AG + GG.		[ 301]
Paclitaxel	N.A.	Event-free Survival	Genotype AA is not associated with increased risk of sensoric neuropathy or neutropenia when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to genotypes AG + GG.		[ 301]
Fexofenadine	N.A.	Event-free Survival	Genotype AA is not associated with plasma concentration of fexofenadine in healthy individuals as compared to genotype GG.		[ 302]
Fexofenadine	N.A.	Event-free Survival	Genotype AA is associated with decreased plasma concentration of fexofenadine in healthy individuals as compared to genotypes AG + GG.		[ 232]
Imatinib	N.A.	Drug Toxicity	Genotype AA is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.		[ 254]
Digoxin	N.A.	Asthenia	Genotype AA is not associated with differences in digoxin absorption after single oral dose of 1 mg digoxin when exposed to digoxin as compared to genotype GG.		[ 303]
Digoxin	N.A.	Asthenia	Genotype AA is associated with decreased duodenal absorption of digoxin after direct delivery to the surface of the duodenum by endoscope when assayed with digoxin as compared to genotype GG.		[ 304]
Clopidogrel	N.A.	Asthenia	Genotype AA is associated with increased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AG + GG.		[ 243]
Clopidogrel	N.A.	Coronary Restenosis	Genotype AA is associated with increased likelihood of Coronary Restenosis when treated with clopidogrel in people with Peripheral Vascular Diseases as compared to genotypes AG + GG.		[ 305]
Trazodone	N.A.	Coronary Restenosis	Genotype AA is associated with increased clearance of trazodone in healthy individuals as compared to genotypes AG + GG.		[ 282]
Clopidogrel	N.A.	Drug Resistance	Genotype AA is associated with increased likelihood of Drug Resistance when treated with clopidogrel in people with Stroke as compared to genotypes AG + GG.		[ 306]
Anthracyclines And Related Substances	N.A.	Death	Genotype AA is associated with increased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to genotypes AG + GG.		[ 307]
Taxanes	N.A.	Death	Genotype AA is associated with increased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to genotypes AG + GG.		[ 307]
Omeprazole	N.A.	Death	Genotype AA is associated with increased response to omeprazole or pantoprazole in people with Helicobacter Infections as compared to genotypes AG + GG.		[ 237]
Pantoprazole	N.A.	Death	Genotype AA is associated with increased response to omeprazole or pantoprazole in people with Helicobacter Infections as compared to genotypes AG + GG.		[ 237]
Fentanyl	N.A.	Diarrhea	Genotype AA is associated with decreased response to fentanyl in people with Neoplasms and Pain as compared to genotypes AG + GG.		[ 195]
Tacrolimus	N.A.	Neutropenia	Genotype AA is not associated with concentrations of tacrolimus in children with liver transplantation.		[ 258]
Tacrolimus	N.A.	Adverse Events	Genotype AA is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype AG.		[ 229]
Antibiotics	N.A.	Adverse Events	Genotype AA is associated with decreased clinical benefit to Antibiotics and esomeprazole in children with Helicobacter Infections as compared to genotypes AG + GG.		[ 308]
Esomeprazole	N.A.	Adverse Events	Genotype AA is associated with decreased clinical benefit to Antibiotics and esomeprazole in children with Helicobacter Infections as compared to genotypes AG + GG.		[ 308]
Cytarabine	N.A.	Adverse Events	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.		[ 259]
Daunorubicin	N.A.	Adverse Events	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.		[ 259]
Dexrazoxane	N.A.	Adverse Events	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.		[ 259]
Efavirenz	N.A.	Central Nervous System Disorder	Genotype AA are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.		[ 309]
Pravastatin	N.A.	Central Nervous System Disorder	Genotype AA is not associated with increased AUC0-12 when exposed to pravastatin in healthy individuals as compared to genotype GG.		[ 310]
Sunitinib	N.A.	Neutropenia	Genotype AA is associated with decreased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.		[ 238]
Methadone	N.A.	Congenital Heart Defects	Genotype AA is not associated with concentrations of methadone as compared to genotypes AG + GG.		[ 311]
Clopidogrel	N.A.	Neurotoxicity Syndromes	Genotype AA is associated with decreased response to clopidogrel as compared to genotypes AG + GG.		[ 227]
Cyclosporine	N.A.	Gingival Overgrowth	Genotype AA is associated with increased likelihood of Gingival Overgrowth when treated with cyclosporine in people with heart transplantation, Kidney Transplantation, liver transplantation or Transplantation as compared to genotypes AG + GG.		[ 312]
Quetiapine	N.A.	Gingival Overgrowth	Genotype AA is not associated with concentrations of quetiapine as compared to genotypes AG + GG.		[ 311]
Sunitinib	N.A.	Gingival Overgrowth	Genotype AA is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.		[ 238]
Opioids	N.A.	Nausea	Genotype AA is associated with decreased dose of opioids in people with Neoplasms and Pain as compared to genotypes AG + GG.		[ 313]
Efavirenz	N.A.	Renal Transplant Failure	Genotype AA is associated with increased clearance of efavirenz in people with HIV Infections as compared to genotype AG.		[ 265]
Daptomycin	N.A.	Renal Transplant Failure	Genotype AA is associated with increased concentrations of daptomycin as compared to genotypes AG + GG.		[ 266]
Fentanyl	N.A.	Hypoventilation	Genotype AA is associated with increased likelihood of Hypoventilation due to fentanyl in people with Pain, Postoperative as compared to genotypes AG + GG.		[ 255]
Tacrolimus	N.A.	Hypersensitivity	Genotype AA is associated with increased success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to genotypes AG + GG.		[ 314]
Axitinib	N.A.	Hypersensitivity	Genotype AA is not associated with metabolism of axitinib in healthy individuals as compared to genotypes AG + GG.		[ 315]
Tacrolimus	N.A.	Hypersensitivity	Genotype AA is not associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 316]
Topiramate	N.A.	Hypersensitivity	Genotype AA is associated with increased response to topiramate in people with Migraine without Aura or Migraine with Aura as compared to genotypes AG + GG.		[ 114]
Doxorubicin	N.A.	Transplant Rejection	Genotype AA is associated with decreased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 241]
Methotrexate	N.A.	Transplant Rejection	Genotype AA is associated with decreased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 241]
Prednisolone	N.A.	Transplant Rejection	Genotype AA is associated with decreased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 241]
Vincristine	N.A.	Transplant Rejection	Genotype AA is associated with decreased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 241]
Tramadol	N.A.	Cholelithiasis	Genotype AA is associated with increased exposure to tramadol as compared to genotype GG.		[ 252]
Olanzapine	N.A.	Peripheral Nervous System Diseases	Genotype AA is associated with increased social and clinical needs when treated with olanzapine in people with Psychotic Disorders as compared to allele G.		[ 122]
Nortriptyline	N.A.	Orthostatic Hypotension	Genotype AA is associated with increased likelihood of Hypotension, Orthostatic when treated with nortriptyline in people with Depressive Disorder, Major as compared to genotypes AG + GG.		[ 267]
Tacrolimus	N.A.	Nephrotoxicity	Genotype AA is not associated with nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 319]
Erlotinib	N.A.	Drug Toxicity	Genotype AA is associated with increased likelihood of Drug Toxicity when treated with erlotinib in people with Carcinoma, Non-Small-Cell Lung.		[ 320]
Doxorubicin	N.A.	Drug Toxicity	Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype GG.		[ 321]
Digoxin	N.A.	Drug Toxicity	Genotype AA is associated with increased clearance of digoxin in healthy individuals as compared to genotype GG.		[ 322]
Risperidone	N.A.	Hyperprolactinemia	Genotype AA is associated with increased severity of Hyperprolactinemia when treated with risperidone in women with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to genotypes AG + GG.		[ 323]
Clopidogrel	N.A.	High On-treatment Platelet Reactivity	Genotype AA is associated with decreased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AG + GG.		[ 324]
Clopidogrel	N.A.	High On-treatment Platelet Reactivity	Genotype AA is associated with decreased exposure to clopidogrel as compared to genotypes AG + GG.		[ 226]
Clopidogrel	N.A.	Drug Toxicity	Genotype AA is associated with decreased bleeding events when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.		[ 225]
Doxorubicin	N.A.	Anemia	Genotype AA is associated with increased risk of Anemia and Thrombocytopenia when treated with doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 241]
Doxorubicin	N.A.	Thrombocytopenia	Genotype AA is associated with increased risk of Anemia and Thrombocytopenia when treated with doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 241]
Methotrexate	N.A.	Anemia	Genotype AA is associated with increased risk of Anemia and Thrombocytopenia when treated with doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 241]
Methotrexate	N.A.	Thrombocytopenia	Genotype AA is associated with increased risk of Anemia and Thrombocytopenia when treated with doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 241]
Prednisolone	N.A.	Anemia	Genotype AA is associated with increased risk of Anemia and Thrombocytopenia when treated with doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 241]
Prednisolone	N.A.	Thrombocytopenia	Genotype AA is associated with increased risk of Anemia and Thrombocytopenia when treated with doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 241]
Vincristine	N.A.	Anemia	Genotype AA is associated with increased risk of Anemia and Thrombocytopenia when treated with doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 241]
Vincristine	N.A.	Thrombocytopenia	Genotype AA is associated with increased risk of Anemia and Thrombocytopenia when treated with doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 241]
Docetaxel	N.A.	Neutropenia	Genotype AA is associated with increased likelihood of Neutropenia when treated with docetaxel as compared to genotypes AG + GG.		[ 325]
Tacrolimus	N.A.	Kidney Disorder	Genotype AA is not associated with Kidney Diseases when treated with tacrolimus in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.		[ 248]
Antivirals For Treatment Of HIV Infections, Combinations	N.A.	Drug-induced Liver Injury	Genotype AA is associated with increased risk of Drug-induced liver injury when treated with Antivirals for treatment of HIV infections, combinations and Drugs For Treatment Of Tuberculosis in people with HIV and tuberculosis co-infection as compared to genotype GG.		[ 326]
Drugs For Treatment Of Tuberculosis	N.A.	Drug-induced Liver Injury	Genotype AA is associated with increased risk of Drug-induced liver injury when treated with Antivirals for treatment of HIV infections, combinations and Drugs For Treatment Of Tuberculosis in people with HIV and tuberculosis co-infection as compared to genotype GG.		[ 326]
Paclitaxel	N.A.	Neutropenia	Genotype AA is associated with increased risk of Neutropenia when treated with paclitaxel in people with Neoplasms as compared to genotypes AG + GG.		[ 327]
Ritonavir	N.A.	Peripheral Nervous System Diseases	Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AG + GG.		[ 293]
Clopidogrel	N.A.	Opioid-related Disorders	Genotype AA is associated with decreased peak plasma concentration (Cmax) and the total area under the plasma concentration-time curve (AUC) of clopidogrel and its active metabolite after a single oral loading dose of 300 or 600 mg of clopidogrel in people with Coronary Artery Disease as compared to genotypes AG + GG.		[ 224]
Antiepileptics	N.A.	Opioid-related Disorders	Genotype AA is associated with increased clinical benefit to antiepileptics in children with Epilepsy as compared to genotypes AG + GG.		[ 328]
Azithromycin	N.A.	Opioid-related Disorders	Genotype AA is associated with decreased concentrations of azithromycin in healthy individuals as compared to genotype GG.		[ 329]
Atorvastatin	N.A.	Statin-related Myopathy	Genotype AA is associated with increased likelihood of statin-related myopathy when exposed to atorvastatin as compared to genotypes AG + GG.		[ 330]
Atazanavir	N.A.	Transplant Rejection	Genotype AA is associated with increased clearance of atazanavir in healthy individuals as compared to genotypes AG + GG.		[ 293]
Vemurafenib	N.A.	Drug Toxicity	Genotype AA is associated with increased likelihood of Drug Toxicity when treated with vemurafenib in people with Melanoma as compared to genotypes AG + GG.		[ 331]
Oxycodone	N.A.	Cns Depression	Genotype AA is not associated with risk of CNS depression and Infant when treated with oxycodone in women with Lactation as compared to genotype GG.		[ 332]
Oxycodone	N.A.	Infant	Genotype AA is not associated with risk of CNS depression and Infant when treated with oxycodone in women with Lactation as compared to genotype GG.		[ 332]
Edoxaban	N.A.	Drug-induced Liver Injury	Genotype AA is not associated with exposure to edoxaban in healthy individuals as compared to genotypes AG + GG.		[ 333]
Granisetron	N.A.	Mucositis	Genotype AA is associated with increased response to granisetron in people with Nausea and Vomiting as compared to genotypes AG + GG.		[ 262]
Palonosetron	N.A.	Mucositis	Genotype AA is not associated with response to palonosetron in people with Nausea and Vomiting as compared to genotypes AG + GG.		[ 262]
Efavirenz	N.A.	Mucositis	Genotype AA is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.		[ 263]
Clopidogrel	N.A.	Platelet Reactivity	Genotype AA is associated with increased platelet reactivity when treated with clopidogrel in people with Myocardial Infarction as compared to genotypes AG + GG.		[ 246]
Fentanyl	N.A.	Dose Reduction	Genotype AA is associated with decreased dose of fentanyl in children as compared to genotypes AG + GG.		[ 334]
Erlotinib	N.A.	Dyspnea	Genotype AA is associated with decreased clearance of erlotinib in people with Carcinoma, Non-Small-Cell Lung.		[ 320]
Methotrexate	N.A.	Toxic Liver Disease	Genotype AA is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Acute lymphoblastic leukemia as compared to genotype GG.		[ 242]
Methotrexate	N.A.	Leukopenia	Genotype AA is associated with increased likelihood of Leukopenia, Neutropenia or mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 335]
Methotrexate	N.A.	Neutropenia	Genotype AA is associated with increased likelihood of Leukopenia, Neutropenia or mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 335]
Methotrexate	N.A.	Mucositis	Genotype AA is associated with increased likelihood of Leukopenia, Neutropenia or mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 335]
Crizotinib	N.A.	Mucositis	Genotype AA is associated with increased exposure to crizotinib in people with.		[ 336]
Hmg Coa Reductase Inhibitors	N.A.	Elevated Circulating Creatine Kinase Concentration	Genotype AA is associated with increased likelihood of Elevated circulating creatine kinase concentration when treated with hmg coa reductase inhibitors as compared to genotypes AG + GG.		[ 337]
Antiepileptics	N.A.	Drug Toxicity	Genotype AA is associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.		[ 338]
Ondansetron	N.A.	Postoperative Nausea And Vomiting	Genotype AA is associated with decreased likelihood of Postoperative Nausea and Vomiting when treated with ondansetron as compared to genotypes AG + GG.		[ 236]
Methadone	N.A.	Postoperative Nausea And Vomiting	Genotype AA is associated with increased clearance of methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.		[ 250]
Methadone	N.A.	Pain	Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.		[ 251]
Carbamazepine	N.A.	Pain	Genotype AA is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes AG + GG.		[ 149]
Methylprednisolone	N.A.	Adverse Events	Genotype AA is associated with decreased risk of Osteonecrosis when treated with methylprednisolone and prednisolone in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 228]
Prednisolone	N.A.	Adverse Events	Genotype AA is associated with decreased risk of Osteonecrosis when treated with methylprednisolone and prednisolone in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 228]
Nelfinavir	N.A.	Adverse Events	Genotype AA is not associated with increased plasma exposure of nelfinavir in people with HIV Infections as compared to genotypes AG + GG.		[ 4]
Tacrolimus	N.A.	Chronic Kidney Failure	Genotype AA is not associated with risk of Kidney Failure, Chronic when treated with tacrolimus in people with liver transplantation as compared to genotypes AG + GG.		[ 340]
Apixaban	N.A.	Hemorrhage	Genotype AA is associated with increased risk of Hemorrhage when treated with apixaban or rivaroxaban in people with Atrial Fibrillation as compared to genotypes AG + GG.		[ 341]
Rivaroxaban	N.A.	Hemorrhage	Genotype AA is associated with increased risk of Hemorrhage when treated with apixaban or rivaroxaban in people with Atrial Fibrillation as compared to genotypes AG + GG.		[ 341]
Nevirapine	N.A.	Adverse Events	Genotype AA is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotypes AG + GG.		[ 342]
Bleomycin	N.A.	Vomiting	Genotype AA is associated with increased risk of Vomiting due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes AG + GG.		[ 155]
Cisplatin	N.A.	Vomiting	Genotype AA is associated with increased risk of Vomiting due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes AG + GG.		[ 155]
Etoposide	N.A.	Vomiting	Genotype AA is associated with increased risk of Vomiting due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes AG + GG.		[ 155]
Cisplatin	N.A.	Neoplasm Of Esophagus	Patients with the AA genotype may have a decreased risk of lymph node metastases and increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.		[ 344]
Fluorouracil	N.A.	Neoplasm Of Esophagus	Patients with the AA genotype may have a decreased risk of lymph node metastases and increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.		[ 344]
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with AA genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.		[ 345]
Rhodamine 123	N.A.	Colorectal Neoplasms	Genotype AA may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported.		[ 346]
Fentanyl	N.A.	Pain	Genotype AA is associated with decreased dose of fentanyl in children as compared to genotypes AG + GG.		[ 334]
Fentanyl	N.A.	Pain, Postoperative	Genotype AA is associated with decreased dose of fentanyl in children as compared to genotypes AG + GG.		[ 334]
Ondansetron	N.A.	Vomiting	Genotype AA is associated with decreased likelihood of Postoperative Nausea and Vomiting when treated with ondansetron as compared to genotypes AG + GG.		[ 236]
Nevirapine	N.A.	HIV Infectious Disease	Patients with the rs1045642 AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment.		[ 52]
Nevirapine	N.A.	Toxic Liver Disease	Patients with the rs1045642 AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment.		[ 52]
Opioids	N.A.	Low Back Pain	Patients with the rs1045642 AA genotype may be less likely to experience nausea when treated with opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of experiencing nausea when treated with opioids.		[ 196]
Antiepileptics	N.A.	Epilepsies, Partial	Genotype AA is associated with increased likelihood of drug-resistance when treated with antiepileptics in people with Epilepsy.		[ 281]
Antiepileptics	N.A.	Epilepsy	Genotype AA is associated with increased likelihood of drug-resistance when treated with antiepileptics in people with Epilepsy.		[ 281]
Antiepileptics	N.A.	Epilepsy, Idiopathic Generalized	Genotype AA is associated with increased likelihood of drug-resistance when treated with antiepileptics in people with Epilepsy.		[ 281]
Antiepileptics	N.A.	Epilepsies, Partial	Genotype AA is associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.		[ 338]
Antiepileptics	N.A.	Epilepsy	Genotype AA is associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.		[ 338]
Antiepileptics	N.A.	Epilepsy, Idiopathic Generalized	Genotype AA is associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.		[ 338]
Antiepileptics	N.A.	Epilepsies, Partial	The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics.		[ 200]
Antiepileptics	N.A.	Epilepsy	The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics.		[ 200]
Antiepileptics	N.A.	Epilepsy, Idiopathic Generalized	The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics.		[ 200]
Codeine	N.A.	HIV Infectious Disease	Patients with the AA genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to codeine.		[ 14]
Methadone	N.A.	Heroin Dependence	Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.		[ 251]
Methadone	N.A.	Opioid-related Disorders	Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.		[ 251]
Methadone	N.A.	Heroin Dependence	Genotype AA is not associated with dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.		[ 280]
Methadone	N.A.	Opioid-related Disorders	Genotype AA is not associated with dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.		[ 280]
Oxycodone	N.A.	Pain	Patients with the AA genotype may have decreased oxycodone dose requirements as compared to patients with the AG or GG genotypes. However, another study did not find an association between this variant and oxycodone dosing. Other genetic and clinical factors may also affect a patient's oxycodone dose requirements.		[ 351]
Methadone	N.A.	Pain	Patients with the rs1045642 AA genotype and who are receiving methadone for analgesia may required a decreased dose as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone dose requirements for analgesia.		[ 70]
Tamoxifen	N.A.	Breast Neoplasms	Women with the AA genotype and breast cancer may have a decreased chance of disease recurrence when treated with tamoxifen as compared to patients with the AG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.		[ 353]
Silibinin	N.A.	Narcolepsy	People with genotype AA may have decreased exposure to silibinin compared to people with genotypes AG or GG. Other clinical and genetic factors may affect a person's exposure to silibinin.		[ 354]
Antivirals For Treatment Of HIV Infections, Combinations	N.A.	HIV Infectious Disease	Genotype AA is associated with increased risk of Drug-induced liver injury when treated with Antivirals for treatment of HIV infections, combinations and Drugs For Treatment Of Tuberculosis in people with HIV and tuberculosis co-infection as compared to genotype GG.		[ 326]
Antivirals For Treatment Of HIV Infections, Combinations	N.A.	Tuberculosis	Genotype AA is associated with increased risk of Drug-induced liver injury when treated with Antivirals for treatment of HIV infections, combinations and Drugs For Treatment Of Tuberculosis in people with HIV and tuberculosis co-infection as compared to genotype GG.		[ 326]
Drugs For Treatment Of Tuberculosis	N.A.	HIV Infectious Disease	Genotype AA is associated with increased risk of Drug-induced liver injury when treated with Antivirals for treatment of HIV infections, combinations and Drugs For Treatment Of Tuberculosis in people with HIV and tuberculosis co-infection as compared to genotype GG.		[ 326]
Drugs For Treatment Of Tuberculosis	N.A.	Tuberculosis	Genotype AA is associated with increased risk of Drug-induced liver injury when treated with Antivirals for treatment of HIV infections, combinations and Drugs For Treatment Of Tuberculosis in people with HIV and tuberculosis co-infection as compared to genotype GG.		[ 326]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Genotype AA is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.		[ 254]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the AA genotype and chronic myeloid leukemia may have a decreased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the GG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response.		[ 355]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.		[ 3]
Simvastatin	N.A.	Myalgia	Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.		[ 3]
Clopidogrel	N.A.	Acute Coronary Syndrome	Genotype AA is associated with increased risk of early major adverse cardiovascular events (MACE) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.		[ 225]
Clopidogrel	N.A.	Myocardial Infarction	Genotype AA is associated with increased risk of early major adverse cardiovascular events (MACE) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.		[ 225]
Clopidogrel	N.A.	Acute Coronary Syndrome	Genotype AA is associated with increased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AG + GG.		[ 243]
Clopidogrel	N.A.	Myocardial Infarction	Genotype AA is associated with increased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AG + GG.		[ 243]
Clopidogrel	N.A.	Acute Coronary Syndrome	Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.		[ 245]
Clopidogrel	N.A.	Myocardial Infarction	Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.		[ 245]
Clopidogrel	N.A.	Acute Coronary Syndrome	Genotype AA is associated with decreased peak plasma concentration (Cmax) and the total area under the plasma concentration-time curve (AUC) of clopidogrel and its active metabolite after a single oral loading dose of 300 or 600 mg of clopidogrel in people with Coronary Artery Disease as compared to genotypes AG + GG.		[ 224]
Clopidogrel	N.A.	Myocardial Infarction	Genotype AA is associated with decreased peak plasma concentration (Cmax) and the total area under the plasma concentration-time curve (AUC) of clopidogrel and its active metabolite after a single oral loading dose of 300 or 600 mg of clopidogrel in people with Coronary Artery Disease as compared to genotypes AG + GG.		[ 224]
Clopidogrel	N.A.	Acute Coronary Syndrome	Genotype AA is associated with decreased exposure to clopidogrel as compared to genotypes AG + GG.		[ 226]
Clopidogrel	N.A.	Myocardial Infarction	Genotype AA is associated with decreased exposure to clopidogrel as compared to genotypes AG + GG.		[ 226]
Clopidogrel	N.A.	Acute Coronary Syndrome	Genotype AA is associated with increased platelet reactivity when treated with clopidogrel in people with Myocardial Infarction as compared to genotypes AG + GG.		[ 246]
Clopidogrel	N.A.	Myocardial Infarction	Genotype AA is associated with increased platelet reactivity when treated with clopidogrel in people with Myocardial Infarction as compared to genotypes AG + GG.		[ 246]
Clopidogrel	N.A.	Acute Coronary Syndrome	Genotype AA is associated with decreased response to clopidogrel as compared to genotypes AG + GG.		[ 227]
Clopidogrel	N.A.	Myocardial Infarction	Genotype AA is associated with decreased response to clopidogrel as compared to genotypes AG + GG.		[ 227]
Clopidogrel	N.A.	Acute Coronary Syndrome	Genotype AA is associated with increased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotypes AG + GG.		[ 244]
Clopidogrel	N.A.	Myocardial Infarction	Genotype AA is associated with increased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotypes AG + GG.		[ 244]
Clopidogrel	N.A.	Acute Coronary Syndrome	People with AA genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG or AG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.		[ 42]
Clopidogrel	N.A.	Myocardial Infarction	People with AA genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG or AG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.		[ 42]
Etoposide	N.A.	Acute Lymphoblastic Leukemia	Patients with the AA genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have decreased metabolism of etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.		[ 358]
Tacrolimus	N.A.	Ulcerative Colitis	Genotype AA is associated with increased success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to genotypes AG + GG.		[ 314]
Modafinil	N.A.	Narcolepsy	Patients with genotype AA and narcolepsy may have decreased response to modafinil compared to patients with genotype AG. Other clinical and genetic factors may affect a patient's response to modafinil.		[ 359]
Sorafenib	N.A.	Hypertension	Patients with the AA genotype may have increased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to sorafenib.		[ 360]
Sorafenib	N.A.	Renal Cell Carcinoma	Patients with the AA genotype may have increased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to sorafenib.		[ 360]
Lansoprazole	N.A.	Gastroesophageal Reflux	Patients with the AA genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have decreased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence lansoprazole clearance.		[ 212]
Lansoprazole	N.A.	Transplantation	Patients with the AA genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have decreased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence lansoprazole clearance.		[ 212]
Tacrolimus	N.A.	Gastroesophageal Reflux	Patients with the AA genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have decreased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence lansoprazole clearance.		[ 212]
Tacrolimus	N.A.	Transplantation	Patients with the AA genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have decreased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence lansoprazole clearance.		[ 212]
Rivaroxaban	N.A.	Transplantation	People with the AA genotype may have increased exposure to rivaroxaban compared to people with the GG genotype when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.		[ 362]
Methadone	N.A.	Opioid-related Disorders	Genotype AA is associated with increased clearance of methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.		[ 250]
Methadone	N.A.	Opioid-related Disorders	Genotype AA is not associated with concentrations of methadone as compared to genotypes AG + GG.		[ 311]
Methadone	N.A.	Opioid-related Disorders	Genotype AA is associated with increased concentrations of methadone as compared to genotypes AG + GG.		[ 276]
Olanzapine	N.A.	Psychotic Disorder	Genotype AA is associated with increased social and clinical needs when treated with olanzapine in people with Psychotic Disorders as compared to allele G.		[ 122]
Everolimus	N.A.	Breast Neoplasms	Patients with the AA genotype and breast cancer who are treated with everolimus may have increased likelihood of Mucositis as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.		[ 19]
Everolimus	N.A.	Mucositis	Patients with the AA genotype and breast cancer who are treated with everolimus may have increased likelihood of Mucositis as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.		[ 19]
Sirolimus	N.A.	Kidney Transplantation	Patients with the AA genotype who underwent kidney transplantation may have increased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.		[ 364]
Anthracyclines And Related Substances	N.A.	Breast Neoplasms	Genotype AA is associated with increased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to genotypes AG + GG.		[ 307]
Taxanes	N.A.	Breast Neoplasms	Genotype AA is associated with increased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to genotypes AG + GG.		[ 307]
Phenobarbital	N.A.	Epilepsy	Patients with genotype AA may have decreased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to phenobarbital.		[ 365]
Carbamazepine	N.A.	Epilepsy	Patients with the AA genotype and epilepsy may need a decreased dose carbamazepine as compared to patients with the AG genotype. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence dose requirements and concentrations of carbamazepine.		[ 159]
Atorvastatin	N.A.	Coronary Artery Disease	Patients with the AA genotype and Coronary Artery Disease who are treated with atorvastatin may have a higher likelihood of developing myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.		[ 163]
Atorvastatin	N.A.	Myalgia	Patients with the AA genotype and Coronary Artery Disease who are treated with atorvastatin may have a higher likelihood of developing myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.		[ 163]
Risperidone	N.A.	Schizophrenia	Patients with the AA genotype and schizophrenia may have a longer QTc interval when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.		[ 368]
Oxaliplatin	N.A.	Colorectal Neoplasms	Patients with the AA genotype and colorectal cancer may have a shorter period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 344]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the AA genotype who are undergoing kidney transplantation and are treated with tacrolimus may have decreased risk of experiencing transplant rejection as compared to patients with the AG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection.		[ 369]
Tramadol	N.A.	Fractures, Bone	Patients with the rs1045642 AA genotype may have an increased analgesic response to tramadol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Tramadol	N.A.	Pain	Patients with the rs1045642 AA genotype may have an increased analgesic response to tramadol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Tramadol	N.A.	Pain, Postoperative	Patients with the rs1045642 AA genotype may have an increased analgesic response to tramadol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Efavirenz	N.A.	HIV Infectious Disease	Genotype AA is associated with increased likelihood of favorable virologic responses when treated with efavirenz in people with HIV as compared to genotypes GG + GT.		[ 4]
Nelfinavir	N.A.	HIV Infectious Disease	Genotype AA is associated with increased likelihood of favorable virologic responses when treated with efavirenz in people with HIV as compared to genotypes GG + GT.		[ 4]
Efavirenz	N.A.	HIV Infectious Disease	Genotype AA is associated with increased rise in CD4-cell count when treated with efavirenz or nelfinavir in people with HIV Infections as compared to genotypes AG + GG.		[ 247]
Nelfinavir	N.A.	HIV Infectious Disease	Genotype AA is associated with increased rise in CD4-cell count when treated with efavirenz or nelfinavir in people with HIV Infections as compared to genotypes AG + GG.		[ 247]
Methylprednisolone	N.A.	Kidney Transplantation	Genotype AA is associated with decreased risk of Osteonecrosis when treated with methylprednisolone and prednisolone in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 228]
Prednisolone	N.A.	Kidney Transplantation	Genotype AA is associated with decreased risk of Osteonecrosis when treated with methylprednisolone and prednisolone in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 228]
Cyclosporine	N.A.	Transplantation	Patients with genotype AA may have increased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine.		[ 371]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the AA genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		[ 372]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the AA genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		[ 372]
Fluorouracil	N.A.	Breast Neoplasms	Patients with the AA genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		[ 372]
Bleomycin	N.A.	Testicular Neoplasms	Genotype AA is associated with increased risk of Vomiting due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes AG + GG.		[ 155]
Cisplatin	N.A.	Testicular Neoplasms	Genotype AA is associated with increased risk of Vomiting due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes AG + GG.		[ 155]
Etoposide	N.A.	Testicular Neoplasms	Genotype AA is associated with increased risk of Vomiting due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes AG + GG.		[ 155]
Phenytoin	N.A.	Glioma	Patients with genotype AA may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.		[ 21]
Dexamethasone	N.A.	Multiple Myeloma	Patients with the AA genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.		[ 374]
Doxorubicin	N.A.	Multiple Myeloma	Patients with the AA genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.		[ 374]
Vincristine	N.A.	Multiple Myeloma	Patients with the AA genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.		[ 374]
Dicloxacillin	N.A.	Multiple Myeloma	Genotype AA may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.		[ 375]
Capecitabine	N.A.	Neoplasms	Patients with AA genotype may have decreased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype GG. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.		[ 376]
Tacrolimus	N.A.	Kidney Transplantation	Patients who receive a kidney with the AA genotype may have decreased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the AG or GG genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR.		[ 377]
Prednisone	N.A.	Organ Transplantation	Pediatric patients with the AA genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.		[ 378]
Prednisone	N.A.	Transplantation	Pediatric patients with the AA genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.		[ 378]
Tacrolimus	N.A.	Organ Transplantation	Pediatric patients with the AA genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.		[ 378]
Tacrolimus	N.A.	Transplantation	Pediatric patients with the AA genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.		[ 378]
Fentanyl	N.A.	Pain	Genotype AA is associated with decreased response to fentanyl in people with Neoplasms and Pain as compared to genotypes AG + GG.		[ 195]
Pantoprazole	N.A.	Helicobacter Infections	Genotype AA is associated with increased response to omeprazole or pantoprazole in people with Helicobacter Infections as compared to genotypes AG + GG.		[ 237]
Oseltamivir	N.A.	Helicobacter Infections	Patients with the rs1045642 AA genotype and acute respiratory diseases and suspected influenza infection may have decreased risk of side effects when treated with oseltamivir as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of oseltamivir side effects.		[ 379]
Venlafaxine	N.A.	Depressive Disorder	Patients with genotype AA and depressive disorder may have decreased response to venlafaxine compared to patients with genotype GG. Patients with AA genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.		[ 380]
Venlafaxine	N.A.	Narcolepsy	Patients with genotype AA and depressive disorder may have decreased response to venlafaxine compared to patients with genotype GG. Patients with AA genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.		[ 380]
Selective Serotonin Reuptake Inhibitors	N.A.	Depressive Disorder	Patients with the AA genotype and depressive disorder may have decreased response to serotonin reuptake inhibitors compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.		[ 380]
Granisetron	N.A.	Neoplasms	Genotype AA is associated with increased response to granisetron in people with Nausea and Vomiting as compared to genotypes AG + GG.		[ 262]
Granisetron	N.A.	Neoplasms	Genotype AA is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AG + GG.		[ 268]
Atazanavir	N.A.	HIV Infectious Disease	Patients with the AA genotype and HIV may have decreased concentrations of atazanavir as compared to patients with the GG genotypes, and may require dose alteration, although this is contradicted in most studies. There is no evidence that the AA genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.		[ 102]
Ritonavir	N.A.	HIV Infectious Disease	Patients with the AA genotype and HIV may have decreased concentrations of atazanavir as compared to patients with the GG genotypes, and may require dose alteration, although this is contradicted in most studies. There is no evidence that the AA genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.		[ 102]
Agomelatine	N.A.	Depressive Disorder	Patients with the AA genotype and depressive disorder may have a decreased response to agomelatine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to agomelatine.		[ 380]
Sunitinib	N.A.	Renal Cell Carcinoma	Genotype AA is associated with decreased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.		[ 238]
Sunitinib	N.A.	Renal Cell Carcinoma	Patients with the AA genotype and renal cell carcinoma may have a lower risk for adverse effects when treated with sunitinib as compared to patients with the GG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities.		[ 41]
Rivaroxaban	N.A.	Renal Cell Carcinoma	Patients with the rs1045642 AA genotype may have decreased risk of Thromboembolism when treated with rivaroxaban as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to rivaroxaban.		[ 383]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the AA genotype who are undergoing kidney transplantation may have a decreased risk of hypokalemia when treated with tacrolimus as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.		[ 32]
Isoniazid	N.A.	Tuberculosis	Genotype AA is associated with increased risk of Drug-induced liver injury when treated with Antivirals for treatment of HIV infections, combinations and Drugs For Treatment Of Tuberculosis in people with HIV and tuberculosis co-infection as compared to genotype GG.		[ 326]
Drugs For Treatment Of Tuberculosis	N.A.	Tuberculosis	Patients with the AA genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hepatotoxicity.		[ 385]
Isoniazid	N.A.	Tuberculosis	Patients with the AA genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hepatotoxicity.		[ 385]
Nortriptyline	N.A.	Depression	Genotype AA is associated with increased likelihood of Hypotension, Orthostatic when treated with nortriptyline in people with Depressive Disorder, Major as compared to genotypes AG + GG.		[ 267]
Nortriptyline	N.A.	Depressive Disorder	Genotype AA is associated with increased likelihood of Hypotension, Orthostatic when treated with nortriptyline in people with Depressive Disorder, Major as compared to genotypes AG + GG.		[ 267]
Nortriptyline	N.A.	Hypotensive Disorder	Genotype AA is associated with increased likelihood of Hypotension, Orthostatic when treated with nortriptyline in people with Depressive Disorder, Major as compared to genotypes AG + GG.		[ 267]
Nortriptyline	N.A.	Major Depressive Disorder	Genotype AA is associated with increased likelihood of Hypotension, Orthostatic when treated with nortriptyline in people with Depressive Disorder, Major as compared to genotypes AG + GG.		[ 267]
Morphine	N.A.	Pain	Genotype AA is associated with increased metabolism of morphine in children as compared to genotypes AG + GG.		[ 253]
Verapamil	N.A.	Pain	Patients with the AA genotype may have increased metabolism of verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.		[ 386]
Antineoplastic Agents	N.A.	Neoplasms	Patients with the AA genotype and receiving chemotherapy treatment may have decreased severity of nausea as compared to patients with the AG genotype. Other genetic and clinical factors may also affect the severity of nausea following chemotherapy treatment.		[ 387]
Opioids	N.A.	Pain	Genotype AA is associated with decreased dose of opioids in people with Pain, Postoperative as compared to genotypes AG + GG.		[ 295]
Opioids	N.A.	Pain, Postoperative	Genotype AA is associated with decreased dose of opioids in people with Pain, Postoperative as compared to genotypes AG + GG.		[ 295]
Opioids	N.A.	Pain	Genotype AA is associated with decreased dose of opioids in people with Neoplasms and Pain as compared to genotypes AG + GG.		[ 313]
Opioids	N.A.	Pain, Postoperative	Genotype AA is associated with decreased dose of opioids in people with Neoplasms and Pain as compared to genotypes AG + GG.		[ 313]
Opioids	N.A.	Pain	Patients with the AA genotype may have decreased opioid dose requirements as compared to patients with the AG or GG genotypes. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements.		[ 388]
Opioids	N.A.	Pain, Postoperative	Patients with the AA genotype may have decreased opioid dose requirements as compared to patients with the AG or GG genotypes. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements.		[ 388]
Morphine	N.A.	Pain	Patients with the AA genotype may have decreased morphine dose requirements as compared to patients with the AG or GG genotypes. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements.		[ 95]
Morphine	N.A.	Pain, Postoperative	Patients with the AA genotype may have decreased morphine dose requirements as compared to patients with the AG or GG genotypes. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements.		[ 95]
Morphine	N.A.	Pain	Genotype AA is associated with increased reduction in pain when treated with morphine in people with Neoplasms as compared to genotypes AG + GG.		[ 256]
Fentanyl	N.A.	Pain, Postoperative	Genotype AA is associated with increased likelihood of Hypoventilation due to fentanyl in people with Pain, Postoperative as compared to genotypes AG + GG.		[ 255]
Hmg Coa Reductase Inhibitors	N.A.	Pain, Postoperative	Genotype AA is associated with increased likelihood of Elevated circulating creatine kinase concentration when treated with hmg coa reductase inhibitors as compared to genotypes AG + GG.		[ 337]
Oxcarbazepine	N.A.	Epilepsy	Patients with epilepsy and the AA genotype may have decreased concentrations of oxcarbazepine and worse response as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy.		[ 51]
Warfarin	N.A.	Epilepsy	Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG or GG genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.		[ 136]
Clozapine	N.A.	Major Depressive Disorder	Genotype AA is associated with increased risk of Agranulocytosis and Neutropenia when treated with clozapine as compared to genotypes AG + GG.		[ 239]
Carbamazepine	N.A.	Epilepsy	Patient with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine.		[ 61]
Paclitaxel	N.A.	Breast Neoplasms	The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paclitaxel.		[ 393]
Paclitaxel	N.A.	Neoplasms	The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paclitaxel.		[ 393]
Docetaxel	N.A.	Breast Neoplasms	The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to docetaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to docetaxel.		[ 86]
Docetaxel	N.A.	Neoplasms	The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to docetaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to docetaxel.		[ 86]
Paclitaxel	N.A.	Drug Toxicity	Genotype AA is associated with increased risk of Neutropenia when treated with paclitaxel in people with Neoplasms as compared to genotypes AG + GG.		[ 327]
Paclitaxel	N.A.	Neoplasms	Genotype AA is associated with increased risk of Neutropenia when treated with paclitaxel in people with Neoplasms as compared to genotypes AG + GG.		[ 327]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Genotype AA is associated with increased risk of Neutropenia when treated with paclitaxel in people with Neoplasms as compared to genotypes AG + GG.		[ 327]
Vincristine	N.A.	Acute Lymphoblastic Leukemia	Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have a decreased likelihood of event-free survival as compared to patients with the GG genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment.		[ 2]
Risperidone	N.A.	Bipolar Disorder	Patients with the AA genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.		[ 173]
Risperidone	N.A.	Depression	Patients with the AA genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.		[ 173]
Risperidone	N.A.	Psychotic Disorder	Patients with the AA genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.		[ 173]
Risperidone	N.A.	Schizophrenia	Patients with the AA genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.		[ 173]
Risperidone	N.A.	Substance-related Disorders	Patients with the AA genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.		[ 173]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.		[ 38]
Digoxin	N.A.	Acute Lymphoblastic Leukemia	Patients with AA genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of digoxin. This annotation only covers the pharmacokinetic relationship between rs1045642 and digoxin and does not include evidence about clinical outcomes.		[ 398]
Losartan	N.A.	Hypertension	Patients with the AA genotype may have better response to losartan in people with hypertension as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to losartan.		[ 399]
Platinum Compounds	N.A.	Non-small Cell Lung Carcinoma	Patients with the AA genotype and non-small-cell lung cancer may have a poorer response to platinum-based chemotherapy as compared to patients with the GG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.		[ 400]
Morphine	N.A.	Pain	Patients with neuropathic pain and the rs1045642 AA genotype may have a decreased response to combined therapy with morphine and nortriptyline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to morphine and nortriptyline.		[ 185]
Nortriptyline	N.A.	Pain	Patients with neuropathic pain and the rs1045642 AA genotype may have a decreased response to combined therapy with morphine and nortriptyline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to morphine and nortriptyline.		[ 185]
Antipsychotics	N.A.	Schizophrenia	Patients with the AA genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of antipsychotics.		[ 187]
Anastrozole	N.A.	Breast Neoplasms	Genotype AA is associated with decreased likelihood of Arthralgia when exposed to anastrozole in women with Breast Neoplasms as compared to genotypes AG + GG.		[ 235]
Omeprazole	N.A.	Gastroesophageal Reflux	Genotype AA is associated with increased response to omeprazole or pantoprazole in people with Helicobacter Infections as compared to genotypes AG + GG.		[ 237]
Clopidogrel	N.A.	Coronary Disease	Patients with coronary disease and the AA genotype who are treated with clopidogrel may have an increased risk of hemorrhage as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.		[ 9]
Clopidogrel	N.A.	Hemorrhage	Patients with coronary disease and the AA genotype who are treated with clopidogrel may have an increased risk of hemorrhage as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.		[ 9]
Clopidogrel	N.A.	Platelet Reactivity	Patients with the AA genotype may have a decreased response to clopidogrel (increased platelet reactivity) as compared to patients with the GG genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel.		[ 404]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype AA is associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 242]
Methotrexate	N.A.	Burkitt Lymphoma	Genotype AA is associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 242]
Methotrexate	N.A.	Lymphoma, T-cell	Genotype AA is associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 242]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype AA is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 296]
Methotrexate	N.A.	Burkitt Lymphoma	Genotype AA is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 296]
Methotrexate	N.A.	Lymphoma, T-cell	Genotype AA is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 296]
Dabigatran	N.A.	Lymphoma, T-cell	People with the AA genotype may have increased exposure to dabigatran compared to patients with the GG genotype, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran.		[ 362]
Methotrexate	N.A.	Drug Toxicity	Genotype AA is associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 242]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype AA is associated with increased risk of Anemia and Thrombocytopenia when treated with doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 241]
Methotrexate	N.A.	Burkitt Lymphoma	Genotype AA is associated with increased risk of Anemia and Thrombocytopenia when treated with doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 241]
Methotrexate	N.A.	Drug Toxicity	Genotype AA is associated with increased risk of Anemia and Thrombocytopenia when treated with doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 241]
Methotrexate	N.A.	Lymphoma, T-cell	Genotype AA is associated with increased risk of Anemia and Thrombocytopenia when treated with doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 241]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype AA is not associated with risk of Neurotoxicity Syndromes when treated with methotrexate in children with Hematologic Neoplasms as compared to genotypes AG + GG.		[ 260]
Methotrexate	N.A.	Burkitt Lymphoma	Genotype AA is not associated with risk of Neurotoxicity Syndromes when treated with methotrexate in children with Hematologic Neoplasms as compared to genotypes AG + GG.		[ 260]
Methotrexate	N.A.	Drug Toxicity	Genotype AA is not associated with risk of Neurotoxicity Syndromes when treated with methotrexate in children with Hematologic Neoplasms as compared to genotypes AG + GG.		[ 260]
Methotrexate	N.A.	Lymphoma, T-cell	Genotype AA is not associated with risk of Neurotoxicity Syndromes when treated with methotrexate in children with Hematologic Neoplasms as compared to genotypes AG + GG.		[ 260]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs1045642 AA genotype and cancer who are treated with methotrexate may have increased risk of toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.		[ 405]
Methotrexate	N.A.	Burkitt Lymphoma	Patients with the rs1045642 AA genotype and cancer who are treated with methotrexate may have increased risk of toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.		[ 405]
Methotrexate	N.A.	Drug Toxicity	Patients with the rs1045642 AA genotype and cancer who are treated with methotrexate may have increased risk of toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.		[ 405]
Methotrexate	N.A.	Lymphoma, T-cell	Patients with the rs1045642 AA genotype and cancer who are treated with methotrexate may have increased risk of toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.		[ 405]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype AA is not associated with risk of Neurotoxicity Syndromes when treated with methotrexate in children with Hematologic Neoplasms as compared to genotypes AG + GG.		[ 260]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the rs1045642 AA genotype and rheumatoid arthritis who are treated with methotrexate may have a decreased risk of drug toxicity as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 406]
Simvastatin	N.A.	Rheumatoid Arthritis	Patients with the AA genotype who are treated with simvastatin may have a better response to treatment (measured by a higher reduction in total cholesterol) compared to patients with the GG genotype. In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.		[ 3]
Atorvastatin	N.A.	Coronary Artery Disease	Genotype AA is associated with increased AUC of atorvastatin in healthy individuals as compared to genotype GG.		[ 290]
Methotrexate	N.A.	Juvenile Rheumatoid Arthritis	Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.		[ 234]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.		[ 234]
Methotrexate	N.A.	Juvenile Rheumatoid Arthritis	Genotype AA is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotypes AG + GG.		[ 299]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype AA is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotypes AG + GG.		[ 299]
Methotrexate	N.A.	Juvenile Rheumatoid Arthritis	The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to methotrexate in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.		[ 407]
Methotrexate	N.A.	Rheumatoid Arthritis	The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to methotrexate in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.		[ 407]
Highly Active Antiretroviral Therapy (haart)	N.A.	HIV Infectious Disease	Patients with the rs1045642 AA genotype and HIV may have an increased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART.		[ 408]
Remifentanil	N.A.	HIV Infectious Disease	Patients with the AA genotype may have decreased remifentanil requirements as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's remifentanil requirements.		[ 206]
Efavirenz	N.A.	HIV Infectious Disease	Genotype AA is associated with increased clearance of efavirenz in people with HIV Infections as compared to genotype AG.		[ 265]
Efavirenz	N.A.	HIV Infectious Disease	Genotype AA is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.		[ 263]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.		[ 259]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the AA genotype may have increased response to cytarabine regimens as compared to patients with the GG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to cytarabine regimens.		[ 410]
Phenytoin	N.A.	Epilepsy	Patients with epilepsy and the AA genotype may have decreased likelihood of drug resistance when treated with phenytoin as compared to patients with the AG or GG genotypes. However, other studies have failed to find this association. Other genetic or clinical factors may influence a patient's response to phenytoin.		[ 162]
Tacrolimus	N.A.	Organ Transplantation	Genotype AA is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 228]
Tacrolimus	N.A.	Organ Transplantation	Genotype AA is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 272]
Tacrolimus	N.A.	Organ Transplantation	Genotype AA is not associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 316]
Tacrolimus	N.A.	Organ Transplantation	Genotype AA is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 230]
Tacrolimus	N.A.	Organ Transplantation	Genotype AA is not associated with concentrations of tacrolimus in children with liver transplantation.		[ 258]
Tacrolimus	N.A.	Organ Transplantation	Genotype AA is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 274]
Tacrolimus	N.A.	Organ Transplantation	Genotype AA is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Arthritis, Rheumatoid as compared to genotype GG.		[ 248]
Tacrolimus	N.A.	Organ Transplantation	Genotype AA is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype AG.		[ 229]
Tacrolimus	N.A.	Organ Transplantation	Genotype AA is not associated with dose of tacrolimus in children with Kidney Transplantation as compared to genotypes AG + GG.		[ 298]
Tacrolimus	N.A.	Organ Transplantation	Genotype AA is not associated with concentrations of tacrolimus in children with Kidney Transplantation as compared to genotypes AG + GG.		[ 297]
Tacrolimus	N.A.	Organ Transplantation	The current evidence base suggests that there is no significant association between rs1045642 AA genotype and the clearance and dose requirements of tacrolimus. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus.		[ 412]
Topiramate	N.A.	Migraine With Aura	Genotype AA is associated with increased response to topiramate in people with Migraine without Aura or Migraine with Aura as compared to genotypes AG + GG.		[ 114]
Topiramate	N.A.	Migraine Without Aura	Genotype AA is associated with increased response to topiramate in people with Migraine without Aura or Migraine with Aura as compared to genotypes AG + GG.		[ 114]
Opioids	N.A.	Opioid-related Disorders	Patients with the AA genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.		[ 413]
Opioids	N.A.	Neoplasm	Correlated with the decreased drug dose in patients (compare with genotypes AG + GG)		[ 313]
Opioids	N.A.	Postoperative Pain	Correlated with the decreased drug dose in patients (compare with genotypes AG + GG)		[ 295]
Antiepileptics	N.A.	Epilepsy	Correlated with the increased drug resistance in patients (compare with genotype GG)		[ 338], [ 281]
Antivirals combinations drugs for treatment of tuberculosis	N.A.	HIV Infection; Tuberculosis Co-Infection	Correlated with the increased drug-induced liver injury risk in patieants (compare with genotype GG)		[ 326]
Anthracyclines	N.A.	Breast Neoplasm	Correlated with the increased likelihood of complete response in patients (compare with genotypes GG + AG)		[ 307]
Taxanes	N.A.	Breast Neoplasm	Correlated with the increased likelihood of complete response in patients (compare with genotypes GG + AG)		[ 307]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:       229 Drugs in Total
Paclitaxel	Drug Info	Breast Neoplasm	Correlated with the decreased disease control rate and lower overall survival rate in patients (compare with genotype GG)		[ 378]
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the decreased drug toxicity risk in patients (compare with genotype GG)		[ 372]
Tamoxifen	Drug Info	Breast Neoplasm	Correlated with the increased disease recurrence risk in patients (compare with genotype GG); Correlated with the increased disease recurrence risk in patients (compare with genotypes AA + GG)		[ 341]
Methadone	Drug Info	Opioid-Related Disorders	Correlated with the increased drug concentrations in patients (compare with genotypes AA + GG)		[ 381]
Tacrolimus	Drug Info	Kidney Transplantation	Correlated with the increased hypokalemia risk in patients (compare with genotypes AA + GG); Correlated with the increased transplant rejection risk in patients (compare with genotypes AA + GG); Irrelevant to the drug concentrations in patients (compare with genotype GG)		[ 32], [ 383]
Oxaliplatin	Drug Info	Colorectal Neoplasm	Correlated with the increased recurrence-free survival in patients (compare with genotype AA)		[ 337]
Carbamazepine	Drug Info	Epilepsy	Irrelevant to the drug metabolism in patients (compare with genotypes AA + GG)		[ 385]
Modafinil	Drug Info	Narcolepsy	Correlated with the increased drug response in patients (compare with genotypes AA + GG)		[ 345]
Paclitaxel	N.A.	Drug Toxicity	Genotype AG is associated with decreased disease control rate and lower overall survival rate when treated with paclitaxel in people with metastatic breast cancer as compared to genotype GG.		[ 378]
Tamoxifen	N.A.	Thrombocytopenia	Genotype AG is associated with increased risk of disease recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes AA + GG.		[ 341]
Imatinib	N.A.	Arthralgia	Genotype AG is associated with decreased trough concentration of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + GG.		[ 387]
Valganciclovir	N.A.	Neutropenia	Genotype AG is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype GG.		[ 273]
Tacrolimus	N.A.	Hypokalemia	Genotype AG is associated with increased risk of Hypokalemia when treated with tacrolimus in children with Kidney Transplantation as compared to genotypes AA + GG.		[ 32]
Tacrolimus	N.A.	Transplant Rejection	Genotype AG is associated with increased risk of transplant rejection when treated with tacrolimus in children with Kidney Transplantation as compared to genotypes AA + GG.		[ 32]
S-eddp	N.A.	Diarrhea	Genotype AG is associated with increased concentrations of (S)-EDDP.		[ 389]
Methadone	N.A.	Diarrhea	Genotype AG is associated with decreased concentrations of methadone.		[ 389]
Clopidogrel	N.A.	Platelet Reactivity	Genotype AG is associated with increased platelet reactivity when treated with clopidogrel as compared to genotypes AA + GG.		[ 390]
Methotrexate	N.A.	Gastrointestinal Toxicity	Genotype AG is associated with increased likelihood of gastrointestinal toxicity when exposed to methotrexate in people with Arthritis, Rheumatoid.		[ 166]
Efavirenz	N.A.	Hyperbilirubinemia	Genotype AG is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.		[ 392]
Tacrolimus	N.A.	Toxic Liver Disease	Genotype AG is not associated with concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 383]
Cyclosporine	N.A.	Gingival Hyperplasia	Genotype AG is associated with increased severity of Gingival Hyperplasia when treated with cyclosporine in people with Kidney Transplantation as compared to genotypes AA + GG.		[ 393]
Levofloxacin	N.A.	Asthenia	Genotype AG is associated with increased risk of seizures due to levofloxacin.		[ 394]
Methotrexate	N.A.	Diarrhea	Genotype AG is associated with increased risk of non-response when treated with methotrexate in people with Arthritis, Rheumatoid.		[ 373]
Methadone	N.A.	Neutropenia	Genotype AG is associated with increased concentrations of methadone in men with Opioid-Related Disorders as compared to genotypes AA + GG.		[ 381]
Tacrolimus	N.A.	Nephrotoxicity	Genotype AG is associated with increased likelihood of nephrotoxicity when treated with tacrolimus in children with Kidney Transplantation and liver transplantation.		[ 396]
Antineoplastic Agents	N.A.	Nausea	Genotype AG is associated with increased severity of Nausea when treated with antineoplastic agents in people with Neoplasms as compared to genotypes AA + GG.		[ 364]
Sunitinib	N.A.	Progression-free Survival	Genotype AG is associated with increased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype GG.		[ 398]
Digoxin	N.A.	Orthostatic Hypotension	Genotype AG is associated with increased clearance of digoxin in healthy individuals as compared to genotype GG.		[ 317]
Methotrexate	N.A.	Orthostatic Hypotension	Genotype AG is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 219]
Phenytoin	N.A.	Urinary Retention	Genotype AG is not associated with dose-adjusted trough concentrations of phenytoin in people with Epilepsy as compared to genotype AA.		[ 401]
Sirolimus	N.A.	Urinary Retention	Genotype AG is associated with increased concentrations of sirolimus as compared to genotypes AA + GG.		[ 402]
Methotrexate	N.A.	Drug Toxicity	Genotype AG is associated with decreased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.		[ 372]
Isoniazid	N.A.	Toxic Liver Disease	Genotype AG is associated with Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in women Tuberculosis.		[ 362]
Pyrazinamide	N.A.	Toxic Liver Disease	Genotype AG is associated with Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in women Tuberculosis.		[ 362]
Rifampin	N.A.	Toxic Liver Disease	Genotype AG is associated with Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in women Tuberculosis.		[ 362]
Oxaliplatin	N.A.	Pain, Postoperative	Genotype AG is associated with increased recurrence-free survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.		[ 337]
Oxycodone	N.A.	Cns Depression	Genotype AG is not associated with risk of CNS depression and Infant when treated with oxycodone in women with Lactation as compared to genotype GG.		[ 327]
Oxycodone	N.A.	Infant	Genotype AG is not associated with risk of CNS depression and Infant when treated with oxycodone in women with Lactation as compared to genotype GG.		[ 327]
Modafinil	N.A.	Anemia	Genotype AG is associated with increased response to modafinil in people with Narcolepsy as compared to genotypes AA + GG.		[ 345]
Carbamazepine	N.A.	Drug Toxicity	Genotype AG is not associated with metabolism of carbamazepine in people with Epilepsy as compared to genotypes AA + GG.		[ 385]
Antiepileptics	N.A.	Drug Toxicity	Genotype AG is associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.		[ 333]
Remifentanil	N.A.	Hypersensitivity	Genotype AG is not associated with dose of remifentanil as compared to genotypes AA + GG.		[ 206]
Cisplatin	N.A.	Neoplasm Of Esophagus	Patients with the AG genotype may have a decreased risk of lymph node metastases and an increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.		[ 337]
Fluorouracil	N.A.	Neoplasm Of Esophagus	Patients with the AG genotype may have a decreased risk of lymph node metastases and an increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.		[ 337]
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with AG genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.		[ 338]
Rhodamine 123	N.A.	Colorectal Neoplasms	Genotype AG may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported.		[ 339]
Fentanyl	N.A.	Pain	Patients with the rs1045642 AG genotype may have decreased fentanyl dose requirements as compared to patients with the GG genotype, but increased fentanyl dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements.		[ 329]
Fentanyl	N.A.	Pain, Postoperative	Patients with the rs1045642 AG genotype may have decreased fentanyl dose requirements as compared to patients with the GG genotype, but increased fentanyl dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements.		[ 329]
Ondansetron	N.A.	Postoperative Nausea And Vomiting	Patients with the rs1045642 AG genotype may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to ondansetron.		[ 235]
Ondansetron	N.A.	Vomiting	Patients with the rs1045642 AG genotype may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to ondansetron.		[ 235]
Nevirapine	N.A.	HIV Infectious Disease	While patients with the rs1045642 AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype, it is not clear what the association is between the AG genotype and risk of neravirapine hepatotoxicity. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment.		[ 52]
Nevirapine	N.A.	Toxic Liver Disease	While patients with the rs1045642 AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype, it is not clear what the association is between the AG genotype and risk of neravirapine hepatotoxicity. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment.		[ 52]
Opioids	N.A.	Low Back Pain	Patients with the rs1045642 AG genotype may be more likely to experience nausea when treated with opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of experiencing nausea when treated with opioids.		[ 196]
Antiepileptics	N.A.	Epilepsies, Partial	Genotype AG is associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.		[ 333]
Antiepileptics	N.A.	Epilepsy	Genotype AG is associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.		[ 333]
Antiepileptics	N.A.	Epilepsy, Idiopathic Generalized	Genotype AG is associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.		[ 333]
Antiepileptics	N.A.	Epilepsies, Partial	The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics.		[ 200]
Antiepileptics	N.A.	Epilepsy	The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics.		[ 200]
Antiepileptics	N.A.	Epilepsy, Idiopathic Generalized	The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics.		[ 200]
Codeine	N.A.	HIV Infectious Disease	Patients with the AG genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype or may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine.		[ 14]
Methadone	N.A.	Heroin Dependence	The current evidence base suggests that there is no significant association between rs1045642 AG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.		[ 250]
Methadone	N.A.	Opioid-related Disorders	The current evidence base suggests that there is no significant association between rs1045642 AG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.		[ 250]
Oxycodone	N.A.	Pain	Patients with the AG genotype may have decreased oxycodone dose requirements as compared to patients with the GG genotype, but increased oxycodone dose requirements as compared to patients with the AA genotype. However, another study did not find an association between this variant and oxycodone dosing. Other genetic and clinical factors may also affect a patient's oxycodone dose requirements.		[ 340]
Methadone	N.A.	Pain	Patients with the rs1045642 AG genotype and who are receiving methadone for analgesia may required a decreased dose as compared to patients with the GG genotype, but an increased dose as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone dose requirements for analgesia.		[ 70]
Tamoxifen	N.A.	Breast Neoplasms	Genotype AG is associated with increased risk of disease recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes AA + GG.		[ 341]
Daptomycin	N.A.	Breast Neoplasms	Patients with the AG genotype may increased clearance of daptomycin, resulting in decreased concentrations of the drug, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of daptomycin.		[ 264]
Silibinin	N.A.	Narcolepsy	People with genotype AG may have decreased exposure to silibinin compared to people with genotypes GG. Other clinical and genetic factors may affect a person's exposure to silibinin.		[ 342]
Antivirals For Treatment Of HIV Infections, Combinations	N.A.	HIV Infectious Disease	Patients with the AG genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.		[ 321]
Antivirals For Treatment Of HIV Infections, Combinations	N.A.	Tuberculosis	Patients with the AG genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.		[ 321]
Drugs For Treatment Of Tuberculosis	N.A.	HIV Infectious Disease	Patients with the AG genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.		[ 321]
Drugs For Treatment Of Tuberculosis	N.A.	Tuberculosis	Patients with the AG genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.		[ 321]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Genotype AG is associated with decreased trough concentration of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + GG.		[ 387]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the AG genotype and chronic myeloid leukemia may have a decreased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the GG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response.		[ 343]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the AG genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the GG genotype or may have a higher risk of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.		[ 3]
Simvastatin	N.A.	Myalgia	Patients with the AG genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the GG genotype or may have a higher risk of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.		[ 3]
Clopidogrel	N.A.	Acute Coronary Syndrome	People with AG genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.		[ 42]
Clopidogrel	N.A.	Myocardial Infarction	People with AG genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.		[ 42]
Etoposide	N.A.	Acute Lymphoblastic Leukemia	Patients with the AG genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have decreased metabolism of etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.		[ 344]
Tacrolimus	N.A.	Ulcerative Colitis	Patients with the AG genotype and ulcerative colitis may have a poorer chance at achieving remission when treated with tacrolimus as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission.		[ 311]
Modafinil	N.A.	Narcolepsy	Genotype AG is associated with increased response to modafinil in people with Narcolepsy as compared to genotypes AA + GG.		[ 345]
Sorafenib	N.A.	Hypertension	Patients with the AG genotype may have increased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to sorafenib.		[ 346]
Sorafenib	N.A.	Renal Cell Carcinoma	Patients with the AG genotype may have increased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to sorafenib.		[ 346]
Lansoprazole	N.A.	Gastroesophageal Reflux	Patients with the AG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.		[ 212]
Lansoprazole	N.A.	Transplantation	Patients with the AG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.		[ 212]
Tacrolimus	N.A.	Gastroesophageal Reflux	Patients with the AG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.		[ 212]
Tacrolimus	N.A.	Transplantation	Patients with the AG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.		[ 212]
Rivaroxaban	N.A.	Transplantation	People with the AG genotype may have increased exposure to rivaroxaban compared to people with the GG genotype when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.		[ 347]
Methadone	N.A.	Opioid-related Disorders	Genotype AG is associated with increased concentrations of methadone in men with Opioid-Related Disorders as compared to genotypes AA + GG.		[ 381]
Methadone	N.A.	Opioid-related Disorders	Genotype AG is associated with decreased concentrations of methadone.		[ 389]
Methadone	N.A.	Opioid-related Disorders	Patients with the rs1045642 AG genotype who are receiving methadone maintenance therapy may have decreased clearance of methadone, leading to increased plasma concentration of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone clearance and plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs1045642 and methadone and does not include evidence about clinical outcomes.		[ 249]
Olanzapine	N.A.	Psychotic Disorder	Patients with the AG genotype and Psychotic Disorders who are treated with olanzapine may have decreased social and clinical needs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.		[ 122]
Everolimus	N.A.	Breast Neoplasms	Patients with the AG genotype and breast cancer who are treated with everolimus may have increased likelihood of mucositis as compared to patients with the GG genotype, and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.		[ 19]
Everolimus	N.A.	Mucositis	Patients with the AG genotype and breast cancer who are treated with everolimus may have increased likelihood of mucositis as compared to patients with the GG genotype, and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.		[ 19]
Sirolimus	N.A.	Kidney Transplantation	Patients with the AG genotype who underwent kidney transplantation may have increased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.		[ 348]
Anthracyclines And Related Substances	N.A.	Breast Neoplasms	Patients with the AG genotype may have decreased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.		[ 304]
Taxanes	N.A.	Breast Neoplasms	Patients with the AG genotype may have decreased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.		[ 304]
Phenobarbital	N.A.	Epilepsy	Patients with genotype AG may have increased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to phenobarbital.		[ 349]
Carbamazepine	N.A.	Epilepsy	Genotype AG is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes AA + GG.		[ 385]
Carbamazepine	N.A.	Epilepsy	Patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine and may need an increased dose as compared to patients with the AA or GG genotypes. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence concentrations of carbamazepine.		[ 159]
Atorvastatin	N.A.	Coronary Artery Disease	Patients with the AG genotype and Coronary Artery Disease who are treated with atorvastatin may have a higher likelihood of developing myalgia as compared to patients with the GG genotype, or may have a lower likelihood of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.		[ 163]
Atorvastatin	N.A.	Myalgia	Patients with the AG genotype and Coronary Artery Disease who are treated with atorvastatin may have a higher likelihood of developing myalgia as compared to patients with the GG genotype, or may have a lower likelihood of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.		[ 163]
Risperidone	N.A.	Schizophrenia	Patients with the AG genotype and schizophrenia may have a longer QTc interval when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.		[ 350]
Oxaliplatin	N.A.	Colorectal Neoplasms	Genotype AG is associated with increased recurrence-free survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.		[ 337]
Tacrolimus	N.A.	Kidney Transplantation	Genotype AG is associated with increased risk of transplant rejection when treated with tacrolimus in children with Kidney Transplantation as compared to genotypes AA + GG.		[ 32]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the AG genotype who are undergoing kidney transplantation and are treated with tacrolimus may have an increased risk of experiencing transplant rejection as compared to patients with the AA or GG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection.		[ 351]
Tramadol	N.A.	Fractures, Bone	Patients with the rs1045642 AG genotype may have an increased analgesic response to tramadol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Tramadol	N.A.	Pain	Patients with the rs1045642 AG genotype may have an increased analgesic response to tramadol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Tramadol	N.A.	Pain, Postoperative	Patients with the rs1045642 AG genotype may have an increased analgesic response to tramadol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Efavirenz	N.A.	HIV Infectious Disease	Patients with the GA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.		[ 4]
Nelfinavir	N.A.	HIV Infectious Disease	Patients with the GA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.		[ 4]
Methylprednisolone	N.A.	Kidney Transplantation	Patients with the AG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.		[ 228]
Prednisolone	N.A.	Kidney Transplantation	Patients with the AG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.		[ 228]
Cyclosporine	N.A.	Transplantation	Patients with genotype AG may have increased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine.		[ 352]
Tramadol	N.A.	Opioid-related Disorders	Patients with the rs1045642 AG genotype may have an increased risk of developing opioid dependence when treated with tramadol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.		[ 88]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the AG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		[ 353]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the AG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		[ 353]
Fluorouracil	N.A.	Breast Neoplasms	Patients with the AG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.		[ 353]
Bleomycin	N.A.	Testicular Neoplasms	Patients with testicular cancer and the AG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.		[ 155]
Bleomycin	N.A.	Vomiting	Patients with testicular cancer and the AG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.		[ 155]
Cisplatin	N.A.	Testicular Neoplasms	Patients with testicular cancer and the AG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.		[ 155]
Cisplatin	N.A.	Vomiting	Patients with testicular cancer and the AG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.		[ 155]
Etoposide	N.A.	Testicular Neoplasms	Patients with testicular cancer and the AG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.		[ 155]
Etoposide	N.A.	Vomiting	Patients with testicular cancer and the AG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.		[ 155]
Phenytoin	N.A.	Glioma	Patients with genotype AG may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.		[ 21]
Dexamethasone	N.A.	Multiple Myeloma	Patients with the AG genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.		[ 354]
Doxorubicin	N.A.	Multiple Myeloma	Patients with the AG genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.		[ 354]
Vincristine	N.A.	Multiple Myeloma	Patients with the AG genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.		[ 354]
Dicloxacillin	N.A.	Multiple Myeloma	Genotype AG may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.		[ 355]
Capecitabine	N.A.	Neoplasms	Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.		[ 356]
Tacrolimus	N.A.	Kidney Transplantation	Patients who receive a kidney with the AG genotype may have decreased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the GG genotype, and increased eGFR as compared to patients with the AA genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR.		[ 357]
Prednisone	N.A.	Organ Transplantation	Pediatric patients with the AG genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.		[ 358]
Prednisone	N.A.	Transplantation	Pediatric patients with the AG genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.		[ 358]
Tacrolimus	N.A.	Organ Transplantation	Pediatric patients with the AG genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.		[ 358]
Tacrolimus	N.A.	Transplantation	Pediatric patients with the AG genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.		[ 358]
Fexofenadine	N.A.	Transplantation	Healthy individuals with the AG genotype who are treated with fexofenadine may have higher plasma drug levels as compared to healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.		[ 232]
Pantoprazole	N.A.	Helicobacter Infections	The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and eradication of Helicobacter infection when treated with pantoprazole. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of response to pantoprazole.		[ 236]
Oseltamivir	N.A.	Helicobacter Infections	Patients with the AG genotype and acute respiratory diseases and suspected influenza infection may have increased risk of side effects when treated with oseltamivir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of oseltamivir side effects.		[ 359]
Venlafaxine	N.A.	Depressive Disorder	Patients with genotype AG and depressive disorder may have decreased response to venlafaxine compared to patients with genotype GG. Patients with AG genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.		[ 360]
Venlafaxine	N.A.	Narcolepsy	Patients with genotype AG and depressive disorder may have decreased response to venlafaxine compared to patients with genotype GG. Patients with AG genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.		[ 360]
Selective Serotonin Reuptake Inhibitors	N.A.	Depressive Disorder	Patients with the AG genotype and depressive disorder may have decreased response to serotonin reuptake inhibitors compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.		[ 360]
Granisetron	N.A.	Neoplasms	Patients with the AG genotype and cancer may have a lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.		[ 261]
Atazanavir	N.A.	HIV Infectious Disease	Patients with the AG genotype and HIV may have increased concentrations of atazanavir as compared to patients with the AA genotypes, although this is contradicted in most studies. There is no evidence that the AG genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.		[ 102]
Ritonavir	N.A.	HIV Infectious Disease	Patients with the AG genotype and HIV may have increased concentrations of atazanavir as compared to patients with the AA genotypes, although this is contradicted in most studies. There is no evidence that the AG genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.		[ 102]
Agomelatine	N.A.	Depressive Disorder	Patients with the AG genotype and depressive disorder may have a decreased response to agomelatine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to agomelatine.		[ 360]
Sunitinib	N.A.	Renal Cell Carcinoma	Patients with the AG genotype and renal cell carcinoma may have a lower risk for adverse effects when treated with sunitinib as compared to patients with the GG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities.		[ 41]
Rivaroxaban	N.A.	Renal Cell Carcinoma	Patients with the rs1045642 AG genotype may have decreased risk of Thromboembolism when treated with rivaroxaban as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to rivaroxaban.		[ 361]
Talinolol	N.A.	Hand-foot Syndrome	Patients with the AG genotype may have decreased clearance of talinolol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of talinolol.		[ 248]
Drugs For Treatment Of Tuberculosis	N.A.	Tuberculosis	Genotype AG is associated with Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in women Tuberculosis.		[ 362]
Isoniazid	N.A.	Tuberculosis	Genotype AG is associated with Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in women Tuberculosis.		[ 362]
Nortriptyline	N.A.	Depression	Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.		[ 265]
Nortriptyline	N.A.	Depressive Disorder	Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.		[ 265]
Nortriptyline	N.A.	Hypotensive Disorder	Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.		[ 265]
Nortriptyline	N.A.	Major Depressive Disorder	Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.		[ 265]
Morphine	N.A.	Pain	Patients with the AG genotype who are treated with morphine may have lower levels of morphine-3-glucuronide formation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.		[ 252]
Verapamil	N.A.	Pain	Patients with the AG genotype may have increased metabolism of verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.		[ 363]
Antineoplastic Agents	N.A.	Neoplasms	Genotype AG is associated with increased severity of Nausea when treated with antineoplastic agents in people with Neoplasms as compared to genotypes AA + GG.		[ 364]
Opioids	N.A.	Pain	Patients with the AG genotype may have decreased opioid dose requirements as compared to patients with the GG genotype, but increased opioid dose requirements as compared to patients with the AA genotype. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements.		[ 365]
Opioids	N.A.	Pain, Postoperative	Patients with the AG genotype may have decreased opioid dose requirements as compared to patients with the GG genotype, but increased opioid dose requirements as compared to patients with the AA genotype. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements.		[ 365]
Morphine	N.A.	Pain	Patients with the AG genotype may have decreased morphine dose requirements as compared to patients with the GG genotype, but increased dose requirements as compared to patients with the AA genotype. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements.		[ 95]
Morphine	N.A.	Pain, Postoperative	Patients with the AG genotype may have decreased morphine dose requirements as compared to patients with the GG genotype, but increased dose requirements as compared to patients with the AA genotype. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements.		[ 95]
Morphine	N.A.	Pain	Patients with the AG genotype may have decreased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence response to morphine.		[ 255]
Fentanyl	N.A.	Hypoventilation	Patients with the AG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Fentanyl	N.A.	Pain, Postoperative	Patients with the AG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Hmg Coa Reductase Inhibitors	N.A.	Pain, Postoperative	Patients with the AG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.		[ 332]
Oxcarbazepine	N.A.	Epilepsy	Patients with epilepsy and the AG genotype may have decreased concentrations of oxcarbazepine and worse response as compared to patients with the GG genotypes but improved response as compared to the AA genotype. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy.		[ 51]
Warfarin	N.A.	Epilepsy	Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype and a decreased dose as compared to the AA genotype, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.		[ 136]
Clozapine	N.A.	Major Depressive Disorder	Patients with the AG genotype may have decreased clozapine plasma concentrations, as well as a decreased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity.		[ 239]
Carbamazepine	N.A.	Epilepsy	Patient with genotype AG may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine.		[ 61]
Paclitaxel	N.A.	Breast Neoplasms	Genotype AG is associated with decreased disease control rate and lower overall survival rate when treated with paclitaxel in people with metastatic breast cancer as compared to genotype GG.		[ 378]
Paclitaxel	N.A.	Neoplasms	Genotype AG is associated with decreased disease control rate and lower overall survival rate when treated with paclitaxel in people with metastatic breast cancer as compared to genotype GG.		[ 378]
Paclitaxel	N.A.	Breast Neoplasms	The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paclitaxel.		[ 366]
Paclitaxel	N.A.	Neoplasms	The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paclitaxel.		[ 366]
Docetaxel	N.A.	Breast Neoplasms	The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to docetaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to docetaxel.		[ 86]
Docetaxel	N.A.	Neoplasms	The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to docetaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to docetaxel.		[ 86]
Paclitaxel	N.A.	Drug Toxicity	The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.		[ 322]
Paclitaxel	N.A.	Neoplasms	The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.		[ 322]
Paclitaxel	N.A.	Neutropenia	The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.		[ 322]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel.		[ 322]
Vincristine	N.A.	Acute Lymphoblastic Leukemia	Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a decreased likelihood of event-free survival as compared to patients with the GG genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment.		[ 2]
Risperidone	N.A.	Bipolar Disorder	Patients with the AG genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.		[ 173]
Risperidone	N.A.	Depression	Patients with the AG genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.		[ 173]
Risperidone	N.A.	Psychotic Disorder	Patients with the AG genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.		[ 173]
Risperidone	N.A.	Schizophrenia	Patients with the AG genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.		[ 173]
Risperidone	N.A.	Substance-related Disorders	Patients with the AG genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.		[ 173]
Tramadol	N.A.	Substance-related Disorders	Patients with the AG genotype may have an increased exposure to tramadol as compared to patients with the GG genotype, but a decreased exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's exposure to tramadol.		[ 251]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.		[ 38]
Digoxin	N.A.	Acute Lymphoblastic Leukemia	Patients with AG genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of digoxin. This annotation only covers the pharmacokinetic relationship between rs1045642 and digoxin and does not include evidence about clinical outcomes.		[ 367]
Losartan	N.A.	Hypertension	Patients with the AG genotype may have better response to losartan in people with hypertension as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to losartan.		[ 368]
Platinum Compounds	N.A.	Non-small Cell Lung Carcinoma	Patients with the AG genotype and non-small-cell lung cancer may have a poorer response to platinum-based chemotherapy as compared to patients with the GG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.		[ 369]
Voriconazole	N.A.	Non-small Cell Lung Carcinoma	Patients with the AG genotype may have decreased clearance of voriconazole as compared to patients with the GG genotype, or increased clearance of voriconazole as compared to patients with the AA genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole.		[ 260]
Morphine	N.A.	Pain	Patients with neuropathic pain and the rs1045642 AG genotype may have a decreased response to combined therapy with morphine and nortriptyline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to morphine and nortriptyline.		[ 185]
Nortriptyline	N.A.	Pain	Patients with neuropathic pain and the rs1045642 AG genotype may have a decreased response to combined therapy with morphine and nortriptyline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to morphine and nortriptyline.		[ 185]
Antipsychotics	N.A.	Schizophrenia	Patients with the AG genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the GG genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.		[ 187]
Anastrozole	N.A.	Arthralgia	Postmenopausal women with HR+ breast cancer and the AG genotype may be more likely to experience arthralgia when treated with anastrozole as compared to women with the AA genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.		[ 234]
Anastrozole	N.A.	Breast Neoplasms	Postmenopausal women with HR+ breast cancer and the AG genotype may be more likely to experience arthralgia when treated with anastrozole as compared to women with the AA genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.		[ 234]
Omeprazole	N.A.	Gastroesophageal Reflux	Patients with the AG genotype and gastroesophageal reflux who are treated with omeprazole may have Increased absorption of omeprazole, but decreased response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence absorption rate and response to omeprazole in patients gastroesophageal reflux.		[ 236]
Clopidogrel	N.A.	Coronary Disease	Patients with coronary disease and the AG genotype who are treated with clopidogrel may have an increased risk of hemorrhage as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.		[ 9]
Clopidogrel	N.A.	Hemorrhage	Patients with coronary disease and the AG genotype who are treated with clopidogrel may have an increased risk of hemorrhage as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.		[ 9]
Clopidogrel	N.A.	Platelet Reactivity	Patients with the AG genotype may have a decreased response to clopidogrel (increased platelet reactivity) as compared to patients with the GG genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel.		[ 370]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype AG is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 219]
Methotrexate	N.A.	Burkitt Lymphoma	Genotype AG is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 219]
Methotrexate	N.A.	Lymphoma, T-cell	Genotype AG is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 219]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs1045642 AG genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 241]
Methotrexate	N.A.	Burkitt Lymphoma	Patients with the rs1045642 AG genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 241]
Methotrexate	N.A.	Lymphoma, T-cell	Patients with the rs1045642 AG genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 241]
Dabigatran	N.A.	Lymphoma, T-cell	People with the AG genotype may have increased exposure to dabigatran compared to patients with the GG genotype, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran.		[ 347]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype AG is associated with increased likelihood of gastrointestinal toxicity when exposed to methotrexate in people with Arthritis, Rheumatoid.		[ 166]
Methotrexate	N.A.	Burkitt Lymphoma	Genotype AG is associated with increased likelihood of gastrointestinal toxicity when exposed to methotrexate in people with Arthritis, Rheumatoid.		[ 166]
Methotrexate	N.A.	Drug Toxicity	Genotype AG is associated with increased likelihood of gastrointestinal toxicity when exposed to methotrexate in people with Arthritis, Rheumatoid.		[ 166]
Methotrexate	N.A.	Lymphoma, T-cell	Genotype AG is associated with increased likelihood of gastrointestinal toxicity when exposed to methotrexate in people with Arthritis, Rheumatoid.		[ 166]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs1045642 AG genotype and cancer who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype, or a decreased risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.		[ 371]
Methotrexate	N.A.	Burkitt Lymphoma	Patients with the rs1045642 AG genotype and cancer who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype, or a decreased risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.		[ 371]
Methotrexate	N.A.	Drug Toxicity	Patients with the rs1045642 AG genotype and cancer who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype, or a decreased risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.		[ 371]
Methotrexate	N.A.	Lymphoma, T-cell	Patients with the rs1045642 AG genotype and cancer who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype, or a decreased risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.		[ 371]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype AG is associated with decreased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.		[ 372]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype AG is associated with increased likelihood of gastrointestinal toxicity when exposed to methotrexate in people with Arthritis, Rheumatoid.		[ 166]
Simvastatin	N.A.	Rheumatoid Arthritis	Patients with the AG genotype who are treated with simvastatin may have a better response to treatment (measured by a higher reduction in total cholesterol) compared to patients with the GG genotype or may have a reduced response (measured by a lower reduction in total cholesterol) as compared to patients with the AA genotype. In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.		[ 3]
Methotrexate	N.A.	Juvenile Rheumatoid Arthritis	Genotype AG is associated with increased risk of non-response when treated with methotrexate in people with Arthritis, Rheumatoid.		[ 373]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype AG is associated with increased risk of non-response when treated with methotrexate in people with Arthritis, Rheumatoid.		[ 373]
Highly Active Antiretroviral Therapy (haart)	N.A.	HIV Infectious Disease	Patients with the rs1045642 AG genotype and HIV may have an increased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART.		[ 374]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the AG genotype may have increased response to cytarabine regimens as compared to patients with the GG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to cytarabine regimens.		[ 375]
Phenytoin	N.A.	Epilepsy	Patients with epilepsy and the AG genotype may have increased likelihood of drug resistance when treated with phenytoin as compared to patients with the AA genotype. However, other studies have failed to find this association. Other genetic or clinical factors may influence a patient's response to phenytoin.		[ 162]
Tacrolimus	N.A.	Organ Transplantation	Genotype AG is not associated with concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 383]
Tacrolimus	N.A.	Organ Transplantation	The current evidence base suggests that there is no significant association between rs1045642 AG genotype and the clearance and dose requirements of tacrolimus. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus.		[ 376]
Topiramate	N.A.	Migraine With Aura	Patients with migraine and the rs1045642 AG genotype may have a decreased response to topiramate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to topiramate.		[ 114]
Topiramate	N.A.	Migraine Without Aura	Patients with migraine and the rs1045642 AG genotype may have a decreased response to topiramate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to topiramate.		[ 114]
Opioids	N.A.	Opioid-related Disorders	Patients with the AG genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the AA or GG genotypes. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.		[ 377]
Antiepileptics	N.A.	Epilepsy	Correlated with the increased drug resistance in patients (compare with genotype GG)		[ 333]
Antineoplastic agents	N.A.	Neoplasm	Correlated with the increased severity of nausea in patients (compare with genotypes AA + GG)		[ 364]
Genotype GA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the increased nonresponse risk in patients		[ 373]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:       415 Drugs in Total
Fluorouracil	Drug Info	Colorectal Neoplasm	Correlated with the decreased diarrhea risk in patients (compare with genotype AA); Irrelevant to the drug response in patients (compare with genotypes AA + AG); Irrelevant to the drug toxicity in patients (compare with genotypes AA + AG)		[ 338], [ 393]
Cyclosporine	Drug Info	Transplantation	Correlated with the decreased drug concentrations in patients (compare with genotype AA); Correlated with the decreased drug intracellular and blood concentration in patients (compare with genotypes AA + AG)		[ 352], [ 394]
Verapamil	Drug Info	Healthy Individuals	Correlated with the decreased drug metabolism in healthy individuals (compare with genotypes AA + AG)		[ 363]
Atorvastatin	Drug Info	Coronary Artery Disease	Correlated with the decreased drug response in patients (compare with genotypes AA + AG); Irrelevant to the drug response in patients (compare with genotype AA)		[ 20], [ 397]
Vincristine	Drug Info	Multiple Myeloma	Correlated with the decreased survival in patients (compare with genotype AA)		[ 354]
Dexamethasone	Drug Info	Multiple Myeloma	Correlated with the decreased survival in patients (compare with genotype AA)		[ 354]
Doxorubicin	Drug Info	Multiple Myeloma	Correlated with the decreased survival in patients (compare with genotype AA)		[ 354]
Fluorouracil	Drug Info	Esophageal Neoplasm	Correlated with the decreased survival rate in patients (compare with genotypes AA + AG)		[ 167]
Cisplatin	Drug Info	Esophageal Neoplasm	Correlated with the decreased survival rate in patients (compare with genotypes AA + AG)		[ 167]
Fluorouracil	Drug Info	Breast Neoplasm	Correlated with the increased anemia risk in patients (compare with genotypes AA + AG)		[ 353]
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the increased anemia risk in patients (compare with genotypes AA + AG)		[ 353]
Cyclophosphamide	Drug Info	Breast Neoplasm	Correlated with the increased anemia risk in patients (compare with genotypes AA + AG)		[ 353]
Probenecid	Drug Info	Gout; Hyperuricemia	Correlated with the increased drug clearance (compare with genotype AG)		[ 355]
Dicloxacillin	Drug Info	Cystic Fibrosis	Correlated with the increased drug clearance (compare with genotype AG)		[ 355]
Carbamazepine	Drug Info	Epilepsy	Correlated with the increased drug concentrations in patients (compare with genotype AG); Irrelevant to the drug resistance in patients (compare with genotypes AA + AG)		[ 381], [ 404]
Paliperidone	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with Genotypes AA + AG)		[ 271]
Risperidone	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with Genotypes AA + AG)		[ 271]
Digoxin	Drug Info	Congestive Cardiac Insufficiency; Arrhythmias; Heart Failure	Correlated with the increased drug metabolism (compare with genotype AA)		[ 406]
Etoposide	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased drug metabolism in patients (compare with genotypes AA + AG)		[ 344]
Tacrolimus	Drug Info	Liver Transplantation	Correlated with the increased drug metabolism in patients (compare with genotypes AA + AG); Irrelevant to the drug dose-adjusted trough concentrations in patients (compare with genotypes AA + AG); Irrelevant to the drug metabolism in patients (compare with genotypes AA + AG)		[ 408], [ 409], [ 410]
Clopidogrel	Drug Info	Hypertension	Correlated with the increased drug resistance in patients (compare with genotype AA)		[ 411]
Phenobarbital	Drug Info	Epilepsy	Correlated with the increased drug resistance in patients (compare with genotype AA)		[ 349]
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the increased drug response in patients (compare with genotypes AA + AG); Irrelevant to the drug response in patients (compare with genotypes AA + AG)		[ 343], [ 414]
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the increased drug toxicity risk in patients (compare with genotypes AA + AG)		[ 415]
Sunitinib	Drug Info	Renal Cell Carcinoma	Correlated with the increased exanthema and mucositis risk in patients (compare with genotypes AA + AG)		[ 416]
Clopidogrel	Drug Info	Acute Coronary Syndrome	Correlated with the increased ischaemic events risk in patients (compare with genotypes AA + AG)		[ 417]
Cytarabine	Drug Info	Acute Myeloid Leukemia	Correlated with the increased likelihood of 3-year Event Free Survival in patients (compare with genotypes AA + AG); Correlated with the increased likelihood of complete remission in patients (compare with genotypes AA + AG)		[ 375]
Cytarabine	Drug Info	Acute Multiple Myeloma	Irrelevant to the decreased survival in patients (compare with genotype AA)		[ 419]
Tacrolimus	Drug Info	Kidney Transplantation	Irrelevant to the drug clearance in patients (compare with genotypes AA + AG); Irrelevant to the drug dose-adjusted trough concentrations in patients (compare with Allele T); Irrelevant to the drug dose-adjusted trough concentrations in patients (compare with genotypes AA + AG); Irrelevant to the drug metabolism in patients (compare with genotypes AA + AG); Irrelevant to the glomerular filtration rate in patients (compare with genotypes AA + AG)		[ 357], [ 420], [ 421], [ 423], [ 424]
Bilirubin	Drug Info	HIV Infection	Irrelevant to the drug concentrations in patients (compare with genotypes AA + AG)		[ 425]
Tacrolimus	Drug Info	Organ Transplantation	Irrelevant to the drug concentrations in patients (compare with genotypes AA + AG)		[ 426]
Tacrolimus	Drug Info	Rheumatoid Arthritis	Irrelevant to the drug dose-adjusted trough concentrations in patients (compare with genotypes AA + AG)		[ 427]
Simvastatin	Drug Info	Hypercholesterolemia	Irrelevant to the drug response in patients (compare with genotypes AA + AG)		[ 3]
Irinotecan	Drug Info	Colorectal Neoplasm	Irrelevant to the drug response in patients (compare with genotypes AA + AG); Irrelevant to the drug toxicity in patients (compare with genotypes AA + AG)		[ 393]
Oxaliplatin	Drug Info	Colorectal Neoplasm	Irrelevant to the drug response in patients (compare with genotypes AA + AG); Irrelevant to the drug toxicity in patients (compare with genotypes AA + AG)		[ 393]
Agomelatine	Drug Info	Depressive Disorder	Correlated with the increased drug response in patients (compare with genotypes AA + AG)		[ 360]
Oxcarbazepine	Drug Info	Epilepsy	Correlated with the increased drug concentrations in patients (compare with genotypes AA + AG)		[ 51]
Venlafaxine	Drug Info	Depressive Disorder	Correlated with the increased drug response in patients (compare with genotypes AA + AG)		[ 360]
Venlafaxine	Drug Info	Narcolepsy	Irrelevant to the drug response in patients (compare with genotypes AA + AG)		[ 345]
Nevirapine	Drug Info	HIV Infection	Irrelevant to the drug metabolism in patients (compare with genotype AA)		[ 432]
Atazanavir	Drug Info	HIV Infection	Correlated with the increased drug concentrations in patients (compare with genotypes AA + AG); Irrelevant to the drug concentrations in patients (compare with genotypes AA + AG)		[ 425], [ 171]
Efavirenz	Drug Info	HIV Infection	Correlated with the decreased drug clearance in patients (compare with genotype AG); Irrelevant to the drug metabolism in patients (compare with genotype AA)		[ 432], [ 263]
Silibinin	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with genotype AA)		[ 342]
Idarubicin	Drug Info	Acute Myeloid Leukemia	Correlated with the increased likelihood of 3-year Event Free Survival in patients (compare with genotypes AA + AG); Correlated with the increased likelihood of complete remission in patients (compare with genotypes AA + AG)		[ 375]
Capecitabine	Drug Info	Colorectal Neoplasm	Correlated with the increased hand-foot syndrome risk in patients (compare with genotype AA)		[ 338]
Aspirin	N.A.	Overall Survival	Genotype GG is associated with increased clinical benefit to aspirin in people with Stroke as compared to genotypes AA + AG.		[ 436]
Posaconazole	N.A.	Vomiting	Genotype GG is associated with decreased dose-adjusted trough concentrations of posaconazole null tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.		[ 437]
Tacrolimus	N.A.	Vomiting	Genotype GG is associated with decreased dose-adjusted trough concentrations of posaconazole null tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.		[ 437]
Methotrexate	N.A.	Drug Toxicity	Genotype GG is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.		[ 415]
Rhodamine 123	N.A.	Drug Toxicity	Genotype GG is associated with increased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes AA + AG.		[ 339]
Tacrolimus	N.A.	Drug Toxicity	Genotype GG is associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.		[ 408]
Prednisone	N.A.	Transplant Rejection	Genotype GG is associated with increased risk of remaining on steroids at 1 year after transplantation when treated with prednisone and tacrolimus in people with heart transplantation as compared to genotypes AA + AG.		[ 358]
Tacrolimus	N.A.	Transplant Rejection	Genotype GG is associated with increased risk of remaining on steroids at 1 year after transplantation when treated with prednisone and tacrolimus in people with heart transplantation as compared to genotypes AA + AG.		[ 358]
Tacrolimus	N.A.	Delayed Graft Function	Genotype GG is associated with increased likelihood of delayed graft function when treated with tacrolimus in people with as compared to genotypes AA + AG.		[ 440]
Apixaban	N.A.	Arthralgia	Genotype GG is not associated with trough concentration of apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes AA + AG.		[ 441]
Dabigatran	N.A.	Arthralgia	Genotype GG is not associated with trough concentration of apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes AA + AG.		[ 441]
Edoxaban	N.A.	Arthralgia	Genotype GG is not associated with trough concentration of apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes AA + AG.		[ 441]
Rivaroxaban	N.A.	Arthralgia	Genotype GG is not associated with trough concentration of apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes AA + AG.		[ 441]
Antidepressants	N.A.	Adverse Events	Genotype GG is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AG.		[ 442]
Paliperidone	N.A.	Platelet Reactivity	Genotype GG is associated with increased exposure to paliperidone or risperidone in healthy individuals as compared to genotypes AA + AG.		[ 271]
Risperidone	N.A.	Platelet Reactivity	Genotype GG is associated with increased exposure to paliperidone or risperidone in healthy individuals as compared to genotypes AA + AG.		[ 271]
Tacrolimus	N.A.	Adverse Events	Genotype GG is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.		[ 272]
Fluorouracil	N.A.	Adverse Events	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.		[ 393]
Irinotecan	N.A.	Adverse Events	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.		[ 393]
Oxaliplatin	N.A.	Adverse Events	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.		[ 393]
Tacrolimus	N.A.	Drug Resistance	Genotype GG is not associated with creatinine clearance when treated with tacrolimus in children with Kidney Transplantation as compared to genotypes AA + AG.		[ 32]
Apixaban	N.A.	Hemorrhage	Genotype GG is not associated with risk of Hemorrhage when treated with apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes AA + AG.		[ 441]
Dabigatran	N.A.	Hemorrhage	Genotype GG is not associated with risk of Hemorrhage when treated with apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes AA + AG.		[ 441]
Edoxaban	N.A.	Hemorrhage	Genotype GG is not associated with risk of Hemorrhage when treated with apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes AA + AG.		[ 441]
Rivaroxaban	N.A.	Hemorrhage	Genotype GG is not associated with risk of Hemorrhage when treated with apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes AA + AG.		[ 441]
Fluorouracil	N.A.	Drug Toxicity	Genotype GG is not associated with Drug Toxicity when treated with fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.		[ 393]
Irinotecan	N.A.	Drug Toxicity	Genotype GG is not associated with Drug Toxicity when treated with fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.		[ 393]
Oxaliplatin	N.A.	Drug Toxicity	Genotype GG is not associated with Drug Toxicity when treated with fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.		[ 393]
Antiepileptics	N.A.	Diarrhea	Genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics in people with Epilepsy as compared to genotype AA.		[ 445]
Morphine	N.A.	Nausea	Genotype GG is associated with decreased likelihood of Nausea and Vomiting due to morphine in people with Pain, Postoperative as compared to genotypes AA + AG.		[ 446]
Morphine	N.A.	Vomiting	Genotype GG is associated with decreased likelihood of Nausea and Vomiting due to morphine in people with Pain, Postoperative as compared to genotypes AA + AG.		[ 446]
Fluorouracil	N.A.	Diarrhea	Genotype GG is associated with decreased risk of Diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.		[ 338]
Capecitabine	N.A.	Hand-foot Syndrome	Genotype GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.		[ 338]
Antipsychotics	N.A.	Thrombotic Disease	Genotype GG is associated with increased dose of antipsychotics in people with Schizophrenia as compared to genotype AA.		[ 187]
Cyclosporine	N.A.	Toxic Liver Disease	Genotype GG is not associated with patient stability when treated with cyclosporine in people with Kidney Transplantation as compared to genotype AG.		[ 448]
Tacrolimus	N.A.	Progression-free Survival	Genotype GG is not associated with metabolism of tacrolimus in children with liver transplantation as compared to genotypes AA + AG.		[ 410]
Antidepressants	N.A.	Treatment Failure	Genotype GG is associated with increased severity of treatment failure and treatment modification when treated with antidepressants and antipsychotics in children with Psychotic Disorders, Attention Deficit Disorder with Hyperactivity and Depressive Disorder, Major as compared to genotype AA.		[ 449]
Antidepressants	N.A.	Treatment Modification	Genotype GG is associated with increased severity of treatment failure and treatment modification when treated with antidepressants and antipsychotics in children with Psychotic Disorders, Attention Deficit Disorder with Hyperactivity and Depressive Disorder, Major as compared to genotype AA.		[ 449]
Antipsychotics	N.A.	Treatment Failure	Genotype GG is associated with increased severity of treatment failure and treatment modification when treated with antidepressants and antipsychotics in children with Psychotic Disorders, Attention Deficit Disorder with Hyperactivity and Depressive Disorder, Major as compared to genotype AA.		[ 449]
Antipsychotics	N.A.	Treatment Modification	Genotype GG is associated with increased severity of treatment failure and treatment modification when treated with antidepressants and antipsychotics in children with Psychotic Disorders, Attention Deficit Disorder with Hyperactivity and Depressive Disorder, Major as compared to genotype AA.		[ 449]
Tacrolimus	N.A.	Transplant Rejection	Genotype GG is not associated with risk of transplant rejection when treated with tacrolimus in people with liver transplantation as compared to genotypes AA + AG.		[ 351]
Fentanyl	N.A.	Myelosuppression	Genotype GG is not associated with decreased metabolism of fentanyl in women with surgery as compared to genotypes AA + AG.		[ 451]
Verapamil	N.A.	Neutropenia	Genotype GG is associated with decreased metabolism of verapamil in healthy individuals as compared to genotypes AA + AG.		[ 363]
Cyclosporine	N.A.	Neutropenia	Genotype GG is associated with decreased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to genotypes AA + AG.		[ 352]
Morphine	N.A.	Death	Genotype GG is associated with increased response to morphine and nortriptyline in people with Pain as compared to genotypes AA + AG.		[ 185]
Nortriptyline	N.A.	Death	Genotype GG is associated with increased response to morphine and nortriptyline in people with Pain as compared to genotypes AA + AG.		[ 185]
Mitotane	N.A.	Death	Genotype GG is not associated with increased mitotane plasma concentrations when treated with mitotane in people with Adrenocortical Carcinoma as compared to genotypes AA + AG.		[ 453]
Digoxin	N.A.	Exanthema	Genotype GG is associated with increased metabolism of digoxin as compared to genotype AA.		[ 406]
Methylprednisolone	N.A.	Muscular Diseases	Genotype GG is associated with increased severity of Muscular Diseases and Osteonecrosis when treated with methylprednisolone in women with Pemphigus.		[ 454]
Methylprednisolone	N.A.	Osteonecrosis	Genotype GG is associated with increased severity of Muscular Diseases and Osteonecrosis when treated with methylprednisolone in women with Pemphigus.		[ 454]
Efavirenz	N.A.	Adverse Events	Genotype GG is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype AA.		[ 432]
Nevirapine	N.A.	Adverse Events	Genotype GG is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype AA.		[ 432]
Etoposide	N.A.	Adverse Events	Genotype GG is associated with increased metabolism of etoposide in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.		[ 344]
Tacrolimus	N.A.	Adverse Events	Genotype GG is associated with increased dose of tacrolimus in people with Transplantation as compared to genotypes AA + AG.		[ 455]
Cytarabine	N.A.	Epistaxis	Genotype GG is not associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype AA.		[ 419]
Opioids	N.A.	Neutropenia	Genotype GG is not associated with dose of opioids in people with Pain, Postoperative as compared to genotypes AA + AG.		[ 456]
Oxycodone	N.A.	Neutropenia	Genotype GG is not associated with dose of oxycodone in people with Neoplasms as compared to genotypes AA + AG.		[ 340]
Fentanyl	N.A.	Drug-induced Liver Injury	Genotype GG is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes AA + AG.		[ 458]
Tacrolimus	N.A.	Transplant Rejection	Genotype GG is not associated with concentrations of tacrolimus in people with laparoscopic sleeve gastrectomy as compared to genotypes AA + AG.		[ 426]
Donepezil	N.A.	Adverse Events	Genotype GG is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype AA.		[ 459]
Anastrozole	N.A.	Peripheral Nervous System Diseases	Genotype GG is not associated with concentrations of anastrozole in women with Breast Neoplasms as compared to genotypes AA + AG.		[ 234]
Tacrolimus	N.A.	Adverse Events	Genotype GG is not associated with dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.		[ 351]
Aripiprazole	N.A.	Adverse Events	Genotype GG is associated with increased concentrations of aripiprazole and dehydroaripiprazole as compared to genotype AA.		[ 461]
Dehydroaripiprazole	N.A.	Adverse Events	Genotype GG is associated with increased concentrations of aripiprazole and dehydroaripiprazole as compared to genotype AA.		[ 461]
Osimertinib	N.A.	Event-free Survival	Genotype GG is associated with decreased event-free survival when treated with osimertinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 462]
Tacrolimus	N.A.	Event-free Survival	Genotype GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Arthritis, Rheumatoid or Lupus Erythematosus, Systemic as compared to genotypes AA + AG.		[ 427]
Anthracyclines And Related Substances	N.A.	Event-free Survival	Genotype GG is associated with increased time to progression when treated with anthracyclines and related substances, doxorubicin and epirubicin in people with Breast Neoplasms as compared to genotypes AA + AG.		[ 463]
Doxorubicin	N.A.	Event-free Survival	Genotype GG is associated with increased time to progression when treated with anthracyclines and related substances, doxorubicin and epirubicin in people with Breast Neoplasms as compared to genotypes AA + AG.		[ 463]
Epirubicin	N.A.	Event-free Survival	Genotype GG is associated with increased time to progression when treated with anthracyclines and related substances, doxorubicin and epirubicin in people with Breast Neoplasms as compared to genotypes AA + AG.		[ 463]
Methotrexate	N.A.	Asthenia	Genotype GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.		[ 464]
Atazanavir	N.A.	Death	Genotype GG is associated with increased concentrations of atazanavir in people with HIV Infections as compared to genotypes AA + AG.		[ 171]
Digoxin	N.A.	Acute Cellular Rejection	Genotype GG is not associated with clearance of digoxin in people with Heart Failure as compared to genotypes AA + AG.		[ 465]
Tacrolimus	N.A.	Acute Cellular Rejection	Genotype GG is associated with increased dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.		[ 466]
Tacrolimus	N.A.	Acute Cellular Rejection	Genotype GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele T.		[ 421]
Irinotecan	N.A.	Neutropenia	Genotype GG is not associated with Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 467]
Phenobarbital	N.A.	Neutropenia	Genotype GG is associated with increased resistance to phenobarbital in people with Epilepsy as compared to genotype AA.		[ 349]
Irinotecan	N.A.	Diarrhea	Genotype GG is not associated with Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 467]
Imatinib	N.A.	Diarrhea	Genotype GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.		[ 468]
Silibinin	N.A.	Diarrhea	Genotype GG is associated with increased exposure to silibinin in healthy individuals as compared to genotype AA.		[ 342]
Digoxin	N.A.	Drug Toxicity	Genotype GG is associated with increased clearance of digoxin in healthy individuals as compared to genotype AA.		[ 469]
Glucocorticoids	N.A.	Neutropenia	Genotype GG is associated with decreased response to glucocorticoids in people with Crohn Disease.		[ 470]
Clopidogrel	N.A.	Neutropenia	Genotype GG is associated with increased resistance to clopidogrel in people with Hypertension as compared to genotype AA.		[ 411]
Folfiri	N.A.	Overall Survival	Genotype GG is associated with decreased overall survival when treated with FOLFIRI, FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.		[ 471]
Folfox	N.A.	Overall Survival	Genotype GG is associated with decreased overall survival when treated with FOLFIRI, FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.		[ 471]
Xelox	N.A.	Overall Survival	Genotype GG is associated with decreased overall survival when treated with FOLFIRI, FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.		[ 471]
Atorvastatin	N.A.	Overall Survival	Genotype GG is not associated with response to atorvastatin as compared to genotype AA.		[ 397]
Ondansetron	N.A.	Vomiting	Genotype GG is associated with increased likelihood of Vomiting when treated with ondansetron in people with Leukemia, Myeloid, Acute.		[ 472]
Simvastatin	N.A.	Nephrotoxicity	Genotype GG is not associated with response to simvastatin in people with Hypercholesterolemia as compared to genotypes AA + AG.		[ 3]
Platinum Compounds	N.A.	Neutropenia	Genotype GG is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 369]
Atorvastatin	N.A.	Renal Transplant Failure	Genotype GG is associated with decreased response to atorvastatin in people with Coronary Artery Disease as compared to genotypes AA + AG.		[ 20]
Efavirenz	N.A.	Renal Transplant Failure	Genotype GG is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype AG.		[ 263]
Imatinib	N.A.	Hypersensitivity	Genotype GG is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.		[ 414]
Sufentanil	N.A.	Pain, Postoperative	Genotype GG is associated with increased severity of Pain, Postoperative when treated with sufentanil in children with Pain, Postoperative as compared to genotypes AA + AG.		[ 474]
Tacrolimus	N.A.	Transplant Rejection	Genotype GG is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.		[ 420]
Sunitinib	N.A.	Transplant Rejection	Genotype GG is associated with increased exposure to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AG.		[ 416]
Remifentanil	N.A.	Transplant Rejection	Genotype GG is not associated with response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.		[ 475]
Sevoflurane	N.A.	Transplant Rejection	Genotype GG is not associated with response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.		[ 475]
Atazanavir	N.A.	Hypersensitivity	Genotype GG is not associated with concentrations of atazanavir or bilirubin in people with HIV Infections as compared to genotypes AA + AG.		[ 425]
Bilirubin	N.A.	Hypersensitivity	Genotype GG is not associated with concentrations of atazanavir or bilirubin in people with HIV Infections as compared to genotypes AA + AG.		[ 425]
Oxcarbazepine	N.A.	Hypertension	Genotype GG is associated with increased concentrations of oxcarbazepine in people with Epilepsy as compared to genotypes AA + AG.		[ 51]
Cyclosporine	N.A.	Hypertension	Genotype GG is associated with decreased concentrations of cyclosporine in people with Kidney Transplantation as compared to genotype AA.		[ 394]
Cytarabine	N.A.	Cholelithiasis	Genotype GG is associated with increased likelihood of Complete Remission when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.		[ 375]
Idarubicin	N.A.	Cholelithiasis	Genotype GG is associated with increased likelihood of Complete Remission when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.		[ 375]
Carbamazepine	N.A.	Cholelithiasis	Genotype GG is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotype AG.		[ 404]
Tacrolimus	N.A.	Hypersensitivity	Genotype GG is not associated with metabolism of tacrolimus in children with Kidney Transplantation as compared to genotypes AA + AG.		[ 423]
Efavirenz	N.A.	Stroke	Genotype GG is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes AA + AG.		[ 476]
Tacrolimus	N.A.	Overall Survival	Genotype GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.		[ 357]
Tacrolimus	N.A.	High On-treatment Platelet Reactivity	Genotype GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.		[ 409]
Amlodipine	N.A.	High On-treatment Platelet Reactivity	Genotype GG is associated with decreased clearance of amlodipine in healthy individuals as compared to genotypes AA + AG.		[ 477]
Gefitinib	N.A.	Hypertension	Genotype GG are not associated with concentrations of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 478]
Gefitinib	N.A.	Cardiotoxicity	Genotype GG is not associated with metabolism of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 479]
Cytarabine	N.A.	Elevated Liver Enzymes	Genotype GG is associated with increased likelihood of elevated liver enzymes when treated with cytarabine and daunorubicin in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.		[ 480]
Daunorubicin	N.A.	Elevated Liver Enzymes	Genotype GG is associated with increased likelihood of elevated liver enzymes when treated with cytarabine and daunorubicin in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.		[ 480]
Sunitinib	N.A.	Exanthema	Genotype GG is associated with increased risk of Exanthema and mucositis when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AG.		[ 416]
Sunitinib	N.A.	Mucositis	Genotype GG is associated with increased risk of Exanthema and mucositis when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AG.		[ 416]
Sufentanil	N.A.	Mucositis	Genotype GG is associated with increased dose of sufentanil in children with Pain, Postoperative as compared to genotypes AA + AG.		[ 474]
Efavirenz	N.A.	Exanthema	Genotype GG is associated with decreased likelihood of Exanthema when treated with efavirenz, lamivudine and tenofovir in people with HIV Infections as compared to genotypes AA + AG.		[ 385]
Lamivudine	N.A.	Exanthema	Genotype GG is associated with decreased likelihood of Exanthema when treated with efavirenz, lamivudine and tenofovir in people with HIV Infections as compared to genotypes AA + AG.		[ 385]
Tenofovir	N.A.	Exanthema	Genotype GG is associated with decreased likelihood of Exanthema when treated with efavirenz, lamivudine and tenofovir in people with HIV Infections as compared to genotypes AA + AG.		[ 385]
Agomelatine	N.A.	Leukopenia	Genotype GG is associated with increased response to agomelatine, Melatonin receptor agonists, Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder as compared to genotypes AA + AG.		[ 360]
Melatonin Receptor Agonists	N.A.	Leukopenia	Genotype GG is associated with increased response to agomelatine, Melatonin receptor agonists, Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder as compared to genotypes AA + AG.		[ 360]
Selective Serotonin Reuptake Inhibitors	N.A.	Leukopenia	Genotype GG is associated with increased response to agomelatine, Melatonin receptor agonists, Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder as compared to genotypes AA + AG.		[ 360]
Venlafaxine	N.A.	Leukopenia	Genotype GG is associated with increased response to agomelatine, Melatonin receptor agonists, Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder as compared to genotypes AA + AG.		[ 360]
Clopidogrel	N.A.	Treatment Failure	Genotype GG is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AA + AG.		[ 417]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Genotype GG is associated with decreased risk of Peripheral Nervous System Diseases when treated with paclitaxel in people with Neoplasms as compared to genotypes AA + AG.		[ 322]
Opioids	N.A.	Opioid-related Disorders	Genotype GG is associated with decreased risk of Opioid-Related Disorders when exposed to opioids as compared to genotype AG.		[ 377]
Dexamethasone	N.A.	Toxic Liver Disease	Genotype GG is associated with decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype AA.		[ 354]
Doxorubicin	N.A.	Toxic Liver Disease	Genotype GG is associated with decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype AA.		[ 354]
Vincristine	N.A.	Toxic Liver Disease	Genotype GG is associated with decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype AA.		[ 354]
Efavirenz	N.A.	Toxic Liver Disease	Genotype GG is not associated with clearance of efavirenz in children with HIV Infections.		[ 484]
Warfarin	N.A.	Drug Toxicity	Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.		[ 485]
Tacrolimus	N.A.	Drug-induced Liver Injury	Genotype GG is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.		[ 424]
Imatinib	N.A.	Drug Toxicity	Genotype GG is associated with decreased severity of Drug Toxicity when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.		[ 468]
Galantamine	N.A.	Drug Toxicity	Genotype GG is not associated with dose-adjusted plasma levels of galantamine in people with Dementia as compared to genotypes AA + AG.		[ 486]
Cisplatin	N.A.	Toxic Liver Disease	Genotype GG is associated with decreased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotypes AA + AG.		[ 167]
Fluorouracil	N.A.	Toxic Liver Disease	Genotype GG is associated with decreased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotypes AA + AG.		[ 167]
Cyclophosphamide	N.A.	Anemia	Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG.		[ 353]
Doxorubicin	N.A.	Anemia	Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG.		[ 353]
Fluorouracil	N.A.	Anemia	Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG.		[ 353]
Venlafaxine	N.A.	Anemia	Genotype GG is not associated with response to venlafaxine in people with Narcolepsy as compared to genotypes AA + AG.		[ 345]
Gefitinib	N.A.	Drug Toxicity	Genotype GG is not associated with risk of Drug Toxicity when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 478]
Imatinib	N.A.	Drug Toxicity	Genotype GG is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.		[ 343]
Tacrolimus	N.A.	Decreased Glomerular Filtration Rate	Genotype GG is not associated with Decreased glomerular filtration rate when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.		[ 357]
Carbamazepine	N.A.	Decreased Glomerular Filtration Rate	Genotype GG is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes AA + AG.		[ 381]
Pantoprazole	N.A.	Adverse Events	Genotype GG is not associated with increased response to pantoprazole in people with Helicobacter Infections as compared to genotypes AA + AG.		[ 487]
Dicloxacillin	N.A.	Adverse Events	Genotype GG is associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG.		[ 355]
Probenecid	N.A.	Adverse Events	Genotype GG is associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG.		[ 355]
Digoxin	N.A.	Neurotoxicity Syndromes	Genotype GG is associated with increased steady-state level of digoxin as compared to genotypes AA + AG.		[ 367]
Remifentanil	N.A.	Hypersensitivity	Genotype GG is associated with increased dose of remifentanil as compared to genotype AA.		[ 206]
Cisplatin	N.A.	Neoplasm Of Esophagus	Genotype GG is associated with decreased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotypes AA + AG.		[ 167]
Fluorouracil	N.A.	Neoplasm Of Esophagus	Genotype GG is associated with decreased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotypes AA + AG.		[ 167]
Cisplatin	N.A.	Neoplasm Of Esophagus	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.		[ 393]
Fluorouracil	N.A.	Neoplasm Of Esophagus	Genotype GG is not associated with response to fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.		[ 393]
Cisplatin	N.A.	Neoplasm Of Esophagus	Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.		[ 337]
Fluorouracil	N.A.	Neoplasm Of Esophagus	Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.		[ 337]
Fluorouracil	N.A.	Colorectal Neoplasms	Genotype GG is associated with decreased risk of Diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.		[ 338]
Fluorouracil	N.A.	Colorectal Neoplasms	Genotype GG is not associated with Drug Toxicity when treated with fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.		[ 393]
Fentanyl	N.A.	Pain	Genotype GG is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes AA + AG.		[ 458]
Fentanyl	N.A.	Pain, Postoperative	Genotype GG is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes AA + AG.		[ 458]
Fentanyl	N.A.	Pain	Patients with the rs1054642 GG genotype may have increased fentanyl dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements.		[ 329]
Fentanyl	N.A.	Pain, Postoperative	Patients with the rs1054642 GG genotype may have increased fentanyl dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements.		[ 329]
Ondansetron	N.A.	Postoperative Nausea And Vomiting	Genotype GG is associated with increased likelihood of Vomiting when treated with ondansetron in people with Leukemia, Myeloid, Acute.		[ 472]
Ondansetron	N.A.	Postoperative Nausea And Vomiting	Patients with the rs1045642 GG genotype may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to ondansetron.		[ 235]
Ondansetron	N.A.	Vomiting	Patients with the rs1045642 GG genotype may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to ondansetron.		[ 235]
Nevirapine	N.A.	HIV Infectious Disease	Patients with the rs1045642 GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment.		[ 52]
Nevirapine	N.A.	Toxic Liver Disease	Patients with the rs1045642 GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment.		[ 52]
Opioids	N.A.	Low Back Pain	Patients with the rs1045642 GG genotype may be more likely to experience nausea when treated with opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of experiencing nausea when treated with opioids.		[ 196]
Antiepileptics	N.A.	Epilepsies, Partial	Genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics in people with Epilepsy as compared to genotype AA.		[ 445]
Antiepileptics	N.A.	Epilepsy	Genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics in people with Epilepsy as compared to genotype AA.		[ 445]
Antiepileptics	N.A.	Epilepsy, Idiopathic Generalized	Genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics in people with Epilepsy as compared to genotype AA.		[ 445]
Antiepileptics	N.A.	Epilepsies, Partial	The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics.		[ 200]
Antiepileptics	N.A.	Epilepsy	The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics.		[ 200]
Antiepileptics	N.A.	Epilepsy, Idiopathic Generalized	The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics.		[ 200]
Codeine	N.A.	HIV Infectious Disease	Patients with the GG genotype may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine.		[ 14]
Methadone	N.A.	Heroin Dependence	The current evidence base suggests that there is no significant association between rs1045642 GG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.		[ 250]
Methadone	N.A.	Opioid-related Disorders	The current evidence base suggests that there is no significant association between rs1045642 GG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.		[ 250]
Oxycodone	N.A.	Pain	Genotype GG is not associated with dose of oxycodone in people with Neoplasms as compared to genotypes AA + AG.		[ 340]
Methadone	N.A.	Pain	Patients with the rs1045642 GG genotype and who are receiving methadone for analgesia may required an increased dose as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's methadone dose requirements for analgesia.		[ 70]
Tamoxifen	N.A.	Breast Neoplasms	Women with the GG genotype and breast cancer may have a decreased chance of disease recurrence when treated with tamoxifen as compared to patients with the AG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.		[ 341]
Daptomycin	N.A.	Breast Neoplasms	Patients with the GG genotype may increased clearance of daptomycin, resulting in decreased concentrations of the drug, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of daptomycin.		[ 264]
Antivirals For Treatment Of HIV Infections, Combinations	N.A.	HIV Infectious Disease	Patients with the GG genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.		[ 321]
Antivirals For Treatment Of HIV Infections, Combinations	N.A.	Tuberculosis	Patients with the GG genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.		[ 321]
Drugs For Treatment Of Tuberculosis	N.A.	HIV Infectious Disease	Patients with the GG genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.		[ 321]
Drugs For Treatment Of Tuberculosis	N.A.	Tuberculosis	Patients with the GG genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.		[ 321]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Genotype GG is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.		[ 343]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Genotype GG is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.		[ 414]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the GG genotype and Hypercholesterolemia who are treated with simvastatin may have a higher risk of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.		[ 3]
Simvastatin	N.A.	Myalgia	Patients with the GG genotype and Hypercholesterolemia who are treated with simvastatin may have a higher risk of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.		[ 3]
Clopidogrel	N.A.	Acute Coronary Syndrome	Genotype GG is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AA + AG.		[ 417]
Clopidogrel	N.A.	Myocardial Infarction	Genotype GG is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AA + AG.		[ 417]
Clopidogrel	N.A.	Acute Coronary Syndrome	People with GG genotype may have decreased, but not absent, risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.		[ 42]
Clopidogrel	N.A.	Myocardial Infarction	People with GG genotype may have decreased, but not absent, risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.		[ 42]
Etoposide	N.A.	Acute Lymphoblastic Leukemia	Genotype GG is associated with increased metabolism of etoposide in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.		[ 344]
Tacrolimus	N.A.	Ulcerative Colitis	Patients with the GG genotype and ulcerative colitis may have a poorer chance at achieving remission when treated with tacrolimus as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission.		[ 311]
Modafinil	N.A.	Narcolepsy	Patients with genotype GG and narcolepsy may have decreased response to modafinil compared to patients with genotype AG. Other clinical and genetic factors may affect a patient's response to modafinil.		[ 345]
Sorafenib	N.A.	Hypertension	Patients with the GG genotype may have decreased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the toxicity to sorafenib.		[ 346]
Sorafenib	N.A.	Renal Cell Carcinoma	Patients with the GG genotype may have decreased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the toxicity to sorafenib.		[ 346]
Lansoprazole	N.A.	Gastroesophageal Reflux	Patients with the GG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.		[ 212]
Lansoprazole	N.A.	Transplantation	Patients with the GG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.		[ 212]
Tacrolimus	N.A.	Gastroesophageal Reflux	Patients with the GG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.		[ 212]
Tacrolimus	N.A.	Transplantation	Patients with the GG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.		[ 212]
Rivaroxaban	N.A.	Transplantation	People with the GG genotype may have decreased exposure to rivaroxaban compared to people with the AA and AG genotypes when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.		[ 347]
Methadone	N.A.	Opioid-related Disorders	Patients with the rs1045642 GG genotype who are receiving methadone maintenance therapy may have decreased clearance of methadone, leading to increased plasma concentration of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone clearance and plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs1045642 and methadone and does not include evidence about clinical outcomes.		[ 249]
Olanzapine	N.A.	Psychotic Disorder	Patients with the GG genotype and Psychotic Disorders who are treated with olanzapine may have decreased social and clinical needs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.		[ 122]
Everolimus	N.A.	Breast Neoplasms	Patients with the GG genotype and breast cancer who are treated with everolimus may have decreased likelihood of Mucositis as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.		[ 19]
Everolimus	N.A.	Mucositis	Patients with the GG genotype and breast cancer who are treated with everolimus may have decreased likelihood of Mucositis as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.		[ 19]
Sirolimus	N.A.	Kidney Transplantation	Patients with the GG genotype who underwent kidney transplantation may have decreased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.		[ 348]
Anthracyclines And Related Substances	N.A.	Breast Neoplasms	Patients with the GG genotype may have decreased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.		[ 304]
Taxanes	N.A.	Breast Neoplasms	Patients with the GG genotype may have decreased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.		[ 304]
Phenobarbital	N.A.	Epilepsy	Genotype GG is associated with increased resistance to phenobarbital in people with Epilepsy as compared to genotype AA.		[ 349]
Carbamazepine	N.A.	Epilepsy	Genotype GG is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotype AG.		[ 404]
Carbamazepine	N.A.	Epilepsy	Patients with the GG genotype and epilepsy may have decreased metabolism of carbamazepine and may need a decreased dose as compared to patients with the AG genotype. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence concentrations of carbamazepine.		[ 159]
Atorvastatin	N.A.	Coronary Artery Disease	Patients with the GG genotype and Coronary Artery Disease who are treated with atorvastatin may have a lower likelihood of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.		[ 163]
Atorvastatin	N.A.	Myalgia	Patients with the GG genotype and Coronary Artery Disease who are treated with atorvastatin may have a lower likelihood of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.		[ 163]
Risperidone	N.A.	Schizophrenia	Patients with the GG genotype and schizophrenia may have a shorter QTc interval when treated with risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.		[ 350]
Oxaliplatin	N.A.	Colorectal Neoplasms	Patients with the GG genotype and colorectal cancer did not have a statistically significant different period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 337]
Tacrolimus	N.A.	Kidney Transplantation	Genotype GG is not associated with risk of transplant rejection when treated with tacrolimus in people with liver transplantation as compared to genotypes AA + AG.		[ 351]
Tramadol	N.A.	Fractures, Bone	Patients with the rs1045642 GG genotype may have a decreased analgesic response to tramadol as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Tramadol	N.A.	Pain	Patients with the rs1045642 GG genotype may have a decreased analgesic response to tramadol as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Tramadol	N.A.	Pain, Postoperative	Patients with the rs1045642 GG genotype may have a decreased analgesic response to tramadol as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Efavirenz	N.A.	HIV Infectious Disease	Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.		[ 4]
Nelfinavir	N.A.	HIV Infectious Disease	Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.		[ 4]
Methylprednisolone	N.A.	Kidney Transplantation	Patients with the GG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.		[ 228]
Prednisolone	N.A.	Kidney Transplantation	Patients with the GG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.		[ 228]
Cyclosporine	N.A.	Transplantation	Genotype GG is associated with decreased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to genotypes AA + AG.		[ 352]
Cyclosporine	N.A.	Transplantation	Genotype GG is associated with decreased concentrations of cyclosporine in people with Kidney Transplantation as compared to genotype AA.		[ 394]
Tramadol	N.A.	Opioid-related Disorders	Patients with the rs1045642 GG genotype may have an increased risk of developing opioid dependence when treated with tramadol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.		[ 88]
Cyclophosphamide	N.A.	Breast Neoplasms	Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG.		[ 353]
Doxorubicin	N.A.	Breast Neoplasms	Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG.		[ 353]
Fluorouracil	N.A.	Breast Neoplasms	Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG.		[ 353]
Bleomycin	N.A.	Testicular Neoplasms	Patients with testicular cancer and the GG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.		[ 155]
Bleomycin	N.A.	Vomiting	Patients with testicular cancer and the GG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.		[ 155]
Cisplatin	N.A.	Testicular Neoplasms	Patients with testicular cancer and the GG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.		[ 155]
Cisplatin	N.A.	Vomiting	Patients with testicular cancer and the GG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.		[ 155]
Etoposide	N.A.	Testicular Neoplasms	Patients with testicular cancer and the GG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.		[ 155]
Etoposide	N.A.	Vomiting	Patients with testicular cancer and the GG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.		[ 155]
Phenytoin	N.A.	Glioma	Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.		[ 21]
Dexamethasone	N.A.	Multiple Myeloma	Genotype GG is associated with decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype AA.		[ 354]
Doxorubicin	N.A.	Multiple Myeloma	Genotype GG is associated with decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype AA.		[ 354]
Vincristine	N.A.	Multiple Myeloma	Genotype GG is associated with decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype AA.		[ 354]
Capecitabine	N.A.	Neoplasms	Genotype GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.		[ 338]
Capecitabine	N.A.	Neoplasms	Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.		[ 356]
Tacrolimus	N.A.	Kidney Transplantation	Genotype GG is not associated with Decreased glomerular filtration rate when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.		[ 357]
Prednisone	N.A.	Organ Transplantation	Genotype GG is associated with increased risk of remaining on steroids at 1 year after transplantation when treated with prednisone and tacrolimus in people with heart transplantation as compared to genotypes AA + AG.		[ 358]
Prednisone	N.A.	Transplantation	Genotype GG is associated with increased risk of remaining on steroids at 1 year after transplantation when treated with prednisone and tacrolimus in people with heart transplantation as compared to genotypes AA + AG.		[ 358]
Tacrolimus	N.A.	Organ Transplantation	Genotype GG is associated with increased risk of remaining on steroids at 1 year after transplantation when treated with prednisone and tacrolimus in people with heart transplantation as compared to genotypes AA + AG.		[ 358]
Tacrolimus	N.A.	Transplantation	Genotype GG is associated with increased risk of remaining on steroids at 1 year after transplantation when treated with prednisone and tacrolimus in people with heart transplantation as compared to genotypes AA + AG.		[ 358]
Fexofenadine	N.A.	Transplantation	Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.		[ 232]
Pantoprazole	N.A.	Helicobacter Infections	Genotype GG is not associated with increased response to pantoprazole in people with Helicobacter Infections as compared to genotypes AA + AG.		[ 487]
Pantoprazole	N.A.	Helicobacter Infections	The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and eradication of Helicobacter infection when treated with pantoprazole. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of response to pantoprazole.		[ 236]
Oseltamivir	N.A.	Helicobacter Infections	Patients with the GG genotype and acute respiratory diseases and suspected influenza infection may have increased risk of side effects when treated with oseltamivir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of oseltamivir side effects.		[ 359]
Venlafaxine	N.A.	Depressive Disorder	Genotype GG is associated with increased response to agomelatine, Melatonin receptor agonists, Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder as compared to genotypes AA + AG.		[ 360]
Venlafaxine	N.A.	Narcolepsy	Genotype GG is associated with increased response to agomelatine, Melatonin receptor agonists, Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder as compared to genotypes AA + AG.		[ 360]
Venlafaxine	N.A.	Depressive Disorder	Genotype GG is not associated with response to venlafaxine in people with Narcolepsy as compared to genotypes AA + AG.		[ 345]
Venlafaxine	N.A.	Narcolepsy	Genotype GG is not associated with response to venlafaxine in people with Narcolepsy as compared to genotypes AA + AG.		[ 345]
Selective Serotonin Reuptake Inhibitors	N.A.	Depressive Disorder	Genotype GG is associated with increased response to agomelatine, Melatonin receptor agonists, Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder as compared to genotypes AA + AG.		[ 360]
Granisetron	N.A.	Neoplasms	Patients with the GG genotype and cancer may have a lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.		[ 261]
Atazanavir	N.A.	HIV Infectious Disease	Genotype GG is associated with increased concentrations of atazanavir in people with HIV Infections as compared to genotypes AA + AG.		[ 171]
Ritonavir	N.A.	HIV Infectious Disease	Genotype GG is associated with increased concentrations of atazanavir in people with HIV Infections as compared to genotypes AA + AG.		[ 171]
Atazanavir	N.A.	HIV Infectious Disease	Genotype GG is not associated with concentrations of atazanavir or bilirubin in people with HIV Infections as compared to genotypes AA + AG.		[ 425]
Ritonavir	N.A.	HIV Infectious Disease	Genotype GG is not associated with concentrations of atazanavir or bilirubin in people with HIV Infections as compared to genotypes AA + AG.		[ 425]
Atazanavir	N.A.	HIV Infectious Disease	Patients with the GG genotype and HIV may have increased concentrations of atazanavir as compared to patients with the AA genotypes, although this is contradicted in most studies. There is no evidence that the GG genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.		[ 102]
Ritonavir	N.A.	HIV Infectious Disease	Patients with the GG genotype and HIV may have increased concentrations of atazanavir as compared to patients with the AA genotypes, although this is contradicted in most studies. There is no evidence that the GG genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.		[ 102]
Agomelatine	N.A.	Depressive Disorder	Genotype GG is associated with increased response to agomelatine, Melatonin receptor agonists, Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder as compared to genotypes AA + AG.		[ 360]
Sunitinib	N.A.	Renal Cell Carcinoma	Genotype GG is associated with increased risk of Exanthema and mucositis when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AG.		[ 416]
Sunitinib	N.A.	Renal Cell Carcinoma	Patients with the GG genotype and renal cell carcinoma may have an increased risk for adverse effects when treated with sunitinib as compared to patients with the AA or AG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities.		[ 41]
Rivaroxaban	N.A.	Renal Cell Carcinoma	Patients with the rs1045642 GG genotype may have increased risk of Thromboembolism when treated with rivaroxaban as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the toxicity to rivaroxaban.		[ 361]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the GG genotype who are undergoing kidney transplantation may have a decreased risk of hypokalemia when treated with tacrolimus as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.		[ 32]
Talinolol	N.A.	Hand-foot Syndrome	Patients with the GG genotype may have decreased clearance of talinolol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of talinolol.		[ 248]
Drugs For Treatment Of Tuberculosis	N.A.	Tuberculosis	Patients with the GG genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatotoxicity.		[ 362]
Isoniazid	N.A.	Tuberculosis	Patients with the GG genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatotoxicity.		[ 362]
Nortriptyline	N.A.	Depression	Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.		[ 265]
Nortriptyline	N.A.	Depressive Disorder	Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.		[ 265]
Nortriptyline	N.A.	Hypotensive Disorder	Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.		[ 265]
Nortriptyline	N.A.	Major Depressive Disorder	Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.		[ 265]
Morphine	N.A.	Pain	Patients with the GG genotype who are treated with morphine may have lower levels of morphine-3-glucuronide formation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.		[ 252]
Antineoplastic Agents	N.A.	Neoplasms	Patients with the GG genotype and receiving chemotherapy treatment may have decreased severity of nausea as compared to patients with the AG genotype. Other genetic and clinical factors may also affect the severity of nausea following chemotherapy treatment.		[ 364]
Opioids	N.A.	Pain	Genotype GG is not associated with dose of opioids in people with Pain, Postoperative as compared to genotypes AA + AG.		[ 456]
Opioids	N.A.	Pain, Postoperative	Genotype GG is not associated with dose of opioids in people with Pain, Postoperative as compared to genotypes AA + AG.		[ 456]
Opioids	N.A.	Pain	Patients with the GG genotype may have increased opioid dose requirements as compared to patients with the AA or AG genotypes. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements.		[ 365]
Opioids	N.A.	Pain, Postoperative	Patients with the GG genotype may have increased opioid dose requirements as compared to patients with the AA or AG genotypes. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements.		[ 365]
Morphine	N.A.	Pain	Patients with the GG genotype may have increased morphine dose requirements as compared to patients with the AA or AG genotypes. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements.		[ 95]
Morphine	N.A.	Pain, Postoperative	Patients with the GG genotype may have increased morphine dose requirements as compared to patients with the AA or AG genotypes. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements.		[ 95]
Morphine	N.A.	Pain	Patients with the GG genotype may have decreased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence response to morphine.		[ 255]
Fentanyl	N.A.	Hypoventilation	Patients with the GG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Fentanyl	N.A.	Pain, Postoperative	Patients with the GG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Hmg Coa Reductase Inhibitors	N.A.	Pain, Postoperative	Patients with the GG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.		[ 332]
Oxcarbazepine	N.A.	Epilepsy	Genotype GG is associated with increased concentrations of oxcarbazepine in people with Epilepsy as compared to genotypes AA + AG.		[ 51]
Warfarin	N.A.	Epilepsy	Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AG or AA genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.		[ 136]
Clozapine	N.A.	Major Depressive Disorder	Patients with the GG genotype may have decreased clozapine plasma concentrations, as well as a decreased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity.		[ 239]
Carbamazepine	N.A.	Epilepsy	Genotype GG is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes AA + AG.		[ 381]
Carbamazepine	N.A.	Epilepsy	Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine.		[ 61]
Paclitaxel	N.A.	Breast Neoplasms	The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paclitaxel.		[ 366]
Paclitaxel	N.A.	Neoplasms	The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paclitaxel.		[ 366]
Docetaxel	N.A.	Breast Neoplasms	The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to docetaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to docetaxel.		[ 86]
Docetaxel	N.A.	Neoplasms	The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to docetaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to docetaxel.		[ 86]
Paclitaxel	N.A.	Drug Toxicity	Genotype GG is associated with decreased risk of Peripheral Nervous System Diseases when treated with paclitaxel in people with Neoplasms as compared to genotypes AA + AG.		[ 322]
Paclitaxel	N.A.	Neoplasms	Genotype GG is associated with decreased risk of Peripheral Nervous System Diseases when treated with paclitaxel in people with Neoplasms as compared to genotypes AA + AG.		[ 322]
Paclitaxel	N.A.	Neutropenia	Genotype GG is associated with decreased risk of Peripheral Nervous System Diseases when treated with paclitaxel in people with Neoplasms as compared to genotypes AA + AG.		[ 322]
Vincristine	N.A.	Acute Lymphoblastic Leukemia	Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased likelihood of event-free survival as compared to patients with the AA genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment.		[ 2]
Risperidone	N.A.	Bipolar Disorder	Genotype GG is associated with increased exposure to paliperidone or risperidone in healthy individuals as compared to genotypes AA + AG.		[ 271]
Risperidone	N.A.	Depression	Genotype GG is associated with increased exposure to paliperidone or risperidone in healthy individuals as compared to genotypes AA + AG.		[ 271]
Risperidone	N.A.	Psychotic Disorder	Genotype GG is associated with increased exposure to paliperidone or risperidone in healthy individuals as compared to genotypes AA + AG.		[ 271]
Risperidone	N.A.	Schizophrenia	Genotype GG is associated with increased exposure to paliperidone or risperidone in healthy individuals as compared to genotypes AA + AG.		[ 271]
Risperidone	N.A.	Substance-related Disorders	Genotype GG is associated with increased exposure to paliperidone or risperidone in healthy individuals as compared to genotypes AA + AG.		[ 271]
Risperidone	N.A.	Bipolar Disorder	Patients with the GG genotype may have increased exposure to risperidone as compared to patients with the AA or AG genotypes. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.		[ 173]
Risperidone	N.A.	Depression	Patients with the GG genotype may have increased exposure to risperidone as compared to patients with the AA or AG genotypes. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.		[ 173]
Risperidone	N.A.	Psychotic Disorder	Patients with the GG genotype may have increased exposure to risperidone as compared to patients with the AA or AG genotypes. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.		[ 173]
Risperidone	N.A.	Schizophrenia	Patients with the GG genotype may have increased exposure to risperidone as compared to patients with the AA or AG genotypes. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.		[ 173]
Risperidone	N.A.	Substance-related Disorders	Patients with the GG genotype may have increased exposure to risperidone as compared to patients with the AA or AG genotypes. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.		[ 173]
Tramadol	N.A.	Substance-related Disorders	Patients with the GG genotype may have a decreased exposure to tramadol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's exposure to tramadol.		[ 251]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.		[ 38]
Losartan	N.A.	Hypertension	Patients with the GG genotype may have poorer response to losartan in people with hypertension as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence the response to losartan.		[ 368]
Platinum Compounds	N.A.	Non-small Cell Lung Carcinoma	Genotype GG is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 369]
Voriconazole	N.A.	Non-small Cell Lung Carcinoma	Patients with the GG genotype may have increased clearance of voriconazole as compared to patients with the AA genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole.		[ 260]
Morphine	N.A.	Pain	Genotype GG is associated with increased response to morphine and nortriptyline in people with Pain as compared to genotypes AA + AG.		[ 185]
Nortriptyline	N.A.	Pain	Genotype GG is associated with increased response to morphine and nortriptyline in people with Pain as compared to genotypes AA + AG.		[ 185]
Antipsychotics	N.A.	Schizophrenia	Genotype GG is associated with increased dose of antipsychotics in people with Schizophrenia as compared to genotype AA.		[ 187]
Anastrozole	N.A.	Arthralgia	Postmenopausal women with HR+ breast cancer and the GG genotype may be more likely to experience arthralgia when treated with anastrozole as compared to women with the AA genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.		[ 234]
Anastrozole	N.A.	Breast Neoplasms	Postmenopausal women with HR+ breast cancer and the GG genotype may be more likely to experience arthralgia when treated with anastrozole as compared to women with the AA genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.		[ 234]
Omeprazole	N.A.	Gastroesophageal Reflux	Patients with the GG genotype and Gastroesphageal reflux who are treated with omeprazole may have decreased absorption rate of omeprazole as compared to patients with the AA or AG genotypes and and decreased response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence Response to and absorption rate of omeprazole in patients gastroesphageal reflux.		[ 236]
Clopidogrel	N.A.	Coronary Disease	Patients with coronary disease and the GG genotype who are treated with clopidogrel may have a decreased risk of hemorrhage as compared to patients with the AG or GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.		[ 9]
Clopidogrel	N.A.	Hemorrhage	Patients with coronary disease and the GG genotype who are treated with clopidogrel may have a decreased risk of hemorrhage as compared to patients with the AG or GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.		[ 9]
Clopidogrel	N.A.	Platelet Reactivity	Genotype GG is associated with increased resistance to clopidogrel in people with Hypertension as compared to genotype AA.		[ 411]
Clopidogrel	N.A.	Platelet Reactivity	Patients with the GG genotype may have an increased response to clopidogrel (increased platelet reactivity) as compared to patients with the AA genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel.		[ 370]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs1045642 GG genotype may have decreased concentrations of methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 241]
Methotrexate	N.A.	Burkitt Lymphoma	Patients with the rs1045642 GG genotype may have decreased concentrations of methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 241]
Methotrexate	N.A.	Lymphoma, T-cell	Patients with the rs1045642 GG genotype may have decreased concentrations of methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 241]
Dabigatran	N.A.	Lymphoma, T-cell	People with the GG genotype may have decreased exposure to dabigatran compared to patients with the AA and AG genotypes, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran.		[ 347]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs1045642 GG genotype and cancer who are treated with methotrexate may have a reduced, but not absent, risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.		[ 371]
Methotrexate	N.A.	Burkitt Lymphoma	Patients with the rs1045642 GG genotype and cancer who are treated with methotrexate may have a reduced, but not absent, risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.		[ 371]
Methotrexate	N.A.	Drug Toxicity	Patients with the rs1045642 GG genotype and cancer who are treated with methotrexate may have a reduced, but not absent, risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.		[ 371]
Methotrexate	N.A.	Lymphoma, T-cell	Patients with the rs1045642 GG genotype and cancer who are treated with methotrexate may have a reduced, but not absent, risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.		[ 371]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype GG is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.		[ 415]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the rs1045642 GG genotype and rheumatoid arthritis who are treated with methotrexate may have an increased risk of drug toxicity as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 372]
Atorvastatin	N.A.	Coronary Artery Disease	Genotype GG is associated with decreased response to atorvastatin in people with Coronary Artery Disease as compared to genotypes AA + AG.		[ 20]
Atorvastatin	N.A.	Coronary Artery Disease	Genotype GG is not associated with response to atorvastatin as compared to genotype AA.		[ 397]
Methotrexate	N.A.	Juvenile Rheumatoid Arthritis	Genotype GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.		[ 464]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.		[ 464]
Methotrexate	N.A.	Juvenile Rheumatoid Arthritis	The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to methotrexate in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.		[ 373]
Methotrexate	N.A.	Rheumatoid Arthritis	The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to methotrexate in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.		[ 373]
Highly Active Antiretroviral Therapy (haart)	N.A.	HIV Infectious Disease	Patients with the rs1045642 GG genotype and HIV may have a decreased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of virological failure on HAART.		[ 374]
Efavirenz	N.A.	HIV Infectious Disease	Genotype GG is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype AG.		[ 263]
Efavirenz	N.A.	HIV Infectious Disease	Genotype GG is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype AA.		[ 432]
Efavirenz	N.A.	HIV Infectious Disease	Genotype GG is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes AA + AG.		[ 476]
Efavirenz	N.A.	HIV Infectious Disease	Genotype GG is not associated with clearance of efavirenz in children with HIV Infections.		[ 484]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Genotype GG is associated with increased likelihood of Complete Remission when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.		[ 375]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Genotype GG is not associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype AA.		[ 419]
Phenytoin	N.A.	Epilepsy	Patients with epilepsy and the GG genotype may have increased likelihood of drug resistance when treated with phenytoin as compared to patients with the AA genotype. However, other studies have failed to find this association. Other genetic or clinical factors may influence a patient's response to phenytoin.		[ 162]
Tacrolimus	N.A.	Organ Transplantation	Genotype GG is associated with increased dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.		[ 376]
Tacrolimus	N.A.	Organ Transplantation	Genotype GG is not associated with metabolism of tacrolimus in children with liver transplantation as compared to genotypes AA + AG.		[ 410]
Tacrolimus	N.A.	Organ Transplantation	Genotype GG is associated with increased dose of tacrolimus in people with Transplantation as compared to genotypes AA + AG.		[ 455]
Tacrolimus	N.A.	Organ Transplantation	Genotype GG is not associated with dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.		[ 351]
Tacrolimus	N.A.	Organ Transplantation	Genotype GG is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.		[ 420]
Tacrolimus	N.A.	Organ Transplantation	Genotype GG is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.		[ 272]
Tacrolimus	N.A.	Organ Transplantation	Genotype GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele T.		[ 421]
Tacrolimus	N.A.	Organ Transplantation	Genotype GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.		[ 357]
Tacrolimus	N.A.	Organ Transplantation	Genotype GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.		[ 409]
Tacrolimus	N.A.	Organ Transplantation	Genotype GG is not associated with metabolism of tacrolimus in children with Kidney Transplantation as compared to genotypes AA + AG.		[ 423]
Tacrolimus	N.A.	Organ Transplantation	Genotype GG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Arthritis, Rheumatoid or Lupus Erythematosus, Systemic as compared to genotypes AA + AG.		[ 427]
Tacrolimus	N.A.	Organ Transplantation	Genotype GG is not associated with concentrations of tacrolimus in people with laparoscopic sleeve gastrectomy as compared to genotypes AA + AG.		[ 426]
Tacrolimus	N.A.	Organ Transplantation	Genotype GG is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.		[ 424]
Tacrolimus	N.A.	Organ Transplantation	Genotype GG is associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.		[ 408]
Topiramate	N.A.	Migraine With Aura	Patients with migraine and the rs1045642 GG genotype may have a decreased response to topiramate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to topiramate.		[ 114]
Topiramate	N.A.	Migraine Without Aura	Patients with migraine and the rs1045642 GG genotype may have a decreased response to topiramate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to topiramate.		[ 114]
Opioids	N.A.	Opioid-Related Disorders	Correlated with the decreased opioid-related disorders risk in patients (compare with genotype AG)		[ 377]
Melatonin receptor agonists	N.A.	Depressive Disorder	Correlated with the increased drug response in patients (compare with genotypes AA + AG)		[ 360]
Platinum compounds	N.A.	Non-Small-Cell Lung Carcinoma	Correlated with the increased drug response in patients (compare with genotypes AA + AG)		[ 369]
Selective serotonin reuptake inhibitors	N.A.	Depressive Disorder	Correlated with the increased drug response in patients (compare with genotypes AA + AG)		[ 360]
Antiepileptics	N.A.	Epilepsy	Correlated with the increased likelihood of drug-resistance in patients (compare with genotype AA)		[ 445]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:       155 Drugs in Total
Clopidogrel	Drug Info	Acute Coronary Syndrome	Correlated with the decreased drug metabolism in patients (compare with genotype GG); Correlated with the decreased drug response in patients (compare with genotype GG); Correlated with the increased early major adverse cardiovascular events (mACE) risk in patients (compare with genotype GG); Irrelevant to the drug response in patients (compare with genotype GG); Irrelevant to the increased high on-treatment platelet reactivity risk in patients (compare with genotype GG)		[ 225], [ 370], [ 453], [ 455], [ 456]
Clopidogrel	Drug Info	Platelet Reactivity	Correlated with the decreased drug response in patients (compare with genotype GG)		[ 453]
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the decreased drug response in patients (compare with genotype GG); Correlated with the decreased drug trough concentration in patients (compare with genotype GG)		[ 343], [ 382]
Tacrolimus	Drug Info	Kidney Transplantation	Correlated with the decreased glomerular filtration rate in patients (compare with genotype GG); Irrelevant to the drug dose-adjusted trough concentrations in patients (compare with genotype GG); Irrelevant to the renal transplant failure risk in patients (compare with genotype GG); Irrelevant to the transplant rejection risk in patients (compare with genotype GG)		[ 460], [ 357], [ 462]
Fluorouracil	Drug Info	Esophageal Neoplasm	Correlated with the decreased lymph node metastases risk in patients (compare with genotype GG)		[ 167]
Cisplatin	Drug Info	Esophageal Neoplasm	Correlated with the decreased lymph node metastases risk in patients (compare with genotype GG)		[ 167]
Tacrolimus	Drug Info	Lung Transplantation	Correlated with the increased drug concentrations in patients (compare with genotype GG)		[ 464]
Rivaroxaban	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with genotype GG)		[ 347]
Dabigatran	Drug Info	Healthy Individuals	Correlated with the increased drug exposure in healthy individuals (compare with genotype GG)		[ 347]
Losartan	Drug Info	Hypertension	Correlated with the increased drug response in patients (compare with genotype GG)		[ 368]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased drug toxicity risk in patients (compare with genotype GG); Irrelevant to the drug concentrations in patients (compare with genotype GG); Irrelevant to the mucositis risk in patients (compare with genotype GG)		[ 38], [ 371]
Sorafenib	Drug Info	Renal Cell Carcinoma	Correlated with the increased hypertension risk in patients (compare with genotype GG)		[ 346]
Sirolimus	Drug Info	Kidney Transplantation	Correlated with the increased low-density lipoprotein cholesterol in patients (compare with genotype GG); Correlated with the increased total cholesterol in patients (compare with genotype GG)		[ 348]
Clopidogrel	Drug Info	Coronary Artery Disease	Correlated with the increased major adverse cardiovascular events (mACE) risk in patients (compare with genotype GG); Irrelevant to the all-cause mortality in patients (compare with genotype GG); Irrelevant to the increased high on-treatment platelet reactivity risk in patients (compare with genotype GG); Irrelevant to the increased ischemic stroke risk in patients (compare with genotype GG); Irrelevant to the increased major adverse cardiovascular events (MACE) risk in patients (compare with genotype GG); Irrelevant to the increased myocardial Infarction risk in patients (compare with genotype GG); Irrelevant to the stent thrombosis in patients (compare with genotype GG)		[ 225]
Clopidogrel	Drug Info	Myocardial Infarction	Correlated with the increased major cardiovascular events (mACE) risk in patients (compare with genotype GG)		[ 471]
Cytarabine	Drug Info	Acute Multiple Myeloma	Correlated with the increased overall survival in patients (compare with genotype GG)		[ 472]
Ritonavir	Drug Info	HIV Infection	Irrelevant to the drug concentrations in patients (compare with genotype GG); Irrelevant to the increased drug discontinuation in patients (compare with genotype GG)		[ 473], [ 474]
Paclitaxel	Drug Info	Breast Neoplasm	Irrelevant to the increased drug response in patients (compare with genotype GG)		[ 366]
Atazanavir	Drug Info	HIV Infection	Irrelevant to the increased drug discontinuation in patients (compare with genotype GG)		[ 473]
Efavirenz	Drug Info	HIV Infection	Irrelevant to the increased drug minimum plasma or PBMC concentrations in patients (compare with genotype GG)		[ 476]
Omeprazole	Drug Info	Gastroesophageal Reflux	Correlated with the increased drug concentrations in patients (compare with genotype GG)		[ 477]
Rivaroxaban	N.A.	Thromboembolism	Genotypes AA + AG is associated with decreased likelihood of Thromboembolism when treated with rivaroxaban in people with Atrial Fibrillation as compared to genotype GG.		[ 478]
Rasagiline	N.A.	Asthenia	Genotypes AA + AG is associated with decreased clearance of rasagiline in healthy individuals as compared to genotype GG.		[ 479]
Risperidone	N.A.	Somnolence	Genotypes AA + AG are associated with tendency toward greater improvement in PANSS-T when treated with risperidone in people with Schizophrenia as compared to genotype GG.		[ 480]
Clopidogrel	N.A.	Hemorrhage	Genotypes AA + AG is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.		[ 456]
Aspirin	N.A.	High On-treatment Platelet Reactivity	Genotypes AA + AG is associated with increased likelihood of high on-treatment platelet reactivity when treated with aspirin null clopidogrel as compared to genotype GG.		[ 481]
Clopidogrel	N.A.	High On-treatment Platelet Reactivity	Genotypes AA + AG is associated with increased likelihood of high on-treatment platelet reactivity when treated with aspirin null clopidogrel as compared to genotype GG.		[ 481]
Aspirin	N.A.	Thrombotic Disease	Genotypes AA + AG is associated with increased likelihood of Thrombosis when treated with aspirin null clopidogrel as compared to genotype GG.		[ 481]
Clopidogrel	N.A.	Thrombotic Disease	Genotypes AA + AG is associated with increased likelihood of Thrombosis when treated with aspirin null clopidogrel as compared to genotype GG.		[ 481]
Sirolimus	N.A.	Neurotoxicity Syndromes	Genotypes AA + AG are associated with increased total cholesterol when treated with sirolimus in people with Kidney Transplantation as compared to genotype GG.		[ 348]
Sunitinib	N.A.	Drug Resistance	Genotypes AA + AG is associated with increased clearance of sunitinib in people with Carcinoma, Renal Cell and Neoplasm Metastasis as compared to genotype GG.		[ 482]
Warfarin	N.A.	Gastrointestinal Toxicity	Genotypes AA + AG is not associated with increased dose of warfarin as compared to genotype GG.		[ 483]
Cyclophosphamide	N.A.	Neutropenia	Genotypes AA + AG are not associated with increased risk of Neutropenia when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to genotype GG.		[ 484]
Doxorubicin	N.A.	Neutropenia	Genotypes AA + AG are not associated with increased risk of Neutropenia when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to genotype GG.		[ 484]
Highly Active Antiretroviral Therapy (haart)	N.A.	Neutropenia	Genotypes AA + AG are associated with increased resistance to highly active antiretroviral therapy (haart) in people with HIV Infections as compared to genotype GG.		[ 374]
Methotrexate	N.A.	Toxic Liver Disease	Genotypes AA + AG is associated with increased likelihood of Toxic liver disease when treated with methotrexate in children with Acute lymphoblastic leukemia as compared to genotype GG.		[ 486]
Paclitaxel	N.A.	Drug Toxicity	Genotypes AA + AG are not associated with increased response to paclitaxel in women with Breast Neoplasms as compared to genotype GG.		[ 366]
Atazanavir	N.A.	Drug Toxicity	Genotypes AA + AG is associated with dose of atazanavir in people with HIV Infections.		[ 487]
Methotrexate	N.A.	Myelosuppression	Genotypes AA + AG is not associated with increased likelihood of Myelosuppression, Mucositis, nephrotoxicity or Gastrointestinal toxicity when treated with methotrexate in children with Acute lymphoblastic leukemia as compared to genotype GG.		[ 486]
Methotrexate	N.A.	Mucositis	Genotypes AA + AG is not associated with increased likelihood of Myelosuppression, Mucositis, nephrotoxicity or Gastrointestinal toxicity when treated with methotrexate in children with Acute lymphoblastic leukemia as compared to genotype GG.		[ 486]
Methotrexate	N.A.	Nephrotoxicity	Genotypes AA + AG is not associated with increased likelihood of Myelosuppression, Mucositis, nephrotoxicity or Gastrointestinal toxicity when treated with methotrexate in children with Acute lymphoblastic leukemia as compared to genotype GG.		[ 486]
Methotrexate	N.A.	Gastrointestinal Toxicity	Genotypes AA + AG is not associated with increased likelihood of Myelosuppression, Mucositis, nephrotoxicity or Gastrointestinal toxicity when treated with methotrexate in children with Acute lymphoblastic leukemia as compared to genotype GG.		[ 486]
Efavirenz	N.A.	Transplant Rejection	Genotypes AA + AG are not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections as compared to genotype GG.		[ 476]
Nevirapine	N.A.	Thrombocytopenia	Genotypes AA + AG are not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.		[ 488]
Methotrexate	N.A.	Neutropenia	Genotypes AA + AG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 38]
Doxorubicin	N.A.	Nausea	Genotypes AA + AG is associated with decreased severity of Nausea and Vomiting when treated with doxorubicin in women with Breast Neoplasms as compared to genotype GG.		[ 489]
Doxorubicin	N.A.	Vomiting	Genotypes AA + AG is associated with decreased severity of Nausea and Vomiting when treated with doxorubicin in women with Breast Neoplasms as compared to genotype GG.		[ 489]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Genotypes AA + AG is associated with decreased severity of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotype GG.		[ 489]
Omeprazole	N.A.	Epistaxis	Genotypes AA + AG are associated with increased concentrations of omeprazole in infants with Gastroesophageal Reflux as compared to genotype GG.		[ 477]
Cyclosporine	N.A.	Neutropenia	Genotypes AA + AG are associated with decreased risk of delayed graft function when treated with cyclosporine in people with Kidney Transplantation as compared to genotype GG.		[ 490]
Dexamethasone	N.A.	Osteonecrosis	Genotypes AA + AG are not associated with increased risk of Osteonecrosis when treated with dexamethasone in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 491]
Tacrolimus	N.A.	Transplant Rejection	Genotypes AA + AG is not associated with risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 462]
Losartan	N.A.	Adverse Events	Genotypes AA + AG are associated with increased response to losartan in people with Hypertension as compared to genotype GG.		[ 368]
Oxaliplatin	N.A.	Peripheral Nervous System Diseases	Genotypes AA + AG is associated with increased likelihood of Peripheral Nervous System Diseases when treated with oxaliplatin or paclitaxel in people with Breast Neoplasms or Colorectal Neoplasms as compared to genotype GG.		[ 492]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Genotypes AA + AG is associated with increased likelihood of Peripheral Nervous System Diseases when treated with oxaliplatin or paclitaxel in people with Breast Neoplasms or Colorectal Neoplasms as compared to genotype GG.		[ 492]
Digoxin	N.A.	Event-free Survival	Genotypes AA + AG are associated with decreased dose of digoxin in healthy individuals as compared to genotype GG.		[ 367]
Apixaban	N.A.	Diarrhea	Genotypes AA + AG are not associated with clearance of apixaban in people with Atrial Fibrillation as compared to genotype GG.		[ 494]
Clopidogrel	N.A.	Neutropenia	Genotypes AA + AG are associated with increased risk of major cardiovascular events (MACE) at 1 year when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.		[ 471]
Azithromycin	N.A.	Pain	Genotypes AA + AG is associated with increased likelihood of Pain or Diarrhea when treated with azithromycin or erythromycin in people with Bacterial Infections and Influenza as compared to genotype GG.		[ 495]
Azithromycin	N.A.	Diarrhea	Genotypes AA + AG is associated with increased likelihood of Pain or Diarrhea when treated with azithromycin or erythromycin in people with Bacterial Infections and Influenza as compared to genotype GG.		[ 495]
Erythromycin	N.A.	Pain	Genotypes AA + AG is associated with increased likelihood of Pain or Diarrhea when treated with azithromycin or erythromycin in people with Bacterial Infections and Influenza as compared to genotype GG.		[ 495]
Erythromycin	N.A.	Diarrhea	Genotypes AA + AG is associated with increased likelihood of Pain or Diarrhea when treated with azithromycin or erythromycin in people with Bacterial Infections and Influenza as compared to genotype GG.		[ 495]
Methotrexate	N.A.	Drug Toxicity	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 371]
Peginterferon Alfa-2a	N.A.	Cryoglobulinemia	Genotypes AA + AG is associated with increased likelihood of cryoglobulinemia when treated with peginterferon alfa-2a in people with as compared to genotype GG.		[ 496]
Sorafenib	N.A.	Hypertension	Genotypes AA + AG are associated with increased risk of Hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype GG.		[ 346]
Sunitinib	N.A.	Diarrhea	Genotypes AA + AG is associated with decreased risk of Diarrhea when treated with sunitinib in people with Carcinoma, Renal Cell.		[ 237]
Sirolimus	N.A.	Gingival Overgrowth	Genotypes AA + AG are associated with increased dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to genotype GG.		[ 498]
Methadone	N.A.	Nausea	Genotypes AA + AG are not associated with decreased likelihood of treatment with methadone or morphine in infants with Neonatal Abstinence Syndrome as compared to genotype GG.		[ 499]
Morphine	N.A.	Nausea	Genotypes AA + AG are not associated with decreased likelihood of treatment with methadone or morphine in infants with Neonatal Abstinence Syndrome as compared to genotype GG.		[ 499]
Atazanavir	N.A.	Nausea	Genotypes AA + AG is not associated with increased discontinuation of atazanavir and ritonavir in people with HIV Infections as compared to genotype GG.		[ 473]
Ritonavir	N.A.	Nausea	Genotypes AA + AG is not associated with increased discontinuation of atazanavir and ritonavir in people with HIV Infections as compared to genotype GG.		[ 473]
Tacrolimus	N.A.	Renal Transplant Failure	Genotypes AA + AG is not associated with risk of renal transplant failure when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 460]
Carboplatin	N.A.	Death	Genotypes AA + AG is associated with increased risk of Death when treated with carboplatin, etoposide and ifosfamide in children with Central Nervous System Neoplasms as compared to genotype GG.		[ 500]
Etoposide	N.A.	Death	Genotypes AA + AG is associated with increased risk of Death when treated with carboplatin, etoposide and ifosfamide in children with Central Nervous System Neoplasms as compared to genotype GG.		[ 500]
Ifosfamide	N.A.	Death	Genotypes AA + AG is associated with increased risk of Death when treated with carboplatin, etoposide and ifosfamide in children with Central Nervous System Neoplasms as compared to genotype GG.		[ 500]
Rivaroxaban	N.A.	Thromboembolism	Genotypes AA + AG are associated with decreased risk of Thromboembolism when treated with rivaroxaban as compared to genotype GG.		[ 361]
Risperidone	N.A.	Peripheral Nervous System Diseases	Genotypes AA + AG are associated with increased response to risperidone in people with Schizophrenia as compared to genotype GG.		[ 502]
Methotrexate	N.A.	Stroke	Genotypes AA + AG are associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 219]
Clopidogrel	N.A.	Drug Toxicity	Genotypes AA + AG are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.		[ 453]
Cytarabine	N.A.	Overall Survival	Genotypes AA + AG is associated with increased overall survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype GG.		[ 472]
Clopidogrel	N.A.	Drug Toxicity	Genotypes AA + AG are not associated with stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.		[ 225]
Clopidogrel	N.A.	Myocardial Infarction	Genotypes AA + AG are not associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.		[ 225]
Rifapentine	N.A.	Mucositis	Genotypes AA + AG is associated with increased clearance of rifapentine as compared to genotype GG.		[ 504]
Oxycodone	N.A.	Adverse Events	Genotypes AA + AG is associated with increased likelihood of adverse events when treated with oxycodone in people with Pain and Neoplasms as compared to genotype GG.		[ 505]
Clopidogrel	N.A.	Diarrhea	Genotypes AA + AG are not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.		[ 370]
Tacrolimus	N.A.	Opioid-related Disorders	Genotypes AA + AG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 462]
Efavirenz	N.A.	Transplant Rejection	Genotypes AA + AG are not associated with concentrations of efavirenz in children with HIV Infections as compared to genotype GG.		[ 474]
Lopinavir	N.A.	Transplant Rejection	Genotypes AA + AG are not associated with concentrations of lopinavir in children with HIV Infections as compared to genotype GG.		[ 474]
Ritonavir	N.A.	Drug Toxicity	Genotypes AA + AG are not associated with concentrations of ritonavir in children with HIV Infections as compared to genotype GG.		[ 474]
Rivaroxaban	N.A.	Hypercholesterolemia	Genotypes AA + AG are associated with increased clearance of rivaroxaban in people with Atrial Fibrillation as compared to genotype GG.		[ 506]
Methotrexate	N.A.	Mucositis	Genotypes AA + AG are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 38]
Tacrolimus	N.A.	Mucositis	Genotypes AA + AG are associated with increased concentrations of tacrolimus in people with lung transplantation as compared to genotype GG.		[ 464]
Lenalidomide	N.A.	Adverse Events	Genotypes AA + AG is associated with increased severity of adverse events when treated with lenalidomide in people with Multiple Myeloma, Lymphoma or Myelodysplastic Syndromes as compared to genotype GG.		[ 507]
Ticagrelor	N.A.	Dyspnea	Genotypes AA + AG is associated with increased likelihood of Dyspnea when treated with ticagrelor in people with Acute coronary syndrome as compared to genotype GG.		[ 508]
Cisplatin	N.A.	Toxic Liver Disease	Genotypes AA + AG are associated with decreased risk of lymph node metastases when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotype GG.		[ 167]
Fluorouracil	N.A.	Toxic Liver Disease	Genotypes AA + AG are associated with decreased risk of lymph node metastases when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotype GG.		[ 167]
Risperidone	N.A.	Prolonged Qtc Interval	Genotypes AA + AG is associated with increased electrocardiogram qt prolonged when treated with risperidone in people with Schizophrenia as compared to genotype GG.		[ 350]
Dabigatran	N.A.	Anemia	Genotypes AA + AG is associated with increased exposure to Dabigatran in healthy individuals as compared to genotype GG.		[ 347]
Rivaroxaban	N.A.	Anemia	Genotypes AA + AG is associated with increased exposure to rivaroxaban in healthy individuals as compared to genotype GG.		[ 347]
Methadone	N.A.	Drug Toxicity	Genotypes AA + AG is associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to genotype GG (assigned as normal metabolizer phenotype) .		[ 510]
Imatinib	N.A.	Drug Toxicity	Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.		[ 343]
Tacrolimus	N.A.	Decreased Glomerular Filtration Rate	Genotypes AA + AG is associated with Decreased glomerular filtration rate when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 357]
Carbamazepine	N.A.	Chronic Kidney Failure	Genotypes AA + AG is associated with decreased clinical benefit to carbamazepine in people with Epilepsy as compared to genotype GG.		[ 511]
Opioids	N.A.	Metabolic Syndrome	Genotypes AA + AG are not associated with dose of opioids in people with Pain as compared to genotype GG.		[ 365]
Cisplatin	N.A.	Neoplasm Of Esophagus	Genotypes AA + AG are associated with decreased risk of lymph node metastases when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotype GG.		[ 167]
Fluorouracil	N.A.	Neoplasm Of Esophagus	Genotypes AA + AG are associated with decreased risk of lymph node metastases when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotype GG.		[ 167]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.		[ 343]
Clopidogrel	N.A.	Acute Coronary Syndrome	Genotypes AA + AG are not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.		[ 370]
Clopidogrel	N.A.	Myocardial Infarction	Genotypes AA + AG are not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.		[ 370]
Clopidogrel	N.A.	Acute Coronary Syndrome	Genotypes AA + AG are associated with increased risk of early major adverse cardiovascular events (MACE) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.		[ 225]
Clopidogrel	N.A.	Acute Coronary Syndrome	Genotypes AA + AG are associated with increased risk of major cardiovascular events (MACE) at 1 year when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.		[ 471]
Clopidogrel	N.A.	Myocardial Infarction	Genotypes AA + AG are associated with increased risk of major cardiovascular events (MACE) at 1 year when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.		[ 471]
Clopidogrel	N.A.	Acute Coronary Syndrome	Genotypes AA + AG is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.		[ 455]
Clopidogrel	N.A.	Myocardial Infarction	Genotypes AA + AG is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.		[ 455]
Clopidogrel	N.A.	Acute Coronary Syndrome	Genotypes AA + AG are associated with decreased metabolism of clopidogrel in people with Acute coronary syndrome as compared to genotype GG.		[ 453]
Clopidogrel	N.A.	Myocardial Infarction	Genotypes AA + AG are associated with decreased metabolism of clopidogrel in people with Acute coronary syndrome as compared to genotype GG.		[ 453]
Sorafenib	N.A.	Renal Cell Carcinoma	Genotypes AA + AG are associated with increased risk of Hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype GG.		[ 346]
Sirolimus	N.A.	Kidney Transplantation	Genotypes AA + AG are associated with increased total cholesterol when treated with sirolimus in people with Kidney Transplantation as compared to genotype GG.		[ 348]
Risperidone	N.A.	Schizophrenia	Genotypes AA + AG is associated with increased electrocardiogram qt prolonged when treated with risperidone in people with Schizophrenia as compared to genotype GG.		[ 350]
Tacrolimus	N.A.	Kidney Transplantation	Genotypes AA + AG is not associated with risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 462]
Tacrolimus	N.A.	Kidney Transplantation	Genotypes AA + AG is not associated with risk of renal transplant failure when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 460]
Efavirenz	N.A.	HIV Infectious Disease	Genotypes AA + AG are not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections as compared to genotype GG.		[ 476]
Nelfinavir	N.A.	HIV Infectious Disease	Genotypes AA + AG are not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections as compared to genotype GG.		[ 476]
Tacrolimus	N.A.	Kidney Transplantation	Genotypes AA + AG is associated with Decreased glomerular filtration rate when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 357]
Atazanavir	N.A.	HIV Infectious Disease	Genotypes AA + AG is not associated with increased discontinuation of atazanavir and ritonavir in people with HIV Infections as compared to genotype GG.		[ 473]
Ritonavir	N.A.	HIV Infectious Disease	Genotypes AA + AG is not associated with increased discontinuation of atazanavir and ritonavir in people with HIV Infections as compared to genotype GG.		[ 473]
Atazanavir	N.A.	HIV Infectious Disease	Genotypes AA + AG is associated with dose of atazanavir in people with HIV Infections.		[ 487]
Ritonavir	N.A.	HIV Infectious Disease	Genotypes AA + AG is associated with dose of atazanavir in people with HIV Infections.		[ 487]
Atazanavir	N.A.	HIV Infectious Disease	Genotypes AA + AG are not associated with concentrations of ritonavir in children with HIV Infections as compared to genotype GG.		[ 474]
Ritonavir	N.A.	HIV Infectious Disease	Genotypes AA + AG are not associated with concentrations of ritonavir in children with HIV Infections as compared to genotype GG.		[ 474]
Sunitinib	N.A.	Renal Cell Carcinoma	Genotypes AA + AG is associated with decreased risk of Diarrhea when treated with sunitinib in people with Carcinoma, Renal Cell.		[ 237]
Rivaroxaban	N.A.	Renal Cell Carcinoma	Genotypes AA + AG are associated with decreased risk of Thromboembolism when treated with rivaroxaban as compared to genotype GG.		[ 361]
Opioids	N.A.	Pain	Genotypes AA + AG are not associated with dose of opioids in people with Pain as compared to genotype GG.		[ 365]
Opioids	N.A.	Pain, Postoperative	Genotypes AA + AG are not associated with dose of opioids in people with Pain as compared to genotype GG.		[ 365]
Paclitaxel	N.A.	Breast Neoplasms	Genotypes AA + AG are not associated with increased response to paclitaxel in women with Breast Neoplasms as compared to genotype GG.		[ 366]
Paclitaxel	N.A.	Neoplasms	Genotypes AA + AG are not associated with increased response to paclitaxel in women with Breast Neoplasms as compared to genotype GG.		[ 366]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes AA + AG are associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 219]
Losartan	N.A.	Hypertension	Genotypes AA + AG are associated with increased response to losartan in people with Hypertension as compared to genotype GG.		[ 368]
Omeprazole	N.A.	Gastroesophageal Reflux	Genotypes AA + AG are associated with increased concentrations of omeprazole in infants with Gastroesophageal Reflux as compared to genotype GG.		[ 477]
Clopidogrel	N.A.	Platelet Reactivity	Genotypes AA + AG are not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.		[ 370]
Clopidogrel	N.A.	Platelet Reactivity	Genotypes AA + AG are not associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.		[ 225]
Clopidogrel	N.A.	Platelet Reactivity	Genotypes AA + AG is not associated with response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.		[ 455]
Clopidogrel	N.A.	Platelet Reactivity	Genotypes AA + AG are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.		[ 453]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes AA + AG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 38]
Methotrexate	N.A.	Burkitt Lymphoma	Genotypes AA + AG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 38]
Methotrexate	N.A.	Lymphoma, T-cell	Genotypes AA + AG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 38]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 371]
Methotrexate	N.A.	Burkitt Lymphoma	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 371]
Methotrexate	N.A.	Lymphoma, T-cell	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 371]
Methotrexate	N.A.	Drug Toxicity	Genotypes AA + AG are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 38]
Highly Active Antiretroviral Therapy (haart)	N.A.	HIV Infectious Disease	Genotypes AA + AG are associated with increased resistance to highly active antiretroviral therapy (haart) in people with HIV Infections as compared to genotype GG.		[ 374]
Efavirenz	N.A.	HIV Infectious Disease	Genotypes AA + AG are not associated with concentrations of efavirenz in children with HIV Infections as compared to genotype GG.		[ 474]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Genotypes AA + AG is associated with increased overall survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype GG.		[ 472]
Tacrolimus	N.A.	Organ Transplantation	Genotypes AA + AG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 462]
Tacrolimus	N.A.	Organ Transplantation	Genotypes AA + AG are associated with increased concentrations of tacrolimus in people with lung transplantation as compared to genotype GG.		[ 464]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:         95 Drugs in Total
Tacrolimus	Drug Info	Liver Transplantation	Correlated with the increased drug clearance in patients (compare with genotype AA)		[ 493]
Tacrolimus	Drug Info	Kidney Transplantation	Correlated with the increased drug clearance in patients (compare with genotype AA); Correlated with the increased drug dose-adjusted trough concentrations in patients (compare with genotype AA); Irrelevant to the drug metabolism in patients (compare with genotype AA)		[ 229], [ 495], [ 496]
Lamivudine	Drug Info	HIV Infection	Correlated with the increased drug resistance in patients (compare with genotype AA)		[ 374]
Lopinavir	Drug Info	HIV Infection	Correlated with the increased drug resistance in patients (compare with genotype AA)		[ 374]
Zidovudine	Drug Info	HIV Infection	Correlated with the increased drug resistance in patients (compare with genotype AA)		[ 374]
Ritonavir	Drug Info	HIV Infection	Correlated with the increased drug resistance in patients (compare with genotype AA)		[ 374]
Gemcitabine	Drug Info	Neoplasm	Irrelevant to the decreased clinical outcome in patients (compare with genotype AA)		[ 356]
Epirubicin	Drug Info	Neoplasm	Irrelevant to the decreased clinical outcome in patients (compare with genotype AA)		[ 356]
Docetaxel	Drug Info	Neoplasm	Irrelevant to the decreased clinical outcome in patients (compare with genotype AA)		[ 356]
Cisplatin	Drug Info	Neoplasm	Irrelevant to the decreased clinical outcome in patients (compare with genotype AA)		[ 356]
Tacrolimus	Drug Info	Ulcerative Colitis	Irrelevant to the drug metabolism in patients (compare with genotype AA); Irrelevant to the drug response in patients (compare with genotype AA)		[ 499]
Fluorouracil	Drug Info	Colorectal Neoplasm	Irrelevant to the prognosis in patients (compare with genotype AA)		[ 337]
Leucovorin	Drug Info	Colorectal Neoplasm	Irrelevant to the prognosis in patients (compare with genotype AA)		[ 337]
Cisplatin	Drug Info	Colorectal Neoplasm	Irrelevant to the prognosis in patients (compare with genotype AA)		[ 337]
Capecitabine	Drug Info	Neoplasm	Irrelevant to the decreased clinical outcome in patients (compare with genotype AA)		[ 356]
Voriconazole	N.A.	Overall Survival	Genotypes AG + GG is not associated with increased concentrations of voriconazole in people with Fungal infectious disease as compared to genotype AA.		[ 501]
Desmethylcitalopram	N.A.	Delayed Graft Function	Genotypes AG + GG are not associated with concentrations of desmethylcitalopram or escitalopram in people with Depressive Disorder, Major as compared to genotype AA.		[ 502]
Escitalopram	N.A.	Delayed Graft Function	Genotypes AG + GG are not associated with concentrations of desmethylcitalopram or escitalopram in people with Depressive Disorder, Major as compared to genotype AA.		[ 502]
Oseltamivir	N.A.	Somnolence	Genotypes AG + GG are associated with increased likelihood of neuropsychiatric adverse events when treated with oseltamivir in children with Influenza, Human as compared to genotype AA.		[ 503]
Tacrolimus	N.A.	Adverse Events	Genotypes AG + GG is associated with increased clearance of tacrolimus in people with liver transplantation as compared to genotype AA.		[ 493]
Tacrolimus	N.A.	Drug Toxicity	Genotypes AG + GG is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA.		[ 504]
Aripiprazole	N.A.	Prolonged Qtc Interval	Genotypes AG + GG are not associated with concentrations of aripiprazole in people with Depressive Disorder, Major as compared to genotype AA.		[ 502]
Paclitaxel	N.A.	Drug Toxicity	Genotypes AG + GG are not associated with likelihood of Drug Toxicity when treated with paclitaxel in people with Neoplasms as compared to genotype AA.		[ 505]
Docetaxel	N.A.	Drug Toxicity	Genotypes AG + GG are not associated with likelihood of Drug Toxicity when treated with docetaxel in people with Neoplasms as compared to genotype AA.		[ 505]
Cannabinoids	N.A.	Drug Toxicity	Genotypes AG + GG is associated with increased clinical benefit to cannabinoids in people with Pain as compared to genotype AA.		[ 506]
Morphine	N.A.	Drug Toxicity	Genotypes AG + GG are not associated with dose of morphine in people with Pain, Postoperative as compared to genotype AA.		[ 420]
Capecitabine	N.A.	Thrombocytopenia	Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.		[ 356]
Cisplatin	N.A.	Thrombocytopenia	Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.		[ 356]
Docetaxel	N.A.	Thrombocytopenia	Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.		[ 356]
Epirubicin	N.A.	Thrombocytopenia	Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.		[ 356]
Gemcitabine	N.A.	Thrombocytopenia	Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.		[ 356]
Methotrexate	N.A.	Mucositis	Genotypes AG + GG are associated with increased risk of mucositis when treated with methotrexate in people with Osteosarcoma.		[ 508]
Tacrolimus	N.A.	Diabetes Mellitus	Genotypes AG + GG is not associated with risk of Diabetes Mellitus when treated with tacrolimus in children with Kidney Transplantation as compared to genotype AA.		[ 509]
Escitalopram	N.A.	Adverse Events	Genotypes AG + GG are not associated with severity of adverse events when treated with escitalopram in people with Depressive Disorder, Major as compared to genotype AA.		[ 502]
Docetaxel	N.A.	Mucositis	Genotypes AG + GG are associated with increased response to docetaxel or paclitaxel in people with Neoplasms as compared to genotype AA.		[ 505]
Paclitaxel	N.A.	Mucositis	Genotypes AG + GG are associated with increased response to docetaxel or paclitaxel in people with Neoplasms as compared to genotype AA.		[ 505]
Tacrolimus	N.A.	Adverse Events	Genotypes AG + GG are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype AA.		[ 495]
Aspirin	N.A.	Drug Resistance	Genotypes AG + GG is associated with increased likelihood of Drug Resistance when treated with aspirin in people with Stroke as compared to genotype AA.		[ 303]
Imatinib	N.A.	Drug Resistance	Genotypes AG + GG is associated with increased trough concentration of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype AA.		[ 511]
Tacrolimus	N.A.	Acute Cellular Rejection	Genotypes AG + GG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA.		[ 229]
Methadone	N.A.	Neonatal Abstinence Syndrome	Genotypes AG + GG are not associated with severity of Neonatal Abstinence Syndrome due to methadone in infants as compared to genotype AA.		[ 512]
Oseltamivir	N.A.	Depression	Genotypes AG + GG are associated with increased risk of Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype AA.		[ 359]
Oseltamivir	N.A.	Gastritis	Genotypes AG + GG are associated with increased risk of Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype AA.		[ 359]
Oseltamivir	N.A.	Hypersensitivity	Genotypes AG + GG are associated with increased risk of Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype AA.		[ 359]
Tacrolimus	N.A.	Hypersensitivity	Genotypes AG + GG is not associated with response to tacrolimus in people with Colitis, Ulcerative as compared to genotype AA.		[ 499]
Tacrolimus	N.A.	Decreased Glomerular Filtration Rate	Genotypes AG + GG is associated with Decreased glomerular filtration rate when treated with tacrolimus in people with Kidney Transplantation as compared to genotype AA.		[ 314]
Morphine	N.A.	Constipation	Genotypes AG + GG are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus, somnolence or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype AA.		[ 515]
Morphine	N.A.	Delirium	Genotypes AG + GG are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus, somnolence or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype AA.		[ 515]
Morphine	N.A.	Nausea	Genotypes AG + GG are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus, somnolence or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype AA.		[ 515]
Morphine	N.A.	Pruritus	Genotypes AG + GG are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus, somnolence or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype AA.		[ 515]
Morphine	N.A.	Somnolence	Genotypes AG + GG are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus, somnolence or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype AA.		[ 515]
Morphine	N.A.	Urinary Retention	Genotypes AG + GG are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus, somnolence or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype AA.		[ 515]
Oxycodone	N.A.	Constipation	Genotypes AG + GG are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus, somnolence or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype AA.		[ 515]
Oxycodone	N.A.	Delirium	Genotypes AG + GG are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus, somnolence or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype AA.		[ 515]
Oxycodone	N.A.	Nausea	Genotypes AG + GG are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus, somnolence or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype AA.		[ 515]
Oxycodone	N.A.	Pruritus	Genotypes AG + GG are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus, somnolence or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype AA.		[ 515]
Oxycodone	N.A.	Somnolence	Genotypes AG + GG are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus, somnolence or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype AA.		[ 515]
Oxycodone	N.A.	Urinary Retention	Genotypes AG + GG are not associated with likelihood of Constipation, Delirium, Nausea, Pruritus, somnolence or Urinary Retention due to morphine or oxycodone in people with Lung Neoplasms as compared to genotype AA.		[ 515]
Clozapine	N.A.	Hypertension	Genotypes AG + GG is associated with increased Hypertension when treated with clozapine in people with Schizophrenia as compared to genotype AA.		[ 516]
Clozapine	N.A.	Weight Gain	Genotypes AG + GG is associated with increased Weight gain when treated with clozapine in men with Schizophrenia as compared to genotype AA.		[ 516]
Everolimus	N.A.	Weight Gain	Genotypes AG + GG are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype AA.		[ 19]
Tacrolimus	N.A.	Pain, Postoperative	Genotypes AG + GG is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype AA.		[ 496]
Atazanavir	N.A.	Statin-related Myopathy	Genotypes AG + GG is associated with decreased clearance of atazanavir in healthy individuals as compared to genotype AA.		[ 518]
Antidepressants	N.A.	Statin-related Myopathy	Genotypes AG + GG are not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA.		[ 502]
Cisplatin	N.A.	Drug Toxicity	Genotypes AG + GG are not associated with prognosis when treated with cisplatin, fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype AA.		[ 337]
Fluorouracil	N.A.	Drug Toxicity	Genotypes AG + GG are not associated with prognosis when treated with cisplatin, fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype AA.		[ 337]
Leucovorin	N.A.	Drug Toxicity	Genotypes AG + GG are not associated with prognosis when treated with cisplatin, fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype AA.		[ 337]
Rivaroxaban	N.A.	Drug-induced Liver Injury	Genotypes AG + GG is associated with decreased concentrations of rivaroxaban in people with Atrial Fibrillation as compared to genotype AA.		[ 519]
Pantoprazole	N.A.	Adverse Events	Genotypes AG + GG is not associated with increased response to pantoprazole in people with Helicobacter Infections as compared to genotype AA.		[ 520]
Olanzapine	N.A.	Metabolic Syndrome	Genotypes AG + GG is not associated with increased likelihood of Metabolic Syndrome when treated with olanzapine or risperidone in women with Schizophrenia as compared to genotype AA.		[ 521]
Risperidone	N.A.	Metabolic Syndrome	Genotypes AG + GG is not associated with increased likelihood of Metabolic Syndrome when treated with olanzapine or risperidone in women with Schizophrenia as compared to genotype AA.		[ 521]
Cisplatin	N.A.	Neoplasm Of Esophagus	Genotypes AG + GG are not associated with prognosis when treated with cisplatin, fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype AA.		[ 337]
Fluorouracil	N.A.	Neoplasm Of Esophagus	Genotypes AG + GG are not associated with prognosis when treated with cisplatin, fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype AA.		[ 337]
Tacrolimus	N.A.	Ulcerative Colitis	Genotypes AG + GG is not associated with response to tacrolimus in people with Colitis, Ulcerative as compared to genotype AA.		[ 499]
Capecitabine	N.A.	Neoplasms	Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.		[ 356]
Pantoprazole	N.A.	Helicobacter Infections	Genotypes AG + GG is not associated with increased response to pantoprazole in people with Helicobacter Infections as compared to genotype AA.		[ 520]
Oseltamivir	N.A.	Helicobacter Infections	Genotypes AG + GG are associated with increased risk of Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype AA.		[ 359]
Morphine	N.A.	Pain	Genotypes AG + GG are not associated with dose of morphine in people with Pain, Postoperative as compared to genotype AA.		[ 420]
Morphine	N.A.	Pain, Postoperative	Genotypes AG + GG are not associated with dose of morphine in people with Pain, Postoperative as compared to genotype AA.		[ 420]
Paclitaxel	N.A.	Breast Neoplasms	Genotypes AG + GG are associated with increased response to docetaxel or paclitaxel in people with Neoplasms as compared to genotype AA.		[ 505]
Paclitaxel	N.A.	Neoplasms	Genotypes AG + GG are associated with increased response to docetaxel or paclitaxel in people with Neoplasms as compared to genotype AA.		[ 505]
Docetaxel	N.A.	Breast Neoplasms	Genotypes AG + GG are associated with increased response to docetaxel or paclitaxel in people with Neoplasms as compared to genotype AA.		[ 505]
Docetaxel	N.A.	Neoplasms	Genotypes AG + GG are associated with increased response to docetaxel or paclitaxel in people with Neoplasms as compared to genotype AA.		[ 505]
Paclitaxel	N.A.	Neutropenia	Genotypes AG + GG are not associated with likelihood of Drug Toxicity when treated with paclitaxel in people with Neoplasms as compared to genotype AA.		[ 505]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Genotypes AG + GG are not associated with likelihood of Drug Toxicity when treated with paclitaxel in people with Neoplasms as compared to genotype AA.		[ 505]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes AG + GG are associated with increased risk of mucositis when treated with methotrexate in people with Osteosarcoma.		[ 508]
Methotrexate	N.A.	Burkitt Lymphoma	Genotypes AG + GG are associated with increased risk of mucositis when treated with methotrexate in people with Osteosarcoma.		[ 508]
Methotrexate	N.A.	Drug Toxicity	Genotypes AG + GG are associated with increased risk of mucositis when treated with methotrexate in people with Osteosarcoma.		[ 508]
Methotrexate	N.A.	Lymphoma, T-cell	Genotypes AG + GG are associated with increased risk of mucositis when treated with methotrexate in people with Osteosarcoma.		[ 508]
Tacrolimus	N.A.	Organ Transplantation	Genotypes AG + GG are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype AA.		[ 495]
Tacrolimus	N.A.	Organ Transplantation	Genotypes AG + GG is associated with increased clearance of tacrolimus in people with liver transplantation as compared to genotype AA.		[ 493]
Tacrolimus	N.A.	Organ Transplantation	Genotypes AG + GG is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype AA.		[ 496]
Tacrolimus	N.A.	Organ Transplantation	Genotypes AG + GG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA.		[ 229]
Tacrolimus	N.A.	Organ Transplantation	Genotypes AG + GG are not associated with metabolism of tacrolimus in people with Colitis, Ulcerative as compared to genotype AA.		[ 499]
Tacrolimus	N.A.	Organ Transplantation	Genotypes AG + GG is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA.		[ 504]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Dolutegravir	N.A.	Discontinuation	Genotype CC is not associated with likelihood of Discontinuation and adverse events when treated with dolutegravir in people with HIV infectious disease as compared to genotypes CT + TT.		[ 513]
Dolutegravir	N.A.	Adverse Events	Genotype CC is not associated with likelihood of Discontinuation and adverse events when treated with dolutegravir in people with HIV infectious disease as compared to genotypes CT + TT.		[ 513]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Allele C is not associated with severity of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to allele A.		[ 514]
Paclitaxel	N.A.	Drug Toxicity	Allele C is not associated with severity of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to allele A.		[ 514]
Paclitaxel	N.A.	Neoplasms	Allele C is not associated with severity of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to allele A.		[ 514]
Paclitaxel	N.A.	Neutropenia	Allele C is not associated with severity of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to allele A.		[ 514]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Gemcitabine	N.A.	Peripheral Nervous System Diseases	Allele T is not associated with response to gemcitabine and paclitaxel in women Breast Neoplasms.		[ 515]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Allele T is not associated with response to gemcitabine and paclitaxel in women Breast Neoplasms.		[ 515]
Fluorouracil	N.A.	Mucositis	Allele T is not associated with response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to allele A.		[ 516]
Leucovorin	N.A.	Mucositis	Allele T is not associated with response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to allele A.		[ 516]
Oxaliplatin	N.A.	Mucositis	Allele T is not associated with response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to allele A.		[ 516]
Genotypes AC + CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antidepressants	N.A.	Adverse Events	Genotypes AC + CC are not associated with risk of adverse events when treated with antidepressants in people with Depressive Disorder, Major as compared to genotype AA.		[ 498]
Genotype GT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Trabectedin	N.A.	Toxic Liver Disease	Genotype GT is associated with Toxic liver disease when treated with trabectedin in men with Sarcoma.		[ 517]
Genotypes GG + GT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Acenocoumarol	N.A.	Over-anticoagulation	Genotypes GG + GT are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to genotype TT.		[ 518]
Genetic Polymorphism	rs1128503
Site of GPD	chr7:87550285 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.4161/2084 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:       149 Drugs in Total
Simvastatin	Drug Info	Hypercholesterolemia	Correlated with the decreased myalgia risk in patients (compare with allele G)		[ 3]
Digoxin	Drug Info	Congestive Cardiac Insufficiency; Arrhythmias; Heart Failure	Correlated with the increased drug serum concentrations in patients (compare with allele G)		[ 13]
Codeine	Drug Info	Pain	Correlated with the increased likelihood of CnS depression when used drug (compare with allele G)		[ 14]
Phenytoin	Drug Info	Healthy Individuals	Correlated with the increased plasma drug levels in healthy individual (compare with genotype GG)		[ 21]
Tacrolimus	Drug Info	Kidney Transplantation	Irrelevant to the dose-adjusted trough concentrations in patients (compare with allele G); Irrelevant to the drug clearance in patients (compare with Allele G); Irrelevant to the drug metabolism in patients (compare with Allele G)		[ 24], [ 25], [ 27]
Cyclosporine	Drug Info	Kidney Transplantation	Irrelevant to the drug clearance in patients (compare with allele G)		[ 23]
Tacrolimus	Drug Info	Liver Transplantation	Irrelevant to the drug clearance in patients (compare with Allele G); Irrelevant to the drug metabolism in patients (compare with Allele G)		[ 36], [ 528]
Carbamazepine	Drug Info	Epilepsy	Irrelevant to the drug concentrations in patients (compare with allele G); Irrelevant to the drug response in patients (compare with Allele G)		[ 161], [ 18]
Methotrexate	Drug Info	Rheumatoid Arthritis	Irrelevant to the drug discontinuation in patients (compare with allele G)		[ 6]
Sirolimus	Drug Info	Kidney Transplantation	Irrelevant to the drug metabolism in patients (compare with Allele G)		[ 24]
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Irrelevant to the drug response in patients (compare with Allele G)		[ 37]
Valproic acid	Drug Info	Epilepsy	Irrelevant to the drug response in patients (compare with Allele G)		[ 161]
Phenytoin	Drug Info	Epilepsy	Irrelevant to the drug response in patients (compare with Allele G)		[ 161]
Phenobarbital	Drug Info	Epilepsy	Irrelevant to the drug response in patients (compare with Allele G)		[ 161]
Sunitinib	Drug Info	Renal Cell Carcinoma	Irrelevant to the drug toxicity in patients (compare with allele G)		[ 41]
Tacrolimus	N.A.	Polycystic Ovary Syndrome	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 534]
Imatinib	N.A.	Arthralgia	Allele A is associated with increased clinical benefit to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.		[ 60]
Tacrolimus	N.A.	Arthralgia	Allele A is not associated with clearance of tacrolimus in people with liver transplantation as compared to allele G.		[ 36]
Carbamazepine	N.A.	Neurotoxicity Syndromes	Allele A is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.		[ 61]
Phenytoin	N.A.	Neurotoxicity Syndromes	Allele A is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.		[ 61]
Valproic Acid	N.A.	Neurotoxicity Syndromes	Allele A is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.		[ 61]
Imatinib	N.A.	Neutropenia	Allele A is associated with increased dose-adjusted trough concentrations of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.		[ 537]
Digoxin	N.A.	Drug Toxicity	Allele A is not associated with functional effect on the P-gp-mediated transport rate of digoxin or imatinib in a X. laevis oocyte expression system as compared to allele G.		[ 59]
Imatinib	N.A.	Drug Toxicity	Allele A is not associated with functional effect on the P-gp-mediated transport rate of digoxin or imatinib in a X. laevis oocyte expression system as compared to allele G.		[ 59]
Codeine	N.A.	Hypokalemia	Allele A is associated with increased likelihood of CNS depression in breast-feeding infants when treated with codeine in women with Pain as compared to allele G.		[ 14]
Labetalol	N.A.	Exanthema	Allele A is not associated with decreased metabolism of labetalol in healthy individuals as compared to allele G.		[ 72]
Tacrolimus	N.A.	Exanthema	Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 540]
Antiepileptics	N.A.	Drug Resistance	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.		[ 69]
Atazanavir	N.A.	Nephrolithiasis	Allele A is not associated with risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele G.		[ 79]
Ritonavir	N.A.	Nephrolithiasis	Allele A is not associated with risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele G.		[ 79]
Tacrolimus	N.A.	Toxic Liver Disease	Allele A is not associated with metabolism of tacrolimus in people with liver transplantation as compared to allele G.		[ 528]
Dexamethasone	N.A.	Anemia	Allele A is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Dexamethasone	N.A.	Neutropenia	Allele A is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Dexamethasone	N.A.	Thrombocytopenia	Allele A is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Lenalidomide	N.A.	Anemia	Allele A is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Lenalidomide	N.A.	Neutropenia	Allele A is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Lenalidomide	N.A.	Thrombocytopenia	Allele A is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Dexamethasone	N.A.	Overall Survival	Allele A is not associated with likelihood of overall survival or progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Dexamethasone	N.A.	Progression-free Survival	Allele A is not associated with likelihood of overall survival or progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Lenalidomide	N.A.	Overall Survival	Allele A is not associated with likelihood of overall survival or progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Lenalidomide	N.A.	Progression-free Survival	Allele A is not associated with likelihood of overall survival or progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele G.		[ 81]
Carbamazepine	N.A.	Progression-free Survival	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.		[ 159]
Lamotrigine	N.A.	Neutropenia	Allele A is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele G.		[ 545]
Digoxin	N.A.	Neutropenia	Allele A is associated with increased serum concentrations of digoxin as compared to allele G.		[ 13]
Phenytoin	N.A.	Death	Allele A is associated with increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG.		[ 21]
Propofol	N.A.	Adverse Events	Allele A is not associated with risk of adverse events due to propofol and remifentanil in children as compared to allele G.		[ 191]
Remifentanil	N.A.	Adverse Events	Allele A is not associated with risk of adverse events due to propofol and remifentanil in children as compared to allele G.		[ 191]
Docetaxel	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele G.		[ 86]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele G.		[ 86]
Gemcitabine	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele G.		[ 515]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele G.		[ 515]
Tacrolimus	N.A.	Transplant Rejection	Allele A is not associated with increased risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 87]
Sunitinib	N.A.	Drug Toxicity	Allele A is not associated with Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G.		[ 41]
Dabigatran	N.A.	Transplant Rejection	Allele A is not associated with decreased dose-adjusted trough concentrations of dabigatran in people with Atrial Fibrillation as compared to allele G.		[ 89]
Raltegravir	N.A.	Hyperbilirubinemia	Allele A is not associated with concentration of raltegravir in people with HIV Infections as compared to allele G.		[ 90]
Sunitinib	N.A.	Overall Survival	Allele A is associated with decreased overall survival and progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G.		[ 552]
Sunitinib	N.A.	Progression-free Survival	Allele A is associated with decreased overall survival and progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G.		[ 552]
Methotrexate	N.A.	Progression-free Survival	Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.		[ 6]
Dexamethasone	N.A.	Drug Toxicity	Allele A is not associated with overall survival when treated with dexamethasone, diphenhydramine, paclitaxel and ranitidine in people with Head and Neck Neoplasms as compared to allele G.		[ 50]
Diphenhydramine	N.A.	Drug Toxicity	Allele A is not associated with overall survival when treated with dexamethasone, diphenhydramine, paclitaxel and ranitidine in people with Head and Neck Neoplasms as compared to allele G.		[ 50]
Paclitaxel	N.A.	Drug Toxicity	Allele A is not associated with overall survival when treated with dexamethasone, diphenhydramine, paclitaxel and ranitidine in people with Head and Neck Neoplasms as compared to allele G.		[ 50]
Ranitidine	N.A.	Drug Toxicity	Allele A is not associated with overall survival when treated with dexamethasone, diphenhydramine, paclitaxel and ranitidine in people with Head and Neck Neoplasms as compared to allele G.		[ 50]
Vincristine	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with increased risk of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 193]
Methotrexate	N.A.	Mucositis	Allele A is associated with increased risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 92]
Imatinib	N.A.	Event-free Survival	Allele A is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.		[ 37]
Talinolol	N.A.	Event-free Survival	Allele A is not associated with clearance of talinolol in healthy individuals as compared to allele G.		[ 556]
Atorvastatin	N.A.	Event-free Survival	Allele A is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele G.		[ 163]
Simvastatin	N.A.	Event-free Survival	Allele A is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele G.		[ 163]
Simvastatin	N.A.	Event-free Survival	Allele A is associated with decreased risk of Myalgia when treated with simvastatin in people with Hypercholesterolemia as compared to allele G.		[ 3]
Carbamazepine	N.A.	Coronary Restenosis	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.		[ 15]
Phenobarbital	N.A.	Coronary Restenosis	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.		[ 15]
Phenytoin	N.A.	Coronary Restenosis	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.		[ 15]
Valproic Acid	N.A.	Coronary Restenosis	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.		[ 15]
Tacrolimus	N.A.	Acute Cellular Rejection	Allele A is not associated with acute cellular rejection when treated with tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 25]
Sirolimus	N.A.	Diarrhea	Allele A is not associated with metabolism of sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 24]
Tacrolimus	N.A.	Diarrhea	Allele A is not associated with metabolism of sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 24]
Quetiapine	N.A.	Transplant Rejection	Allele A is not associated with differences pharmacokinetic parameters when treated with quetiapine in healthy individuals as compared to allele G.		[ 105]
Dolutegravir	N.A.	Adverse Events	Allele A is not associated with concentrations of dolutegravir in people with HIV Infections as compared to allele G.		[ 107]
Risperidone	N.A.	Central Nervous System Disorder	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele G.		[ 34]
Carbamazepine	N.A.	Diarrhea	Allele A is associated with increased clearance of carbamazepine in children with Epilepsy as compared to allele G.		[ 108]
Selective Serotonin Reuptake Inhibitors	N.A.	Congenital Heart Defects	Allele A is associated with increased likelihood of Heart Defects, Congenital when exposed to Selective serotonin reuptake inhibitors in women with Pregnancy as compared to allele G.		[ 563]
Opioids	N.A.	Neurotoxicity Syndromes	Allele A is not associated with dose of opioids in people with Pain as compared to allele G.		[ 109]
Tenofovir	N.A.	Cardiotoxicity	Allele A is not associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G.		[ 112]
Tacrolimus	N.A.	Hypersensitivity	Allele A is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.		[ 566]
Efavirenz	N.A.	Pain, Postoperative	Allele A is not associated with exposure to efavirenz in healthy individuals as compared to allele G.		[ 113]
Tacrolimus	N.A.	Transplant Rejection	Allele A is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 25]
Doxorubicin	N.A.	Hypersensitivity	Allele A is not associated with resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 240]
Methotrexate	N.A.	Hypersensitivity	Allele A is not associated with resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 240]
Prednisolone	N.A.	Hypersensitivity	Allele A is not associated with resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 240]
Vincristine	N.A.	Hypersensitivity	Allele A is not associated with resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 240]
Cyclosporine	N.A.	Hypertension	Allele A is not associated with response to cyclosporine in people with Psoriasis as compared to allele G.		[ 118]
Dactinomycin	N.A.	Hypersensitivity	Allele A is not associated with clearance of dactinomycin in children with Neoplasms as compared to allele G.		[ 119]
Morphine	N.A.	Hypersensitivity	Allele A is not associated with concentrations of morphine in women with Pain, Postoperative as compared to allele G.		[ 121]
Antipsychotics	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with drug response when exposed to antipsychotics in people with Psychotic Disorders as compared to allele G.		[ 122]
Methadone	N.A.	Hyperprolactinemia	Allele A is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele G.		[ 208]
Rivaroxaban	N.A.	Hyperprolactinemia	Allele A is not associated with increased dose-adjusted trough concentrations of rivaroxaban in people with Atrial Fibrillation as compared to allele G.		[ 125]
Ceftriaxone	N.A.	Hyperprolactinemia	Allele A is not associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to allele G.		[ 99]
Temozolomide	N.A.	Urinary Retention	Allele A is not associated with response to temozolomide in people with Glioma as compared to allele G.		[ 126]
Methotrexate	N.A.	High On-treatment Platelet Reactivity	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G.		[ 577]
Methadone	N.A.	Weight Gain	Allele A is not associated with response to methadone in people with Heroin Dependence as compared to allele G.		[ 130]
Cabazitaxel	N.A.	Drug Toxicity	Allele A is associated with decreased likelihood of Drug Toxicity when treated with cabazitaxel in people with Carcinoma, Transitional Cell as compared to allele G.		[ 131]
Risperidone	N.A.	Mucositis	Allele A is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele G.		[ 33]
Mycophenolate Mofetil	N.A.	Diarrhea	Allele A is not associated with increased risk of Diarrhea when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.		[ 132]
Carbamazepine	N.A.	Diarrhea	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele G.		[ 18]
Carbamazepine	N.A.	Diarrhea	Allele A is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele G.		[ 161]
Phenobarbital	N.A.	Diarrhea	Allele A is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele G.		[ 161]
Phenytoin	N.A.	Diarrhea	Allele A is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele G.		[ 161]
Valproic Acid	N.A.	Diarrhea	Allele A is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele G.		[ 161]
Nevirapine	N.A.	Drug Toxicity	Allele A is not associated with increased plasma level when treated with nevirapine in people with HIV Infections as compared to allele G.		[ 133]
Atorvastatin	N.A.	Statin-related Myopathy	Allele A is associated with increased likelihood of statin-related myopathy when exposed to atorvastatin as compared to allele G.		[ 325]
Antidepressants	N.A.	Statin-related Myopathy	Allele A is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele G.		[ 498]
Mycophenolate Mofetil	N.A.	Leukopenia	Allele A is not associated with increased risk of Leukopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.		[ 132]
Antineoplastic Agents	N.A.	Dose Reduction	Allele A is not associated with survival when treated with antineoplastic agents in women with Ovarian Neoplasms as compared to allele G.		[ 144]
Tenofovir	N.A.	Dose Reduction	Allele A is not associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele G.		[ 145]
Cyclosporine	N.A.	Toxic Liver Disease	Allele A is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 23]
Tacrolimus	N.A.	Toxic Liver Disease	Allele A is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 23]
Sunitinib	N.A.	Adverse Events	Allele A is not associated with concentrations of sunitinib in people with Carcinoma, Renal Cell as compared to allele G.		[ 150]
Antiepileptics	N.A.	Hemorrhage	Allele A is associated with increased risk of drug resistance when treated with antiepileptics in people with Epilepsy.		[ 17]
Sufentanil	N.A.	Adverse Events	Allele A is not associated with likelihood of adverse events due to sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to allele G.		[ 117]
Fentanyl	N.A.	Adverse Events	Allele A is not associated with risk of adverse events when treated with fentanyl in people with Neoplasms as compared to allele G.		[ 153]
Methadone	N.A.	Heroin Dependence	Allele A is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele G.		[ 208]
Methadone	N.A.	Opioid-related Disorders	Allele A is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele G.		[ 208]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Allele A is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.		[ 37]
Codeine	N.A.	Pain	Allele A is associated with increased likelihood of CNS depression in breast-feeding infants when treated with codeine in women with Pain as compared to allele G.		[ 14]
Antidepressants	N.A.	Major Depressive Disorder	Allele A is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele G.		[ 498]
Antiepileptics	N.A.	Epilepsy	Allele A is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.		[ 61]
Antiepileptics	N.A.	Epilepsy	Allele A is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele G.		[ 161]
Antiepileptics	N.A.	Epilepsy	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.		[ 69]
Antiepileptics	N.A.	Epilepsy	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.		[ 15]
Antiepileptics	N.A.	Epilepsy	Allele A is associated with increased risk of drug resistance when treated with antiepileptics in people with Epilepsy.		[ 17]
Simvastatin	N.A.	Hypercholesterolemia	Allele A is associated with decreased risk of Myalgia when treated with simvastatin in people with Hypercholesterolemia as compared to allele G.		[ 3]
Tacrolimus	N.A.	Transplantation	Allele A is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 23]
Tacrolimus	N.A.	Transplantation	Allele A is not associated with clearance of tacrolimus in people with liver transplantation as compared to allele G.		[ 36]
Tacrolimus	N.A.	Transplantation	Allele A is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 25]
Tacrolimus	N.A.	Transplantation	Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 540]
Tacrolimus	N.A.	Transplantation	Allele A is not associated with metabolism of tacrolimus in people with liver transplantation as compared to allele G.		[ 528]
Tacrolimus	N.A.	Transplantation	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 26]
Tacrolimus	N.A.	Transplantation	Allele A is not associated with metabolism of sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 24]
Carbamazepine	N.A.	Epilepsy	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.		[ 159]
Carbamazepine	N.A.	Epilepsy	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele G.		[ 18]
Sunitinib	N.A.	Renal Cell Carcinoma	Allele A is not associated with Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G.		[ 41]
Cyclosporine	N.A.	Kidney Transplantation	Allele A is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 23]
Cyclosporine	N.A.	Myasthenia Gravis	Allele A is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.		[ 23]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele A is associated with increased risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 92]
Methotrexate	N.A.	Lymphoma	Allele A is associated with increased risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 92]
Methotrexate	N.A.	Osteosarcoma	Allele A is associated with increased risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 92]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele A is not associated with discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to allele G.		[ 6]
Efavirenz	N.A.	HIV Infectious Disease	Allele A is not associated with exposure to efavirenz in healthy individuals as compared to allele G.		[ 113]
Antiepileptics	N.A.	Epilepsy	Irrelevant to the drug resistance in patients (compare with allele G); Irrelevant to the drug response in patients (compare with Allele G); Irrelevant to the likelihood of drug resistance in patients (compare with Allele G)		[ 15], [ 61], [ 69]
Allele G	Click to Show/Hide the Full List of Affected Drugs:         57 Drugs in Total
Methotrexate	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with Allele A)		[ 529]
Vincristine	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with Allele A)		[ 529]
Cisplatin	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with Allele A)		[ 529]
Doxorubicin	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with Allele A)		[ 529]
Cyclophosphamide	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with Allele A)		[ 529]
Carbamazepine	Drug Info	Epilepsy	Irrelevant to the drug metabolism in patients (compare with allele A)		[ 16]
Doxorubicin	Drug Info	Breast Neoplasm	Irrelevant to the drug response in patients (compare with allele A)		[ 531]
Cyclophosphamide	Drug Info	Breast Neoplasm	Irrelevant to the drug response in patients (compare with allele A)		[ 531]
Edoxaban	N.A.	Drug Toxicity	Allele G is not associated with decreased clearance of edoxaban in people with Atrial Fibrillation as compared to allele A.		[ 532]
Temsirolimus	N.A.	Adverse Events	Allele G is not associated with likelihood of adverse events when treated with temsirolimus in people with Urinary Bladder Neoplasms as compared to allele A.		[ 179]
Methadone	N.A.	Transplant Rejection	Allele G is not associated with concentrations of methadone as compared to allele A.		[ 274]
Citalopram	N.A.	Drug Resistance	Allele G is not associated with differences in remission or tolerance when treated with citalopram in people with Depressive Disorder, Major as compared to allele A.		[ 184]
Antipsychotics	N.A.	Vomiting	Allele G is associated with increased response to antipsychotics in people with Schizophrenia.		[ 187]
Tramadol	N.A.	Gastrointestinal Toxicity	Allele G is not associated with response to tramadol in people with Pain, Postoperative as compared to allele A.		[ 221]
Opioids	N.A.	Death	Allele G is not associated with risk of Death due to opioids in people with Opioid-Related Disorders as compared to allele A.		[ 190]
Methotrexate	N.A.	Mucositis	Allele G is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 38]
Atorvastatin	N.A.	Opioid-related Disorders	Allele G is not associated with response to atorvastatin in people with Hypercholesterolemia as compared to allele A.		[ 540]
Aripiprazole	N.A.	Adverse Events	Allele G is not associated with concentrations of aripiprazole in healthy individuals as compared to allele A.		[ 192]
Losartan	N.A.	Adverse Events	Allele G is not associated with increased response to losartan in people with Hypertension as compared to allele A.		[ 368]
Fentanyl	N.A.	Acute Cellular Rejection	Allele G is not associated with concentrations of fentanyl in people with Neoplasms and Pain as compared to allele A.		[ 195]
Risperidone	N.A.	Transplant Rejection	Allele G is not associated with response to risperidone in people with Schizophrenia as compared to allele A.		[ 544]
Methotrexate	N.A.	Nephrotoxicity	Allele G is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 199]
Antiepileptics	N.A.	Neurotoxicity Syndromes	Allele G is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.		[ 200]
Fentanyl	N.A.	Hypertension	Allele G is not associated with response to fentanyl in healthy individuals as compared to allele A.		[ 116]
Cyclophosphamide	N.A.	Gastrointestinal Toxicity	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 531]
Doxorubicin	N.A.	Gastrointestinal Toxicity	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 531]
Imatinib	N.A.	Myelosuppression	Allele G is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A.		[ 210]
Cisplatin	N.A.	Overall Survival	Allele G is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele A.		[ 529]
Cyclophosphamide	N.A.	Overall Survival	Allele G is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele A.		[ 529]
Doxorubicin	N.A.	Overall Survival	Allele G is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele A.		[ 529]
Methotrexate	N.A.	Overall Survival	Allele G is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele A.		[ 529]
Vincristine	N.A.	Overall Survival	Allele G is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele A.		[ 529]
Methadone	N.A.	Mucositis	Allele G is not associated with dose of methadone in people with Neoplasms and Pain as compared to allele A.		[ 213]
Carbamazepine	N.A.	Mucositis	Allele G is not associated with metabolism of carbamazepine in people with Epilepsy as compared to allele A.		[ 16]
Fentanyl	N.A.	Dose Reduction	Allele G is not associated with dose of fentanyl in children as compared to allele A.		[ 329]
Vincristine	N.A.	Nephrotoxicity	Allele G is not associated with impaired motor performance when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 147]
Lamotrigine	N.A.	Mucositis	Allele G is not associated with dose of lamotrigine in people with Epilepsy as compared to allele A.		[ 148]
Methadone	N.A.	Infectious Disease	Allele G is not associated with dose of methadone in people with Heroin Dependence as compared to allele A.		[ 218]
Methadone	N.A.	Pain	Allele G is not associated with severity of Pain when treated with methadone in people with Opioid-Related Disorders as compared to allele A.		[ 220]
Fentanyl	N.A.	Adverse Events	Allele G is not associated with likelihood of adverse events due to fentanyl in healthy individuals as compared to allele A.		[ 116]
Methadone	N.A.	Heroin Dependence	Allele G is not associated with dose of methadone in people with Heroin Dependence as compared to allele A.		[ 218]
Methadone	N.A.	Opioid-related Disorders	Allele G is not associated with dose of methadone in people with Heroin Dependence as compared to allele A.		[ 218]
Antiepileptics	N.A.	Epilepsy	Allele G is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.		[ 200]
Cisplatin	N.A.	Osteosarcoma	Allele G is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele A.		[ 529]
Cyclophosphamide	N.A.	Osteosarcoma	Allele G is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele A.		[ 529]
Doxorubicin	N.A.	Osteosarcoma	Allele G is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele A.		[ 529]
Methotrexate	N.A.	Osteosarcoma	Allele G is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele A.		[ 529]
Vincristine	N.A.	Osteosarcoma	Allele G is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele A.		[ 529]
Cisplatin	N.A.	Osteosarcoma	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 531]
Cyclophosphamide	N.A.	Osteosarcoma	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 531]
Doxorubicin	N.A.	Osteosarcoma	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 531]
Methotrexate	N.A.	Osteosarcoma	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 531]
Vincristine	N.A.	Osteosarcoma	Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.		[ 531]
Fentanyl	N.A.	Pain	Allele G is not associated with dose of fentanyl in children as compared to allele A.		[ 329]
Fentanyl	N.A.	Pain, Postoperative	Allele G is not associated with dose of fentanyl in children as compared to allele A.		[ 329]
Carbamazepine	N.A.	Epilepsy	Allele G is not associated with metabolism of carbamazepine in people with Epilepsy as compared to allele A.		[ 16]
Antiepileptics	N.A.	Epilepsy	Irrelevant to the drug response in patients (compare with allele A)		[ 158], [ 200]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:       162 Drugs in Total
Tacrolimus	Drug Info	Kidney Transplantation	Correlated with the decreased drug clearance in patients (compare with genotypes AG + GG); Irrelevant to the drug clearance in patients (compare with genotypes AG + GG); Irrelevant to the drug concentrations in patients (compare with genotypes AG + GG)		[ 230], [ 294], [ 535]
Fentanyl	Drug Info	Neoplasm	Correlated with the decreased drug response in patients (compare with Genotype AG + GG )		[ 195]
Sunitinib	Drug Info	Renal Cell Carcinoma	Correlated with the decreased neutropenia risk in patients (compare with genotypes AG + GG)		[ 237]
Gefitinib	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased diarrhea and exanthema risk in patients (compare with genotypes AG + GG)		[ 539]
Tramadol	Drug Info	Pain	Correlated with the increased drug exposure (compare with genotype GG)		[ 251]
Fentanyl	Drug Info	Postoperative Pain	Correlated with the increased likelihood of respiratory insufficiency in patients (compare with Genotype AG + GG)		[ 254]
Cyclosporine	Drug Info	Kidney Transplantation	Correlated with the increased nephrotoxicity risk in patients (compare with genotypes AG + GG)		[ 285]
Oxaliplatin	Drug Info	Colorectal Neoplasm	Correlated with the increased overall survival in patients (compare with genotype GG)		[ 337]
Simvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased reduction in total cholesterol in patients (compare with genotype GG)		[ 256]
Sirolimus	Drug Info	Kidney Transplantation	Correlated with the increased triglycerides in patients (compare with genotypes AG + GG)		[ 348]
Cyclosporine	Drug Info	Myasthenia Gravis	Correlated with the increased trough blood concentration in patients (compare with genotype GG)		[ 546]
Daunorubicin	Drug Info	Acute Myeloid Leukemia	Irrelevant to the drug response in patients (compare with genotypes AG + GG)		[ 258]
Cytarabine	Drug Info	Acute Myeloid Leukemia	Irrelevant to the drug response in patients (compare with genotypes AG + GG)		[ 258]
Tacrolimus	Drug Info	Ulcerative Colitis	Irrelevant to the increased success rate in achieving short-term remission in patients (compare with genotypes AG + GG)		[ 311]
Rocuronium	Drug Info	Muscle Relaxant	Correlated with the increased drug response in patients (compare with genotypes AG + GG)		[ 549]
Dexrazoxane	Drug Info	Acute Myeloid Leukemia	Irrelevant to the drug response in patients (compare with genotypes AG + GG)		[ 258]
Efavirenz	Drug Info	HIV Infection	Correlated with the decreased drug concentrations in patients (compare with genotypes AG + GG)		[ 262]
Capecitabine	Drug Info	Colorectal Neoplasm	Correlated with the decreased hand-foot syndrome and neutropenia risk in patients (compare with genotype GG)		[ 338]
Rivaroxaban	N.A.	Hemorrhage	Genotype AA is associated with increased concentrations of rivaroxaban in people with Atrial Fibrillation as compared to genotypes AG + GG.		[ 267]
Cyclosporine	N.A.	Transplant Rejection	Genotype AA is associated with increased trough blood concentration of cyclosporine in people with Myasthenia Gravis as compared to genotype GG.		[ 546]
Digoxin	N.A.	Sudden Cardiac Death	Genotype AA is associated with increased likelihood of Death, Sudden, Cardiac when treated with digoxin as compared to genotypes AG + GG.		[ 268]
Cytarabine	N.A.	Arthralgia	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.		[ 258]
Daunorubicin	N.A.	Arthralgia	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.		[ 258]
Dexrazoxane	N.A.	Arthralgia	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.		[ 258]
Antipsychotics	N.A.	Arthralgia	Genotype AA is associated with increased dose of antipsychotics in people with Schizophrenia.		[ 187]
Tacrolimus	N.A.	Adverse Events	Genotype AA is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 230]
Platinum Compounds	N.A.	Drug Toxicity	Genotype AA is associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 555]
Sirolimus	N.A.	Drug Toxicity	Genotype AA is associated with increased triglycerides when treated with sirolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 348]
Gefitinib	N.A.	Exanthema	Genotype AA is associated with increased likelihood of Exanthema when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 277]
Methadone	N.A.	Diarrhea	Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.		[ 278]
Abemaciclib	N.A.	Neutropenia	Genotype AA is associated with increased likelihood of Neutropenia when treated with abemaciclib, palbociclib or ribociclib in women with Breast Neoplasms as compared to genotypes AG + GG.		[ 83]
Palbociclib	N.A.	Neutropenia	Genotype AA is associated with increased likelihood of Neutropenia when treated with abemaciclib, palbociclib or ribociclib in women with Breast Neoplasms as compared to genotypes AG + GG.		[ 83]
Ribociclib	N.A.	Neutropenia	Genotype AA is associated with increased likelihood of Neutropenia when treated with abemaciclib, palbociclib or ribociclib in women with Breast Neoplasms as compared to genotypes AG + GG.		[ 83]
Aripiprazole	N.A.	Neutropenia	Genotype AA is associated with increased concentrations of aripiprazole in people with Depressive Disorder, Major as compared to genotypes AG + GG.		[ 498]
Fluorouracil	N.A.	Diarrhea	Genotype AA is not associated with decreased risk of Diarrhea, hand-foot syndrome and Neutropenia when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.		[ 338]
Fluorouracil	N.A.	Hand-foot Syndrome	Genotype AA is not associated with decreased risk of Diarrhea, hand-foot syndrome and Neutropenia when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.		[ 338]
Fluorouracil	N.A.	Neutropenia	Genotype AA is not associated with decreased risk of Diarrhea, hand-foot syndrome and Neutropenia when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.		[ 338]
Capecitabine	N.A.	Hand-foot Syndrome	Genotype AA is associated with decreased risk of hand-foot syndrome and Neutropenia when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype GG.		[ 338]
Capecitabine	N.A.	Neutropenia	Genotype AA is associated with decreased risk of hand-foot syndrome and Neutropenia when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype GG.		[ 338]
Sunitinib	N.A.	Gastrointestinal Toxicity	Genotype AA is not associated with response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.		[ 237]
Efavirenz	N.A.	Transplant Rejection	Genotype AA is not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections.		[ 463]
Tacrolimus	N.A.	Neutropenia	Genotype AA is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 535]
Gefitinib	N.A.	Diarrhea	Genotype AA is associated with increased risk of Diarrhea and Exanthema when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 539]
Gefitinib	N.A.	Exanthema	Genotype AA is associated with increased risk of Diarrhea and Exanthema when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 539]
Cyclosporine	N.A.	Adverse Events	Genotype AA is associated with increased risk of nephrotoxicity when treated with cyclosporine in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 285]
Mitoxantrone	N.A.	Epistaxis	Genotype AA is associated with increased sensitivity in vitro when treated with mitoxantrone.		[ 405]
Atorvastatin	N.A.	Hemorrhage	Genotype AA is associated with increased AUC of atorvastatin in healthy individuals as compared to genotype GG.		[ 288]
Simvastatin	N.A.	Hemorrhage	Genotype AA is associated with increased AUC simvastatin acid when treated with simvastatin in healthy individuals as compared to genotype GG.		[ 288]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Genotype AA is associated with increased severity of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotypes AG + GG.		[ 514]
Aripiprazole	N.A.	Opioid-related Disorders	Genotype AA is associated with decreased clearance of aripiprazole in healthy individuals as compared to genotypes AG + GG.		[ 192]
Donepezil	N.A.	Adverse Events	Genotype AA is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype GG.		[ 429]
Atazanavir	N.A.	Hyperbilirubinemia	Genotype AA is associated with increased risk of Hyperbilirubinemia when exposed to atazanavir in healthy individuals as compared to genotypes AG + GG.		[ 290]
Tacrolimus	N.A.	Adverse Events	Genotype AA is not associated with concentrations of tacrolimus in children with Kidney Transplantation as compared to genotypes AG + GG.		[ 294]
Methotrexate	N.A.	Peripheral Nervous System Diseases	Genotype AA is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotypes AG + GG.		[ 296]
Lamotrigine	N.A.	Toxic Liver Disease	Genotype AA is not associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotypes AG + GG.		[ 297]
Simvastatin	N.A.	Drug Toxicity	Genotype AA is associated with increased reduction in total cholesterol when treated with simvastatin as compared to genotype GG.		[ 256]
Granisetron	N.A.	Asthenia	Genotype AA is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AG + GG.		[ 266]
Palonosetron	N.A.	Asthenia	Genotype AA is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AG + GG.		[ 266]
Imatinib	N.A.	Asthenia	Genotype AA is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.		[ 570]
Fentanyl	N.A.	Diarrhea	Genotype AA is associated with decreased response to fentanyl in people with Neoplasms and Pain as compared to genotypes AG + GG.		[ 195]
Tacrolimus	N.A.	Neutropenia	Genotype AA is not associated with concentrations of tacrolimus in children with liver transplantation.		[ 257]
Fentanyl	N.A.	Diarrhea	Genotype AA is associated with increased dose of fentanyl in women with Pain, Postoperative as compared to genotypes AG + GG.		[ 572]
Tacrolimus	N.A.	Transplant Rejection	Genotype AA is associated with increased response to tacrolimus in people with Nephrotic Syndrome as compared to genotypes AG + GG.		[ 573]
Tacrolimus	N.A.	Cardiotoxicity	Genotype AA is not associated with decreased dose of tacrolimus in people with liver transplantation as compared to genotypes AG + GG.		[ 376]
Tipifarnib	N.A.	Hemorrhage	Genotype AA is associated with decreased metabolism of tipifarnib as compared to genotypes AG + GG.		[ 203]
Doxorubicin	N.A.	Neonatal Abstinence Syndrome	Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype GG.		[ 316]
Fentanyl	N.A.	Hypoventilation	Genotype AA is associated with increased likelihood of Hypoventilation due to fentanyl in people with Pain, Postoperative as compared to genotypes AG + GG.		[ 254]
Tacrolimus	N.A.	Hypersensitivity	Genotype AA is not associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 313]
Tacrolimus	N.A.	Hypersensitivity	Genotype AA is not associated with increased success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to genotypes AG + GG.		[ 311]
Tramadol	N.A.	Cholelithiasis	Genotype AA is associated with increased exposure to tramadol as compared to genotype GG.		[ 251]
Valproic Acid	N.A.	Adverse Events	Genotype AA is associated with decreased clinical benefit to valproic acid in children with Epilepsy as compared to genotypes AG + GG.		[ 578]
Sunitinib	N.A.	Overall Survival	Genotype AA is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.		[ 579]
Erlotinib	N.A.	Drug Toxicity	Genotype AA is associated with increased likelihood of Drug Toxicity when treated with erlotinib in people with Carcinoma, Non-Small-Cell Lung.		[ 315]
Rocuronium	N.A.	Hyperprolactinemia	Genotype AA is associated with decreased response to rocuronium as compared to genotypes AG + GG.		[ 549]
Gefitinib	N.A.	Weight Gain	Genotype AA are not associated with concentrations of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 446]
Sunitinib	N.A.	Neutropenia	Genotype AA is associated with decreased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.		[ 237]
Ritonavir	N.A.	Eye Diseases	Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AG + GG.		[ 290]
Oxaliplatin	N.A.	Pain, Postoperative	Genotype AA is associated with increased overall survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.		[ 337]
Atazanavir	N.A.	Transplant Rejection	Genotype AA is associated with increased clearance of atazanavir in healthy individuals as compared to genotypes AG + GG.		[ 290]
Diazepam	N.A.	Drug Toxicity	Genotype AA is associated with increased exposure to diazepam in healthy individuals as compared to genotype GG (assigned as normal metabolizer phenotype) .		[ 582]
Efavirenz	N.A.	Mucositis	Genotype AA is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.		[ 262]
Erlotinib	N.A.	Dyspnea	Genotype AA is associated with decreased clearance of erlotinib in people with Carcinoma, Non-Small-Cell Lung.		[ 315]
Crizotinib	N.A.	Mucositis	Genotype AA is associated with increased exposure to crizotinib in people with.		[ 331]
Hmg Coa Reductase Inhibitors	N.A.	Elevated Circulating Creatine Kinase Concentration	Genotype AA is associated with increased likelihood of Elevated circulating creatine kinase concentration when treated with hmg coa reductase inhibitors as compared to genotypes AG + GG.		[ 332]
Sunitinib	N.A.	Postoperative Nausea And Vomiting	Genotype AA is associated with increased dose of sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.		[ 579]
Methadone	N.A.	Chronic Kidney Failure	Genotype AA is not associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.		[ 250]
Nevirapine	N.A.	Hemorrhage	Genotype AA is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotypes AG + GG.		[ 336]
Gefitinib	N.A.	Non-small Cell Lung Carcinoma	Genotype AA is associated with increased risk of Diarrhea and Exanthema when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 539]
Simvastatin	N.A.	Hypercholesterolemia	Genotype AA is associated with increased reduction in total cholesterol when treated with simvastatin as compared to genotype GG.		[ 256]
Methadone	N.A.	Heroin Dependence	Genotype AA is not associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.		[ 250]
Methadone	N.A.	Opioid-related Disorders	Genotype AA is not associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.		[ 250]
Methadone	N.A.	Heroin Dependence	Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.		[ 278]
Methadone	N.A.	Opioid-related Disorders	Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.		[ 278]
Platinum Compounds	N.A.	Non-small Cell Lung Carcinoma	Genotype AA is associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 555]
Phenytoin	N.A.	Breast Neoplasms	Patients with the AA genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.		[ 21]
Modafinil	N.A.	Narcolepsy	Patients with AA genotype and narcolepsy may have decreased response to modafinil compared to patients with AG genotype. Other clinical and genetic factors may affect response to modafinil.		[ 345]
Tipifarnib	N.A.	Neoplasms	Genotype AA is associated with decreased metabolism of tipifarnib as compared to genotypes AG + GG.		[ 203]
Hmg Coa Reductase Inhibitors	N.A.	Neoplasms	Genotype AA is associated with increased likelihood of Elevated circulating creatine kinase concentration when treated with hmg coa reductase inhibitors as compared to genotypes AG + GG.		[ 332]
Remifentanil	N.A.	Tonsillectomy	Pediatric patients undergoing surgery with the AA genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.		[ 443]
Sevoflurane	N.A.	Tonsillectomy	Pediatric patients undergoing surgery with the AA genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.		[ 443]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the AA genotype and chronic myeloid leukemia may have a poorer response to imatinib treatment as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to imatinib.		[ 253]
Tacrolimus	N.A.	Ulcerative Colitis	Genotype AA is not associated with increased success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to genotypes AG + GG.		[ 311]
Codeine	N.A.	Pain	Breast-feeding infants whose mothers have the AA genotype and are taking codeine may be at increased risk for CNS depression as compared to those whose mothers have the GG genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants.		[ 14]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.		[ 258]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the AA genotype and acute myeloid leukemia may have a better response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the GG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine.		[ 405]
Antidepressants	N.A.	Major Depressive Disorder	Patients with the rs1128503 AA genotype may have an increased response to antidepressants as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to antidepressants.		[ 498]
Aripiprazole	N.A.	Major Depressive Disorder	Genotype AA is associated with increased concentrations of aripiprazole in people with Depressive Disorder, Major as compared to genotypes AG + GG.		[ 498]
Temozolomide	N.A.	Glioma	Patients with glioma and the rs1128503 AA genotype may have decreased concentrations of temozolomide as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs1128503 and temozolomide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence temozolomide concentrations.		[ 592]
Risperidone	N.A.	Autism	Patients with the AA genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response.		[ 593]
Antiepileptics	N.A.	Epilepsy	Patients with the AA genotype and specificially localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics.		[ 61]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the AA genotype and hypercholesterolemia may have a decreased risk for myalgia when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for myalgia.		[ 3]
Fentanyl	N.A.	Pain, Postoperative	Genotype AA is associated with increased likelihood of Hypoventilation due to fentanyl in people with Pain, Postoperative as compared to genotypes AG + GG.		[ 254]
Tacrolimus	N.A.	Transplantation	Genotype AA is not associated with decreased dose of tacrolimus in people with liver transplantation as compared to genotypes AG + GG.		[ 376]
Tacrolimus	N.A.	Transplantation	Genotype AA is not associated with clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 535]
Tacrolimus	N.A.	Transplantation	Genotype AA is not associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 313]
Tacrolimus	N.A.	Transplantation	Genotype AA is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 230]
Tacrolimus	N.A.	Transplantation	Genotype AA is not associated with concentrations of tacrolimus in children with Kidney Transplantation as compared to genotypes AG + GG.		[ 294]
Tacrolimus	N.A.	Transplantation	Genotype AA is not associated with concentrations of tacrolimus in children with liver transplantation.		[ 257]
Capecitabine	N.A.	Colorectal Neoplasms	Genotype AA is associated with decreased risk of hand-foot syndrome and Neutropenia when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype GG.		[ 338]
Oxaliplatin	N.A.	Colorectal Neoplasms	Genotype AA is associated with increased overall survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.		[ 337]
Digoxin	N.A.	Pain	Patients with the AA genotype may have increased serum concentrations of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.		[ 13]
Sirolimus	N.A.	Kidney Transplantation	Genotype AA is associated with increased triglycerides when treated with sirolimus in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 348]
Cisplatin	N.A.	Osteosarcoma	Patients with the AA genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Cyclophosphamide	N.A.	Osteosarcoma	Patients with the AA genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Doxorubicin	N.A.	Osteosarcoma	Patients with the AA genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Methotrexate	N.A.	Osteosarcoma	Patients with the AA genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Vincristine	N.A.	Osteosarcoma	Patients with the AA genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Fentanyl	N.A.	Pain	Genotype AA is associated with decreased response to fentanyl in people with Neoplasms and Pain as compared to genotypes AG + GG.		[ 195]
Fentanyl	N.A.	Pain, Postoperative	Genotype AA is associated with decreased response to fentanyl in people with Neoplasms and Pain as compared to genotypes AG + GG.		[ 195]
Fentanyl	N.A.	Pain	Genotype AA is associated with increased dose of fentanyl in women with Pain, Postoperative as compared to genotypes AG + GG.		[ 572]
Fentanyl	N.A.	Pain, Postoperative	Genotype AA is associated with increased dose of fentanyl in women with Pain, Postoperative as compared to genotypes AG + GG.		[ 572]
Fentanyl	N.A.	Pain	Patients with the AA genotype may have a decreased response to fentanyl and may therefore require an increased dose as compared to patients with the AG or GG genotypes. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.		[ 329]
Fentanyl	N.A.	Pain, Postoperative	Patients with the AA genotype may have a decreased response to fentanyl and may therefore require an increased dose as compared to patients with the AG or GG genotypes. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.		[ 329]
Propofol	N.A.	Ovarian Neoplasms	Patients with the AA genotype who are undergoing surgery may have a decreased response to propofol and remifentanil administered as anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.		[ 191]
Remifentanil	N.A.	Ovarian Neoplasms	Patients with the AA genotype who are undergoing surgery may have a decreased response to propofol and remifentanil administered as anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.		[ 191]
Clopidogrel	N.A.	Pain	Patients with the AA genotype who are taking clopidogrel may have increased resistance to clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clopidogrel in patients.		[ 400]
Carbamazepine	N.A.	Epilepsy	African American and white patients with the AA genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.		[ 601]
Sunitinib	N.A.	Renal Cell Carcinoma	Genotype AA is associated with decreased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.		[ 237]
Sunitinib	N.A.	Renal Cell Carcinoma	Patients with renal cell carcinoma and the AA genotype who are treated with sunitinib may have a decreased risk of neutropenia, leukopenia, and diarrhea as compared to patients with the AG and GG genotypes, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib.		[ 41]
Tacrolimus	N.A.	Nephrotic Syndrome	Genotype AA is associated with increased response to tacrolimus in people with Nephrotic Syndrome as compared to genotypes AG + GG.		[ 573]
Cyclosporine	N.A.	Kidney Transplantation	Genotype AA is associated with increased trough blood concentration of cyclosporine in people with Myasthenia Gravis as compared to genotype GG.		[ 546]
Cyclosporine	N.A.	Myasthenia Gravis	Genotype AA is associated with increased trough blood concentration of cyclosporine in people with Myasthenia Gravis as compared to genotype GG.		[ 546]
Cyclosporine	N.A.	Kidney Transplantation	Genotype AA is associated with increased risk of nephrotoxicity when treated with cyclosporine in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 285]
Cyclosporine	N.A.	Myasthenia Gravis	Genotype AA is associated with increased risk of nephrotoxicity when treated with cyclosporine in people with Kidney Transplantation as compared to genotypes AG + GG.		[ 285]
Cyclosporine	N.A.	Kidney Transplantation	Patients with the AA genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine and therefore may require a decreased dose of cyclosporine, compared to patients with the GG genotype. Patients with the AA genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.		[ 23]
Cyclosporine	N.A.	Myasthenia Gravis	Patients with the AA genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine and therefore may require a decreased dose of cyclosporine, compared to patients with the GG genotype. Patients with the AA genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.		[ 23]
Sirolimus	N.A.	Urinary Bladder Neoplasms	Patients with the AA genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.		[ 179]
Temsirolimus	N.A.	Urinary Bladder Neoplasms	Patients with the AA genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.		[ 179]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs1128503 AA genotype may be at an increased risk of experiencing side effects when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.		[ 38]
Methotrexate	N.A.	Lymphoma	Patients with the rs1128503 AA genotype may be at an increased risk of experiencing side effects when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.		[ 38]
Methotrexate	N.A.	Mucositis	Patients with the rs1128503 AA genotype may be at an increased risk of experiencing side effects when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.		[ 38]
Methotrexate	N.A.	Osteosarcoma	Patients with the rs1128503 AA genotype may be at an increased risk of experiencing side effects when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.		[ 38]
Cyclosporine	N.A.	Hematopoietic Stem Cell Transplantation	Patients with the AA genotype may be at a decreased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the GG genotype. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment.		[ 606]
Cyclosporine	N.A.	Neurotoxicity Syndromes	Patients with the AA genotype may be at a decreased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the GG genotype. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment.		[ 606]
Methotrexate	N.A.	Rheumatoid Arthritis	The current evidence base suggests that there is no significant association between the rs1128503 AA genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 607]
Efavirenz	N.A.	HIV Infectious Disease	Genotype AA is not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections.		[ 463]
Efavirenz	N.A.	HIV Infectious Disease	Genotype AA is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.		[ 262]
Sufentanil	N.A.	HIV Infectious Disease	Patients with the AA genotype may have increased sufentanil dose requirements as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's sufentantil dose requirements.		[ 117]
Paclitaxel	N.A.	Breast Neoplasms	Genotype AA is associated with increased severity of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotypes AG + GG.		[ 609]
Morphine	N.A.	Epilepsy	Patients with the AA genotype may have increased concentrations of morphine as compared to patients with the AG or GG genotypes. However, one study failed to find this association. Other genetic and clinical factors may also affect morphine concentrations in a patient.		[ 121]
Tipifarnib	N.A.	Neoplasm	Correlated with the decreased drug metabolism in patients (compare with genotypes AG + GG)		[ 203]
Platinum compounds	N.A.	Non-Small-Cell Lung Carcinoma	Correlated with the increased drug toxicity risk in patients (compare with genotype GG); Correlated with the increased drug toxicity risk in patients (compare with genotypes AG + GG)		[ 555]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:         79 Drugs in Total
Tacrolimus	Drug Info	Kidney Transplantation	Correlated with the increased drug trough concentrations in patients (compare with genotype GG)		[ 551]
Methotrexate	Drug Info	Rheumatoid Arthritis; Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of drug toxicity in patients (compare with genotype GG)		[ 549]
Oxaliplatin	Drug Info	Colorectal Neoplasm	Correlated with the increased overall survival in patients (compare with genotype GG)		[ 337]
Modafinil	Drug Info	Narcolepsy	Correlated with the increased drug response in patients (compare with genotypes AA + GG)		[ 345]
Valganciclovir	N.A.	Neutropenia	Genotype AG is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype AA.		[ 273]
S-eddp	N.A.	Diarrhea	Genotype AG is associated with increased concentrations of (S)-EDDP.		[ 383]
Methadone	N.A.	Diarrhea	Genotype AG is associated with decreased concentrations of methadone.		[ 383]
Phenytoin	N.A.	Drug Toxicity	Genotype AG is not associated with dose-adjusted trough concentrations of phenytoin in people with Epilepsy as compared to genotype AA.		[ 390]
Levofloxacin	N.A.	Asthenia	Genotype AG is associated with increased risk of seizures due to levofloxacin.		[ 387]
Tacrolimus	N.A.	Acute Cellular Rejection	Genotype AG is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 229]
Tacrolimus	N.A.	Diarrhea	Genotype AG is associated with increased trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 551]
Digoxin	N.A.	Drug Toxicity	Genotype AG is associated with decreased clearance of digoxin in healthy individuals as compared to genotype AA.		[ 438]
Sunitinib	N.A.	Progression-free Survival	Genotype AG is associated with increased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype AA.		[ 389]
Fentanyl	N.A.	Hypertension	Genotype AG is associated with decreased exposure to fentanyl in healthy individuals as compared to genotypes AA + GG.		[ 116]
Oxaliplatin	N.A.	Drug Toxicity	Genotype AG is associated with increased overall survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.		[ 337]
Methotrexate	N.A.	Drug Toxicity	Genotype AG is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.		[ 549]
Modafinil	N.A.	Anemia	Genotype AG is associated with increased response to modafinil in people with Narcolepsy as compared to genotypes AA + GG.		[ 345]
Methadone	N.A.	Postoperative Nausea And Vomiting	Genotype AG is associated with increased concentrations of methadone in men with Opioid-Related Disorders as compared to genotypes AA + GG.		[ 379]
Gefitinib	N.A.	Non-small Cell Lung Carcinoma	Patients with the AG genotype and non-small cell lung cancer may have a decreased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.		[ 535]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the AG genotype and hypercholesterolemia may greater reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence cholesterol levels.		[ 256]
Methadone	N.A.	Heroin Dependence	The current evidence base suggests that there is no significant association between the rs1128503 AG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.		[ 250]
Methadone	N.A.	Opioid-related Disorders	The current evidence base suggests that there is no significant association between the rs1128503 AG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.		[ 250]
Platinum Compounds	N.A.	Non-small Cell Lung Carcinoma	Patients with the AG genotype and non-small cell lung cancer may have reduced risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.		[ 538]
Phenytoin	N.A.	Breast Neoplasms	Patients with the AG genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.		[ 21]
Modafinil	N.A.	Narcolepsy	Genotype AG is associated with increased response to modafinil in people with Narcolepsy as compared to genotypes AA + GG.		[ 345]
Tipifarnib	N.A.	Neoplasms	Patients with the AG genotype and cancer may have decreased exposure to tipifarnib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.		[ 203]
Hmg Coa Reductase Inhibitors	N.A.	Neoplasms	Patients with the rs1128503 AG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.		[ 332]
Remifentanil	N.A.	Tonsillectomy	Pediatric patients undergoing surgery with the AG genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.		[ 443]
Sevoflurane	N.A.	Tonsillectomy	Pediatric patients undergoing surgery with the AG genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.		[ 443]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Patients with the AG genotype and chronic myeloid leukemia may have a poorer response to imatinib treatment as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to imatinib.		[ 253]
Tacrolimus	N.A.	Ulcerative Colitis	Patients with the AG genotype and ulcerative colitis may have an increased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus response.		[ 311]
Codeine	N.A.	Pain	Breast-feeding infants whose mothers have the AG genotype and are taking codeine may be at increased risk for CNS depression as compared to those whose mothers have the GG genotype, or at decreased risk as compared to those whose mothers have the AA genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants.		[ 14]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the AG genotype and acute myeloid leukemia may have a better response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the GG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine.		[ 405]
Antidepressants	N.A.	Major Depressive Disorder	Patients with the rs1128503 AG genotype may have an increased response to antidepressants as compared to patients with the GG genotype but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to antidepressants.		[ 498]
Aripiprazole	N.A.	Major Depressive Disorder	Patients with the rs1128503 AG genotype may have decreased plasma concentrations of aripiprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also affect may also affect aripiprazole concentrations. This annotation only covers the pharmacokinetic relationship between rs1128503 and aripiprazole and does not include evidence about clinical outcomes.		[ 498]
Temozolomide	N.A.	Glioma	Patients with glioma and the rs1128503 AG genotype may have decreased concentrations of temozolomide as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs1128503 and temozolomide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence temozolomide concentrations.		[ 545]
Risperidone	N.A.	Autism	Patients with the AG genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response.		[ 546]
Antiepileptics	N.A.	Epilepsy	Patients with the AG genotype and specifically localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics.		[ 61]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the AG genotype and hypercholesterolemia may have a decreased risk for myalgia when treated with simvastatin as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for myalgia.		[ 3]
Fentanyl	N.A.	Hypoventilation	Patients with the AG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Fentanyl	N.A.	Pain, Postoperative	Patients with the AG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Tacrolimus	N.A.	Transplantation	Genotype AG is associated with increased trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 551]
Tacrolimus	N.A.	Transplantation	Genotype AG is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 229]
Tacrolimus	N.A.	Transplantation	Patients with the AG genotype who are undergoing organ transplantation may have increased concentrations of tacrolimus as compared to patients with the GG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus.		[ 376]
Capecitabine	N.A.	Colorectal Neoplasms	Patients with the AG genotype and colorectal cancer may have a decreased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.		[ 338]
Oxaliplatin	N.A.	Colorectal Neoplasms	Genotype AG is associated with increased overall survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.		[ 337]
Digoxin	N.A.	Pain	Patients with the AA genotype may have increased serum concentrations of digoxin as compared to patients with the GG genotype, or decreased serum concentrations of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.		[ 13]
Sirolimus	N.A.	Kidney Transplantation	Patients with the AG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels.		[ 348]
Tramadol	N.A.	Urinary Bladder Neoplasms	There is currently no evidence to show whether the AG genotype affects a patient's exposure to tramadol.		[ 251]
Cisplatin	N.A.	Osteosarcoma	Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Cyclophosphamide	N.A.	Osteosarcoma	Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Doxorubicin	N.A.	Osteosarcoma	Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Methotrexate	N.A.	Osteosarcoma	Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Vincristine	N.A.	Osteosarcoma	Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Fentanyl	N.A.	Pain	Patients with the AG genotype may have an increased response to fentanyl and may therefore require a decreased dose as compared to patients with the AA genotype. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.		[ 329]
Fentanyl	N.A.	Pain, Postoperative	Patients with the AG genotype may have an increased response to fentanyl and may therefore require a decreased dose as compared to patients with the AA genotype. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.		[ 329]
Propofol	N.A.	Ovarian Neoplasms	Patients with the AG genotype who are undergoing surgery may have a decreased response to propofol and remifentanil administered as anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.		[ 191]
Remifentanil	N.A.	Ovarian Neoplasms	Patients with the AG genotype who are undergoing surgery may have a decreased response to propofol and remifentanil administered as anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.		[ 191]
Clopidogrel	N.A.	Pain	Patients with the AG genotype who are taking clopidogrel may have increased resistance to clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clopidogrel in patients.		[ 400]
Carbamazepine	N.A.	Epilepsy	African American and white patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.		[ 547]
Rocuronium	N.A.	Pain	Patients with the AG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype but a decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rocuronium.		[ 537]
Sunitinib	N.A.	Renal Cell Carcinoma	Patients with renal cell carcinoma and the AG genotype who are treated with sunitinib may have an increased risk of neutropenia, leukopenia as compared to patients with the AA genotypes and a decreased risk of diarrhea as compared to patients with the GG genotype, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib.		[ 41]
Tacrolimus	N.A.	Nephrotic Syndrome	Patients with the AG genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.		[ 541]
Cyclosporine	N.A.	Kidney Transplantation	Patients with the AG genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype, and therefore may require an adjusted dose of the drug. Patients with the AG genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.		[ 23]
Cyclosporine	N.A.	Myasthenia Gravis	Patients with the AG genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype, and therefore may require an adjusted dose of the drug. Patients with the AG genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.		[ 23]
Sirolimus	N.A.	Urinary Bladder Neoplasms	Patients with the AG genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.		[ 179]
Temsirolimus	N.A.	Urinary Bladder Neoplasms	Patients with the AG genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.		[ 179]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs1128503 AG genotype may be at an increased risk of experiencing side effects when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.		[ 38]
Methotrexate	N.A.	Lymphoma	Patients with the rs1128503 AG genotype may be at an increased risk of experiencing side effects when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.		[ 38]
Methotrexate	N.A.	Mucositis	Patients with the rs1128503 AG genotype may be at an increased risk of experiencing side effects when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.		[ 38]
Methotrexate	N.A.	Osteosarcoma	Patients with the rs1128503 AG genotype may be at an increased risk of experiencing side effects when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.		[ 38]
Cyclosporine	N.A.	Hematopoietic Stem Cell Transplantation	Patients with the AG genotype may be at a decreased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the GG genotype. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment.		[ 548]
Cyclosporine	N.A.	Neurotoxicity Syndromes	Patients with the AG genotype may be at a decreased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the GG genotype. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment.		[ 548]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype AG is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.		[ 549]
Efavirenz	N.A.	HIV Infectious Disease	Patients with AG genotype and HIV may have increased concentrations of efavirenz in plasma compared to patients with AA genotype. However, this association was not significant and has not been found in other studies. Other clinical and genetic factors may affect efavirenz concentrations.		[ 463]
Sufentanil	N.A.	HIV Infectious Disease	Patients with the AG genotype may have increased sufentanil dose requirements as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's sufentantil dose requirements.		[ 117]
Paclitaxel	N.A.	Breast Neoplasms	Patients with the rs1128503 AG genotype may have decreased severity of peripheral neuropathy when treated with paclitaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of peripheral neuropathy when treated with paclitaxel.		[ 550]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Patients with the rs1128503 AG genotype may have decreased severity of peripheral neuropathy when treated with paclitaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of peripheral neuropathy when treated with paclitaxel.		[ 550]
Morphine	N.A.	Epilepsy	Patients with the AG genotype may have decreased concentrations of morphine as compared to patients with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also affect morphine concentrations in a patient.		[ 121]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:       111 Drugs in Total
Tacrolimus	Drug Info	Liver Transplantation	Correlated with the decreased drug concentrations in patients (compare with genotypes AA + AG)		[ 552]
Sirolimus	Drug Info	Urinary Bladder Neoplasm	Correlated with the decreased drug exposure in patients (compare with genotypes AA + AG)		[ 179]
Temsirolimus	Drug Info	Urinary Bladder Neoplasm	Correlated with the decreased drug exposure in patients (compare with genotypes AA + AG)		[ 179]
Simvastatin	Drug Info	Hypercholesterolemia	Correlated with the decreased drug response in patients (compare with genotypes AA + AG)		[ 3]
Imatinib	Drug Info	Bcr-Abl Positive Chronic Myelogenous Leukemia	Correlated with the decreased drug response in patients (compare with genotypes AA + AG); Correlated with the increased drug response in patients (compare with genotypes AA + AG)		[ 253], [ 401]
Cytarabine	Drug Info	Acute Myeloid Leukemia	Correlated with the decreased survival in patients (compare with genotypes AA + AG)		[ 405]
Gefitinib	Drug Info	Non-Small-Cell Lung Carcinoma	Irrelevant to the drug toxicity risk in patients (compare with genotypes AA + AG)		[ 446]
Sevoflurane	Drug Info	Tonsillectomy	Correlated with the decreased likelihood of adverse events in patients (compare with genotypes AA + AG); Correlated with the increased drug response in patients (compare with genotypes AA + AG)		[ 443]
Remifentanil	Drug Info	Tonsillectomy	Correlated with the increased drug response (compare with genotypes AA + AG); Correlated with the increased drug response in patients (compare with genotypes AA + AG)		[ 191], [ 443]
Propofol	Drug Info	Anesthesia	Correlated with the increased drug response (compare with genotypes AA + AG)		[ 191]
Cyclosporine	N.A.	Transplant Rejection	Genotype GG is associated with increased risk of transplant rejection when treated with cyclosporine or tacrolimus in people with liver transplantation as compared to genotype AA.		[ 561]
Tacrolimus	N.A.	Transplant Rejection	Genotype GG is associated with increased risk of transplant rejection when treated with cyclosporine or tacrolimus in people with liver transplantation as compared to genotype AA.		[ 561]
Imatinib	N.A.	Thrombocytopenia	Genotype GG is associated with increased likelihood of Thrombocytopenia when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.		[ 60]
Sirolimus	N.A.	Somnolence	Genotype GG is associated with decreased exposure to sirolimus and temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AG.		[ 179]
Temsirolimus	N.A.	Somnolence	Genotype GG is associated with decreased exposure to sirolimus and temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AG.		[ 179]
Cisplatin	N.A.	Toxic Liver Disease	Genotype GG is associated with increased likelihood of Toxic liver disease when treated with cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotypes AA + AG.		[ 563]
Doxorubicin	N.A.	Toxic Liver Disease	Genotype GG is associated with increased likelihood of Toxic liver disease when treated with cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotypes AA + AG.		[ 563]
Methotrexate	N.A.	Toxic Liver Disease	Genotype GG is associated with increased likelihood of Toxic liver disease when treated with cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotypes AA + AG.		[ 563]
Clopidogrel	N.A.	Platelet Reactivity	Genotype GG is associated with decreased platelet reactivity when treated with clopidogrel in people with Stroke as compared to genotypes AA + AG.		[ 564]
Valganciclovir	N.A.	Neutropenia	Genotype GG is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype AA.		[ 273]
Cyclosporine	N.A.	Neurotoxicity Syndromes	Genotype GG is associated with increased risk of Neurotoxicity Syndromes when treated with cyclosporine in people with hematopoietic stem cell transplantation as compared to genotypes AA + AG.		[ 548]
Tacrolimus	N.A.	Neurotoxicity Syndromes	Genotype GG is not associated with risk of Neurotoxicity Syndromes when treated with tacrolimus in people with hematopoietic stem cell transplantation as compared to genotypes AA + AG.		[ 548]
Lamotrigine	N.A.	Prolonged Qtc Interval	Genotype GG are associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotypes AA + AG.		[ 282]
Tacrolimus	N.A.	Transplant Rejection	Genotype GG is not associated with risk of transplant rejection when treated with tacrolimus in people with liver transplantation as compared to genotypes AA + AG.		[ 351]
Cytarabine	N.A.	Peripheral Nervous System Diseases	Genotype GG is associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.		[ 405]
Anastrozole	N.A.	Neutropenia	Genotype GG is not associated with concentrations of anastrozole in women with Breast Neoplasms as compared to genotypes AA + AG.		[ 234]
Tacrolimus	N.A.	Adverse Events	Genotype GG is not associated with dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.		[ 351]
Aripiprazole	N.A.	Adverse Events	Genotype GG is associated with increased concentrations of aripiprazole and dehydroaripiprazole as compared to genotype AA.		[ 430]
Dehydroaripiprazole	N.A.	Adverse Events	Genotype GG is associated with increased concentrations of aripiprazole and dehydroaripiprazole as compared to genotype AA.		[ 430]
Carboplatin	N.A.	Event-free Survival	Genotype GG is not associated with increased risk of sensoric neuropathy or neutropenia when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to genotypes AA + AG.		[ 298]
Paclitaxel	N.A.	Event-free Survival	Genotype GG is not associated with increased risk of sensoric neuropathy or neutropenia when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to genotypes AA + AG.		[ 298]
Imatinib	N.A.	Drug Toxicity	Genotype GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.		[ 253]
Irinotecan	N.A.	Diarrhea	Genotype GG is not associated with Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 436]
Irinotecan	N.A.	Neutropenia	Genotype GG is not associated with Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 436]
Glucocorticoids	N.A.	Neutropenia	Genotype GG is associated with decreased response to glucocorticoids in people with Crohn Disease.		[ 439]
Simvastatin	N.A.	Nephrotoxicity	Genotype GG is associated with decreased response to simvastatin in people with Hypercholesterolemia as compared to genotypes AA + AG.		[ 3]
Imatinib	N.A.	Hypersensitivity	Genotype GG is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.		[ 401]
Remifentanil	N.A.	Transplant Rejection	Genotype GG is associated with increased response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.		[ 443]
Sevoflurane	N.A.	Transplant Rejection	Genotype GG is associated with increased response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.		[ 443]
Tacrolimus	N.A.	Hypertension	Genotype GG is associated with decreased concentrations of tacrolimus in children with liver transplantation as compared to genotypes AA + AG.		[ 552]
Methotrexate	N.A.	Mucositis	Genotype GG is associated with increased severity of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.		[ 574]
Cytarabine	N.A.	Cardiotoxicity	Genotype GG is associated with increased likelihood of cardiotoxicity when treated with cytarabine and daunorubicin in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.		[ 448]
Daunorubicin	N.A.	Cardiotoxicity	Genotype GG is associated with increased likelihood of cardiotoxicity when treated with cytarabine and daunorubicin in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.		[ 448]
Gefitinib	N.A.	Cardiotoxicity	Genotype GG is not associated with metabolism of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 447]
Sevoflurane	N.A.	Adverse Events	Genotype GG is associated with decreased likelihood of adverse events when exposed to sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.		[ 443]
Sufentanil	N.A.	Pain, Postoperative	Genotype GG is associated with decreased severity of Pain, Postoperative when treated with sufentanil in people with Surgical procedure and Bone Fracture as compared to genotypes AA + AG.		[ 577]
Gefitinib	N.A.	Exanthema	Genotype GG is associated with increased severity of Exanthema when treated with gefitinib in women with Carcinoma, Non-Small-Cell Lung.		[ 578]
Propofol	N.A.	Exanthema	Genotype GG is associated with increased response to propofol and remifentanil in children as compared to genotypes AA + AG.		[ 191]
Remifentanil	N.A.	Exanthema	Genotype GG is associated with increased response to propofol and remifentanil in children as compared to genotypes AA + AG.		[ 191]
Venlafaxine	N.A.	Anemia	Genotype GG is not associated with response to venlafaxine in people with Narcolepsy as compared to genotypes AA + AG.		[ 345]
Gefitinib	N.A.	Drug Toxicity	Genotype GG is not associated with risk of Drug Toxicity when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 446]
Gefitinib	N.A.	Non-small Cell Lung Carcinoma	Genotype GG is not associated with risk of Drug Toxicity when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.		[ 446]
Gefitinib	N.A.	Non-small Cell Lung Carcinoma	Patients with the GG genotype and non-small cell lung cancer may have a decreased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.		[ 535]
Simvastatin	N.A.	Hypercholesterolemia	Genotype GG is associated with decreased response to simvastatin in people with Hypercholesterolemia as compared to genotypes AA + AG.		[ 3]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the GG genotype and hypercholesterolemia may lesser reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence cholesterol levels.		[ 256]
Methadone	N.A.	Heroin Dependence	The current evidence base suggests that there is no significant association between the rs1128503 GG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.		[ 250]
Methadone	N.A.	Opioid-related Disorders	The current evidence base suggests that there is no significant association between the rs1128503 GG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.		[ 250]
Platinum Compounds	N.A.	Non-small Cell Lung Carcinoma	Patients with the GG genotype and non-small cell lung cancer may have reduced risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.		[ 538]
Phenytoin	N.A.	Breast Neoplasms	Patients with the GG genotype who receive phenytoin may have decreased plasma drug levels of phenytoin as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.		[ 21]
Modafinil	N.A.	Narcolepsy	Patients with GG genotype and narcolepsy may have decreased response to modafinil compared to patients with AG genotype. Other clinical and genetic factors may affect response to modafinil.		[ 345]
Tipifarnib	N.A.	Neoplasms	Patients with the GG genotype and cancer may have decreased exposure to tipifarnib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.		[ 203]
Hmg Coa Reductase Inhibitors	N.A.	Neoplasms	Patients with the rs1128503 GG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.		[ 332]
Remifentanil	N.A.	Tonsillectomy	Genotype GG is associated with increased response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.		[ 443]
Sevoflurane	N.A.	Tonsillectomy	Genotype GG is associated with increased response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.		[ 443]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Genotype GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.		[ 253]
Imatinib	N.A.	Chronic Myelogenous Leukemia, Bcr-abl1 Positive	Genotype GG is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.		[ 401]
Tacrolimus	N.A.	Ulcerative Colitis	Patients with the GG genotype and ulcerative colitis may have an increased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus response.		[ 311]
Codeine	N.A.	Pain	Breast-feeding infants whose mothers have the GG genotype and are taking codeine may be at decreased risk for CNS depression as compared to those whose mothers have the AA genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants.		[ 14]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Genotype GG is associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.		[ 405]
Antidepressants	N.A.	Major Depressive Disorder	Patients with the rs1128503 GG genotype may have a decreased response to antidepressants as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect response to antidepressants.		[ 498]
Aripiprazole	N.A.	Major Depressive Disorder	Patients with the rs1128503 GG genotype may have decreased plasma concentrations of aripiprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also affect may also affect aripiprazole concentrations. This annotation only covers the pharmacokinetic relationship between rs1128503 and aripiprazole and does not include evidence about clinical outcomes.		[ 498]
Temozolomide	N.A.	Glioma	Patients with glioma and the rs1128503 GG genotype may have increased concentrations of temozolomide as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs1128503 and temozolomide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence temozolomide concentrations.		[ 545]
Risperidone	N.A.	Autism	Patients with the GG genotype may have poorer response to risperidone in Children with Autism, than patients with AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.		[ 546]
Antiepileptics	N.A.	Epilepsy	Patients with the GG genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the AA genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics.		[ 61]
Fentanyl	N.A.	Hypoventilation	Patients with the GG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Fentanyl	N.A.	Pain, Postoperative	Patients with the GG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Tacrolimus	N.A.	Transplantation	Genotype GG is not associated with dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.		[ 351]
Tacrolimus	N.A.	Transplantation	Genotype GG is associated with increased dose of tacrolimus in children with liver transplantation as compared to genotypes AA + AG.		[ 552]
Tacrolimus	N.A.	Transplantation	Patients with the GG genotype who are undergoing organ transplantation may have decreased concentrations of tacrolimus as compared to patients with the AA or AG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus.		[ 376]
Capecitabine	N.A.	Colorectal Neoplasms	Patients with the GG genotype and colorectal cancer may have an increased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.		[ 338]
Oxaliplatin	N.A.	Colorectal Neoplasms	Patients with the GG genotype and colorectal cancer may have a decreased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.		[ 337]
Digoxin	N.A.	Pain	Patients with the GG genotype may have decreased serum concentrations of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.		[ 13]
Sirolimus	N.A.	Kidney Transplantation	Patients with the GG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels.		[ 348]
Tramadol	N.A.	Urinary Bladder Neoplasms	Patients with the GG genotype may have a decreased exposure to tramadol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's exposure to tramadol.		[ 251]
Cisplatin	N.A.	Osteosarcoma	Patients with the GG genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Cyclophosphamide	N.A.	Osteosarcoma	Patients with the GG genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Doxorubicin	N.A.	Osteosarcoma	Patients with the GG genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Methotrexate	N.A.	Osteosarcoma	Patients with the GG genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Vincristine	N.A.	Osteosarcoma	Patients with the GG genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Fentanyl	N.A.	Pain	Patients with the GG genotype may have an increased response to fentanyl and may therefore require a decreased dose as compared to patients with the AA genotype. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.		[ 329]
Fentanyl	N.A.	Pain, Postoperative	Patients with the GG genotype may have an increased response to fentanyl and may therefore require a decreased dose as compared to patients with the AA genotype. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.		[ 329]
Clopidogrel	N.A.	Pain	Patients with the GG genotype who are taking clopidogrel may have decreased resistance to clopidogrel as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence resistance to clopidogrel in patients.		[ 400]
Carbamazepine	N.A.	Epilepsy	African American and white patients with the GG genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AA or AG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.		[ 547]
Rocuronium	N.A.	Pain	Patients with the GG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.		[ 537]
Sunitinib	N.A.	Renal Cell Carcinoma	Patients with renal cell carcinoma and the GG genotype who are treated with sunitinib may have an increased risk of neutropenia, leukopenia, and diarrhea as compared to patients with the AA genotypes, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib.		[ 41]
Tacrolimus	N.A.	Nephrotic Syndrome	Patients with the GG genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.		[ 541]
Cyclosporine	N.A.	Kidney Transplantation	Patients with the GG genotype and myasthenia gravis or organ transplantation may have increased clearance of cyclosporine and therefore may require an increased dose of cyclosporine, compared to patients with the AA genotype. Patients with the GG genotype may also have a decreased risk of infection as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.		[ 23]
Cyclosporine	N.A.	Myasthenia Gravis	Patients with the GG genotype and myasthenia gravis or organ transplantation may have increased clearance of cyclosporine and therefore may require an increased dose of cyclosporine, compared to patients with the AA genotype. Patients with the GG genotype may also have a decreased risk of infection as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.		[ 23]
Sirolimus	N.A.	Urinary Bladder Neoplasms	Genotype GG is associated with decreased exposure to sirolimus and temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AG.		[ 179]
Temsirolimus	N.A.	Urinary Bladder Neoplasms	Genotype GG is associated with decreased exposure to sirolimus and temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AG.		[ 179]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the rs1128503 GG genotype may be at a decreased risk of experiencing side effects when treated with methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.		[ 38]
Methotrexate	N.A.	Lymphoma	Patients with the rs1128503 GG genotype may be at a decreased risk of experiencing side effects when treated with methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.		[ 38]
Methotrexate	N.A.	Mucositis	Patients with the rs1128503 GG genotype may be at a decreased risk of experiencing side effects when treated with methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.		[ 38]
Methotrexate	N.A.	Osteosarcoma	Patients with the rs1128503 GG genotype may be at a decreased risk of experiencing side effects when treated with methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.		[ 38]
Cyclosporine	N.A.	Hematopoietic Stem Cell Transplantation	Genotype GG is associated with increased risk of Neurotoxicity Syndromes when treated with cyclosporine in people with hematopoietic stem cell transplantation as compared to genotypes AA + AG.		[ 548]
Methotrexate	N.A.	Rheumatoid Arthritis	The current evidence base suggests that there is no significant association between the rs1128503 GG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 549]
Efavirenz	N.A.	HIV Infectious Disease	Patients with GG genotype and HIV may have increased concentrations of efavirenz in plasma compared to patients with AA genotype. However, this association was not significant and has not been found in other studies. Other clinical and genetic factors may affect efavirenz concentrations.		[ 463]
Sufentanil	N.A.	HIV Infectious Disease	Patients with the GG genotype may have decreased sufentanil dose requirements as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's sufentantil dose requirements.		[ 117]
Paclitaxel	N.A.	Breast Neoplasms	Patients with the rs1128503 GG genotype may have decreased severity of peripheral neuropathy when treated with paclitaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of peripheral neuropathy when treated with paclitaxel.		[ 550]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Patients with the rs1128503 GG genotype may have decreased severity of peripheral neuropathy when treated with paclitaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of peripheral neuropathy when treated with paclitaxel.		[ 550]
Morphine	N.A.	Epilepsy	Patients with the GG genotype may have decreased concentrations of morphine as compared to patients with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also affect morphine concentrations in a patient.		[ 121]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:         47 Drugs in Total
Sunitinib	Drug Info	Renal Cell Carcinoma	Correlated with the decreased diarrhea risk in patients (compare with genotype GG)		[ 237]
Carbamazepine	Drug Info	Epilepsy	Correlated with the increased drug clearance in patients (compare with genotype GG)		[ 547]
Clopidogrel	Drug Info	Acute Coronary Syndrome	Correlated with the increased drug resistance (compare with genotype GG)		[ 400]
Risperidone	Drug Info	Autistic Disorder	Correlated with the increased drug response in patients (compare with genotype GG)		[ 546]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased drug toxicity risk in patients (compare with genotype GG)		[ 371]
Tacrolimus	Drug Info	Heart Transplantation	Correlated with the increased infection risk in patients (compare with genotype GG)		[ 564]
Cyclosporine	Drug Info	Heart Transplantation	Correlated with the increased infection risk in patients (compare with genotype GG)		[ 564]
Cytarabine	Drug Info	Acute Multiple Myeloma	Correlated with the increased overall survival in patients (compare with genotype GG)		[ 460]
Avatrombopag	N.A.	Drug Toxicity	Genotypes AA + AG is associated with increased exposure to avatrombopag in healthy individuals as compared to genotype GG.		[ 566]
Sunitinib	N.A.	Diarrhea	Genotypes AA + AG are associated with decreased risk of Diarrhea when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype GG.		[ 237]
Nilotinib	N.A.	Event-free Survival	Genotypes AA + AG is not associated with likelihood of event-free survival when treated with nilotinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.		[ 567]
Risperidone	N.A.	Platelet Reactivity	Genotypes AA + AG are associated with increased response to risperidone in children with Autistic Disorder as compared to genotype GG.		[ 546]
Carbamazepine	N.A.	Drug Toxicity	Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.		[ 547]
Rivaroxaban	N.A.	Epistaxis	Genotypes AA + AG is associated with increased likelihood of Epistaxis rivaroxaban in people with Atrial Fibrillation as compared to genotype GG.		[ 510]
Sunitinib	N.A.	Hand-foot Syndrome	Genotypes AA + AG is associated with increased likelihood of hand-foot syndrome when treated with sunitinib in people with Carcinoma, Renal Cell or Gastrointestinal Stromal Tumors as compared to genotype GG.		[ 569]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Genotypes AA + AG is associated with increased likelihood of Peripheral Nervous System Diseases when treated with paclitaxel in people with Breast Neoplasms or Colorectal Neoplasms as compared to genotype GG.		[ 478]
Apixaban	N.A.	Death	Genotypes AA + AG are not associated with clearance of apixaban in people with Atrial Fibrillation as compared to genotype GG.		[ 479]
Methotrexate	N.A.	Drug Toxicity	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 371]
Clopidogrel	N.A.	Adverse Events	Genotypes AA + AG is associated with increased resistance to clopidogrel as compared to genotype GG.		[ 400]
Methadone	N.A.	Nausea	Genotypes AA + AG are not associated with decreased likelihood of treatment with methadone or morphine in infants with Neonatal Abstinence Syndrome as compared to genotype GG.		[ 483]
Morphine	N.A.	Nausea	Genotypes AA + AG are not associated with decreased likelihood of treatment with methadone or morphine in infants with Neonatal Abstinence Syndrome as compared to genotype GG.		[ 483]
Temozolomide	N.A.	Cardiotoxicity	Genotypes AA + AG are associated with decreased concentrations of temozolomide in people with Glioma as compared to genotype GG.		[ 545]
Tacrolimus	N.A.	Renal Transplant Failure	Genotypes AA + AG is not associated with risk of renal transplant failure when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.		[ 456]
Sufentanil	N.A.	Hypertension	Genotypes AA + AG are associated with increased dose of sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to genotype GG.		[ 117]
Everolimus	N.A.	Weight Gain	Genotypes AA + AG are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype GG.		[ 19]
Cytarabine	N.A.	Overall Survival	Genotypes AA + AG is associated with increased overall survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype GG.		[ 460]
Cisplatin	N.A.	Drug Toxicity	Genotypes AA + AG are not associated with prognosis when treated with cisplatin, fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.		[ 337]
Fluorouracil	N.A.	Drug Toxicity	Genotypes AA + AG are not associated with prognosis when treated with cisplatin, fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.		[ 337]
Leucovorin	N.A.	Drug Toxicity	Genotypes AA + AG are not associated with prognosis when treated with cisplatin, fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.		[ 337]
Dexamethasone	N.A.	Drug-induced Liver Injury	Genotypes AA + AG are associated with increased response to dexamethasone, diphenhydramine, paclitaxel and ranitidine in people with Head and Neck Neoplasms as compared to genotype GG.		[ 50]
Diphenhydramine	N.A.	Drug-induced Liver Injury	Genotypes AA + AG are associated with increased response to dexamethasone, diphenhydramine, paclitaxel and ranitidine in people with Head and Neck Neoplasms as compared to genotype GG.		[ 50]
Paclitaxel	N.A.	Drug-induced Liver Injury	Genotypes AA + AG are associated with increased response to dexamethasone, diphenhydramine, paclitaxel and ranitidine in people with Head and Neck Neoplasms as compared to genotype GG.		[ 50]
Ranitidine	N.A.	Drug-induced Liver Injury	Genotypes AA + AG are associated with increased response to dexamethasone, diphenhydramine, paclitaxel and ranitidine in people with Head and Neck Neoplasms as compared to genotype GG.		[ 50]
Cyclosporine	N.A.	Infectious Disease	Genotypes AA + AG is associated with increased risk of Infection when treated with cyclosporine and tacrolimus in people with heart transplantation as compared to genotype GG.		[ 564]
Tacrolimus	N.A.	Infectious Disease	Genotypes AA + AG is associated with increased risk of Infection when treated with cyclosporine and tacrolimus in people with heart transplantation as compared to genotype GG.		[ 564]
Carbamazepine	N.A.	Chronic Kidney Failure	Genotypes AA + AG is associated with decreased clinical benefit to carbamazepine in people with Epilepsy as compared to genotype GG.		[ 492]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Genotypes AA + AG is associated with increased overall survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype GG.		[ 460]
Temozolomide	N.A.	Glioma	Genotypes AA + AG are associated with decreased concentrations of temozolomide in people with Glioma as compared to genotype GG.		[ 545]
Risperidone	N.A.	Autism	Genotypes AA + AG are associated with increased response to risperidone in children with Autistic Disorder as compared to genotype GG.		[ 546]
Carbamazepine	N.A.	Epilepsy	Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.		[ 547]
Sunitinib	N.A.	Renal Cell Carcinoma	Genotypes AA + AG are associated with decreased risk of Diarrhea when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype GG.		[ 237]
Cyclosporine	N.A.	Kidney Transplantation	Genotypes AA + AG is associated with increased risk of Infection when treated with cyclosporine and tacrolimus in people with heart transplantation as compared to genotype GG.		[ 564]
Cyclosporine	N.A.	Myasthenia Gravis	Genotypes AA + AG is associated with increased risk of Infection when treated with cyclosporine and tacrolimus in people with heart transplantation as compared to genotype GG.		[ 564]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 371]
Methotrexate	N.A.	Lymphoma	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 371]
Methotrexate	N.A.	Mucositis	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 371]
Methotrexate	N.A.	Osteosarcoma	Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 371]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:         30 Drugs in Total
Tacrolimus	Drug Info	Ulcerative Colitis	Correlated with the increased drug response in patients (compare with genotype AA); Irrelevant to the drug metabolism in patients (compare with genotype AA)		[ 496]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Irrelevant to the mucositis risk in patients (compare with genotype AA)		[ 38]
Carboplatin	N.A.	Nausea	Genotypes AG + GG is associated with increased risk of Nausea when treated with carboplatin and paclitaxel in people with Non-Small Cell Lung Carcinoma as compared to genotype AA.		[ 565]
Paclitaxel	N.A.	Nausea	Genotypes AG + GG is associated with increased risk of Nausea when treated with carboplatin and paclitaxel in people with Non-Small Cell Lung Carcinoma as compared to genotype AA.		[ 565]
Carboplatin	N.A.	Vomiting	Genotypes AG + GG is associated with increased risk of Vomiting when treated with carboplatin and paclitaxel in people with Non-Small Cell Lung Carcinoma as compared to genotype AA.		[ 565]
Paclitaxel	N.A.	Vomiting	Genotypes AG + GG is associated with increased risk of Vomiting when treated with carboplatin and paclitaxel in people with Non-Small Cell Lung Carcinoma as compared to genotype AA.		[ 565]
Desmethylcitalopram	N.A.	Thrombocytopenia	Genotypes AG + GG are not associated with concentrations of desmethylcitalopram or escitalopram in people with Depressive Disorder, Major as compared to genotype AA.		[ 498]
Escitalopram	N.A.	Thrombocytopenia	Genotypes AG + GG are not associated with concentrations of desmethylcitalopram or escitalopram in people with Depressive Disorder, Major as compared to genotype AA.		[ 498]
Anastrozole	N.A.	Arthralgia	Genotypes AG + GG are not associated with likelihood of Arthralgia when exposed to anastrozole in women with Breast Neoplasms as compared to genotype AA.		[ 234]
Morphine	N.A.	Adverse Events	Genotypes AG + GG are associated with decreased concentrations of morphine as compared to genotype AA.		[ 66]
Sunitinib	N.A.	Progression-free Survival	Genotypes AG + GG is associated with increased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype AA.		[ 569]
Methotrexate	N.A.	Neutropenia	Genotypes AG + GG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 38]
Methotrexate	N.A.	Drug-induced Liver Injury	Genotypes AG + GG is associated with increased likelihood of Drug-induced liver injury when treated with methotrexate in people with Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Osteosarcoma or Non-Hodgkin Lymphoma as compared to genotype AA.		[ 570]
Antidepressants	N.A.	Adverse Events	Genotypes AG + GG are not associated with risk of adverse events when treated with antidepressants in people with Depressive Disorder, Major as compared to genotype AA.		[ 498]
Escitalopram	N.A.	Adverse Events	Genotypes AG + GG are not associated with severity of adverse events when treated with escitalopram in people with Depressive Disorder, Major as compared to genotype AA.		[ 498]
Irinotecan	N.A.	Neutropenia	Genotypes AG + GG are not associated with severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype AA.		[ 571]
Methadone	N.A.	Neonatal Abstinence Syndrome	Genotypes AG + GG are not associated with severity of Neonatal Abstinence Syndrome due to methadone in infants as compared to genotype AA.		[ 506]
Tacrolimus	N.A.	Hypersensitivity	Genotypes AG + GG are associated with increased response to tacrolimus in people with Colitis, Ulcerative as compared to genotype AA.		[ 496]
Oseltamivir	N.A.	Depression	Genotypes AG + GG are not associated with Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype AA.		[ 359]
Oseltamivir	N.A.	Gastritis	Genotypes AG + GG are not associated with Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype AA.		[ 359]
Oseltamivir	N.A.	Hypersensitivity	Genotypes AG + GG are not associated with Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype AA.		[ 359]
Risperidone	N.A.	Peripheral Nervous System Diseases	Genotypes AG + GG are not associated with response to risperidone in people with Schizophrenia as compared to genotype AA.		[ 485]
Atazanavir	N.A.	Statin-related Myopathy	Genotypes AG + GG is associated with decreased clearance of atazanavir in healthy individuals as compared to genotype AA.		[ 509]
Rivaroxaban	N.A.	Drug-induced Liver Injury	Genotypes AG + GG is associated with decreased concentrations of rivaroxaban in people with Atrial Fibrillation as compared to genotype AA.		[ 510]
Methotrexate	N.A.	Mucositis	Genotypes AG + GG are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 38]
Tacrolimus	N.A.	Ulcerative Colitis	Genotypes AG + GG are associated with increased response to tacrolimus in people with Colitis, Ulcerative as compared to genotype AA.		[ 496]
Tacrolimus	N.A.	Transplantation	Genotypes AG + GG is not associated with metabolism of tacrolimus in people with Colitis, Ulcerative as compared to genotype AA.		[ 496]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes AG + GG are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 38]
Methotrexate	N.A.	Lymphoma	Genotypes AG + GG are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 38]
Methotrexate	N.A.	Osteosarcoma	Genotypes AG + GG are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 38]
Genetic Polymorphism	rs2032582
Site of GPD	chr7:87531302 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>T
Minor Allele Frequency	A=0.3343/1674 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:       152 Drugs in Total
Digoxin	Drug Info	Congestive Cardiac Insufficiency; Arrhythmias; Heart Failure	Correlated with the increased drug serum concentrations in patients (compare with allele C)		[ 13]
Everolimus	Drug Info	Breast Neoplasm	Correlated with the increased likelihood of lymphopenia in patients (compare with allele C)		[ 19]
Mycophenolate mofetil	Drug Info	Kidney Transplantation	Correlated with the increased transplant rejection risk in patients (compare with genotype CC)		[ 569]
Cyclosporine	Drug Info	Kidney Transplantation	Correlated with the increased transplant rejection risk in patients (compare with genotype CC)		[ 569]
Atorvastatin	Drug Info	Hypercholesterolemia	Irrelevant to the dose decrease or drug switching risk in patients (compare with Allele T)		[ 163]
Simvastatin	Drug Info	Hypercholesterolemia	Irrelevant to the dose decrease or drug switching risk in patients (compare with Allele T)		[ 163]
Tacrolimus	Drug Info	Kidney Transplantation	Irrelevant to the dose-adjusted trough concentrations in patients (compare with allele C); Irrelevant to the drug trough concentrations in patients (compare with Allele C)		[ 26], [ 31]
Tacrolimus	Drug Info	Hemopoietic Stem Cell Transplant	Irrelevant to the drug clearance in patients (compare with Allele C)		[ 35]
Tacrolimus	Drug Info	Liver Transplantation	Irrelevant to the drug metabolism in patients (compare with Allele C)		[ 519]
Clomipramine	Drug Info	Depression	Correlated with the increased suicidal ideation risk in patients (compare with allele C)		[ 575]
Nefazodone	Drug Info	Depression	Correlated with the increased suicidal ideation risk in patients (compare with allele C)		[ 575]
Fluoxetine	Drug Info	Depressive Disorder	Correlated with the increased drug response in patients (compare with allele C)		[ 178]
Venlafaxine	Drug Info	Depression	Correlated with the increased suicidal ideation risk in patients (compare with allele C)		[ 575]
Efavirenz	Drug Info	HIV Infection	Correlated with the decreased likelihood of emerging viral drug resistance in patients (compare with allele C)		[ 4]
Paroxetine	Drug Info	Depression	Correlated with the increased suicidal ideation risk in patients (compare with allele C)		[ 575]
Edoxaban	N.A.	Drug Toxicity	Allele A is not associated with decreased clearance of edoxaban in people with Atrial Fibrillation as compared to allele C.		[ 531]
Paroxetine	N.A.	Drug Toxicity	Allele A is not associated with response to paroxetine in people with Depressive Disorder, Major as compared to allele C.		[ 63]
Oxycodone	N.A.	Pain	Allele A is not associated with severity of Pain when treated with oxycodone in people with Pain, Postoperative as compared to allele C.		[ 55]
O-desmethyltramadol	N.A.	Somnolence	Allele A is not associated with clearance of o-desmethyltramadol or tramadol in healthy individuals as compared to allele T.		[ 120]
Tramadol	N.A.	Somnolence	Allele A is not associated with clearance of o-desmethyltramadol or tramadol in healthy individuals as compared to allele T.		[ 120]
Digoxin	N.A.	Hemorrhage	Allele A is not associated with functional effect on the P-gp-mediated transport rate of digoxin or imatinib in a X. laevis oocyte expression system as compared to allele C.		[ 59]
Imatinib	N.A.	Hemorrhage	Allele A is not associated with functional effect on the P-gp-mediated transport rate of digoxin or imatinib in a X. laevis oocyte expression system as compared to allele C.		[ 59]
Fluoxetine	N.A.	Arthralgia	Allele A is associated with increased response to fluoxetine in children with Depressive Disorder as compared to allele C.		[ 178]
Imatinib	N.A.	Arthralgia	Allele A is associated with increased clinical benefit to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele C.		[ 60]
Dabigatran	N.A.	Neutropenia	Allele A is not associated with decreased dose-adjusted trough concentrations of dabigatran in people with Atrial Fibrillation as compared to allele C.		[ 89]
Morphine	N.A.	Adverse Events	Allele A is not associated with likelihood of adverse events due to morphine in people with Pain, Postoperative as compared to allele C.		[ 65]
Codeine	N.A.	Adverse Events	Allele A is not associated with concentrations of codeine or morphine as compared to allele C.		[ 66]
Morphine	N.A.	Adverse Events	Allele A is not associated with concentrations of codeine or morphine as compared to allele C.		[ 66]
Morphine	N.A.	Neutropenia	Allele A is not associated with concentrations of morphine in people with Pain, Postoperative as compared to allele C.		[ 65]
Antiepileptics	N.A.	Drug Resistance	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele C.		[ 69]
Methadone	N.A.	Adverse Events	Allele A is not associated with concentrations of methadone as compared to allele C.		[ 274]
Desmethylcitalopram	N.A.	Hemorrhage	Allele A is not associated with concentrations of desmethylcitalopram or escitalopram in people with Depressive Disorder, Major as compared to allele C.		[ 498]
Escitalopram	N.A.	Hemorrhage	Allele A is not associated with concentrations of desmethylcitalopram or escitalopram in people with Depressive Disorder, Major as compared to allele C.		[ 498]
Methadone	N.A.	Diarrhea	Allele A is not associated with dose of methadone in people with Heroin Dependence as compared to allele C.		[ 278]
Aripiprazole	N.A.	Prolonged Qtc Interval	Allele A is not associated with concentrations of aripiprazole in people with Depressive Disorder, Major as compared to allele C.		[ 498]
Morphine	N.A.	Vomiting	Allele A is not associated with dose of morphine in people with Pain, Postoperative as compared to allele T.		[ 420]
Paroxetine	N.A.	Vomiting	Allele A is not associated with plasma concentrations when treated with paroxetine in people with Depressive Disorder, Major as compared to allele C.		[ 77]
Tacrolimus	N.A.	Toxic Liver Disease	Allele A is not associated with metabolism of tacrolimus in people with liver transplantation as compared to allele C.		[ 519]
Carbamazepine	N.A.	Thrombocytopenia	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C.		[ 159]
Sunitinib	N.A.	Neutropenia	Allele A is associated with decreased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell.		[ 237]
Digoxin	N.A.	Neutropenia	Allele A is associated with increased serum concentrations digoxin as compared to allele C.		[ 13]
Valproic Acid	N.A.	Death	Allele A is not associated with decreased dose-adjusted trough concentrations of valproic acid in people with Epilepsy as compared to allele C.		[ 595]
Propofol	N.A.	Adverse Events	Allele A is not associated with risk of adverse events due to propofol and remifentanil in children as compared to allele C.		[ 191]
Remifentanil	N.A.	Adverse Events	Allele A is not associated with risk of adverse events due to propofol and remifentanil in children as compared to allele C.		[ 191]
Lamotrigine	N.A.	Adverse Events	Allele A is associated with decreased clinical benefit to lamotrigine in children with Epilepsy as compared to allele C.		[ 597]
Docetaxel	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele C.		[ 86]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele C.		[ 86]
Gemcitabine	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with response to gemcitabine and paclitaxel as compared to allele T.		[ 515]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with response to gemcitabine and paclitaxel as compared to allele T.		[ 515]
Antidepressants	N.A.	Adverse Events	Allele A is not associated with risk of adverse events when treated with antidepressants in people with Depressive Disorder, Major as compared to allele C.		[ 498]
Tacrolimus	N.A.	Transplant Rejection	Allele A is not associated with increased risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 87]
Tacrolimus	N.A.	Opioid-related Disorders	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 26]
Escitalopram	N.A.	Adverse Events	Allele A is not associated with severity of adverse events when treated with escitalopram in people with Depressive Disorder, Major as compared to allele C.		[ 498]
Atorvastatin	N.A.	Event-free Survival	Allele A is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele T.		[ 163]
Simvastatin	N.A.	Event-free Survival	Allele A is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele T.		[ 163]
Lamotrigine	N.A.	Asthenia	Allele A is not associated with decreased clinical benefit to lamotrigine in children with Epilepsy as compared to allele C.		[ 601]
Phenytoin	N.A.	Coronary Restenosis	Allele A is not associated with dose-adjusted trough concentrations of phenytoin in people with Epilepsy as compared to allele C.		[ 390]
Ritonavir	N.A.	Death	Allele A is not associated with phase 1 or phase 2 viral decay, changes in lymphocyte subsets over time, or plasma trough ritonavir concentrations when treated with ritonavir in people with HIV Infections as compared to allele C.		[ 97]
Apixaban	N.A.	Acute Cellular Rejection	Allele A is not associated with clearance of apixaban in people with Atrial Fibrillation as compared to allele C.		[ 479]
Tacrolimus	N.A.	Drug Toxicity	Allele A is not associated with adverse events when treated with tacrolimus in children with hematopoietic stem cell transplant as compared to allele C.		[ 35]
Clopidogrel	N.A.	Drug Toxicity	Allele A is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to allele C.		[ 100]
Lamivudine	N.A.	Neutropenia	Allele A is associated with response to lamivudine, nevirapine or zidovudine in people with HIV Infections as compared to allele C.		[ 104]
Nevirapine	N.A.	Neutropenia	Allele A is associated with response to lamivudine, nevirapine or zidovudine in people with HIV Infections as compared to allele C.		[ 104]
Zidovudine	N.A.	Neutropenia	Allele A is associated with response to lamivudine, nevirapine or zidovudine in people with HIV Infections as compared to allele C.		[ 104]
Tacrolimus	N.A.	Transplant Rejection	Allele A is associated with increased likelihood of transplant rejection when treated with tacrolimus in children with Kidney Transplantation as compared to allele C.		[ 197]
Risperidone	N.A.	Central Nervous System Disorder	Allele A is not associated with clearance of risperidone in people with Psychotic Disorders as compared to allele C.		[ 34]
Carbamazepine	N.A.	Diarrhea	Allele A is associated with increased clearance of carbamazepine in children with Epilepsy as compared to allele C.		[ 108]
Methotrexate	N.A.	Drug Toxicity	Allele A is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele C.		[ 214]
Methotrexate	N.A.	Nausea	Allele A is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele C.		[ 214]
Efavirenz	N.A.	Hemorrhage	Allele A is not associated with exposure to efavirenz in healthy individuals as compared to allele C.		[ 113]
Sunitinib	N.A.	Progression-free Survival	Allele A is associated with decreased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele C.		[ 524]
Doxorubicin	N.A.	Hypersensitivity	Allele A is not associated with resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 240]
Methotrexate	N.A.	Hypersensitivity	Allele A is not associated with resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 240]
Prednisolone	N.A.	Hypersensitivity	Allele A is not associated with resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 240]
Vincristine	N.A.	Hypersensitivity	Allele A is not associated with resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.		[ 240]
Fentanyl	N.A.	Hypertension	Allele A is not associated with exposure to fentanyl in healthy individuals as compared to allele C.		[ 116]
Cyclosporine	N.A.	Hypertension	Allele A is not associated with response to cyclosporine in people with Psoriasis as compared to allele C.		[ 118]
Atazanavir	N.A.	Cholelithiasis	Allele A is not associated with Cholelithiasis when treated with atazanavir and ritonavir in people with HIV Infections.		[ 616]
Ritonavir	N.A.	Cholelithiasis	Allele A is not associated with Cholelithiasis when treated with atazanavir and ritonavir in people with HIV Infections.		[ 616]
Dactinomycin	N.A.	Hypersensitivity	Allele A is not associated with clearance of dactinomycin in children with Neoplasms.		[ 119]
Morphine	N.A.	Hypersensitivity	Allele A is not associated with concentrations of morphine in women with Pain, Postoperative as compared to allele C.		[ 121]
Antipsychotics	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with drug response when exposed to antipsychotics in people with Psychotic Disorders as compared to allele C.		[ 122]
Rivaroxaban	N.A.	Hyperprolactinemia	Allele A is not associated with increased dose-adjusted trough concentrations of rivaroxaban in people with Atrial Fibrillation as compared to allele C.		[ 125]
Ceftriaxone	N.A.	Hyperprolactinemia	Allele A is not associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to allele C.		[ 99]
Pantoprazole	N.A.	Weight Gain	Allele A is not associated with response to pantoprazole in people with Helicobacter Infections as compared to allele C.		[ 127]
Cabazitaxel	N.A.	Gastrointestinal Toxicity	Allele A is associated with decreased likelihood of gastrointestinal toxicity when treated with cabazitaxel in people with Carcinoma, Transitional Cell as compared to allele C.		[ 131]
Carbamazepine	N.A.	Diarrhea	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele C.		[ 18]
Atazanavir	N.A.	Treatment Failure	Allele A is not associated with likelihood of treatment failure when treated with atazanavir in people with HIV Infections as compared to allele C.		[ 49]
Cyclophosphamide	N.A.	Peripheral Nervous System Diseases	Allele A is associated with increased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele C.		[ 211]
Epirubicin	N.A.	Peripheral Nervous System Diseases	Allele A is associated with increased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele C.		[ 211]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Allele A is associated with increased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele C.		[ 211]
Lopinavir	N.A.	Statin-related Myopathy	Allele A is not associated with exposure to lopinavir or ritonavir in children with HIV Infections as compared to allele C.		[ 137]
Ritonavir	N.A.	Statin-related Myopathy	Allele A is not associated with exposure to lopinavir or ritonavir in children with HIV Infections as compared to allele C.		[ 137]
Antidepressants	N.A.	Statin-related Myopathy	Allele A is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to allele C.		[ 498]
Sirolimus	N.A.	Statin-related Myopathy	Allele A is associated with increased concentrations of sirolimus in people with hematopoietic stem cell transplantation.		[ 628]
Risperidone	N.A.	Statin-related Myopathy	Allele A is not associated with dose of risperidone as compared to allele C.		[ 629]
Cyclosporine	N.A.	Transplant Rejection	Allele A is associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype CC.		[ 569]
Mycophenolate Mofetil	N.A.	Transplant Rejection	Allele A is associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype CC.		[ 569]
Docetaxel	N.A.	Leukopenia	Allele A is associated with decreased likelihood of Leukopenia when treated with docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele C.		[ 86]
Paclitaxel	N.A.	Leukopenia	Allele A is associated with decreased likelihood of Leukopenia when treated with docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele C.		[ 86]
Tacrolimus	N.A.	Nephrotoxicity	Allele A is not associated with risk of nephrotoxicity and Neurotoxicity Syndromes when treated with tacrolimus in people with liver transplantation as compared to allele C.		[ 630]
Tacrolimus	N.A.	Neurotoxicity Syndromes	Allele A is not associated with risk of nephrotoxicity and Neurotoxicity Syndromes when treated with tacrolimus in people with liver transplantation as compared to allele C.		[ 630]
Antineoplastic Agents	N.A.	Dose Reduction	Allele A is not associated with survival when treated with antineoplastic agents in women with Ovarian Neoplasms as compared to allele C.		[ 144]
Tacrolimus	N.A.	Nephrotoxicity	Allele A is not associated with trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 31]
Clopidogrel	N.A.	Toxic Liver Disease	Allele A is not associated with response to clopidogrel in people with Angina Pectoris as compared to allele C.		[ 39]
Tacrolimus	N.A.	Mucositis	Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 160]
Everolimus	N.A.	Lymphopenia	Allele A is associated with increased likelihood of Lymphopenia when treated with everolimus in women with Breast Neoplasms as compared to allele C.		[ 19]
Clomipramine	N.A.	Pain	Allele A is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 575]
Liothyronine	N.A.	Pain	Allele A is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 575]
Lithium	N.A.	Pain	Allele A is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 575]
Nefazodone	N.A.	Pain	Allele A is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 575]
Paroxetine	N.A.	Pain	Allele A is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 575]
Venlafaxine	N.A.	Pain	Allele A is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 575]
Efavirenz	N.A.	Hemorrhage	Allele A is associated with decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to allele C.		[ 4]
Sufentanil	N.A.	Adverse Events	Allele A is not associated with likelihood of adverse events due to sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to allele C.		[ 117]
Risperidone	N.A.	Weight Gain	Allele A is associated with increased Weight gain when treated with risperidone in women with Schizophrenia as compared to allele C.		[ 152]
Fentanyl	N.A.	Adverse Events	Allele A is not associated with likelihood of adverse events due to fentanyl in healthy individuals as compared to allele C.		[ 116]
Tramadol	N.A.	Neurotoxicity Syndromes	Allele A is associated with increased likelihood of a decrease in visual analog scale >30mm within 6 hours when treated with tramadol in people with Fractures, Bone as compared to allele C.		[ 157]
Atorvastatin	N.A.	Hypercholesterolemia	Allele A is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele T.		[ 163]
Ritonavir	N.A.	HIV Infectious Disease	Allele A is not associated with phase 1 or phase 2 viral decay, changes in lymphocyte subsets over time, or plasma trough ritonavir concentrations when treated with ritonavir in people with HIV Infections as compared to allele C.		[ 97]
Efavirenz	N.A.	HIV Infectious Disease	Allele A is associated with decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to allele C.		[ 4]
Fluoxetine	N.A.	Depressive Disorder	Allele A is associated with increased response to fluoxetine in children with Depressive Disorder as compared to allele C.		[ 178]
Everolimus	N.A.	Breast Neoplasms	Allele A is associated with increased likelihood of Lymphopenia when treated with everolimus in women with Breast Neoplasms as compared to allele C.		[ 19]
Tramadol	N.A.	Fractures, Bone	Allele A is associated with increased likelihood of a decrease in visual analog scale >30mm within 6 hours when treated with tramadol in people with Fractures, Bone as compared to allele C.		[ 157]
Tramadol	N.A.	Pain	Allele A is associated with increased likelihood of a decrease in visual analog scale >30mm within 6 hours when treated with tramadol in people with Fractures, Bone as compared to allele C.		[ 157]
Tramadol	N.A.	Pain, Postoperative	Allele A is associated with increased likelihood of a decrease in visual analog scale >30mm within 6 hours when treated with tramadol in people with Fractures, Bone as compared to allele C.		[ 157]
Simvastatin	N.A.	Hypercholesterolemia	Allele A is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele T.		[ 163]
Simvastatin	N.A.	Myalgia	Allele A is not associated with risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to allele T.		[ 163]
Antiepileptics	N.A.	Epilepsy	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele C.		[ 69]
Antiepileptics	N.A.	Epilepsy	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C.		[ 159]
Carbamazepine	N.A.	Epilepsy	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C.		[ 159]
Tacrolimus	N.A.	Kidney Transplantation	Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 160]
Tacrolimus	N.A.	Liver Transplantation	Allele A is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 160]
Tacrolimus	N.A.	Kidney Transplantation	Allele A is not associated with trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 31]
Tacrolimus	N.A.	Liver Transplantation	Allele A is not associated with trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 31]
Tacrolimus	N.A.	Kidney Transplantation	Allele A is not associated with dose of tacrolimus in children with hemopoietic stem cell transplant as compared to allele C.		[ 35]
Tacrolimus	N.A.	Liver Transplantation	Allele A is not associated with dose of tacrolimus in children with hemopoietic stem cell transplant as compared to allele C.		[ 35]
Tacrolimus	N.A.	Kidney Transplantation	Allele A is not associated with metabolism of tacrolimus in people with liver transplantation as compared to allele C.		[ 519]
Tacrolimus	N.A.	Liver Transplantation	Allele A is not associated with metabolism of tacrolimus in people with liver transplantation as compared to allele C.		[ 519]
Tacrolimus	N.A.	Kidney Transplantation	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 26]
Tacrolimus	N.A.	Liver Transplantation	Allele A is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 26]
Cyclosporine	N.A.	Kidney Transplantation	Allele A is associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype CC.		[ 569]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Allele A is associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype CC.		[ 569]
Clomipramine	N.A.	Depression	Allele A is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 575]
Lithium	N.A.	Depression	Allele A is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 575]
Nefazodone	N.A.	Depression	Allele A is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 575]
Paroxetine	N.A.	Depression	Allele A is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 575]
Venlafaxine	N.A.	Depression	Allele A is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 575]
Methadone	N.A.	Opioid-related Disorders	Allele A is not associated with concentrations of methadone as compared to allele C.		[ 274]
Sunitinib	N.A.	Renal Cell Carcinoma	Allele A is associated with decreased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell.		[ 237]
Lithium	N.A.	Depression	Correlated with the increased suicidal ideation risk in patients (compare with allele C)		[ 575]
Antiepileptics	N.A.	Epilepsy	Irrelevant to the likelihood of drug resistance in patients (compare with Allele C)		[ 69]
Allele C	Click to Show/Hide the Full List of Affected Drugs:         89 Drugs in Total
Atorvastatin	Drug Info	Coronary Artery Disease	Correlated with the increased drug-induced liver injury risk in patients (compare with Allele T)		[ 576]
Sirolimus	Drug Info	Kidney Transplantation	Irrelevant to the drug metabolism in patients (compare with Allele A)		[ 24]
Tacrolimus	Drug Info	Kidney Transplantation	Irrelevant to the drug metabolism in patients (compare with Allele A)		[ 24]
Carbamazepine	Drug Info	Epilepsy	Irrelevant to the drug metabolism in patients (compare with Allele A); Irrelevant to the increased drug response in patients (compare with Allele T)		[ 15], [ 16]
Pravastatin	Drug Info	Hyperlipoproteinemia	Irrelevant to the drug response in patients (compare with allele A)		[ 209]
Valproic acid	Drug Info	Epilepsy	Irrelevant to the increased drug response in patients (compare with Allele T)		[ 15]
Phenytoin	Drug Info	Epilepsy	Irrelevant to the increased drug response in patients (compare with Allele T)		[ 15]
Phenobarbital	Drug Info	Epilepsy	Irrelevant to the increased drug response in patients (compare with Allele T)		[ 15]
Fluoxetine	Drug Info	Depressive Disorder	Irrelevant to the increased fluoxetine/in patients (S)-norfluoxetine ratio in patients (compare with Allele A)		[ 178]
Rhodamine 123	N.A.	Drug Toxicity	Allele C is not associated with transport of rhodamine 123 CD56+ NK cells and CD4+ T-helper cells as compared to allele A.		[ 57]
Olanzapine	N.A.	Platelet Reactivity	Allele C is not associated with exposure to olanzapine in healthy individuals as compared to allele A.		[ 182]
Risperidone	N.A.	Hemorrhage	Allele C is not associated with increased metabolism of risperidone in people with Schizophrenia as compared to allele A.		[ 173]
Temsirolimus	N.A.	Adverse Events	Allele C is not associated with likelihood of adverse events when treated with temsirolimus in people with Urinary Bladder Neoplasms as compared to allele T.		[ 179]
Nimodipine	N.A.	Hemorrhage	Allele C is not associated with exposure to nimodipine in healthy individuals as compared to allele A.		[ 68]
Atazanavir	N.A.	Toxic Liver Disease	Allele C is not associated with trough concentration of atazanavir in people with HIV Infections as compared to allele A.		[ 172]
Lopinavir	N.A.	Toxic Liver Disease	Allele C is not associated with trough concentration of lopinavir in people with HIV Infections as compared to allele A.		[ 172]
Labetalol	N.A.	Exanthema	Allele C is not associated with decreased metabolism of labetalol in healthy individuals as compared to allele T.		[ 72]
Citalopram	N.A.	Drug Resistance	Allele C is not associated with differences in remission or tolerance when treated with citalopram in people with Depressive Disorder, Major as compared to allele A.		[ 184]
Fluoxetine	N.A.	Hand-foot Syndrome	Allele C is not associated with increased fluoxetine/(S)-norfluoxetine ratio when treated with fluoxetine in children with Depressive Disorder as compared to allele A.		[ 178]
Paclitaxel	N.A.	Drug Toxicity	Allele C is not associated with increased response to paclitaxel in women with Breast Neoplasms.		[ 366]
Dexamethasone	N.A.	Overall Survival	Allele C is not associated with likelihood of overall survival or progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele A.		[ 81]
Dexamethasone	N.A.	Progression-free Survival	Allele C is not associated with likelihood of overall survival or progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele A.		[ 81]
Lenalidomide	N.A.	Overall Survival	Allele C is not associated with likelihood of overall survival or progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele A.		[ 81]
Lenalidomide	N.A.	Progression-free Survival	Allele C is not associated with likelihood of overall survival or progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele A.		[ 81]
Dexamethasone	N.A.	Anemia	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.		[ 81]
Dexamethasone	N.A.	Neutropenia	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.		[ 81]
Dexamethasone	N.A.	Thrombocytopenia	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.		[ 81]
Lenalidomide	N.A.	Anemia	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.		[ 81]
Lenalidomide	N.A.	Neutropenia	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.		[ 81]
Lenalidomide	N.A.	Thrombocytopenia	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.		[ 81]
Opioids	N.A.	Death	Allele C is not associated with risk of Death due to opioids in people with Opioid-Related Disorders as compared to allele A.		[ 190]
Tenofovir	N.A.	Kidney Disorder	Allele C is not associated with Kidney Disorder when exposed to tenofovir in people with HIV infectious disease as compared to allele A.		[ 593]
Opioids	N.A.	Neutropenia	Allele C is not associated with dose of opioids in people with Pain, Postoperative.		[ 427]
Losartan	N.A.	Adverse Events	Allele C is not associated with increased response to losartan in people with Hypertension as compared to allele A.		[ 368]
Talinolol	N.A.	Event-free Survival	Allele C is not associated with clearance of talinolol in healthy individuals as compared to allele A.		[ 525]
Simvastatin	N.A.	Event-free Survival	Allele C is associated with increased risk of Myalgia when treated with simvastatin in people with Hypercholesterolemia.		[ 3]
Imatinib	N.A.	Drug Toxicity	Allele C is not associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A.		[ 253]
Carbamazepine	N.A.	Coronary Restenosis	Allele C is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele T.		[ 15]
Phenobarbital	N.A.	Coronary Restenosis	Allele C is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele T.		[ 15]
Phenytoin	N.A.	Coronary Restenosis	Allele C is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele T.		[ 15]
Valproic Acid	N.A.	Coronary Restenosis	Allele C is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele T.		[ 15]
Digoxin	N.A.	Acute Cellular Rejection	Allele C is not associated with clearance of digoxin in people with Heart Failure as compared to allele A.		[ 434]
Fentanyl	N.A.	Acute Cellular Rejection	Allele C is not associated with concentrations of fentanyl in people with Neoplasms and Pain as compared to allele A.		[ 195]
Sirolimus	N.A.	Diarrhea	Allele C is not associated with metabolism of sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele A.		[ 24]
Tacrolimus	N.A.	Diarrhea	Allele C is not associated with metabolism of sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele A.		[ 24]
Quetiapine	N.A.	Transplant Rejection	Allele C is not associated with differences pharmacokinetic parameters when treated with quetiapine in healthy individuals as compared to allele T.		[ 105]
Sufentanil	N.A.	Adverse Events	Allele C is not associated with likelihood of adverse events due to sufentanil in people with Pain, Postoperative as compared to allele A.		[ 106]
Fentanyl	N.A.	Central Nervous System Disorder	Allele C is not associated with dose of fentanyl in women with Pain, Postoperative as compared to allele A.		[ 198]
Antiepileptics	N.A.	Nausea	Allele C is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.		[ 200]
Sufentanil	N.A.	Renal Transplant Failure	Allele C is not associated with dose of sufentanil in people with Pain, Postoperative as compared to allele A.		[ 106]
Imatinib	N.A.	Hypersensitivity	Allele C is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive.		[ 401]
Atorvastatin	N.A.	Drug-induced Liver Injury	Allele C is associated with increased risk of drug-induced liver injury when treated with atorvastatin as compared to allele T.		[ 576]
Antipsychotics	N.A.	Overall Survival	Allele C is associated with increased response to antipsychotics in people with Schizophrenia.		[ 187]
Methadone	N.A.	Hyperprolactinemia	Allele C is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele A.		[ 208]
Pravastatin	N.A.	High On-treatment Platelet Reactivity	Allele C is not associated with response to pravastatin in children with Hyperlipoproteinemia Type II as compared to allele A.		[ 209]
Methadone	N.A.	Weight Gain	Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele T.		[ 130]
Cyclophosphamide	N.A.	Gastrointestinal Toxicity	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.		[ 530]
Doxorubicin	N.A.	Gastrointestinal Toxicity	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.		[ 530]
Risperidone	N.A.	Mucositis	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele A.		[ 33]
Tamoxifen	N.A.	Opioid-related Disorders	Allele C is not associated with increased or decreased recurrence-free survival time when treated with tamoxifen as compared to allele T.		[ 611]
Propofol	N.A.	Exanthema	Allele C is not associated with response to propofol and remifentanil in children as compared to allele T.		[ 191]
Remifentanil	N.A.	Exanthema	Allele C is not associated with response to propofol and remifentanil in children as compared to allele T.		[ 191]
Methadone	N.A.	Mucositis	Allele C is not associated with response to methadone in people with Neoplasms and Pain as compared to allele T.		[ 213]
Carbamazepine	N.A.	Mucositis	Allele C is not associated with metabolism of carbamazepine in people with Epilepsy as compared to allele A.		[ 16]
Vincristine	N.A.	Nephrotoxicity	Allele C is not associated with impaired motor performance when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 147]
Lamotrigine	N.A.	Drug Toxicity	Allele C is not associated with concentrations of lamotrigine in people with Epilepsy as compared to allele A.		[ 148]
Sunitinib	N.A.	Adverse Events	Allele C is not associated with concentrations of sunitinib in people with Carcinoma, Renal Cell as compared to allele T.		[ 150]
Antiepileptics	N.A.	Hemorrhage	Allele C is associated with protection from drug resistance when treated with antiepileptics in people with Epilepsy.		[ 17]
Sufentanil	N.A.	Pain, Postoperative	Allele C is not associated with dose of sufentanil in people with Pain, Postoperative as compared to allele A.		[ 106]
Cyclophosphamide	N.A.	Breast Neoplasms	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.		[ 530]
Doxorubicin	N.A.	Breast Neoplasms	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.		[ 530]
Atorvastatin	N.A.	Narcolepsy	Allele C is associated with increased risk of drug-induced liver injury when treated with atorvastatin as compared to allele T.		[ 576]
Fluoxetine	N.A.	Depressive Disorder	Allele C is not associated with increased fluoxetine/(S)-norfluoxetine ratio when treated with fluoxetine in children with Depressive Disorder as compared to allele A.		[ 178]
Carbamazepine	N.A.	Epilepsy	Allele C is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele T.		[ 15]
Phenytoin	N.A.	Epilepsy	Allele C is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele T.		[ 15]
Valproic Acid	N.A.	Epilepsy	Allele C is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele T.		[ 15]
Simvastatin	N.A.	Hypercholesterolemia	Allele C is associated with increased risk of Myalgia when treated with simvastatin in people with Hypercholesterolemia.		[ 3]
Simvastatin	N.A.	Myalgia	Allele C is associated with increased risk of Myalgia when treated with simvastatin in people with Hypercholesterolemia.		[ 3]
Antiepileptics	N.A.	Epilepsy	Allele C is not associated with response to antiepileptics in people with Epilepsy as compared to allele A.		[ 200]
Antiepileptics	N.A.	Epilepsy	Allele C is not associated with metabolism of carbamazepine in people with Epilepsy as compared to allele A.		[ 16]
Carbamazepine	N.A.	Epilepsy	Allele C is not associated with metabolism of carbamazepine in people with Epilepsy as compared to allele A.		[ 16]
Antiepileptics	N.A.	Epilepsy	Allele C is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele T.		[ 15]
Antiepileptics	N.A.	Epilepsy	Allele C is associated with protection from drug resistance when treated with antiepileptics in people with Epilepsy.		[ 17]
Carbamazepine	N.A.	Epilepsy	Allele C is associated with protection from drug resistance when treated with antiepileptics in people with Epilepsy.		[ 17]
Tacrolimus	N.A.	Kidney Transplantation	Allele C is not associated with metabolism of sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele A.		[ 24]
Tacrolimus	N.A.	Liver Transplantation	Allele C is not associated with metabolism of sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele A.		[ 24]
Pravastatin	N.A.	Acute Coronary Syndrome	Allele C is not associated with response to pravastatin in children with Hyperlipoproteinemia Type II as compared to allele A.		[ 209]
Pravastatin	N.A.	Hyperlipoproteinemia Type Ii	Allele C is not associated with response to pravastatin in children with Hyperlipoproteinemia Type II as compared to allele A.		[ 209]
Antiepileptics	N.A.	Epilepsy	Irrelevant to the drug response in patients (compare with Allele A)		[ 158], [ 200]
Allele T	Click to Show/Hide the Full List of Affected Drugs:         55 Drugs in Total
Carbamazepine	Drug Info	Epilepsy	Correlated with the drug-resistant phenotype in patients (compare with allele C)		[ 61]
Valproic acid	Drug Info	Epilepsy	Correlated with the drug-resistant phenotype in patients (compare with allele C)		[ 61]
Phenytoin	Drug Info	Epilepsy	Correlated with the drug-resistant phenotype in patients (compare with allele C)		[ 61]
Atorvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug response in patients (compare with allele A); Correlated with the increased drug response in patients(compare with allele C)		[ 580]
Clopidogrel	Drug Info	Coronary Artery Disease	Correlated with the increased Hemorrhage risk in patients (compare with allele A)		[ 581]
Desmethylcitalopram	N.A.	Cardiac Rhythm Disease	Allele T is not associated with concentrations of desmethylcitalopram or escitalopram in people with Depressive Disorder, Major as compared to allele C.		[ 498]
Escitalopram	N.A.	Cardiac Rhythm Disease	Allele T is not associated with concentrations of desmethylcitalopram or escitalopram in people with Depressive Disorder, Major as compared to allele C.		[ 498]
Olanzapine	N.A.	Hemorrhage	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele A.		[ 182]
Nevirapine	N.A.	Neurotoxicity Syndromes	Allele T is not associated with increased risk of toxicity when treated with nevirapine in people with HIV Infections as compared to allele C.		[ 62]
Carbamazepine	N.A.	Neutropenia	Allele T is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele C.		[ 61]
Phenytoin	N.A.	Neutropenia	Allele T is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele C.		[ 61]
Valproic Acid	N.A.	Neutropenia	Allele T is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele C.		[ 61]
Morphine	N.A.	Adverse Events	Allele T is not associated with likelihood of adverse events due to morphine in people with Pain, Postoperative as compared to allele C.		[ 65]
Codeine	N.A.	Neutropenia	Allele T is not associated with concentrations of codeine or morphine as compared to allele C.		[ 66]
Morphine	N.A.	Neutropenia	Allele T is not associated with concentrations of codeine or morphine as compared to allele C.		[ 66]
Morphine	N.A.	Neutropenia	Allele T is not associated with concentrations of morphine in people with Pain, Postoperative as compared to allele C.		[ 65]
Imatinib	N.A.	Hemorrhage	Allele T is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A.		[ 37]
Axitinib	N.A.	Drug Resistance	Allele T is associated with concentrations of axitinib in people with Carcinoma, Renal Cell as compared to allele C.		[ 74]
Aripiprazole	N.A.	Prolonged Qtc Interval	Allele T is not associated with concentrations of aripiprazole in people with Depressive Disorder, Major as compared to allele C.		[ 498]
Carbamazepine	N.A.	Transplant Rejection	Allele T is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C.		[ 159]
Opioids	N.A.	Death	Allele T is not associated with risk of Death due to opioids in people with Opioid-Related Disorders as compared to allele A.		[ 190]
Propofol	N.A.	Adverse Events	Allele T is not associated with risk of adverse events due to propofol and remifentanil in children as compared to allele C.		[ 191]
Remifentanil	N.A.	Adverse Events	Allele T is not associated with risk of adverse events due to propofol and remifentanil in children as compared to allele C.		[ 191]
Clozapine	N.A.	Agranulocytosis	Allele T is not associated with risk of Agranulocytosis or Neutropenia when treated with clozapine as compared to allele C.		[ 238]
Clozapine	N.A.	Neutropenia	Allele T is not associated with risk of Agranulocytosis or Neutropenia when treated with clozapine as compared to allele C.		[ 238]
Tenofovir	N.A.	Kidney Disorder	Allele T is not associated with Kidney Disorder when exposed to tenofovir in people with HIV infectious disease as compared to allele A.		[ 577]
Atorvastatin	N.A.	Peripheral Nervous System Diseases	Allele T is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to allele C.		[ 580]
Antidepressants	N.A.	Adverse Events	Allele T is not associated with risk of adverse events when treated with antidepressants in people with Depressive Disorder, Major as compared to allele C.		[ 498]
Escitalopram	N.A.	Adverse Events	Allele T is not associated with severity of adverse events when treated with escitalopram in people with Depressive Disorder, Major as compared to allele C.		[ 498]
Fentanyl	N.A.	Acute Cellular Rejection	Allele T is not associated with concentrations of fentanyl in people with Neoplasms and Pain as compared to allele A.		[ 195]
Dolutegravir	N.A.	Adverse Events	Allele T is not associated with concentrations of dolutegravir in people with HIV Infections as compared to allele C.		[ 107]
Tipifarnib	N.A.	Mucositis	Allele T is not associated with increased metabolism of tipifarnib.		[ 203]
Clopidogrel	N.A.	Hemorrhage	Allele T is associated with increased risk of Hemorrhage when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.		[ 581]
Methotrexate	N.A.	Drug Toxicity	Allele T is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele C.		[ 214]
Methotrexate	N.A.	Nausea	Allele T is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele C.		[ 214]
Fentanyl	N.A.	Hypertension	Allele T is not associated with exposure to fentanyl in healthy individuals as compared to allele C.		[ 116]
Atazanavir	N.A.	Cholelithiasis	Allele T is not associated with Cholelithiasis when treated with atazanavir and ritonavir in people with HIV Infections.		[ 572]
Ritonavir	N.A.	Cholelithiasis	Allele T is not associated with Cholelithiasis when treated with atazanavir and ritonavir in people with HIV Infections.		[ 572]
Temozolomide	N.A.	Urinary Retention	Allele T is not associated with response to temozolomide in people with Glioma as compared to allele A.		[ 126]
Antidepressants	N.A.	Statin-related Myopathy	Allele T is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to allele C.		[ 498]
Tacrolimus	N.A.	Drug-induced Liver Injury	Allele T is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation.		[ 409]
Tacrolimus	N.A.	Mucositis	Allele T is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 160]
Lamotrigine	N.A.	Adverse Events	Allele T is not associated with dose of lamotrigine in people with Epilepsy as compared to allele A.		[ 148]
Fentanyl	N.A.	Adverse Events	Allele T is not associated with likelihood of adverse events due to fentanyl in healthy individuals as compared to allele C.		[ 116]
Atorvastatin	N.A.	Hypercholesterolemia	Allele T is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to allele C.		[ 580]
Clopidogrel	N.A.	Coronary Artery Disease	Allele T is associated with increased risk of Hemorrhage when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.		[ 581]
Carbamazepine	N.A.	Epilepsy	Allele T is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele C.		[ 61]
Phenytoin	N.A.	Epilepsy	Allele T is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele C.		[ 61]
Valproic Acid	N.A.	Epilepsy	Allele T is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele C.		[ 61]
Antiepileptics	N.A.	Epilepsy	Allele T is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C.		[ 159]
Carbamazepine	N.A.	Epilepsy	Allele T is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C.		[ 159]
Tacrolimus	N.A.	Kidney Transplantation	Allele T is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 160]
Tacrolimus	N.A.	Liver Transplantation	Allele T is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 160]
Tacrolimus	N.A.	Kidney Transplantation	Allele T is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation.		[ 409]
Tacrolimus	N.A.	Liver Transplantation	Allele T is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation.		[ 409]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:       179 Drugs in Total
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the decreased drug metabolism in patients (compare with genotype CC)		[ 316]
Doxorubicin	Drug Info	Leukemia	Correlated with the decreased drug metabolism in patients (compare with genotype CC)		[ 316]
Anastrozole	Drug Info	Breast Neoplasm	Correlated with the increased drug concentrations in patients (compare with genotypes AC + CC)		[ 234]
Tramadol	Drug Info	Pain	Correlated with the increased drug exposure (compare with genotype CC)		[ 251]
Cyclosporine	Drug Info	Ulcerative Colitis	Correlated with the increased drug resistance risk in patients (compare with genotypes CC + AC)		[ 154]
Cyclosporine	Drug Info	Myasthenia Gravis	Correlated with the increased drug trough blood concentration in patients (compare with genotype CC)		[ 536]
Carbamazepine	Drug Info	Epilepsy	Correlated with the increased likelihood of drug resistance in patients (compare with genotype CC)		[ 16]
Fentanyl	Drug Info	Postoperative Pain	Correlated with the increased likelihood of respiratory insufficiency in patients (compare with Genotype AA)		[ 254]
Simvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased reduction in total cholesterol in patients (compare with genotype CC)		[ 256]
Mitoxantrone	Drug Info	Breast Neoplasm	Correlated with the increased sensitivity to drug in vitro (compare with genotypes CC + AC)		[ 405]
Daunorubicin	Drug Info	Acute Myeloid Leukemia	Irrelevant to the drug response in patients (compare with genotypes AC + CC)		[ 258]
Cytarabine	Drug Info	Acute Myeloid Leukemia	Irrelevant to the drug response in patients (compare with genotypes AC + CC)		[ 258]
Nevirapine	Drug Info	HIV Infection	Irrelevant to the drug metabolism in patients (compare with genotype CC)		[ 413]
Dexrazoxane	Drug Info	Acute Myeloid Leukemia	Irrelevant to the drug response in patients (compare with genotypes AC + CC)		[ 258]
Efavirenz	Drug Info	HIV Infection	Correlated with the decreased drug concentrations in patients (compare with genotypes AC + CC); Irrelevant to the drug metabolism in patients (compare with genotype CC)		[ 262], [ 413]
Idarubicin	Drug Info	Acute Myeloid Leukemia	Irrelevant to the drug response in patients (compare with genotypes AC + CC)		[ 258]
Carboplatin	N.A.	Overall Survival	Genotype AA is associated with decreased overall survival when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to genotypes AC + CC.		[ 593]
Paclitaxel	N.A.	Overall Survival	Genotype AA is associated with decreased overall survival when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to genotypes AC + CC.		[ 593]
Methadone	N.A.	Discontinuation	Genotype AA is not associated with increased likelihood of Discontinuation when treated with methadone in people with Opioid-Related Disorders as compared to genotypes AC + CC.		[ 177]
Paclitaxel	N.A.	Drug Toxicity	Genotype AA is associated with increased chance of positive response to paclitaxel when treated with paclitaxel in people with Ovarian Neoplasms as compared to genotype CC.		[ 595]
Cyclosporine	N.A.	Transplant Rejection	Genotype AA is associated with increased trough blood concentration of cyclosporine in people with Myasthenia Gravis as compared to genotype CC.		[ 536]
Digoxin	N.A.	Sudden Cardiac Death	Genotype AA is associated with increased likelihood of Death, Sudden, Cardiac when treated with digoxin as compared to genotypes AC + CC.		[ 268]
Mitoxantrone	N.A.	Hemorrhage	Genotype AA is associated with increased sensitivity in vitro when treated with mitoxantrone as compared to genotypes AC + CC.		[ 405]
Imatinib	N.A.	Diarrhea	Genotype AA is associated with increased likelihood of Diarrhea when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AC + CC.		[ 60]
Anastrozole	N.A.	Arthralgia	Genotype AA is not associated with likelihood of Arthralgia when exposed to anastrozole in women with Breast Neoplasms as compared to genotypes AC + CC.		[ 234]
Antiepileptics	N.A.	Adverse Events	Genotype AA is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to genotype CC.		[ 16]
Carbamazepine	N.A.	Adverse Events	Genotype AA is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to genotype CC.		[ 16]
Tacrolimus	N.A.	Adverse Events	Genotype AA is associated with decreased clearance of tacrolimus in people with Kidney Transplantation.		[ 230]
Valganciclovir	N.A.	Neutropenia	Genotype AA is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype CC.		[ 273]
Codeine	N.A.	Drug Resistance	Genotype AA is associated with increased likelihood of CNS depression in breast-feeding infants when treated with codeine in women with Pain.		[ 14]
Sunitinib	N.A.	Diarrhea	Genotype AA is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell.		[ 237]
Antipsychotics	N.A.	Thrombotic Disease	Genotype AA is associated with increased dose of antipsychotics in people with Schizophrenia.		[ 187]
Aripiprazole	N.A.	Nephrolithiasis	Genotype AA is associated with decreased dose-adjusted trough concentrations of aripiprazole in children as compared to genotypes AC + CC.		[ 283]
Tacrolimus	N.A.	Gastrointestinal Toxicity	Genotype AA is associated with decreased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AC + CC.		[ 604]
Efavirenz	N.A.	Transplant Rejection	Genotype AA is not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections.		[ 463]
Efavirenz	N.A.	Adverse Events	Genotype AA is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype CC.		[ 413]
Nevirapine	N.A.	Adverse Events	Genotype AA is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype CC.		[ 413]
Cyclosporine	N.A.	Adverse Events	Genotype AA is associated with increased risk of nephrotoxicity when treated with cyclosporine in people with Kidney Transplantation as compared to genotypes AC + CC.		[ 285]
Etoposide	N.A.	Epistaxis	Genotype AA is associated with increased sensitivity in vitro when treated with etoposide as compared to genotypes AC + CC.		[ 405]
Simvastatin	N.A.	Hemorrhage	Genotype AA is associated with increased reduction in total cholesterol when treated with simvastatin as compared to genotype CC.		[ 256]
Atorvastatin	N.A.	Hemorrhage	Genotype AA is associated with increased AUC of atorvastatin in healthy individuals as compared to genotype CC.		[ 288]
Simvastatin	N.A.	Transplant Rejection	Genotype AA is associated with increased AUC simvastatin acid when treated with simvastatin in healthy individuals as compared to genotype CC.		[ 288]
Atazanavir	N.A.	Hyperbilirubinemia	Genotype AA is associated with increased risk of Hyperbilirubinemia when exposed to atazanavir in healthy individuals as compared to genotypes AC + CC.		[ 290]
Tacrolimus	N.A.	Adverse Events	Genotype AA is not associated with concentrations of tacrolimus in children with Kidney Transplantation.		[ 294]
Anastrozole	N.A.	Neutropenia	Genotype AA is associated with increased concentrations of anastrozole in women with Breast Neoplasms as compared to genotypes AC + CC.		[ 234]
Fexofenadine	N.A.	Event-free Survival	Genotype AA is associated with decreased plasma concentration of fexofenadine in healthy individuals as compared to genotypes AC + CC.		[ 232]
Imatinib	N.A.	Asthenia	Genotype AA is not associated with increased concentrations of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AT + CT.		[ 539]
Ezetimibe	N.A.	Neutropenia	Genotype AA is associated with decreased dose-adjusted trough concentrations of ezetimibe in healthy individuals as compared to genotypes CC + TT.		[ 612]
Tacrolimus	N.A.	Adverse Events	Genotype AA is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AC + CC.		[ 229]
Cytarabine	N.A.	Adverse Events	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AC + CC.		[ 258]
Daunorubicin	N.A.	Adverse Events	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AC + CC.		[ 258]
Dexrazoxane	N.A.	Adverse Events	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AC + CC.		[ 258]
(r)-methadone	N.A.	Nausea	Genotype AA is associated with decreased clearance of (R)-methadone in people with HIV Infections as compared to genotypes AT + TT.		[ 614]
Fentanyl	N.A.	Hypoventilation	Genotype AA is associated with increased likelihood of Hypoventilation due to fentanyl in people with Pain, Postoperative.		[ 254]
Tacrolimus	N.A.	Hypersensitivity	Genotype AA is associated with increased success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to genotypes AC + CC.		[ 311]
Tacrolimus	N.A.	Thromboembolism	Genotype AA is not associated with response to tacrolimus in people with Colitis, Ulcerative.		[ 496]
Remifentanil	N.A.	Transplant Rejection	Genotype AA is not associated with response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AC + CC.		[ 443]
Sevoflurane	N.A.	Transplant Rejection	Genotype AA is not associated with response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AC + CC.		[ 443]
Tramadol	N.A.	Cholelithiasis	Genotype AA is associated with increased exposure to tramadol as compared to genotype CC.		[ 251]
Digoxin	N.A.	Orthostatic Hypotension	Genotype AA is associated with increased clearance of digoxin in healthy individuals as compared to genotype CC.		[ 317]
Doxorubicin	N.A.	Drug Toxicity	Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype CC.		[ 316]
Erlotinib	N.A.	Drug Toxicity	Genotype AA is associated with increased likelihood of Drug Toxicity when treated with erlotinib in people with Carcinoma, Non-Small-Cell Lung.		[ 315]
Clopidogrel	N.A.	High On-treatment Platelet Reactivity	Genotype AA is associated with decreased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AC + CC.		[ 319]
Lenalidomide	N.A.	Myelosuppression	Genotype AA is associated with decreased likelihood of Myelosuppression when treated with lenalidomide in people with Lymphoma, Mantle-Cell as compared to genotypes AC + CC.		[ 621]
Carbamazepine	N.A.	Diarrhea	Genotype AA is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Phenobarbital	N.A.	Diarrhea	Genotype AA is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Phenytoin	N.A.	Diarrhea	Genotype AA is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Valproic Acid	N.A.	Diarrhea	Genotype AA is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Ritonavir	N.A.	Eye Diseases	Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AC + CC.		[ 290]
Paclitaxel	N.A.	Neutropenia	Genotype AA is associated with increased risk of Neutropenia when treated with paclitaxel in people with Neoplasms as compared to genotypes AC + CC.		[ 322]
Antiepileptics	N.A.	Opioid-related Disorders	Genotype AA is associated with increased clinical benefit to antiepileptics in children with Epilepsy as compared to genotypes AC + CC.		[ 323]
Azithromycin	N.A.	Opioid-related Disorders	Genotype AA is associated with decreased concentrations of azithromycin in healthy individuals as compared to genotype CC.		[ 324]
Atorvastatin	N.A.	Statin-related Myopathy	Genotype AA is associated with increased likelihood of statin-related myopathy when exposed to atorvastatin as compared to genotypes AC + CC.		[ 325]
Atazanavir	N.A.	Transplant Rejection	Genotype AA is associated with increased clearance of atazanavir in healthy individuals as compared to genotypes AC + CC.		[ 290]
Oxycodone	N.A.	Cns Depression	Genotype AA is not associated with risk of CNS depression and Infant when treated with oxycodone in women with Lactation as compared to genotype CC.		[ 327]
Oxycodone	N.A.	Infant	Genotype AA is not associated with risk of CNS depression and Infant when treated with oxycodone in women with Lactation as compared to genotype CC.		[ 327]
Granisetron	N.A.	Mucositis	Genotype AA is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting.		[ 261]
Palonosetron	N.A.	Mucositis	Genotype AA is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting.		[ 261]
Efavirenz	N.A.	Mucositis	Genotype AA is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to genotypes AC + CC.		[ 262]
Erlotinib	N.A.	Toxic Liver Disease	Genotype AA is associated with decreased clearance of erlotinib in people with Carcinoma, Non-Small-Cell Lung.		[ 315]
Crizotinib	N.A.	Drug Toxicity	Genotype AA is associated with increased exposure to crizotinib in people with.		[ 331]
Ondansetron	N.A.	Postoperative Nausea And Vomiting	Genotype AA is associated with decreased likelihood of Postoperative Nausea and Vomiting when treated with ondansetron.		[ 235]
Methadone	N.A.	Chronic Kidney Failure	Genotype AA is not associated with increased dose of methadone in people with Heroin Dependence as compared to genotype CC.		[ 250]
Nevirapine	N.A.	Adverse Events	Genotype AA is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotypes AC + CC.		[ 336]
Methylphenidate	N.A.	Adverse Events	Genotype AA is associated with increased adverse events when treated with methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AC + CC.		[ 633]
Cyclosporine	N.A.	Metabolic Syndrome	Genotype AA is associated with increased risk of resistance when treated with cyclosporine in people with Colitis, Ulcerative as compared to genotypes AC + CC.		[ 154]
Olanzapine	N.A.	Metabolic Syndrome	Genotype AA is not associated with increased likelihood of Metabolic Syndrome when treated with olanzapine or risperidone in women with Schizophrenia as compared to genotypes AC + CC.		[ 512]
Risperidone	N.A.	Metabolic Syndrome	Genotype AA is not associated with increased likelihood of Metabolic Syndrome when treated with olanzapine or risperidone in women with Schizophrenia as compared to genotypes AC + CC.		[ 512]
Ondansetron	N.A.	Vomiting	Genotype AA is associated with decreased likelihood of Postoperative Nausea and Vomiting when treated with ondansetron.		[ 235]
Atorvastatin	N.A.	Hypercholesterolemia	Patients with the rs2032582 AA genotype who are treated with atorvastatin may have a decreased response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment.		[ 394]
Sufentanil	N.A.	Pain, Postoperative	Patients with the rs2032582 AA genotype may have increased dose requirements of sufentanil as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect dose requirements of sufentanil.		[ 117]
Ritonavir	N.A.	HIV Infectious Disease	Patients with the AA genotype who are treated with ritonavir may have a decreased intracellular/plasma trough concentration as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.		[ 97]
Efavirenz	N.A.	HIV Infectious Disease	Genotype AA is not associated with increased minimum plasma or PBMC concentrations of efavirenz in people with HIV Infections.		[ 463]
Efavirenz	N.A.	HIV Infectious Disease	Genotype AA is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype CC.		[ 413]
Efavirenz	N.A.	HIV Infectious Disease	Genotype AA is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to genotypes AC + CC.		[ 262]
Efavirenz	N.A.	HIV Infectious Disease	Patients with the AA genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz.		[ 4]
Clopidogrel	N.A.	Coronary Artery Disease	Patients with the AA and stable coronary artery disease who are treated with clopidogrel may have a decreased risk of hemorrhage as compared to patients with the AT or TT genotypes. Other clinical and genetic factors may also influence risk hemorrhage in patients with stable coronary artery disease who are treated with clopidogrel.		[ 580]
Fluoxetine	N.A.	Depressive Disorder	Patients with the AA genotype and Depressive Disorder may have increased response to fluoxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.		[ 178]
Carbamazepine	N.A.	Epilepsy	Genotype AA is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Phenytoin	N.A.	Epilepsy	Genotype AA is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Valproic Acid	N.A.	Epilepsy	Genotype AA is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Dabigatran	N.A.	Transplantation	People with the AA genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.		[ 347]
Rivaroxaban	N.A.	Transplantation	People with the AA genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.		[ 347]
Everolimus	N.A.	Breast Neoplasms	Patients with the AA genotype and breast cancer who are treated with everolimus may have increased likelihood of Lymphopenia as compared to patients with the AC or CC genotypes. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.		[ 19]
Everolimus	N.A.	Lymphopenia	Patients with the AA genotype and breast cancer who are treated with everolimus may have increased likelihood of Lymphopenia as compared to patients with the AC or CC genotypes. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.		[ 19]
Tramadol	N.A.	Fractures, Bone	Patients with the rs2032582 AA genotype may be more likely to respond to tramadol treatment as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Tramadol	N.A.	Pain	Patients with the rs2032582 AA genotype may be more likely to respond to tramadol treatment as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Tramadol	N.A.	Pain, Postoperative	Patients with the rs2032582 AA genotype may be more likely to respond to tramadol treatment as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.		[ 3]
Simvastatin	N.A.	Myalgia	Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.		[ 3]
Simvastatin	N.A.	Hypercholesterolemia	Genotype AA is associated with increased reduction in total cholesterol when treated with simvastatin as compared to genotype CC.		[ 256]
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Genotype AA is associated with increased adverse events when treated with methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AC + CC.		[ 633]
Antiepileptics	N.A.	Epilepsy	Genotype AA is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to genotype CC.		[ 16]
Antiepileptics	N.A.	Epilepsy	Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics.		[ 200]
Dexamethasone	N.A.	Multiple Myeloma	Patients with the AA genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.		[ 354]
Doxorubicin	N.A.	Multiple Myeloma	Patients with the AA genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.		[ 354]
Vincristine	N.A.	Multiple Myeloma	Patients with the AA genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.		[ 354]
Doxorubicin	N.A.	Breast Neoplasms	Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype CC.		[ 316]
Digoxin	N.A.	Breast Neoplasms	Patients with genotype AA may have decreased metabolism of digoxin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of digoxin.		[ 13]
Platinum Compounds	N.A.	Ovarian Neoplasms	Patients with the AA genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.		[ 648]
Taxanes	N.A.	Ovarian Neoplasms	Patients with the AA genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.		[ 648]
Cyclosporine	N.A.	Ulcerative Colitis	Genotype AA is associated with increased risk of resistance when treated with cyclosporine in people with Colitis, Ulcerative as compared to genotypes AC + CC.		[ 154]
Carbamazepine	N.A.	Epilepsy	Genotype AA is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to genotype CC.		[ 16]
Antiepileptics	N.A.	Epilepsy	Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AA is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.		[ 159]
Carbamazepine	N.A.	Epilepsy	Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AA is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.		[ 159]
Antipsychotics	N.A.	Schizophrenia	Patients with the AA genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of antipsychotics.		[ 187]
Tacrolimus	N.A.	Kidney Transplantation	Genotype AA is associated with decreased clearance of tacrolimus in people with Kidney Transplantation.		[ 230]
Tacrolimus	N.A.	Liver Transplantation	Genotype AA is associated with decreased clearance of tacrolimus in people with Kidney Transplantation.		[ 230]
Tacrolimus	N.A.	Kidney Transplantation	Genotype AA is not associated with metabolism of tacrolimus in people with Colitis, Ulcerative.		[ 496]
Tacrolimus	N.A.	Liver Transplantation	Genotype AA is not associated with metabolism of tacrolimus in people with Colitis, Ulcerative.		[ 496]
Tacrolimus	N.A.	Kidney Transplantation	Genotype AA is not associated with concentrations of tacrolimus in children with Kidney Transplantation.		[ 294]
Tacrolimus	N.A.	Liver Transplantation	Genotype AA is not associated with concentrations of tacrolimus in children with Kidney Transplantation.		[ 294]
Tacrolimus	N.A.	Kidney Transplantation	Genotype AA is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AC + CC.		[ 229]
Tacrolimus	N.A.	Liver Transplantation	Genotype AA is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AC + CC.		[ 229]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the AA genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.		[ 376]
Tacrolimus	N.A.	Liver Transplantation	Patients with the AA genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.		[ 376]
Cyclosporine	N.A.	Cystic Fibrosis	Patients with the AA genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.		[ 355]
Dicloxacillin	N.A.	Cystic Fibrosis	Patients with the AA genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.		[ 355]
Cyclosporine	N.A.	Kidney Transplantation	Patients with the AA genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		[ 567]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Patients with the AA genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		[ 567]
Capecitabine	N.A.	Colorectal Neoplasms	Patients with genotype AA may have decreased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to capecitabine.		[ 338]
Capecitabine	N.A.	Hand-foot Syndrome	Patients with genotype AA may have decreased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to capecitabine.		[ 338]
Verapamil	N.A.	Tuberculosis	Patients with the AA genotype may have increased metabolism of verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.		[ 363]
Clomipramine	N.A.	Depression	Patients with the AA genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.		[ 568]
Lithium	N.A.	Depression	Patients with the AA genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.		[ 568]
Nefazodone	N.A.	Depression	Patients with the AA genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.		[ 568]
Paroxetine	N.A.	Depression	Patients with the AA genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.		[ 568]
Venlafaxine	N.A.	Depression	Patients with the AA genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.		[ 568]
Sirolimus	N.A.	Hematopoietic Stem Cell Transplantation	Patients with the AA genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus and sirolimus.		[ 179]
Sirolimus	N.A.	Kidney Transplantation	Patients with the AA genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus and sirolimus.		[ 179]
Sirolimus	N.A.	Urinary Bladder Neoplasms	Patients with the AA genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus and sirolimus.		[ 179]
Temsirolimus	N.A.	Hematopoietic Stem Cell Transplantation	Patients with the AA genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus and sirolimus.		[ 179]
Temsirolimus	N.A.	Kidney Transplantation	Patients with the AA genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus and sirolimus.		[ 179]
Temsirolimus	N.A.	Urinary Bladder Neoplasms	Patients with the AA genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus and sirolimus.		[ 179]
Fentanyl	N.A.	Pain, Postoperative	Genotype AA is associated with increased likelihood of Hypoventilation due to fentanyl in people with Pain, Postoperative.		[ 254]
Tacrolimus	N.A.	Ulcerative Colitis	Genotype AA is associated with increased success rate in achieving short-term remission when treated with tacrolimus in people with Colitis, Ulcerative as compared to genotypes AC + CC.		[ 311]
Tacrolimus	N.A.	Ulcerative Colitis	Genotype AA is not associated with response to tacrolimus in people with Colitis, Ulcerative.		[ 496]
Paclitaxel	N.A.	Breast Neoplasms	Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.		[ 595]
Paclitaxel	N.A.	Ovarian Neoplasms	Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.		[ 595]
Fentanyl	N.A.	Neoplasms	Patients with the AA genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.		[ 195]
Fentanyl	N.A.	Pain	Patients with the AA genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.		[ 195]
Cyclosporine	N.A.	Pain	Patients with the AA genotype may have higher blood trough concentrations of cyclosporine compared to patients with the AC and CC genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.		[ 23]
Methadone	N.A.	Opioid-related Disorders	Patients with the rs2032582 AA genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.		[ 274]
Sunitinib	N.A.	Neutropenia	Patients with renal cell carcinoma and the AA genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.		[ 237]
Sunitinib	N.A.	Renal Cell Carcinoma	Patients with renal cell carcinoma and the AA genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.		[ 237]
Tacrolimus	N.A.	Nephrotic Syndrome	Patients with the AA genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the CC, CT or AC genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.		[ 541]
Anastrozole	N.A.	Breast Neoplasms	Genotype AA is associated with increased concentrations of anastrozole in women with Breast Neoplasms as compared to genotypes AC + CC.		[ 234]
Atazanavir	N.A.	HIV Infectious Disease	Patients with the AA genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.		[ 102]
Pravastatin	N.A.	Acute Coronary Syndrome	Patients with the rs2032582 AA genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the AC, CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.		[ 662]
Pravastatin	N.A.	Hyperlipoproteinemia Type Ii	Patients with the rs2032582 AA genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the AC, CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.		[ 662]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AC + CC.		[ 258]
Daunorubicin	N.A.	Leukemia, Myeloid, Acute	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AC + CC.		[ 258]
Dexrazoxane	N.A.	Leukemia, Myeloid, Acute	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AC + CC.		[ 258]
Idarubicin	N.A.	Leukemia, Myeloid, Acute	Genotype AA is not associated with response to cytarabine, daunorubicin and dexrazoxane in people with Leukemia, Myeloid, Acute as compared to genotypes AC + CC.		[ 258]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytarabine, daunorubicin and dexrazoxane may have an increased response as compared to the AC, AT, CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.		[ 375]
Daunorubicin	N.A.	Leukemia, Myeloid, Acute	Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytarabine, daunorubicin and dexrazoxane may have an increased response as compared to the AC, AT, CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.		[ 375]
Dexrazoxane	N.A.	Leukemia, Myeloid, Acute	Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytarabine, daunorubicin and dexrazoxane may have an increased response as compared to the AC, AT, CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.		[ 375]
Idarubicin	N.A.	Leukemia, Myeloid, Acute	Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytarabine, daunorubicin and dexrazoxane may have an increased response as compared to the AC, AT, CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.		[ 375]
Antiepileptics	N.A.	Epilepsy	Correlated with the increased likelihood of drug resistance in patients (compare with genotype CC)		[ 16]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:         89 Drugs in Total
Methadone	Drug Info	Opioid-Related Disorders	Correlated with the increased drug concentrations in patients (compare with genotypes AA + CC)		[ 379]
Simvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased reduction in total cholesterol in patients (compare with genotype CC)		[ 256]
Valganciclovir	N.A.	Neutropenia	Genotype AC is not associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype CC.		[ 273]
Simvastatin	N.A.	Hemorrhage	Genotype AC is associated with increased reduction in total cholesterol when treated with simvastatin as compared to genotype CC.		[ 256]
Trabectedin	N.A.	Toxic Liver Disease	Genotype AC is associated with Toxic liver disease when treated with trabectedin in men with Sarcoma.		[ 517]
Levofloxacin	N.A.	Asthenia	Genotype AC is associated with increased risk of seizures due to levofloxacin.		[ 387]
Sunitinib	N.A.	Progression-free Survival	Genotype AC is associated with increased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype AA.		[ 389]
Moxifloxacin	N.A.	Overall Survival	Genotype AC is not associated with increased exposure to moxifloxacin in people with Drug Resistance and Tuberculosis as compared to genotype CC.		[ 596]
Carbamazepine	N.A.	Diarrhea	Genotype AC is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Phenobarbital	N.A.	Diarrhea	Genotype AC is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Phenytoin	N.A.	Diarrhea	Genotype AC is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Valproic Acid	N.A.	Diarrhea	Genotype AC is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Oxycodone	N.A.	Cns Depression	Genotype AC is not associated with risk of CNS depression and Infant when treated with oxycodone in women with Lactation as compared to genotype CC.		[ 327]
Oxycodone	N.A.	Infant	Genotype AC is not associated with risk of CNS depression and Infant when treated with oxycodone in women with Lactation as compared to genotype CC.		[ 327]
Methadone	N.A.	Drug Toxicity	Genotype AC is associated with increased concentrations of methadone in men with Opioid-Related Disorders as compared to genotypes AA + CC.		[ 379]
Ondansetron	N.A.	Postoperative Nausea And Vomiting	Patients with the rs2032582 AC genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.		[ 235]
Ondansetron	N.A.	Vomiting	Patients with the rs2032582 AC genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.		[ 235]
Atorvastatin	N.A.	Hypercholesterolemia	Patients with the rs2032582 AC genotype who are treated with atorvastatin may have a decreased response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype or may have an increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment.		[ 394]
Sufentanil	N.A.	Pain, Postoperative	Patients with the rs2032582 AC genotype may have increased dose requirements of sufentanil as compared to patients with the CC genotype but decreased dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect dose requirements of sufentanil.		[ 117]
Ritonavir	N.A.	HIV Infectious Disease	Patients with the AC genotype who are treated with ritonavir may have a increased intracellular/plasma trough concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.		[ 97]
Efavirenz	N.A.	HIV Infectious Disease	Patients with the AC genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz.		[ 4]
Fluoxetine	N.A.	Depressive Disorder	Patients with the AA genotype and Depressive Disorder may have increased response to fluoxetine as compared to patients with the CC genotype or may have decreased response to fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.		[ 178]
Carbamazepine	N.A.	Epilepsy	Genotype AC is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Phenytoin	N.A.	Epilepsy	Genotype AC is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Valproic Acid	N.A.	Epilepsy	Genotype AC is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Dabigatran	N.A.	Transplantation	People with the AC genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.		[ 347]
Rivaroxaban	N.A.	Transplantation	People with the AC genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.		[ 347]
Everolimus	N.A.	Breast Neoplasms	Patients with the AC genotype and breast cancer who are treated with everolimus may have increased likelihood of Lymphopenia as compared to patients with the CC genotype, and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.		[ 19]
Everolimus	N.A.	Lymphopenia	Patients with the AC genotype and breast cancer who are treated with everolimus may have increased likelihood of Lymphopenia as compared to patients with the CC genotype, and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.		[ 19]
Tramadol	N.A.	Fractures, Bone	Patients with the rs2032582 AC genotype may be more likely to respond to tramadol treatment as compared to patients with the CC genotype, or less likely as compared to those with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Tramadol	N.A.	Pain	Patients with the rs2032582 AC genotype may be more likely to respond to tramadol treatment as compared to patients with the CC genotype, or less likely as compared to those with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Tramadol	N.A.	Pain, Postoperative	Patients with the rs2032582 AC genotype may be more likely to respond to tramadol treatment as compared to patients with the CC genotype, or less likely as compared to those with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the AC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.		[ 3]
Simvastatin	N.A.	Myalgia	Patients with the AC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.		[ 3]
Simvastatin	N.A.	Hypercholesterolemia	Genotype AC is associated with increased reduction in total cholesterol when treated with simvastatin as compared to genotype CC.		[ 256]
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Patients with the AC genotype and attention deficit disorder with hyperactivity who are treated with methylphenidate may have lower adverse drug reaction scores (ADR scores using Barkley Stimulant Side Effect Rating Scale (BSSERS)) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.		[ 587]
Tramadol	N.A.	Vomiting	There is currently no evidence to show whether the AC genotype affects a patient's exposure to tramadol.		[ 251]
Antiepileptics	N.A.	Epilepsy	Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics.		[ 200]
Dexamethasone	N.A.	Multiple Myeloma	Patients with the AC genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.		[ 354]
Doxorubicin	N.A.	Multiple Myeloma	Patients with the AC genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.		[ 354]
Vincristine	N.A.	Multiple Myeloma	Patients with the AC genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.		[ 354]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the AC genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin.		[ 316]
Digoxin	N.A.	Breast Neoplasms	Patients with genotype AC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.		[ 13]
Platinum Compounds	N.A.	Ovarian Neoplasms	Patients with the AC genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.		[ 588]
Taxanes	N.A.	Ovarian Neoplasms	Patients with the AC genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.		[ 588]
Cyclosporine	N.A.	Ulcerative Colitis	Patients with the AC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.		[ 154]
Antiepileptics	N.A.	Epilepsy	Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.		[ 159]
Carbamazepine	N.A.	Epilepsy	Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.		[ 159]
Antipsychotics	N.A.	Schizophrenia	Patients with the AC genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.		[ 187]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the AC genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.		[ 376]
Tacrolimus	N.A.	Liver Transplantation	Patients with the AC genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.		[ 376]
Cyclosporine	N.A.	Cystic Fibrosis	Patients with the AC genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.		[ 355]
Dicloxacillin	N.A.	Cystic Fibrosis	Patients with the AC genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.		[ 355]
Cyclosporine	N.A.	Kidney Transplantation	Patients with the AC genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		[ 567]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Patients with the AC genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		[ 567]
Capecitabine	N.A.	Colorectal Neoplasms	Patients with genotype AC may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to capecitabine.		[ 338]
Capecitabine	N.A.	Hand-foot Syndrome	Patients with genotype AC may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to capecitabine.		[ 338]
Verapamil	N.A.	Tuberculosis	Patients with the AC genotype may have increased metabolism of verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.		[ 363]
Clomipramine	N.A.	Depression	Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.		[ 568]
Lithium	N.A.	Depression	Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.		[ 568]
Nefazodone	N.A.	Depression	Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.		[ 568]
Paroxetine	N.A.	Depression	Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.		[ 568]
Venlafaxine	N.A.	Depression	Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.		[ 568]
Sirolimus	N.A.	Hematopoietic Stem Cell Transplantation	Patients with the AC genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus.		[ 179]
Sirolimus	N.A.	Kidney Transplantation	Patients with the AC genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus.		[ 179]
Sirolimus	N.A.	Urinary Bladder Neoplasms	Patients with the AC genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus.		[ 179]
Temsirolimus	N.A.	Hematopoietic Stem Cell Transplantation	Patients with the AC genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus.		[ 179]
Temsirolimus	N.A.	Kidney Transplantation	Patients with the AC genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus.		[ 179]
Temsirolimus	N.A.	Urinary Bladder Neoplasms	Patients with the AC genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus.		[ 179]
Fentanyl	N.A.	Hypoventilation	Patients with the AC genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Fentanyl	N.A.	Pain, Postoperative	Patients with the AC genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Tacrolimus	N.A.	Ulcerative Colitis	Patients with AC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus.		[ 311]
Fentanyl	N.A.	Neoplasms	Patients with the AC genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.		[ 195]
Fentanyl	N.A.	Pain	Patients with the AC genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.		[ 195]
Cyclosporine	N.A.	Pain	Patients with the AC genotype may have higher blood trough concentrations of cyclosporine compared to patients with the CC genotype, and may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.		[ 23]
Methadone	N.A.	Opioid-related Disorders	Genotype AC is associated with increased concentrations of methadone in men with Opioid-Related Disorders as compared to genotypes AA + CC.		[ 379]
Methadone	N.A.	Opioid-related Disorders	Patients with the rs2032582 AC genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.		[ 274]
Sunitinib	N.A.	Neutropenia	Patients with renal cell carcinoma and the AC genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.		[ 237]
Sunitinib	N.A.	Renal Cell Carcinoma	Patients with renal cell carcinoma and the AC genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.		[ 237]
Tacrolimus	N.A.	Nephrotic Syndrome	Patients with the AC genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.		[ 541]
Modafinil	N.A.	Narcolepsy	Patients with the AC genotype and narcolepsy may have an increased response to modafinil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to modafinil.		[ 345]
Anastrozole	N.A.	Breast Neoplasms	Postmenopausal women with HR+ breast cancer and the AC genotype may have decreased plasma concentrations of anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.		[ 234]
Atazanavir	N.A.	HIV Infectious Disease	Patients with the AC genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.		[ 102]
Pravastatin	N.A.	Acute Coronary Syndrome	Patients with the rs2032582 AC genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype, or may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA, AT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.		[ 589]
Pravastatin	N.A.	Hyperlipoproteinemia Type Ii	Patients with the rs2032582 AC genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype, or may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA, AT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.		[ 589]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.		[ 375]
Daunorubicin	N.A.	Leukemia, Myeloid, Acute	Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.		[ 375]
Dexrazoxane	N.A.	Leukemia, Myeloid, Acute	Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.		[ 375]
Idarubicin	N.A.	Leukemia, Myeloid, Acute	Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.		[ 375]
Genotype AT	Click to Show/Hide the Full List of Affected Drugs:         45 Drugs in Total
Tacrolimus	Drug Info	Kidney Transplantation	Irrelevant to the drug clearance in patients (compare with allele C)		[ 23]
Cyclosporine	Drug Info	Kidney Transplantation	Irrelevant to the drug clearance in patients (compare with allele C)		[ 23]
Tacrolimus	N.A.	Polycystic Ovary Syndrome	Genotype AT is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 522]
Atazanavir	N.A.	Hyperbilirubinemia	Genotype AT is associated with increased risk of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections.		[ 102]
Oseltamivir	N.A.	Depression	Genotype AT is not associated with Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype AA.		[ 359]
Oseltamivir	N.A.	Gastritis	Genotype AT is not associated with Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype AA.		[ 359]
Oseltamivir	N.A.	Hypersensitivity	Genotype AT is not associated with Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype AA.		[ 359]
Digoxin	N.A.	Peripheral Nervous System Diseases	Genotype AT is associated with increased clearance of digoxin in healthy individuals as compared to genotype CC.		[ 317]
Carbamazepine	N.A.	Treatment Failure	Genotype AT is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Phenobarbital	N.A.	Treatment Failure	Genotype AT is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Phenytoin	N.A.	Treatment Failure	Genotype AT is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Valproic Acid	N.A.	Treatment Failure	Genotype AT is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Cyclosporine	N.A.	Nephrotoxicity	Genotype AT is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 23]
Tacrolimus	N.A.	Nephrotoxicity	Genotype AT is not associated with clearance of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 23]
Ondansetron	N.A.	Postoperative Nausea And Vomiting	Patients with the rs2032582 AT genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.		[ 235]
Ondansetron	N.A.	Vomiting	Patients with the rs2032582 AT genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.		[ 235]
Atorvastatin	N.A.	Hypercholesterolemia	Patients with the rs2032582 AT genotype who are treated with atorvastatin may have an increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment.		[ 394]
Clopidogrel	N.A.	Coronary Artery Disease	Patients with the AT genotype and stable coronary artery disease who are treated with clopidogrel may have increased risk of hemorrhage as compared to patients with the AA genotype and decreased risk as compared to the TT genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with stable coronary artery disease who are treated with clopidogrel.		[ 580]
Carbamazepine	N.A.	Epilepsy	Genotype AT is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Phenytoin	N.A.	Epilepsy	Genotype AT is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Valproic Acid	N.A.	Epilepsy	Genotype AT is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.		[ 161]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the AT genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.		[ 3]
Simvastatin	N.A.	Myalgia	Patients with the AT genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.		[ 3]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the AT genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.		[ 256]
Platinum Compounds	N.A.	Ovarian Neoplasms	Patients with the AT genotype and cancer who are treated with taxanes and platinum therapy may have a decreased, but not absent, risk for gastrointestinal toxicity as compared to patients with the CA and AA genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxanes and platinum therapy.		[ 588]
Taxanes	N.A.	Ovarian Neoplasms	Patients with the AT genotype and cancer who are treated with taxanes and platinum therapy may have a decreased, but not absent, risk for gastrointestinal toxicity as compared to patients with the CA and AA genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxanes and platinum therapy.		[ 588]
Tacrolimus	N.A.	Kidney Transplantation	Genotype AT is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 522]
Tacrolimus	N.A.	Liver Transplantation	Genotype AT is not associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 522]
Fentanyl	N.A.	Hypoventilation	Patients with the AT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Fentanyl	N.A.	Pain, Postoperative	Patients with the AT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Paclitaxel	N.A.	Breast Neoplasms	Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.		[ 582]
Paclitaxel	N.A.	Ovarian Neoplasms	Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.		[ 582]
Fentanyl	N.A.	Neoplasms	Patients with the AT genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.		[ 195]
Fentanyl	N.A.	Pain	Patients with the AT genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.		[ 195]
Methadone	N.A.	Opioid-related Disorders	Patients with the rs2032582 AT genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.		[ 274]
Sunitinib	N.A.	Neutropenia	Patients with renal cell carcinoma and the AT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.		[ 237]
Sunitinib	N.A.	Renal Cell Carcinoma	Patients with renal cell carcinoma and the AT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.		[ 237]
Tacrolimus	N.A.	Nephrotic Syndrome	Patients with the AT genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the CC, CT or AC genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.		[ 541]
Atazanavir	N.A.	HIV Infectious Disease	Genotype AT is associated with increased risk of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections.		[ 102]
Pravastatin	N.A.	Acute Coronary Syndrome	Patients with the rs2032582 AT genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the AC, CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.		[ 589]
Pravastatin	N.A.	Hyperlipoproteinemia Type Ii	Patients with the rs2032582 AT genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the AC, CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.		[ 589]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.		[ 375]
Daunorubicin	N.A.	Leukemia, Myeloid, Acute	Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.		[ 375]
Dexrazoxane	N.A.	Leukemia, Myeloid, Acute	Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.		[ 375]
Idarubicin	N.A.	Leukemia, Myeloid, Acute	Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.		[ 375]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:       168 Drugs in Total
Methadone	Drug Info	Opioid-Related Disorders	Correlated with the decreased drug clearance in patients (compare with genotypes AC + Ct)		[ 591]
Rivaroxaban	Drug Info	Healthy Individuals	Correlated with the decreased drug exposure in healthy individuals (compare with genotypes AA + AC)		[ 347]
Dabigatran	Drug Info	Healthy Individuals	Correlated with the decreased drug exposure in healthy individuals (compare with genotypes AA + AC)		[ 347]
Verapamil	Drug Info	Healthy Individuals	Correlated with the decreased drug metabolism in healthy individuals (compare with genotypes AA + AC)		[ 363]
Cytarabine	Drug Info	Acute Multiple Myeloma	Correlated with the decreased survival in patients (compare with genotypes AA + AC)		[ 405]
Cyclosporine	Drug Info	Cystic Fibrosis	Correlated with the increased drug clearance in patients (compare with genotype AA)		[ 355]
Dicloxacillin	Drug Info	Cystic Fibrosis	Correlated with the increased drug clearance in patients (compare with genotype AA)		[ 355]
Digoxin	Drug Info	Congestive Cardiac Insufficiency; Arrhythmias; Heart Failure	Correlated with the increased drug metabolism (compare with genotype AA)		[ 396]
Temsirolimus	Drug Info	Urinary Bladder Neoplasm	Correlated with the increased drug metabolism in patients (compare with genotypes AA + AC)		[ 179]
Atorvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug response in patients (compare with genotype AA)		[ 394]
Pravastatin	Drug Info	Acute Coronary Syndrome	Correlated with the increased percent reduction in LDL-cholesterol in patients		[ 589]
Capecitabine	Drug Info	Colorectal Neoplasm	Correlated with the increased hand-foot syndrome risk in patients (compare with genotype AA)		[ 338]
Cytarabine	N.A.	Drug Toxicity	Genotype CC is associated with increased likelihood of 3 year event free survival when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute.		[ 375]
Idarubicin	N.A.	Drug Toxicity	Genotype CC is associated with increased likelihood of 3 year event free survival when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute.		[ 375]
Oseltamivir	N.A.	Somnolence	Genotype CC is associated with decreased likelihood of neuropsychiatric adverse events when treated with oseltamivir in children with Influenza, Human as compared to genotypes AT + TT.		[ 499]
Fluorouracil	N.A.	Diarrhea	Genotype CC is not associated with increased risk of Diarrhea, hand-foot syndrome and Neutropenia when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.		[ 338]
Fluorouracil	N.A.	Hand-foot Syndrome	Genotype CC is not associated with increased risk of Diarrhea, hand-foot syndrome and Neutropenia when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.		[ 338]
Fluorouracil	N.A.	Neutropenia	Genotype CC is not associated with increased risk of Diarrhea, hand-foot syndrome and Neutropenia when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.		[ 338]
Cyclosporine	N.A.	Neurotoxicity Syndromes	Genotype CC is not associated with risk of Neurotoxicity Syndromes when treated with cyclosporine in people with hematopoietic stem cell transplantation.		[ 548]
Temsirolimus	N.A.	Exanthema	Genotype CC is associated with increased metabolism of temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AC.		[ 179]
Capecitabine	N.A.	Hand-foot Syndrome	Genotype CC is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.		[ 338]
Tacrolimus	N.A.	Drug Toxicity	Genotype CC is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation.		[ 27]
Tacrolimus	N.A.	Transplant Rejection	Genotype CC is not associated with risk of transplant rejection when treated with tacrolimus in people with liver transplantation as compared to genotypes AA + AC.		[ 351]
Tacrolimus	N.A.	Neutropenia	Genotype CC is not associated with clearance of tacrolimus in people with Kidney Transplantation.		[ 534]
Verapamil	N.A.	Death	Genotype CC is associated with decreased metabolism of verapamil in healthy individuals as compared to genotypes AA + AC.		[ 363]
Digoxin	N.A.	Exanthema	Genotype CC is associated with increased metabolism of digoxin as compared to genotype AA.		[ 396]
Pravastatin	N.A.	Peripheral Nervous System Diseases	Genotype CC is associated with increased percent reduction in LDL-cholesterol when treated with pravastatin in people with Acute coronary syndrome.		[ 589]
Cytarabine	N.A.	Epistaxis	Genotype CC is associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AC.		[ 405]
Donepezil	N.A.	Adverse Events	Genotype CC is not associated with clearance of donepezil in people with Alzheimer Disease as compared to genotype AA.		[ 429]
Oxaliplatin	N.A.	Peripheral Nervous System Diseases	Genotype CC is not associated with increased likelihood of Peripheral Nervous System Diseases when treated with oxaliplatin or paclitaxel in people with Breast Neoplasms or Colorectal Neoplasms as compared to genotypes AA + AC.		[ 478]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Genotype CC is not associated with increased likelihood of Peripheral Nervous System Diseases when treated with oxaliplatin or paclitaxel in people with Breast Neoplasms or Colorectal Neoplasms as compared to genotypes AA + AC.		[ 478]
Morphine	N.A.	Nausea	Genotype CC is associated with decreased likelihood of Nausea and Vomiting due to morphine in people with Pain, Postoperative.		[ 420]
Morphine	N.A.	Vomiting	Genotype CC is associated with decreased likelihood of Nausea and Vomiting due to morphine in people with Pain, Postoperative.		[ 420]
Tacrolimus	N.A.	Adverse Events	Genotype CC is not associated with dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AC.		[ 351]
Aripiprazole	N.A.	Adverse Events	Genotype CC is associated with increased concentrations of aripiprazole and dehydroaripiprazole as compared to genotype AA.		[ 430]
Dehydroaripiprazole	N.A.	Adverse Events	Genotype CC is associated with increased concentrations of aripiprazole and dehydroaripiprazole as compared to genotype AA.		[ 430]
Fluorouracil	N.A.	Event-free Survival	Genotype CC is associated with overall survival when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes CT + TT.		[ 611]
Irinotecan	N.A.	Event-free Survival	Genotype CC is associated with overall survival when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes CT + TT.		[ 611]
Leucovorin	N.A.	Event-free Survival	Genotype CC is associated with overall survival when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes CT + TT.		[ 611]
Carboplatin	N.A.	Event-free Survival	Genotype CC is not associated with increased risk of sensoric neuropathy or neutropenia when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to genotypes CT + TT.		[ 298]
Paclitaxel	N.A.	Event-free Survival	Genotype CC is not associated with increased risk of sensoric neuropathy or neutropenia when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to genotypes CT + TT.		[ 298]
Methadone	N.A.	Acute Cellular Rejection	Genotype CC is associated with decreased clearance of methadone in people with Opioid-Related Disorders as compared to genotypes AC + CT.		[ 591]
Digoxin	N.A.	Neutropenia	Genotype CC is associated with increased clearance of digoxin in people with Heart Failure as compared to genotype AC.		[ 434]
Digoxin	N.A.	Drug Toxicity	Genotype CC is associated with increased clearance of digoxin in healthy individuals as compared to genotype AA.		[ 438]
Atorvastatin	N.A.	Transplant Rejection	Genotype CC is associated with increased response to atorvastatin as compared to genotype AA.		[ 394]
Ondansetron	N.A.	Vomiting	Genotype CC is associated with increased likelihood of Vomiting when treated with ondansetron in people with Leukemia, Myeloid, Acute.		[ 441]
Simvastatin	N.A.	Nephrotoxicity	Genotype CC is associated with decreased response to simvastatin in people with Hypercholesterolemia.		[ 3]
Platinum Compounds	N.A.	Diarrhea	Genotype CC is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.		[ 369]
Tacrolimus	N.A.	Gingival Overgrowth	Genotype CC is not associated with decreased dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AC.		[ 376]
Tacrolimus	N.A.	Hypersensitivity	Genotype CC is associated with increased dose of tacrolimus in people with Kidney Transplantation.		[ 313]
Axitinib	N.A.	Hypersensitivity	Genotype CC is not associated with metabolism of axitinib in healthy individuals.		[ 312]
Sunitinib	N.A.	Adverse Events	Genotype CC is associated with increased likelihood of adverse events, hand-foot syndrome and Hypertension when treated with sunitinib in people with Carcinoma, Renal Cell.		[ 621]
Sunitinib	N.A.	Hand-foot Syndrome	Genotype CC is associated with increased likelihood of adverse events, hand-foot syndrome and Hypertension when treated with sunitinib in people with Carcinoma, Renal Cell.		[ 621]
Sunitinib	N.A.	Hypertension	Genotype CC is associated with increased likelihood of adverse events, hand-foot syndrome and Hypertension when treated with sunitinib in people with Carcinoma, Renal Cell.		[ 621]
Platinum	N.A.	Hypertension	Genotype CC is associated with decreased risk of grade 3 or 4 gastrointestinal toxicity when treated with platinum and taxanes in people with Ovarian Neoplasms.		[ 588]
Taxanes	N.A.	Hypertension	Genotype CC is associated with decreased risk of grade 3 or 4 gastrointestinal toxicity when treated with platinum and taxanes in people with Ovarian Neoplasms.		[ 588]
Risperidone	N.A.	Peripheral Nervous System Diseases	Genotype CC is not associated with response to risperidone in people with Schizophrenia as compared to genotype AA.		[ 485]
Antipsychotics	N.A.	Overall Survival	Genotype CC is associated with increased dose of antipsychotics in people with Schizophrenia as compared to genotype AA.		[ 187]
Paclitaxel	N.A.	Drug Toxicity	Genotype CC is associated with decreased response to paclitaxel in women with Breast Neoplasms.		[ 378]
Amlodipine	N.A.	Major Adverse Cardiac Events (mace)	Genotype CC is associated with decreased clearance of amlodipine in healthy individuals as compared to genotypes AA + AC.		[ 445]
Gefitinib	N.A.	Hypertension	Genotype CC are not associated with concentrations of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.		[ 446]
Gefitinib	N.A.	Cardiotoxicity	Genotype CC is not associated with metabolism of gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AC + CT.		[ 447]
Galantamine	N.A.	Drug Toxicity	Genotype CC is not associated with dose-adjusted plasma levels of galantamine in people with Dementia as compared to genotypes AA + AC.		[ 451]
Methadone	N.A.	Pain	Genotype CC is associated with increased severity of Pain when treated with methadone in people with Opioid-Related Disorders as compared to genotype AT.		[ 220]
Risperidone	N.A.	Prolonged Qtc Interval	Genotype CC is not associated with electrocardiogram qt prolonged when treated with risperidone in people with Schizophrenia as compared to genotypes AC + CT.		[ 350]
Dabigatran	N.A.	Lymphopenia	Genotype CC is associated with decreased exposure to Dabigatran in healthy individuals as compared to genotypes AA + AC.		[ 347]
Venlafaxine	N.A.	Anemia	Genotype CC is not associated with response to venlafaxine in people with Narcolepsy as compared to genotypes AA + TT.		[ 345]
Rivaroxaban	N.A.	Anemia	Genotype CC is associated with decreased exposure to rivaroxaban in healthy individuals as compared to genotypes AA + AC.		[ 347]
Gefitinib	N.A.	Drug Toxicity	Genotype CC is not associated with risk of Drug Toxicity when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.		[ 446]
Methadone	N.A.	Pain	Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes AA + AC.		[ 218]
Cyclosporine	N.A.	Adverse Events	Genotype CC is associated with increased clearance of dicloxacillin when treated with cyclosporine and dicloxacillin as compared to genotype AA.		[ 355]
Dicloxacillin	N.A.	Adverse Events	Genotype CC is associated with increased clearance of dicloxacillin when treated with cyclosporine and dicloxacillin as compared to genotype AA.		[ 355]
Opioids	N.A.	Metabolic Syndrome	Genotype CC is not associated with dose of opioids in people with Pain.		[ 365]
Anthracyclines And Related Substances	N.A.	Adverse Events	Genotype CC is associated with increased risk of resistance when treated with anthracyclines and related substances in people with Breast Neoplasms as compared to genotype AC.		[ 378]
Lenalidomide	N.A.	Overall Survival	Genotype CC is associated with decreased overall survival when treated with lenalidomide in people with Lymphoma, Mantle-Cell as compared to genotypes AA + AC.		[ 586]
Ondansetron	N.A.	Postoperative Nausea And Vomiting	Genotype CC is associated with increased likelihood of Vomiting when treated with ondansetron in people with Leukemia, Myeloid, Acute.		[ 441]
Ondansetron	N.A.	Postoperative Nausea And Vomiting	Patients with the rs2032582 CC genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA, AC, AT, CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to ondansetron.		[ 235]
Ondansetron	N.A.	Vomiting	Patients with the rs2032582 CC genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA, AC, AT, CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to ondansetron.		[ 235]
Atorvastatin	N.A.	Hypercholesterolemia	Genotype CC is associated with increased response to atorvastatin as compared to genotype AA.		[ 394]
Sufentanil	N.A.	Pain, Postoperative	Patients with the rs2032582 CC genotype may have decreased dose requirements of sufentanil as compared to patients with the AA or AC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect dose requirements of sufentanil.		[ 117]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the CC genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CT or TT. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.		[ 638]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the CC genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CT or TT. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.		[ 638]
Ritonavir	N.A.	HIV Infectious Disease	Patients with the CC genotype who are treated with ritonavir may have a increased intracellular/plasma trough concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.		[ 97]
Atorvastatin	N.A.	Narcolepsy	Patients with the CC genotype may have increased risk of drug-induced liver injury compared to patients with the TT genotype. Other factors may affect liver toxicity when treated with atorvastatin.		[ 576]
Efavirenz	N.A.	HIV Infectious Disease	Patients with the CC genotype may have increased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the AA genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz		[ 4]
Fluoxetine	N.A.	Depressive Disorder	Patients with the CC genotype and Depressive Disorder may have decreased response to fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.		[ 178]
Carbamazepine	N.A.	Epilepsy	Patients with the CC genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have decreased risk for non-response as compared to patients with the TT genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid.		[ 61]
Phenytoin	N.A.	Epilepsy	Patients with the CC genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have decreased risk for non-response as compared to patients with the TT genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid.		[ 61]
Valproic Acid	N.A.	Epilepsy	Patients with the CC genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have decreased risk for non-response as compared to patients with the TT genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid.		[ 61]
Everolimus	N.A.	Breast Neoplasms	Patients with the CC genotype and breast cancer who are treated with everolimus may have decreased likelihood of Lymphopenia as compared to patients with the AA and AC genotypes. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.		[ 19]
Everolimus	N.A.	Lymphopenia	Patients with the CC genotype and breast cancer who are treated with everolimus may have decreased likelihood of Lymphopenia as compared to patients with the AA and AC genotypes. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.		[ 19]
Tramadol	N.A.	Fractures, Bone	Patients with the rs2032582 CC genotype may be less likely to respond to tramadol treatment as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Tramadol	N.A.	Pain	Patients with the rs2032582 CC genotype may be less likely to respond to tramadol treatment as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Tramadol	N.A.	Pain, Postoperative	Patients with the rs2032582 CC genotype may be less likely to respond to tramadol treatment as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.		[ 157]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the CC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.		[ 3]
Simvastatin	N.A.	Myalgia	Patients with the CC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.		[ 3]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the CC genotype who are treated with simvastatin may have a reduced response (as measured by lower reductions in total cholesterol) as compared to patients with the AC, AA, TT or AT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.		[ 256]
Methylphenidate	N.A.	Attention Deficit Disorder With Hyperactivity	Patients with the CC genotype and attention deficit disorder with hyperactivity who are treated with methylphenidate may have lower adverse drug reaction scores (ADR scores using Barkley Stimulant Side Effect Rating Scale (BSSERS)) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.		[ 587]
Tramadol	N.A.	Vomiting	Patients with the CC genotype may have a decreased exposure to tramadol as compared to patients with the AA genotype. However, another study found no association between this variant and exposure to tramadol. Other genetic and clinical factors may also influence a patient's exposure to tramadol.		[ 251]
Antiepileptics	N.A.	Epilepsy	Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics.		[ 200]
Dexamethasone	N.A.	Multiple Myeloma	Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.		[ 354]
Doxorubicin	N.A.	Multiple Myeloma	Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.		[ 354]
Vincristine	N.A.	Multiple Myeloma	Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.		[ 354]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the CC genotype may have increased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of doxorubicin.		[ 316]
Digoxin	N.A.	Breast Neoplasms	Patients with genotype CC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.		[ 13]
Platinum Compounds	N.A.	Ovarian Neoplasms	Genotype CC is associated with decreased risk of grade 3 or 4 gastrointestinal toxicity when treated with platinum and taxanes in people with Ovarian Neoplasms.		[ 588]
Taxanes	N.A.	Ovarian Neoplasms	Genotype CC is associated with decreased risk of grade 3 or 4 gastrointestinal toxicity when treated with platinum and taxanes in people with Ovarian Neoplasms.		[ 588]
Cyclosporine	N.A.	Ulcerative Colitis	Patients with the CC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.		[ 154]
Antiepileptics	N.A.	Epilepsy	Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.		[ 159]
Carbamazepine	N.A.	Epilepsy	Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.		[ 159]
Antipsychotics	N.A.	Schizophrenia	Genotype CC is associated with increased dose of antipsychotics in people with Schizophrenia as compared to genotype AA.		[ 187]
Tacrolimus	N.A.	Kidney Transplantation	Genotype CC is not associated with decreased dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AC.		[ 376]
Tacrolimus	N.A.	Liver Transplantation	Genotype CC is not associated with decreased dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AC.		[ 376]
Tacrolimus	N.A.	Kidney Transplantation	Genotype CC is not associated with dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AC.		[ 351]
Tacrolimus	N.A.	Liver Transplantation	Genotype CC is not associated with dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AC.		[ 351]
Tacrolimus	N.A.	Kidney Transplantation	Genotype CC is not associated with clearance of tacrolimus in people with Kidney Transplantation.		[ 534]
Tacrolimus	N.A.	Liver Transplantation	Genotype CC is not associated with clearance of tacrolimus in people with Kidney Transplantation.		[ 534]
Tacrolimus	N.A.	Kidney Transplantation	Genotype CC is associated with increased dose of tacrolimus in people with Kidney Transplantation.		[ 313]
Tacrolimus	N.A.	Liver Transplantation	Genotype CC is associated with increased dose of tacrolimus in people with Kidney Transplantation.		[ 313]
Tacrolimus	N.A.	Kidney Transplantation	Genotype CC is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation.		[ 27]
Tacrolimus	N.A.	Liver Transplantation	Genotype CC is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation.		[ 27]
Cyclosporine	N.A.	Cystic Fibrosis	Genotype CC is associated with increased clearance of dicloxacillin when treated with cyclosporine and dicloxacillin as compared to genotype AA.		[ 355]
Dicloxacillin	N.A.	Cystic Fibrosis	Genotype CC is associated with increased clearance of dicloxacillin when treated with cyclosporine and dicloxacillin as compared to genotype AA.		[ 355]
Cyclosporine	N.A.	Kidney Transplantation	Patients with the CC genotype may have a decreased, but not absent, risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		[ 567]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Patients with the CC genotype may have a decreased, but not absent, risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		[ 567]
Capecitabine	N.A.	Colorectal Neoplasms	Genotype CC is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.		[ 338]
Clomipramine	N.A.	Depression	Patients with the CC genotype and depression may have a decreased, but not absent, risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.		[ 568]
Lithium	N.A.	Depression	Patients with the CC genotype and depression may have a decreased, but not absent, risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.		[ 568]
Nefazodone	N.A.	Depression	Patients with the CC genotype and depression may have a decreased, but not absent, risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.		[ 568]
Paroxetine	N.A.	Depression	Patients with the CC genotype and depression may have a decreased, but not absent, risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.		[ 568]
Venlafaxine	N.A.	Depression	Patients with the CC genotype and depression may have a decreased, but not absent, risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.		[ 568]
Sirolimus	N.A.	Hematopoietic Stem Cell Transplantation	Genotype CC is associated with increased metabolism of temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AC.		[ 179]
Sirolimus	N.A.	Kidney Transplantation	Genotype CC is associated with increased metabolism of temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AC.		[ 179]
Sirolimus	N.A.	Urinary Bladder Neoplasms	Genotype CC is associated with increased metabolism of temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AC.		[ 179]
Temsirolimus	N.A.	Hematopoietic Stem Cell Transplantation	Genotype CC is associated with increased metabolism of temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AC.		[ 179]
Temsirolimus	N.A.	Kidney Transplantation	Genotype CC is associated with increased metabolism of temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AC.		[ 179]
Temsirolimus	N.A.	Urinary Bladder Neoplasms	Genotype CC is associated with increased metabolism of temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AC.		[ 179]
Fentanyl	N.A.	Hypoventilation	Patients with the CC genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Fentanyl	N.A.	Pain, Postoperative	Patients with the CC genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Tacrolimus	N.A.	Ulcerative Colitis	Patients with CC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus.		[ 311]
Paclitaxel	N.A.	Breast Neoplasms	Genotype CC is associated with decreased response to paclitaxel in women with Breast Neoplasms.		[ 378]
Paclitaxel	N.A.	Ovarian Neoplasms	Genotype CC is associated with decreased response to paclitaxel in women with Breast Neoplasms.		[ 378]
Paclitaxel	N.A.	Breast Neoplasms	Patients with the CC genotype may have decreased response to paclitaxel as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.		[ 582]
Paclitaxel	N.A.	Ovarian Neoplasms	Patients with the CC genotype may have decreased response to paclitaxel as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.		[ 582]
Fentanyl	N.A.	Neoplasms	Patients with the CC genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.		[ 195]
Fentanyl	N.A.	Pain	Patients with the CC genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.		[ 195]
Cyclosporine	N.A.	Pain	Patients with the CC genotype may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.		[ 23]
Methadone	N.A.	Opioid-related Disorders	Genotype CC is associated with decreased clearance of methadone in people with Opioid-Related Disorders as compared to genotypes AC + CT.		[ 591]
Methadone	N.A.	Opioid-related Disorders	Patients with the rs2032582 CC genotype may have decreased clearance of methadone compared to patients with the AA, AC, AT, CT or TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.		[ 274]
Sunitinib	N.A.	Neutropenia	Genotype CC is associated with increased likelihood of adverse events, hand-foot syndrome and Hypertension when treated with sunitinib in people with Carcinoma, Renal Cell.		[ 621]
Sunitinib	N.A.	Renal Cell Carcinoma	Genotype CC is associated with increased likelihood of adverse events, hand-foot syndrome and Hypertension when treated with sunitinib in people with Carcinoma, Renal Cell.		[ 621]
Sunitinib	N.A.	Neutropenia	Patients with renal cell carcinoma and the CC genotypes may have an INCREASED risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the AA, AC, AT, CT, or TT genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.		[ 237]
Sunitinib	N.A.	Renal Cell Carcinoma	Patients with renal cell carcinoma and the CC genotypes may have an INCREASED risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the AA, AC, AT, CT, or TT genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.		[ 237]
Tacrolimus	N.A.	Nephrotic Syndrome	Patients with the CC genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.		[ 541]
Modafinil	N.A.	Narcolepsy	Patients with the CC genotype and narcolepsy may have a decreased response to modafinil as compared to patients with the AC or CT genotypes. Other genetic and clinical factors may also influence a patient's response to modafinil.		[ 345]
Anastrozole	N.A.	Breast Neoplasms	Postmenopausal women with HR+ breast cancer and the CC genotype may have decreased plasma concentrations of anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.		[ 234]
Atazanavir	N.A.	HIV Infectious Disease	Patients with the CC genotype who are administered atazanavir may have decreased risk of hyperbilirubinemia as compared to patients with the AA, AT, TT, AC, or CT genotypes. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.		[ 102]
Pravastatin	N.A.	Acute Coronary Syndrome	Genotype CC is associated with increased percent reduction in LDL-cholesterol when treated with pravastatin in people with Acute coronary syndrome.		[ 589]
Pravastatin	N.A.	Hyperlipoproteinemia Type Ii	Genotype CC is associated with increased percent reduction in LDL-cholesterol when treated with pravastatin in people with Acute coronary syndrome.		[ 589]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Genotype CC is associated with increased likelihood of complete remission when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute.		[ 375]
Daunorubicin	N.A.	Leukemia, Myeloid, Acute	Genotype CC is associated with increased likelihood of complete remission when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute.		[ 375]
Dexrazoxane	N.A.	Leukemia, Myeloid, Acute	Genotype CC is associated with increased likelihood of complete remission when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute.		[ 375]
Idarubicin	N.A.	Leukemia, Myeloid, Acute	Genotype CC is associated with increased likelihood of complete remission when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute.		[ 375]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Genotype CC is associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AC.		[ 405]
Daunorubicin	N.A.	Leukemia, Myeloid, Acute	Genotype CC is associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AC.		[ 405]
Dexrazoxane	N.A.	Leukemia, Myeloid, Acute	Genotype CC is associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AC.		[ 405]
Idarubicin	N.A.	Leukemia, Myeloid, Acute	Genotype CC is associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AC.		[ 405]
Anthracyclines	N.A.	Breast Neoplasm	Correlated with the increased drug resistance risk in patients (compare with genotype AC)		[ 378]
Genotypes AA + AC	Click to Show/Hide the Full List of Affected Drugs:         25 Drugs in Total
Atorvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug response in patients (compare with genotype CC)		[ 595]
Cytarabine	Drug Info	Acute Myeloid Leukemia	Irrelevant to the increased overall survival in patients (compare with genotype CC)		[ 460]
Rivaroxaban	N.A.	Epistaxis	Genotypes AA + AC is associated with increased likelihood of Epistaxis rivaroxaban in people with Atrial Fibrillation as compared to genotype CC.		[ 510]
Sunitinib	N.A.	Hand-foot Syndrome	Genotypes AA + AC is associated with increased likelihood of hand-foot syndrome when treated with sunitinib in people with Carcinoma, Renal Cell or Gastrointestinal Stromal Tumors as compared to genotype CC.		[ 562]
Proton Pump Inhibitors	N.A.	Mucositis	Genotypes AA + AC is associated with increased response to Proton pump inhibitors in people with eosinophilic esophagitis as compared to genotypes CC + CT.		[ 599]
Methadone	N.A.	Nausea	Genotypes AA + AC are not associated with decreased likelihood of treatment with methadone or morphine in infants with Neonatal Abstinence Syndrome as compared to genotype CC.		[ 483]
Morphine	N.A.	Nausea	Genotypes AA + AC are not associated with decreased likelihood of treatment with methadone or morphine in infants with Neonatal Abstinence Syndrome as compared to genotype CC.		[ 483]
Tacrolimus	N.A.	Renal Transplant Failure	Genotypes AA + AC is not associated with risk of renal transplant failure when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.		[ 456]
Atorvastatin	N.A.	Hypertension	Genotypes AA + AC are associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype CC.		[ 595]
Sufentanil	N.A.	Hypertension	Genotypes AA + AC are associated with increased dose of sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to genotype CC.		[ 117]
Everolimus	N.A.	Weight Gain	Genotypes AA + AC are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype CC.		[ 19]
Cytarabine	N.A.	Overall Survival	Genotypes AA + AC is associated with increased overall survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 460]
Dexamethasone	N.A.	Eye Diseases	Genotypes AA + AC are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype CC.		[ 354]
Doxorubicin	N.A.	Eye Diseases	Genotypes AA + AC are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype CC.		[ 354]
Vincristine	N.A.	Eye Diseases	Genotypes AA + AC are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype CC.		[ 354]
Carbamazepine	N.A.	Chronic Kidney Failure	Genotypes AA + AC is associated with decreased clinical benefit to carbamazepine in people with Epilepsy as compared to genotype CC.		[ 492]
Atorvastatin	N.A.	Hypercholesterolemia	Genotypes AA + AC are associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype CC.		[ 595]
Sufentanil	N.A.	Pain, Postoperative	Genotypes AA + AC are associated with increased dose of sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to genotype CC.		[ 117]
Dexamethasone	N.A.	Multiple Myeloma	Genotypes AA + AC are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype CC.		[ 354]
Doxorubicin	N.A.	Multiple Myeloma	Genotypes AA + AC are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype CC.		[ 354]
Vincristine	N.A.	Multiple Myeloma	Genotypes AA + AC are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype CC.		[ 354]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Genotypes AA + AC is associated with increased overall survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 460]
Daunorubicin	N.A.	Leukemia, Myeloid, Acute	Genotypes AA + AC is associated with increased overall survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 460]
Dexrazoxane	N.A.	Leukemia, Myeloid, Acute	Genotypes AA + AC is associated with increased overall survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 460]
Idarubicin	N.A.	Leukemia, Myeloid, Acute	Genotypes AA + AC is associated with increased overall survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype CC.		[ 460]
Genotypes AA + AT	Click to Show/Hide the Full List of Affected Drugs:         17 Drugs in Total
Sunitinib	Drug Info	Renal Cell Carcinoma	Correlated with the decreased overall survival in patients (compare with genotypes AC + CC)		[ 543]
Paclitaxel	Drug Info	Ovarian Neoplasm	Correlated with the increased drug response in patients (compare with genotypes AC + CC)		[ 582]
Tramadol	N.A.	Gastrointestinal Toxicity	Genotypes AA + AT are not associated with response to tramadol in people with Pain, Postoperative as compared to genotype CC.		[ 221]
Aripiprazole	N.A.	Opioid-related Disorders	Genotypes AA + AT is not associated with concentrations of aripiprazole in healthy individuals as compared to genotype CC.		[ 192]
Amitriptyline	N.A.	Event-free Survival	Genotypes AA + AT are not associated with increased risk of side effects when treated with amitriptyline in people with Depression as compared to genotype CC.		[ 601]
Digoxin	N.A.	Neutropenia	Genotypes AA + AT are associated with decreased clearance of digoxin in people with Heart Failure as compared to genotype AC.		[ 434]
Sunitinib	N.A.	Overall Survival	Genotypes AA + AT is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AC + CC.		[ 543]
Paclitaxel	N.A.	Drug Toxicity	Genotypes AA + AT are associated with increased response to paclitaxel in women with Ovarian Neoplasms as compared to genotypes AC + CC.		[ 582]
Abemaciclib	N.A.	Discontinuation	Genotypes AA + AT is associated with increased likelihood of discontinuation or dose reduction when treated with abemaciclib in women with Breast Neoplasms as compared to genotypes CC + CT.		[ 603]
Abemaciclib	N.A.	Dose Reduction	Genotypes AA + AT is associated with increased likelihood of discontinuation or dose reduction when treated with abemaciclib in women with Breast Neoplasms as compared to genotypes CC + CT.		[ 603]
Sunitinib	N.A.	Postoperative Nausea And Vomiting	Genotypes AA + AT is associated with increased dose of sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AC + CC.		[ 543]
Tramadol	N.A.	Fractures, Bone	Genotypes AA + AT are not associated with response to tramadol in people with Pain, Postoperative as compared to genotype CC.		[ 221]
Tramadol	N.A.	Pain	Genotypes AA + AT are not associated with response to tramadol in people with Pain, Postoperative as compared to genotype CC.		[ 221]
Tramadol	N.A.	Pain, Postoperative	Genotypes AA + AT are not associated with response to tramadol in people with Pain, Postoperative as compared to genotype CC.		[ 221]
Paclitaxel	N.A.	Breast Neoplasms	Genotypes AA + AT are associated with increased response to paclitaxel in women with Ovarian Neoplasms as compared to genotypes AC + CC.		[ 582]
Paclitaxel	N.A.	Ovarian Neoplasms	Genotypes AA + AT are associated with increased response to paclitaxel in women with Ovarian Neoplasms as compared to genotypes AC + CC.		[ 582]
Sunitinib	N.A.	Renal Cell Carcinoma	Genotypes AA + AT is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AC + CC.		[ 543]
Genotypes AA + TT	Click to Show/Hide the Full List of Affected Drugs:         12 Drugs in Total
Tacrolimus	Drug Info	Nephrotic Syndrome	Correlated with the increased drug response in patients (compare with genotypes CC + CT)		[ 541]
Cyclophosphamide	N.A.	Neutropenia	Genotypes AA + TT are associated with increased risk of Neutropenia when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to genotype CC.		[ 471]
Doxorubicin	N.A.	Neutropenia	Genotypes AA + TT are associated with increased risk of Neutropenia when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to genotype CC.		[ 471]
Tacrolimus	N.A.	Transplant Rejection	Genotypes AA + TT is associated with increased response to tacrolimus in people with Nephrotic Syndrome as compared to genotypes CC + CT.		[ 541]
Cisplatin	N.A.	Drug Toxicity	Genotypes AA + TT are not associated with prognosis when treated with cisplatin, fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 337]
Fluorouracil	N.A.	Drug Toxicity	Genotypes AA + TT are not associated with prognosis when treated with cisplatin, fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 337]
Leucovorin	N.A.	Drug Toxicity	Genotypes AA + TT are not associated with prognosis when treated with cisplatin, fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 337]
Oxaliplatin	N.A.	Drug Toxicity	Genotypes AA + TT are not associated with prognosis when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype CC.		[ 337]
Tacrolimus	N.A.	Prolonged Qtc Interval	Genotypes AA + TT is associated with decreased clearance of tacrolimus in children with liver transplantation.		[ 602]
Tacrolimus	N.A.	Kidney Transplantation	Genotypes AA + TT is associated with decreased clearance of tacrolimus in children with liver transplantation.		[ 602]
Tacrolimus	N.A.	Liver Transplantation	Genotypes AA + TT is associated with decreased clearance of tacrolimus in children with liver transplantation.		[ 602]
Tacrolimus	N.A.	Nephrotic Syndrome	Genotypes AA + TT is associated with increased response to tacrolimus in people with Nephrotic Syndrome as compared to genotypes CC + CT.		[ 541]
Genotypes AC + CC	Click to Show/Hide the Full List of Affected Drugs:         15 Drugs in Total
Cyclosporine	Drug Info	Kidney Transplantation	Correlated with the decreased drug dose-adjusted trough concentrations as in patients (compare with genotypes AA + Ct); Correlated with the increased drug dose in patients (compare with genotypes AA + Ct)		[ 600]
Ritonavir	Drug Info	HIV Infection	Correlated with the drug concentrations in patients (compare with genotype AA)		[ 601]
Tacrolimus	Drug Info	Kidney Transplantation	Correlated with the increased drug dose-adjusted trough concentrations in patients (compare with genotype AA)		[ 229]
Fentanyl	Drug Info	Neoplasm	Correlated with the increased likelihood of constipation in patients (compare with genotype AA)		[ 195]
Cyclosporine	N.A.	Death	Genotypes AC + CC is associated with increased dose of cyclosporine in people with Kidney Transplantation as compared to genotypes AA + CT.		[ 600]
Tacrolimus	N.A.	Acute Cellular Rejection	Genotypes AC + CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA.		[ 229]
Ritonavir	N.A.	Neurotoxicity Syndromes	Genotypes AC + CC is associated with concentrations of ritonavir in people with HIV Infections as compared to genotype AA.		[ 601]
Methadone	N.A.	Neonatal Abstinence Syndrome	Genotypes AC + CC are not associated with severity of Neonatal Abstinence Syndrome due to methadone in infants as compared to genotype AA.		[ 506]
Atazanavir	N.A.	Statin-related Myopathy	Genotypes AC + CC is associated with decreased clearance of atazanavir in healthy individuals as compared to genotype AA.		[ 509]
Fentanyl	N.A.	Constipation	Genotypes AC + CC are associated with increased likelihood of Constipation due to fentanyl in people with Neoplasms and Pain as compared to genotype AA.		[ 195]
Ritonavir	N.A.	HIV Infectious Disease	Genotypes AC + CC is associated with concentrations of ritonavir in people with HIV Infections as compared to genotype AA.		[ 601]
Tacrolimus	N.A.	Kidney Transplantation	Genotypes AC + CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA.		[ 229]
Tacrolimus	N.A.	Liver Transplantation	Genotypes AC + CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA.		[ 229]
Fentanyl	N.A.	Neoplasms	Genotypes AC + CC are associated with increased likelihood of Constipation due to fentanyl in people with Neoplasms and Pain as compared to genotype AA.		[ 195]
Fentanyl	N.A.	Pain	Genotypes AC + CC are associated with increased likelihood of Constipation due to fentanyl in people with Neoplasms and Pain as compared to genotype AA.		[ 195]
Genotypes AC + CT	Click to Show/Hide the Full List of Affected Drugs:         19 Drugs in Total
Tacrolimus	Drug Info	Kidney Transplantation	Correlated with the increased drug trough concentrations in patients (compare with genotype CC)		[ 551]
Modafinil	Drug Info	Narcolepsy	Correlated with the increased drug response in patients (compare with genotype CC)		[ 345]
Cyclophosphamide	N.A.	Neutropenia	Genotypes AC + CT are associated with increased risk of Neutropenia when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to genotype CC.		[ 471]
Doxorubicin	N.A.	Neutropenia	Genotypes AC + CT are associated with increased risk of Neutropenia when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to genotype CC.		[ 471]
Tramadol	N.A.	Gastrointestinal Toxicity	Genotypes AC + CT are not associated with response to tramadol in people with Pain, Postoperative as compared to genotype CC.		[ 221]
Tacrolimus	N.A.	Diarrhea	Genotypes AC + CT is associated with increased trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.		[ 551]
Mycophenolate Mofetil	N.A.	Diarrhea	Genotypes AC + CT are not associated with increased risk of Diarrhea when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype CC.		[ 132]
Cisplatin	N.A.	Drug Toxicity	Genotypes AC + CT are not associated with prognosis when treated with cisplatin, fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 337]
Fluorouracil	N.A.	Drug Toxicity	Genotypes AC + CT are not associated with prognosis when treated with cisplatin, fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 337]
Leucovorin	N.A.	Drug Toxicity	Genotypes AC + CT are not associated with prognosis when treated with cisplatin, fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 337]
Oxaliplatin	N.A.	Drug Toxicity	Genotypes AC + CT are not associated with prognosis when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype CC.		[ 337]
Mycophenolate Mofetil	N.A.	Leukopenia	Genotypes AC + CT are not associated with increased risk of Leukopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype CC.		[ 132]
Modafinil	N.A.	Anemia	Genotypes AC + CT is associated with increased response to modafinil in people with Narcolepsy as compared to genotype CC.		[ 345]
Tramadol	N.A.	Fractures, Bone	Genotypes AC + CT are not associated with response to tramadol in people with Pain, Postoperative as compared to genotype CC.		[ 221]
Tramadol	N.A.	Pain	Genotypes AC + CT are not associated with response to tramadol in people with Pain, Postoperative as compared to genotype CC.		[ 221]
Tramadol	N.A.	Pain, Postoperative	Genotypes AC + CT are not associated with response to tramadol in people with Pain, Postoperative as compared to genotype CC.		[ 221]
Tacrolimus	N.A.	Kidney Transplantation	Genotypes AC + CT is associated with increased trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.		[ 551]
Tacrolimus	N.A.	Liver Transplantation	Genotypes AC + CT is associated with increased trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.		[ 551]
Modafinil	N.A.	Narcolepsy	Genotypes AC + CT is associated with increased response to modafinil in people with Narcolepsy as compared to genotype CC.		[ 345]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:         10 Drugs in Total
Fentanyl	Drug Info	Neoplasm	Correlated with the increased likelihood of constipation in patients (compare with Genotype TT)		[ 195]
Tacrolimus	Drug Info	Kidney Transplantation	Irrelevant to the drug metabolism in patients (compare with genotypes AC + At)		[ 165]
Tacrolimus	N.A.	Thromboembolism	Genotypes CC + CT is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes AC + AT.		[ 165]
Cyclosporine	N.A.	Transplant Rejection	Genotypes CC + CT is not associated with risk of transplant rejection when treated with cyclosporine in people with Kidney Transplantation as compared to genotypes AA + AC.		[ 600]
Paroxetine	N.A.	Peripheral Nervous System Diseases	Genotypes CC + CT are associated with decreased response to paroxetine in people with Depression as compared to genotypes AA + AT.		[ 605]
Fentanyl	N.A.	Constipation	Genotypes CC + CT are associated with increased likelihood of Constipation due to fentanyl in people with Neoplasms and Pain as compared to genotype TT.		[ 195]
Tacrolimus	N.A.	Kidney Transplantation	Genotypes CC + CT is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes AC + AT.		[ 165]
Tacrolimus	N.A.	Liver Transplantation	Genotypes CC + CT is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes AC + AT.		[ 165]
Fentanyl	N.A.	Neoplasms	Genotypes CC + CT are associated with increased likelihood of Constipation due to fentanyl in people with Neoplasms and Pain as compared to genotype TT.		[ 195]
Fentanyl	N.A.	Pain	Genotypes CC + CT are associated with increased likelihood of Constipation due to fentanyl in people with Neoplasms and Pain as compared to genotype TT.		[ 195]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Doxorubicin	Drug Info	Breast Neoplasm	Correlated with the decreased survival in patients(compare with Genotypes AC + CC)		[ 594]
Cyclophosphamide	Drug Info	Breast Neoplasm	Correlated with the decreased survival in patients(compare with Genotypes AC + CC)		[ 594]
Iguratimod	N.A.	Peripheral Nervous System Diseases	Genotypes CT + TT is associated with increased clinical benefit to iguratimod in people with Arthritis, Rheumatoid as compared to genotype CC.		[ 604]
Cyclophosphamide	N.A.	Adverse Events	Genotypes CT + TT are associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes AC + CC.		[ 594]
Doxorubicin	N.A.	Adverse Events	Genotypes CT + TT are associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes AC + CC.		[ 594]
Rivaroxaban	N.A.	Thromboembolism	Genotypes CT + TT are not associated with decreased risk of Thromboembolism when treated with rivaroxaban as compared to genotype CC.		[ 361]
Cyclophosphamide	N.A.	Breast Neoplasms	Genotypes CT + TT are associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes AC + CC.		[ 594]
Doxorubicin	N.A.	Breast Neoplasms	Genotypes CT + TT are associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes AC + CC.		[ 594]
Genotypes AT + CT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Efavirenz	Drug Info	HIV Infection	Irrelevant to the increased drug plasma exposure in patients (compare with genotypes CC + CT)		[ 4]
Nelfinavir	N.A.	Chronic Kidney Failure	Genotypes AT + CT are not associated with increased plamsa exposure of nelfinavir in people with HIV Infections as compared to genotypes CC + CT.		[ 4]
Efavirenz	N.A.	Hemorrhage	Genotypes AT + CT are not associated with increased plasma exposure of efavirenz in people with HIV Infections as compared to genotypes CC + CT.		[ 4]
Efavirenz	N.A.	HIV Infectious Disease	Genotypes AT + CT are not associated with increased plasma exposure of efavirenz in people with HIV Infections as compared to genotypes CC + CT.		[ 4]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:         34 Drugs in Total
Paclitaxel	N.A.	Neutropenia	Genotype CT is associated with increased metabolism of paclitaxel in people with Ovarian Neoplasms.		[ 604]
Efavirenz	N.A.	Pain, Postoperative	Genotype CT is not associated with exposure to efavirenz in healthy individuals as compared to genotype CC.		[ 113]
Oseltamivir	N.A.	Depression	Genotype CT is not associated with Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype CC.		[ 359]
Oseltamivir	N.A.	Gastritis	Genotype CT is not associated with Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype CC.		[ 359]
Oseltamivir	N.A.	Hypersensitivity	Genotype CT is not associated with Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype CC.		[ 359]
Ondansetron	N.A.	Postoperative Nausea And Vomiting	Patients with the rs2032582 CT genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.		[ 235]
Ondansetron	N.A.	Vomiting	Patients with the rs2032582 CT genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.		[ 235]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the CT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.		[ 594]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the CT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.		[ 594]
Atorvastatin	N.A.	Narcolepsy	Patients with the CT genotype may have increased risk of drug-induced liver injury compared to patients with the TT genotype. Other factors may affect liver toxicity when treated with atorvastatin.		[ 576]
Carbamazepine	N.A.	Epilepsy	Patients with the CT genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for non-response as compared to patients with the CC genotype or may have decreased risk for non-response as compared to patients with the TT genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid.		[ 61]
Phenytoin	N.A.	Epilepsy	Patients with the CT genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for non-response as compared to patients with the CC genotype or may have decreased risk for non-response as compared to patients with the TT genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid.		[ 61]
Valproic Acid	N.A.	Epilepsy	Patients with the CT genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for non-response as compared to patients with the CC genotype or may have decreased risk for non-response as compared to patients with the TT genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid.		[ 61]
Dabigatran	N.A.	Transplantation	People with the CT genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.		[ 347]
Rivaroxaban	N.A.	Transplantation	People with the CT genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.		[ 347]
Platinum Compounds	N.A.	Ovarian Neoplasms	Patients with the CT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.		[ 588]
Taxanes	N.A.	Ovarian Neoplasms	Patients with the CT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.		[ 588]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the CT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.		[ 376]
Tacrolimus	N.A.	Liver Transplantation	Patients with the CT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.		[ 376]
Fentanyl	N.A.	Hypoventilation	Patients with the CT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Fentanyl	N.A.	Pain, Postoperative	Patients with the CT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Paclitaxel	N.A.	Breast Neoplasms	Patients with the CA or CT genotype may have increased response to paclitaxel as compared to the CC genotype, but decreased response as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.		[ 582]
Paclitaxel	N.A.	Ovarian Neoplasms	Patients with the CA or CT genotype may have increased response to paclitaxel as compared to the CC genotype, but decreased response as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.		[ 582]
Fentanyl	N.A.	Neoplasms	Patients with the CT genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.		[ 195]
Fentanyl	N.A.	Pain	Patients with the CT genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.		[ 195]
Cyclosporine	N.A.	Pain	Patients with the CT genotype may have higher blood trough concentrations of cyclosporine compared to patients with the AC and CC genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.		[ 23]
Methadone	N.A.	Opioid-related Disorders	Patients with the rs2032582 CT genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.		[ 274]
Sunitinib	N.A.	Neutropenia	Patients with renal cell carcinoma and the CT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.		[ 237]
Sunitinib	N.A.	Renal Cell Carcinoma	Patients with renal cell carcinoma and the CT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.		[ 237]
Tacrolimus	N.A.	Nephrotic Syndrome	Patients with the CT genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.		[ 541]
Modafinil	N.A.	Narcolepsy	Patients with the CT genotype and narcolepsy may have an increased response to modafinil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to modafinil.		[ 345]
Atazanavir	N.A.	HIV Infectious Disease	Patients with the CT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.		[ 102]
Pravastatin	N.A.	Acute Coronary Syndrome	Patients with the rs2032582 CT genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype, or may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA, AT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.		[ 589]
Pravastatin	N.A.	Hyperlipoproteinemia Type Ii	Patients with the rs2032582 CT genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype, or may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA, AT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.		[ 589]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:         41 Drugs in Total
Granisetron	N.A.	Mucositis	Genotype TT is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes CT + TT.		[ 266]
Palonosetron	N.A.	Mucositis	Genotype TT is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes CT + TT.		[ 266]
Tacrolimus	N.A.	Neutropenia	Genotype TT is not associated with concentrations of tacrolimus in children with liver transplantation.		[ 257]
Ondansetron	N.A.	Postoperative Nausea And Vomiting	Patients with the rs2032582 TT genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.		[ 235]
Ondansetron	N.A.	Vomiting	Patients with the rs2032582 TT genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.		[ 235]
Atorvastatin	N.A.	Hypercholesterolemia	Patients with the rs2032582 TT genotype who are treated with atorvastatin may have a increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment.		[ 394]
Cyclophosphamide	N.A.	Breast Neoplasms	Patients with the TT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.		[ 594]
Doxorubicin	N.A.	Breast Neoplasms	Patients with the TT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.		[ 594]
Atorvastatin	N.A.	Narcolepsy	Patients with the TT genotype may have decreased risk of drug-induced liver injury compared to patients with the CC genotype. Other factors may affect liver toxicity when treated with atorvastatin.		[ 576]
Clopidogrel	N.A.	Coronary Artery Disease	Patients with the TT genotype and stable coronary artery disease who are treated with clopidogrel may have Increased risk of of hemorrhage as compared to patients with the AT or AA genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with stable coronary artery disease who are treated with clopidogrel.		[ 580]
Carbamazepine	N.A.	Epilepsy	Patients with the TT genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for non-response as compared to patients with the CC genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid.		[ 61]
Phenytoin	N.A.	Epilepsy	Patients with the TT genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for non-response as compared to patients with the CC genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid.		[ 61]
Valproic Acid	N.A.	Epilepsy	Patients with the TT genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for non-response as compared to patients with the CC genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid.		[ 61]
Dabigatran	N.A.	Transplantation	People with the TT genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.		[ 347]
Rivaroxaban	N.A.	Transplantation	People with the TT genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.		[ 347]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the TT genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.		[ 3]
Simvastatin	N.A.	Myalgia	Patients with the TT genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.		[ 3]
Simvastatin	N.A.	Hypercholesterolemia	Patients with the TT genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.		[ 256]
Platinum Compounds	N.A.	Ovarian Neoplasms	Patients with the TT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.		[ 588]
Taxanes	N.A.	Ovarian Neoplasms	Patients with the TT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.		[ 588]
Tacrolimus	N.A.	Kidney Transplantation	Genotype TT is not associated with concentrations of tacrolimus in children with liver transplantation.		[ 257]
Tacrolimus	N.A.	Liver Transplantation	Genotype TT is not associated with concentrations of tacrolimus in children with liver transplantation.		[ 257]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the TT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.		[ 376]
Tacrolimus	N.A.	Liver Transplantation	Patients with the TT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.		[ 376]
Fentanyl	N.A.	Hypoventilation	Patients with the TT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Fentanyl	N.A.	Pain, Postoperative	Patients with the TT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.		[ 254]
Paclitaxel	N.A.	Breast Neoplasms	Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.		[ 582]
Paclitaxel	N.A.	Ovarian Neoplasms	Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.		[ 582]
Fentanyl	N.A.	Neoplasms	Patients with the TT genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.		[ 195]
Fentanyl	N.A.	Pain	Patients with the TT genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.		[ 195]
Methadone	N.A.	Opioid-related Disorders	Patients with the rs2032582 TT genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.		[ 274]
Sunitinib	N.A.	Neutropenia	Patients with renal cell carcinoma and the TT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.		[ 237]
Sunitinib	N.A.	Renal Cell Carcinoma	Patients with renal cell carcinoma and the TT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.		[ 237]
Tacrolimus	N.A.	Nephrotic Syndrome	Patients with the TT genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the CC, CT or AC genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.		[ 541]
Atazanavir	N.A.	HIV Infectious Disease	Patients with the TT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.		[ 102]
Pravastatin	N.A.	Acute Coronary Syndrome	Patients with the rs2032582 TT genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the AC, CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.		[ 589]
Pravastatin	N.A.	Hyperlipoproteinemia Type Ii	Patients with the rs2032582 TT genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the AC, CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.		[ 589]
Cytarabine	N.A.	Leukemia, Myeloid, Acute	Patients with the TT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytarabine, daunorubicin and dexrazoxane may have an decreased response as compared to the AC, AT, or AA genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.		[ 375]
Daunorubicin	N.A.	Leukemia, Myeloid, Acute	Patients with the TT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytarabine, daunorubicin and dexrazoxane may have an decreased response as compared to the AC, AT, or AA genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.		[ 375]
Dexrazoxane	N.A.	Leukemia, Myeloid, Acute	Patients with the TT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytarabine, daunorubicin and dexrazoxane may have an decreased response as compared to the AC, AT, or AA genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.		[ 375]
Idarubicin	N.A.	Leukemia, Myeloid, Acute	Patients with the TT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytarabine, daunorubicin and dexrazoxane may have an decreased response as compared to the AC, AT, or AA genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.		[ 375]
Genotypes AT + TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Hypoventilation	Genotypes AT + TT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.		[ 210]
Genotype CA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Paclitaxel	N.A.	Breast Neoplasms	Patients with the CA or CT genotype may have increased response to paclitaxel as compared to the CC genotype, but decreased response as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.		[ 582]
Paclitaxel	N.A.	Ovarian Neoplasms	Patients with the CA or CT genotype may have increased response to paclitaxel as compared to the CC genotype, but decreased response as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.		[ 582]
Genetic Polymorphism	rs11983225
Site of GPD	chr7:87532204 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.1456/729 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:         13 Drugs in Total
Citalopram	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele T)		[ 605]
Amitriptyline	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele T)		[ 605]
Venlafaxine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele T)		[ 605]
Paroxetine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele T)		[ 605]
Olanzapine	N.A.	Arthralgia	Allele C is not associated with exposure to olanzapine in healthy individuals as compared to allele T.		[ 182]
Amitriptyline	N.A.	Exanthema	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Citalopram	N.A.	Exanthema	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Paroxetine	N.A.	Exanthema	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Venlafaxine	N.A.	Exanthema	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Amitriptyline	N.A.	Depression	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Citalopram	N.A.	Depression	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Paroxetine	N.A.	Depression	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Venlafaxine	N.A.	Depression	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Amitriptyline	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Amitriptyline	N.A.	Depression	Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Depression	Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Depression	Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Amitriptyline	N.A.	Depression	Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Depression	Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Depression	Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Genetic Polymorphism	rs12720067
Site of GPD	chr7:87540040 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.0899/450 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:         13 Drugs in Total
Citalopram	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Amitriptyline	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Venlafaxine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Paroxetine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Olanzapine	N.A.	Pain	Allele T is not associated with exposure to olanzapine in healthy individuals as compared to allele C.		[ 182]
Amitriptyline	N.A.	Exanthema	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Citalopram	N.A.	Exanthema	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Paroxetine	N.A.	Exanthema	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Venlafaxine	N.A.	Exanthema	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Amitriptyline	N.A.	Depression	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Citalopram	N.A.	Depression	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Paroxetine	N.A.	Depression	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Venlafaxine	N.A.	Depression	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Amitriptyline	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Amitriptyline	N.A.	Depression	Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype and a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Depression	Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype and a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Depression	Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype and a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype and a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Amitriptyline	N.A.	Depression	Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Depression	Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Depression	Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Genetic Polymorphism	rs17160359
Site of GPD	chr7:87717503 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>T
Minor Allele Frequency	T=0.0092/46 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Fluorouracil	Drug Info	Neoplasm	Correlated with the increased drug response in patients (compare with allele G)		[ 606]
Capecitabine	Drug Info	Neoplasm	Correlated with the increased drug response in patients (compare with allele G)		[ 606]
Capecitabine	N.A.	Drug Toxicity	Allele T is associated with increased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele G.		[ 606]
Fluorouracil	N.A.	Drug Toxicity	Allele T is associated with increased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele G.		[ 606]
Capecitabine	N.A.	Metastatic Neoplasm	Allele T is associated with increased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele G.		[ 606]
Fluorouracil	N.A.	Metastatic Neoplasm	Allele T is associated with increased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele G.		[ 606]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Capecitabine	N.A.	Metastatic Neoplasm	Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.		[ 606]
Fluorouracil	N.A.	Metastatic Neoplasm	Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.		[ 606]
Genotype GT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Capecitabine	N.A.	Metastatic Neoplasm	Patients with metastasized cancer and the GT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.		[ 606]
Fluorouracil	N.A.	Metastatic Neoplasm	Patients with metastasized cancer and the GT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.		[ 606]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Capecitabine	N.A.	Metastatic Neoplasm	Patients with metastasized cancer and the TT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.		[ 606]
Fluorouracil	N.A.	Metastatic Neoplasm	Patients with metastasized cancer and the TT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model.		[ 606]
Genetic Polymorphism	rs1922242
Site of GPD	chr7:87544351 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>T
Minor Allele Frequency	T=0.3790/1898 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluvastatin	Drug Info	Hypercholesterolemia	Correlated with the increased drug response in patients (compare with genotype At)		[ 607]
Fluvastatin	N.A.	Neutropenia	Genotype AA is associated with increased response to fluvastatin in people with Hypercholesterolemia as compared to genotype AT.		[ 607]
Fluvastatin	N.A.	Hypercholesterolemia	Genotype AA is associated with increased response to fluvastatin in people with Hypercholesterolemia as compared to genotype AT.		[ 607]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methadone	N.A.	Diarrhea	Allele A is not associated with dose of methadone in people with Heroin Dependence as compared to allele T.		[ 278]
Genotype AT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Fluvastatin	N.A.	Hypercholesterolemia	Patients with the AT genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.		[ 607]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Fluvastatin	N.A.	Hypercholesterolemia	Patients with the TT genotype were not studied, however patients with the AT genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.		[ 607]
Genetic Polymorphism	rs2032583
Site of GPD	chr7:87531245 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.1454/728 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:         32 Drugs in Total
Citalopram	Drug Info	Major Depressive Disorder	Correlated with the increased likelihood of adverse effects in patients (compare with Allele A)		[ 608]
Fluvoxamine	Drug Info	Major Depressive Disorder	Correlated with the increased likelihood of adverse effects in patients (compare with Allele A)		[ 608]
Venlafaxine	Drug Info	Major Depressive Disorder	Correlated with the increased likelihood of adverse effects in patients (compare with Allele A)		[ 608]
Sertraline	Drug Info	Major Depressive Disorder	Correlated with the increased likelihood of adverse effects in patients (compare with Allele A)		[ 608]
Paroxetine	Drug Info	Major Depressive Disorder	Correlated with the increased likelihood of adverse effects in patients (compare with Allele A)		[ 608]
Methadone	N.A.	Diarrhea	Allele G is not associated with dose of methadone in people with Heroin Dependence as compared to allele A.		[ 278]
Citalopram	N.A.	Opioid-related Disorders	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Fluvoxamine	N.A.	Opioid-related Disorders	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Paroxetine	N.A.	Opioid-related Disorders	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Sertraline	N.A.	Opioid-related Disorders	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Venlafaxine	N.A.	Opioid-related Disorders	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Amitriptyline	N.A.	Depression	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Amitriptyline	N.A.	Depressive Disorder	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Amitriptyline	N.A.	Major Depressive Disorder	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Antidepressants	N.A.	Depression	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Antidepressants	N.A.	Depressive Disorder	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Antidepressants	N.A.	Major Depressive Disorder	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Citalopram	N.A.	Depression	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Citalopram	N.A.	Depressive Disorder	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Citalopram	N.A.	Major Depressive Disorder	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Fluvoxamine	N.A.	Depression	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Fluvoxamine	N.A.	Depressive Disorder	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Fluvoxamine	N.A.	Major Depressive Disorder	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Paroxetine	N.A.	Depression	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Paroxetine	N.A.	Depressive Disorder	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Paroxetine	N.A.	Major Depressive Disorder	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Sertraline	N.A.	Depression	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Sertraline	N.A.	Depressive Disorder	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Sertraline	N.A.	Major Depressive Disorder	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Venlafaxine	N.A.	Depression	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Venlafaxine	N.A.	Depressive Disorder	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Venlafaxine	N.A.	Major Depressive Disorder	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.		[ 608]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:         60 Drugs in Total
Citalopram	Drug Info	Bipolar Disorder	Irrelevant to the drug response in patients (compare with genotypes AA + AG)		[ 609]
Amitriptyline	Drug Info	Bipolar Disorder	Irrelevant to the drug response in patients (compare with genotypes AA + AG)		[ 609]
Venlafaxine	Drug Info	Bipolar Disorder	Irrelevant to the drug response in patients (compare with genotypes AA + AG)		[ 609]
Sertraline	Drug Info	Bipolar Disorder	Irrelevant to the drug response in patients (compare with genotypes AA + AG)		[ 609]
Escitalopram	Drug Info	Bipolar Disorder	Irrelevant to the drug response in patients (compare with genotypes AA + AG)		[ 609]
Paroxetine	Drug Info	Bipolar Disorder	Irrelevant to the drug response in patients (compare with genotypes AA + AG)		[ 609]
Nortriptyline	Drug Info	Bipolar Disorder	Irrelevant to the drug response in patients (compare with genotypes AA + AG)		[ 609]
Trimipramine	Drug Info	Bipolar Disorder	Irrelevant to the drug response in patients (compare with genotypes AA + AG)		[ 609]
Amitriptyline	N.A.	Stroke	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Citalopram	N.A.	Stroke	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Escitalopram	N.A.	Stroke	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Nortriptyline	N.A.	Stroke	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Paroxetine	N.A.	Stroke	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Selective Serotonin Reuptake Inhibitors	N.A.	Stroke	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Sertraline	N.A.	Stroke	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Trimipramine	N.A.	Stroke	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Venlafaxine	N.A.	Stroke	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Amitriptyline	N.A.	Depression	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Amitriptyline	N.A.	Depressive Disorder	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Amitriptyline	N.A.	Major Depressive Disorder	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Antidepressants	N.A.	Depression	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Antidepressants	N.A.	Depressive Disorder	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Antidepressants	N.A.	Major Depressive Disorder	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Citalopram	N.A.	Depression	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Citalopram	N.A.	Depressive Disorder	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Citalopram	N.A.	Major Depressive Disorder	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Fluvoxamine	N.A.	Depression	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Fluvoxamine	N.A.	Depressive Disorder	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Fluvoxamine	N.A.	Major Depressive Disorder	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Paroxetine	N.A.	Depression	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Paroxetine	N.A.	Depressive Disorder	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Paroxetine	N.A.	Major Depressive Disorder	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Sertraline	N.A.	Depression	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Sertraline	N.A.	Depressive Disorder	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Sertraline	N.A.	Major Depressive Disorder	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Venlafaxine	N.A.	Depression	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Venlafaxine	N.A.	Depressive Disorder	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Venlafaxine	N.A.	Major Depressive Disorder	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.		[ 609]
Amitriptyline	N.A.	Depression	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Amitriptyline	N.A.	Depressive Disorder	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Amitriptyline	N.A.	Major Depressive Disorder	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Antidepressants	N.A.	Depression	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Antidepressants	N.A.	Depressive Disorder	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Antidepressants	N.A.	Major Depressive Disorder	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Citalopram	N.A.	Depression	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Citalopram	N.A.	Depressive Disorder	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Fluvoxamine	N.A.	Depression	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Fluvoxamine	N.A.	Depressive Disorder	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Fluvoxamine	N.A.	Major Depressive Disorder	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Paroxetine	N.A.	Depression	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Paroxetine	N.A.	Depressive Disorder	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Sertraline	N.A.	Depression	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Sertraline	N.A.	Depressive Disorder	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Sertraline	N.A.	Major Depressive Disorder	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Venlafaxine	N.A.	Depressive Disorder	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Selective serotonin reuptake inhibitors	N.A.	Bipolar Disorder	Irrelevant to the drug response in patients (compare with genotypes AA + AG)		[ 609]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:         34 Drugs in Total
Citalopram	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with genotype AA)		[ 605]
Fluvoxamine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with genotype AA)		[ 605]
Amitriptyline	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with genotype AA)		[ 605]
Venlafaxine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with genotype AA)		[ 605]
Sertraline	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with genotype AA)		[ 605]
Paroxetine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with genotype AA)		[ 605]
Antidepressants	N.A.	Adverse Events	Genotypes AG + GG are not associated with risk of adverse events when treated with antidepressants in people with Depressive Disorder, Major as compared to genotype AA.		[ 498]
Amitriptyline	N.A.	Event-free Survival	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Citalopram	N.A.	Event-free Survival	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Paroxetine	N.A.	Event-free Survival	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Venlafaxine	N.A.	Event-free Survival	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Antidepressants	N.A.	Statin-related Myopathy	Genotypes AG + GG are not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA.		[ 498]
Amitriptyline	N.A.	Depression	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Amitriptyline	N.A.	Depressive Disorder	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Amitriptyline	N.A.	Major Depressive Disorder	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Antidepressants	N.A.	Depression	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Antidepressants	N.A.	Depressive Disorder	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Antidepressants	N.A.	Major Depressive Disorder	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Citalopram	N.A.	Depression	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Citalopram	N.A.	Depressive Disorder	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Fluvoxamine	N.A.	Depression	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Fluvoxamine	N.A.	Depressive Disorder	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Fluvoxamine	N.A.	Major Depressive Disorder	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Paroxetine	N.A.	Depression	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Paroxetine	N.A.	Depressive Disorder	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Sertraline	N.A.	Depression	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Sertraline	N.A.	Depressive Disorder	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Sertraline	N.A.	Major Depressive Disorder	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Venlafaxine	N.A.	Depression	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Venlafaxine	N.A.	Depressive Disorder	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.		[ 605]
Antidepressants	N.A.	Depression	Correlated with the increased likelihood of remission in patients (compare with genotype AA)		[ 605]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:         25 Drugs in Total
Desmethylcitalopram	N.A.	Cardiac Rhythm Disease	Genotype AG is not associated with concentrations of desmethylcitalopram or escitalopram in people with Depressive Disorder, Major as compared to genotypes AA + GG.		[ 498]
Escitalopram	N.A.	Cardiac Rhythm Disease	Genotype AG is not associated with concentrations of desmethylcitalopram or escitalopram in people with Depressive Disorder, Major as compared to genotypes AA + GG.		[ 498]
Aripiprazole	N.A.	Hand-foot Syndrome	Genotype AG is not associated with concentrations of aripiprazole in people with Depressive Disorder, Major as compared to genotypes AA + GG.		[ 498]
Escitalopram	N.A.	Adverse Events	Genotype AG is not associated with severity of adverse events when treated with escitalopram in people with Depressive Disorder, Major as compared to genotypes AA + GG.		[ 498]
Amitriptyline	N.A.	Depression	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Amitriptyline	N.A.	Depressive Disorder	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Amitriptyline	N.A.	Major Depressive Disorder	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Antidepressants	N.A.	Depression	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Antidepressants	N.A.	Depressive Disorder	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Antidepressants	N.A.	Major Depressive Disorder	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Citalopram	N.A.	Depression	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Citalopram	N.A.	Depressive Disorder	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Fluvoxamine	N.A.	Depression	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Fluvoxamine	N.A.	Depressive Disorder	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Fluvoxamine	N.A.	Major Depressive Disorder	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Paroxetine	N.A.	Depression	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Paroxetine	N.A.	Depressive Disorder	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Sertraline	N.A.	Depression	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Sertraline	N.A.	Depressive Disorder	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Sertraline	N.A.	Major Depressive Disorder	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Venlafaxine	N.A.	Depressive Disorder	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:         21 Drugs in Total
Amitriptyline	N.A.	Depression	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Amitriptyline	N.A.	Depressive Disorder	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Amitriptyline	N.A.	Major Depressive Disorder	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Antidepressants	N.A.	Depression	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Antidepressants	N.A.	Depressive Disorder	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Antidepressants	N.A.	Major Depressive Disorder	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Citalopram	N.A.	Depression	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Citalopram	N.A.	Depressive Disorder	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Fluvoxamine	N.A.	Depression	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Fluvoxamine	N.A.	Depressive Disorder	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Fluvoxamine	N.A.	Major Depressive Disorder	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Paroxetine	N.A.	Depression	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Paroxetine	N.A.	Depressive Disorder	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Sertraline	N.A.	Depression	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Sertraline	N.A.	Depressive Disorder	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Sertraline	N.A.	Major Depressive Disorder	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Venlafaxine	N.A.	Depressive Disorder	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects.		[ 605]
Genetic Polymorphism	rs2229109
Site of GPD	chr7:87550493 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	T=0.0126/63 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:         16 Drugs in Total
Dexamethasone	Drug Info	Multiple Myeloma	Irrelevant to the anemia, neutropenia or thrombocytopenia risk in patients (compare with Allele T)		[ 81]
Lenalidomide	Drug Info	Multiple Myeloma	Irrelevant to the anemia, neutropenia or thrombocytopenia risk in patients (compare with Allele T)		[ 81]
Dexamethasone	N.A.	Anemia	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.		[ 81]
Dexamethasone	N.A.	Neutropenia	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.		[ 81]
Dexamethasone	N.A.	Thrombocytopenia	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.		[ 81]
Lenalidomide	N.A.	Anemia	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.		[ 81]
Lenalidomide	N.A.	Neutropenia	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.		[ 81]
Lenalidomide	N.A.	Thrombocytopenia	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.		[ 81]
Cyclosporine	N.A.	Hypertension	Allele C is not associated with response to cyclosporine in people with Psoriasis as compared to allele T.		[ 118]
Cyclophosphamide	N.A.	Drug Toxicity	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.		[ 530]
Doxorubicin	N.A.	Drug Toxicity	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.		[ 530]
Risperidone	N.A.	Mucositis	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele T.		[ 33]
Dexamethasone	N.A.	Multiple Myeloma	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.		[ 81]
Dexamethasone	N.A.	Progression-free Survival	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.		[ 81]
Lenalidomide	N.A.	Multiple Myeloma	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.		[ 81]
Lenalidomide	N.A.	Progression-free Survival	Allele C is not associated with risk of Anemia, Neutropenia or Thrombocytopenia when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to allele T.		[ 81]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:         56 Drugs in Total
Vincristine	Drug Info	Non-Hodgkin Lymphoma	Correlated with the increased diarrhea and vomiting risk in patients (compare with genotype CC)		[ 610]
Doxorubicin	Drug Info	Non-Hodgkin Lymphoma	Correlated with the increased diarrhea and vomiting risk in patients (compare with genotype CC)		[ 610]
Cyclophosphamide	Drug Info	Non-Hodgkin Lymphoma	Correlated with the increased diarrhea and vomiting risk in patients (compare with genotype CC)		[ 610]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased drug resistance in patients (compare with genotype CC)		[ 240]
Vincristine	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased drug resistance in patients (compare with genotype CC)		[ 240]
Doxorubicin	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased drug resistance in patients (compare with genotype CC)		[ 240]
Prednisolone	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased drug resistance in patients (compare with genotype CC)		[ 240]
Dexamethasone	Drug Info	Multiple Myeloma	Correlated with the increased likelihood of progression-free survival in patients (compare with genotype CC); Irrelevant to the likelihood of overall survival in patients (compare with genotype CC)		[ 81]
Lenalidomide	Drug Info	Multiple Myeloma	Correlated with the increased likelihood of progression-free survival in patients (compare with genotype CC); Irrelevant to the likelihood of overall survival in patients (compare with genotype CC)		[ 81]
Valganciclovir	Drug Info	Kidney Transplantation	Correlated with the increased neutropenia risk in patients (compare with genotype CC)		[ 273]
Prednisone	Drug Info	Non-Hodgkin Lymphoma	Correlated with the increased diarrhea and vomiting risk in patients (compare with genotype CC)		[ 610]
Rituximab	Drug Info	Non-Hodgkin Lymphoma	Correlated with the increased diarrhea and vomiting risk in patients (compare with genotype CC)		[ 610]
Bleomycin	Drug Info	Non-Hodgkin Lymphoma	Correlated with the increased diarrhea and vomiting risk in patients (compare with genotype CC)		[ 610]
Vindesine	Drug Info	Non-Hodgkin Lymphoma	Correlated with the increased diarrhea and vomiting risk in patients (compare with genotype CC)		[ 610]
Paclitaxel	N.A.	Delayed Graft Function	Genotype CT is associated with decreased clearance of paclitaxel.		[ 614]
Valganciclovir	N.A.	Neutropenia	Genotype CT is associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype CC.		[ 273]
Bleomycin	N.A.	Diarrhea	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Bleomycin	N.A.	Vomiting	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Cyclophosphamide	N.A.	Diarrhea	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Cyclophosphamide	N.A.	Vomiting	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Doxorubicin	N.A.	Diarrhea	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Doxorubicin	N.A.	Vomiting	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Prednisone	N.A.	Diarrhea	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Prednisone	N.A.	Vomiting	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Rituximab	N.A.	Diarrhea	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Rituximab	N.A.	Vomiting	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Vincristine	N.A.	Diarrhea	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Vincristine	N.A.	Vomiting	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Vindesine	N.A.	Diarrhea	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Vindesine	N.A.	Vomiting	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Dexamethasone	N.A.	Progression-free Survival	Genotype CT is associated with increased likelihood of progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC.		[ 81]
Lenalidomide	N.A.	Progression-free Survival	Genotype CT is associated with increased likelihood of progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC.		[ 81]
Dexamethasone	N.A.	Overall Survival	Genotype CT is not associated with likelihood of overall survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC.		[ 81]
Lenalidomide	N.A.	Overall Survival	Genotype CT is not associated with likelihood of overall survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC.		[ 81]
Tacrolimus	N.A.	Transplant Rejection	Genotype CT is not associated with increased risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.		[ 87]
Doxorubicin	N.A.	Transplant Rejection	Genotype CT is associated with increased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 240]
Methotrexate	N.A.	Transplant Rejection	Genotype CT is associated with increased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 240]
Prednisolone	N.A.	Transplant Rejection	Genotype CT is associated with increased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 240]
Vincristine	N.A.	Transplant Rejection	Genotype CT is associated with increased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 240]
Temozolomide	N.A.	Urinary Retention	Genotype CT is associated with decreased response to temozolomide in people with Glioma as compared to genotype CC.		[ 126]
Bleomycin	N.A.	Non-hodgkin Lymphoma	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Cyclophosphamide	N.A.	Non-hodgkin Lymphoma	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Doxorubicin	N.A.	Non-hodgkin Lymphoma	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Prednisone	N.A.	Non-hodgkin Lymphoma	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Rituximab	N.A.	Non-hodgkin Lymphoma	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Vincristine	N.A.	Non-hodgkin Lymphoma	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Vindesine	N.A.	Non-hodgkin Lymphoma	Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.		[ 610]
Dexamethasone	N.A.	Multiple Myeloma	Genotype CT is associated with increased likelihood of progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC.		[ 81]
Lenalidomide	N.A.	Multiple Myeloma	Genotype CT is associated with increased likelihood of progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC.		[ 81]
Valganciclovir	N.A.	Kidney Transplantation	Genotype CT is associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype CC.		[ 273]
Doxorubicin	N.A.	Acute Lymphoblastic Leukemia	Genotype CT is associated with increased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 240]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype CT is associated with increased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 240]
Prednisolone	N.A.	Acute Lymphoblastic Leukemia	Genotype CT is associated with increased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 240]
Vincristine	N.A.	Acute Lymphoblastic Leukemia	Genotype CT is associated with increased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 240]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the CT genotype who are undergoing kidney transplantation may have an increased risk for allograft loss when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for allograft loss.		[ 456]
Temozolomide	N.A.	Glioma	Genotype CT is associated with decreased response to temozolomide in people with Glioma as compared to genotype CC.		[ 126]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Tacrolimus	Drug Info	Kidney Transplantation	Correlated with the increased renal transplant failure risk in patients (compare with genotype CC)		[ 456]
Tacrolimus	N.A.	Renal Transplant Failure	Genotypes CT + TT is associated with increased risk of renal transplant failure when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.		[ 456]
Tacrolimus	N.A.	Kidney Transplantation	Genotypes CT + TT is associated with increased risk of renal transplant failure when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.		[ 456]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Tacrolimus	N.A.	Polycystic Ovary Syndrome	Allele T is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele C.		[ 520]
Amisulpride	N.A.	Transplant Rejection	Allele T is associated with decreased transport of ABCB1 when assayed with amisulpride, aripiprazole, olanzapine or risperidone in LLC-PK1 cells as compared to allele C.		[ 613]
Aripiprazole	N.A.	Transplant Rejection	Allele T is associated with decreased transport of ABCB1 when assayed with amisulpride, aripiprazole, olanzapine or risperidone in LLC-PK1 cells as compared to allele C.		[ 613]
Olanzapine	N.A.	Transplant Rejection	Allele T is associated with decreased transport of ABCB1 when assayed with amisulpride, aripiprazole, olanzapine or risperidone in LLC-PK1 cells as compared to allele C.		[ 613]
Risperidone	N.A.	Transplant Rejection	Allele T is associated with decreased transport of ABCB1 when assayed with amisulpride, aripiprazole, olanzapine or risperidone in LLC-PK1 cells as compared to allele C.		[ 613]
Morphine	N.A.	Hypersensitivity	Allele T is not associated with dose of morphine in women with Pain, Postoperative as compared to allele C.		[ 121]
Methadone	N.A.	Hyperprolactinemia	Allele T is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele C.		[ 208]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:         20 Drugs in Total
Prazosin	N.A.	Thromboembolism	Genotype TT is not associated with decreased clearance of prazosin.		[ 611]
Calcein	N.A.	Drug Toxicity	Genotype TT is not associated with decreased clearance of calcein.		[ 611]
Forskolin	N.A.	Drug Toxicity	Genotype TT is not associated with decreased clearance of forskolin.		[ 611]
Bisantrene	N.A.	Drug Toxicity	Genotype TT is not associated with decreased clearance of bisantrene.		[ 611]
Verapamil	N.A.	Drug Toxicity	Genotype TT is not associated with decreased clearance of verapamil.		[ 611]
Paclitaxel	N.A.	Delayed Graft Function	Genotype TT is associated with decreased clearance of paclitaxel.		[ 611]
Vinblastine	N.A.	Delayed Graft Function	Genotype TT is not associated with decreased clearance of vinblastine.		[ 611]
Bleomycin	N.A.	Non-hodgkin Lymphoma	No patients with the TT genotype were studied, but patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		[ 610]
Cyclophosphamide	N.A.	Non-hodgkin Lymphoma	No patients with the TT genotype were studied, but patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		[ 610]
Doxorubicin	N.A.	Non-hodgkin Lymphoma	No patients with the TT genotype were studied, but patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		[ 610]
Prednisone	N.A.	Non-hodgkin Lymphoma	No patients with the TT genotype were studied, but patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		[ 610]
Rituximab	N.A.	Non-hodgkin Lymphoma	No patients with the TT genotype were studied, but patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		[ 610]
Vincristine	N.A.	Non-hodgkin Lymphoma	No patients with the TT genotype were studied, but patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		[ 610]
Vindesine	N.A.	Non-hodgkin Lymphoma	No patients with the TT genotype were studied, but patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		[ 610]
Doxorubicin	N.A.	Acute Lymphoblastic Leukemia	No patients with the TT genotype were studied, but patients with the CT genotype and acute lymphoblastic leukemia may have a greater risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of relapse.		[ 240]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	No patients with the TT genotype were studied, but patients with the CT genotype and acute lymphoblastic leukemia may have a greater risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of relapse.		[ 240]
Prednisolone	N.A.	Acute Lymphoblastic Leukemia	No patients with the TT genotype were studied, but patients with the CT genotype and acute lymphoblastic leukemia may have a greater risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of relapse.		[ 240]
Vincristine	N.A.	Acute Lymphoblastic Leukemia	No patients with the TT genotype were studied, but patients with the CT genotype and acute lymphoblastic leukemia may have a greater risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of relapse.		[ 240]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the TT genotype who are undergoing kidney transplantation may have an increased risk for allograft loss when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for allograft loss.		[ 456]
Temozolomide	N.A.	Glioma	There is currently no available evidence regarding an association between the TT genotype and response to temozolomide as part of radiochemotherapy.		[ 126]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:         24 Drugs in Total
Dolutegravir	N.A.	Discontinuation	Genotype CC is not associated with likelihood of Discontinuation and adverse events when treated with dolutegravir in people with HIV infectious disease as compared to genotype CT.		[ 513]
Dolutegravir	N.A.	Adverse Events	Genotype CC is not associated with likelihood of Discontinuation and adverse events when treated with dolutegravir in people with HIV infectious disease as compared to genotype CT.		[ 513]
Cyclosporine	N.A.	Toxic Liver Disease	Genotype CC is not associated with patient stability when treated with cyclosporine in people with Kidney Transplantation as compared to genotype CT.		[ 421]
Cyclosporine	N.A.	Death	Genotype CC is associated with increased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to genotypes CT + TT.		[ 352]
Cytarabine	N.A.	Peripheral Nervous System Diseases	Genotype CC is associated with increased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes CT + TT.		[ 405]
Paclitaxel	N.A.	Breast Neoplasms	Cells with the CC genotype have normal ability to efflux fluorescently labelled paclitaxel.		[ 611]
Bleomycin	N.A.	Non-hodgkin Lymphoma	Patients with the CC genotype and non-Hodgkin lymphoma may have a lower risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		[ 610]
Cyclophosphamide	N.A.	Non-hodgkin Lymphoma	Patients with the CC genotype and non-Hodgkin lymphoma may have a lower risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		[ 610]
Doxorubicin	N.A.	Non-hodgkin Lymphoma	Patients with the CC genotype and non-Hodgkin lymphoma may have a lower risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		[ 610]
Prednisone	N.A.	Non-hodgkin Lymphoma	Patients with the CC genotype and non-Hodgkin lymphoma may have a lower risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		[ 610]
Rituximab	N.A.	Non-hodgkin Lymphoma	Patients with the CC genotype and non-Hodgkin lymphoma may have a lower risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		[ 610]
Vincristine	N.A.	Non-hodgkin Lymphoma	Patients with the CC genotype and non-Hodgkin lymphoma may have a lower risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		[ 610]
Vindesine	N.A.	Non-hodgkin Lymphoma	Patients with the CC genotype and non-Hodgkin lymphoma may have a lower risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens.		[ 610]
Dexamethasone	N.A.	Multiple Myeloma	Patients with the CC genotype and multiple myeloma who are treated with lenalidomide and dexamethasone may have shorter of progression-free survival as compared to patients with the CT genotype but only in a sub-group of patients with "standard risk cytogenetic profiles". The genotype was not significantly associated with hematologic toxicities or overall survival. Other clinical and genetic factors may also influence progression-free survival in patients multiple myeloma.		[ 81]
Dexamethasone	N.A.	Progression-free Survival	Patients with the CC genotype and multiple myeloma who are treated with lenalidomide and dexamethasone may have shorter of progression-free survival as compared to patients with the CT genotype but only in a sub-group of patients with "standard risk cytogenetic profiles". The genotype was not significantly associated with hematologic toxicities or overall survival. Other clinical and genetic factors may also influence progression-free survival in patients multiple myeloma.		[ 81]
Lenalidomide	N.A.	Multiple Myeloma	Patients with the CC genotype and multiple myeloma who are treated with lenalidomide and dexamethasone may have shorter of progression-free survival as compared to patients with the CT genotype but only in a sub-group of patients with "standard risk cytogenetic profiles". The genotype was not significantly associated with hematologic toxicities or overall survival. Other clinical and genetic factors may also influence progression-free survival in patients multiple myeloma.		[ 81]
Lenalidomide	N.A.	Progression-free Survival	Patients with the CC genotype and multiple myeloma who are treated with lenalidomide and dexamethasone may have shorter of progression-free survival as compared to patients with the CT genotype but only in a sub-group of patients with "standard risk cytogenetic profiles". The genotype was not significantly associated with hematologic toxicities or overall survival. Other clinical and genetic factors may also influence progression-free survival in patients multiple myeloma.		[ 81]
Valganciclovir	N.A.	Kidney Transplantation	Patients with the CC genotype and kidney transplantation may have reduced risk of neutropenia when taking valganciclovir compared to patients with the CT genotype. Other genetic and clinical factors may affect response to valganciclovir.		[ 273]
Doxorubicin	N.A.	Acute Lymphoblastic Leukemia	Patients with the CC genotype and acute lymphoblastic leukemia may have a lower risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of relapse.		[ 240]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with the CC genotype and acute lymphoblastic leukemia may have a lower risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of relapse.		[ 240]
Prednisolone	N.A.	Acute Lymphoblastic Leukemia	Patients with the CC genotype and acute lymphoblastic leukemia may have a lower risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of relapse.		[ 240]
Vincristine	N.A.	Acute Lymphoblastic Leukemia	Patients with the CC genotype and acute lymphoblastic leukemia may have a lower risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of relapse.		[ 240]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the CC genotype who are undergoing kidney transplantation may have a decreased risk for allograft loss when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for allograft loss.		[ 456]
Temozolomide	N.A.	Glioma	Patients with glioma and the CC genotype may have increased survival rates when treated with temozolomide as part of radiochemotherapy as compared to patients with the CT genotype. However, this association was not replicated in other cohorts. Other genetic and clinical factors may also affect response to temozolomide.		[ 126]
Genetic Polymorphism	rs2235015
Site of GPD	chr7:87570248 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	A=0.2157/1080 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:         23 Drugs in Total
Citalopram	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Amitriptyline	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Venlafaxine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Paroxetine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Amitriptyline	N.A.	Drug Resistance	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Citalopram	N.A.	Drug Resistance	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Paroxetine	N.A.	Drug Resistance	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Venlafaxine	N.A.	Drug Resistance	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Amitriptyline	N.A.	Depression	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Amitriptyline	N.A.	Depressive Disorder	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Amitriptyline	N.A.	Major Depressive Disorder	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Antidepressants	N.A.	Depression	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Antidepressants	N.A.	Depressive Disorder	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Antidepressants	N.A.	Major Depressive Disorder	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Citalopram	N.A.	Depression	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Citalopram	N.A.	Depressive Disorder	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Paroxetine	N.A.	Depression	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Paroxetine	N.A.	Depressive Disorder	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Venlafaxine	N.A.	Depression	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Venlafaxine	N.A.	Depressive Disorder	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:         52 Drugs in Total
Citalopram	Drug Info	Depression	Irrelevant to the drug response in patients (compare with genotypes AA + AC)		[ 609]
Amitriptyline	Drug Info	Depression	Irrelevant to the drug response in patients (compare with genotypes AA + AC)		[ 609]
Venlafaxine	Drug Info	Depression	Irrelevant to the drug response in patients (compare with genotypes AA + AC)		[ 609]
Sertraline	Drug Info	Depression	Irrelevant to the drug response in patients (compare with genotypes AA + AC)		[ 609]
Escitalopram	Drug Info	Depression	Irrelevant to the drug response in patients (compare with genotypes AA + AC)		[ 609]
Paroxetine	Drug Info	Depression	Irrelevant to the drug response in patients (compare with genotypes AA + AC)		[ 609]
Nortriptyline	Drug Info	Depression	Irrelevant to the drug response in patients (compare with genotypes AA + AC)		[ 609]
Trimipramine	Drug Info	Depression	Irrelevant to the drug response in patients (compare with genotypes AA + AC)		[ 609]
Desmethylcitalopram	N.A.	Delayed Graft Function	Genotype AA is not associated with concentrations of desmethylcitalopram or escitalopram in people with Depressive Disorder, Major as compared to genotype CC.		[ 498]
Escitalopram	N.A.	Delayed Graft Function	Genotype AA is not associated with concentrations of desmethylcitalopram or escitalopram in people with Depressive Disorder, Major as compared to genotype CC.		[ 498]
Aripiprazole	N.A.	Hand-foot Syndrome	Genotype AA is not associated with concentrations of aripiprazole in people with Depressive Disorder, Major as compared to genotype CC.		[ 498]
Escitalopram	N.A.	Adverse Events	Genotype AA is not associated with severity of adverse events when treated with escitalopram in people with Depressive Disorder, Major as compared to genotype CC.		[ 498]
Amitriptyline	N.A.	Peripheral Nervous System Diseases	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Citalopram	N.A.	Peripheral Nervous System Diseases	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Escitalopram	N.A.	Peripheral Nervous System Diseases	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Nortriptyline	N.A.	Peripheral Nervous System Diseases	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Paroxetine	N.A.	Peripheral Nervous System Diseases	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Selective Serotonin Reuptake Inhibitors	N.A.	Peripheral Nervous System Diseases	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Sertraline	N.A.	Peripheral Nervous System Diseases	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Trimipramine	N.A.	Peripheral Nervous System Diseases	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Venlafaxine	N.A.	Peripheral Nervous System Diseases	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Amitriptyline	N.A.	Depression	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Amitriptyline	N.A.	Depressive Disorder	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Amitriptyline	N.A.	Major Depressive Disorder	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Antidepressants	N.A.	Depression	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Antidepressants	N.A.	Depressive Disorder	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Antidepressants	N.A.	Major Depressive Disorder	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Citalopram	N.A.	Depression	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Citalopram	N.A.	Depressive Disorder	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Citalopram	N.A.	Major Depressive Disorder	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Paroxetine	N.A.	Depression	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Paroxetine	N.A.	Depressive Disorder	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Paroxetine	N.A.	Major Depressive Disorder	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Venlafaxine	N.A.	Depression	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Venlafaxine	N.A.	Depressive Disorder	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Venlafaxine	N.A.	Major Depressive Disorder	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.		[ 609]
Amitriptyline	N.A.	Depression	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Amitriptyline	N.A.	Depressive Disorder	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Amitriptyline	N.A.	Major Depressive Disorder	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Antidepressants	N.A.	Depression	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Antidepressants	N.A.	Depressive Disorder	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Antidepressants	N.A.	Major Depressive Disorder	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Citalopram	N.A.	Depression	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Citalopram	N.A.	Depressive Disorder	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Paroxetine	N.A.	Depression	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Paroxetine	N.A.	Depressive Disorder	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Venlafaxine	N.A.	Depressive Disorder	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Selective serotonin reuptake inhibitors	N.A.	Depression	Irrelevant to the drug response in patients (compare with genotypes AA + AC)		[ 609]
Genotypes AA + AC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Antidepressants	N.A.	Adverse Events	Genotypes AA + AC are not associated with risk of adverse events when treated with antidepressants in people with Depressive Disorder, Major as compared to genotype CC.		[ 498]
Antidepressants	N.A.	Transplant Rejection	Genotypes AA + AC are not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotype CC.		[ 498]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:         15 Drugs in Total
Amitriptyline	N.A.	Depression	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Amitriptyline	N.A.	Depressive Disorder	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Amitriptyline	N.A.	Major Depressive Disorder	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Antidepressants	N.A.	Depression	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Antidepressants	N.A.	Depressive Disorder	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Antidepressants	N.A.	Major Depressive Disorder	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Citalopram	N.A.	Depression	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Citalopram	N.A.	Depressive Disorder	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Paroxetine	N.A.	Depression	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Paroxetine	N.A.	Depressive Disorder	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Venlafaxine	N.A.	Depressive Disorder	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:         15 Drugs in Total
Amitriptyline	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Amitriptyline	N.A.	Depressive Disorder	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Amitriptyline	N.A.	Major Depressive Disorder	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Antidepressants	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Antidepressants	N.A.	Depressive Disorder	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Antidepressants	N.A.	Major Depressive Disorder	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Citalopram	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Citalopram	N.A.	Depressive Disorder	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Paroxetine	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Paroxetine	N.A.	Depressive Disorder	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Venlafaxine	N.A.	Depressive Disorder	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Genetic Polymorphism	rs2235040
Site of GPD	chr7:87536434 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G / C>T
Minor Allele Frequency	T=0.1396/699 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:         24 Drugs in Total
Citalopram	Drug Info	Major Depressive Disorder	Correlated with the increased likelihood of adverse effects in patients (compare with allele C)		[ 608]
Fluvoxamine	Drug Info	Major Depressive Disorder	Correlated with the increased likelihood of adverse effects in patients (compare with allele C)		[ 608]
Citalopram	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Amitriptyline	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Venlafaxine	Drug Info	Major Depressive Disorder	Correlated with the increased likelihood of adverse effects in patients (compare with allele C)		[ 608]
Venlafaxine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Sertraline	Drug Info	Major Depressive Disorder	Correlated with the increased likelihood of adverse effects in patients (compare with allele C)		[ 608]
Paroxetine	Drug Info	Major Depressive Disorder	Correlated with the increased likelihood of adverse effects in patients (compare with allele C)		[ 608]
Paroxetine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Cabazitaxel	N.A.	Asthenia	Allele T is associated with decreased likelihood of Asthenia when treated with cabazitaxel in people with Neoplasm Metastasis and Prostatic Neoplasms as compared to allele C.		[ 615]
Citalopram	N.A.	Opioid-related Disorders	Allele T is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele C.		[ 608]
Fluvoxamine	N.A.	Opioid-related Disorders	Allele T is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele C.		[ 608]
Paroxetine	N.A.	Opioid-related Disorders	Allele T is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele C.		[ 608]
Sertraline	N.A.	Opioid-related Disorders	Allele T is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele C.		[ 608]
Venlafaxine	N.A.	Opioid-related Disorders	Allele T is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele C.		[ 608]
Amitriptyline	N.A.	Exanthema	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Citalopram	N.A.	Exanthema	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Paroxetine	N.A.	Exanthema	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Venlafaxine	N.A.	Exanthema	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Amitriptyline	N.A.	Depression	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Citalopram	N.A.	Depression	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Paroxetine	N.A.	Depression	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Venlafaxine	N.A.	Depression	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Antidepressants	N.A.	Pain	Allele T is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele C.		[ 608]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:         14 Drugs in Total
Imatinib	Drug Info	Gastrointestinal Stromal Tumors	Correlated with the decreased periorbital edema risk in patients (compare with genotype CC)		[ 614]
Imatinib	N.A.	Drug Toxicity	Genotype CT is associated with decreased risk of Drug Toxicity and Eye Disorder when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.		[ 614]
Imatinib	N.A.	Eye Diseases	Genotype CT is associated with decreased risk of Drug Toxicity and Eye Disorder when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.		[ 614]
Amitriptyline	N.A.	Depression	Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype and a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Depression	Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype and a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Depression	Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype and a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype and a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Antidepressants	N.A.	Pain	Patients with the CT genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype or may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Citalopram	N.A.	Pain	Patients with the CT genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype or may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Fluvoxamine	N.A.	Pain	Patients with the CT genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype or may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Paroxetine	N.A.	Pain	Patients with the CT genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype or may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Sertraline	N.A.	Pain	Patients with the CT genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype or may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Venlafaxine	N.A.	Pain	Patients with the CT genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype or may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Genotype CT is associated with decreased risk of Drug Toxicity and Eye Disorder when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.		[ 614]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Desmethylcitalopram	N.A.	Thrombocytopenia	Genotypes CC + CT are not associated with concentrations of desmethylcitalopram or escitalopram in people with Depressive Disorder, Major as compared to genotype TT.		[ 498]
Escitalopram	N.A.	Thrombocytopenia	Genotypes CC + CT are not associated with concentrations of desmethylcitalopram or escitalopram in people with Depressive Disorder, Major as compared to genotype TT.		[ 498]
Aripiprazole	N.A.	Hand-foot Syndrome	Genotypes CC + CT are not associated with concentrations of aripiprazole in people with Depressive Disorder, Major as compared to genotype TT.		[ 498]
Escitalopram	N.A.	Adverse Events	Genotypes CC + CT are not associated with severity of adverse events when treated with escitalopram in people with Depressive Disorder, Major as compared to genotype TT.		[ 498]
Antidepressants	N.A.	Transplant Rejection	Genotypes CC + CT are not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotype TT.		[ 498]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:         11 Drugs in Total
Amitriptyline	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Antidepressants	N.A.	Pain	Patients with the CC genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Citalopram	N.A.	Pain	Patients with the CC genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Fluvoxamine	N.A.	Pain	Patients with the CC genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Paroxetine	N.A.	Pain	Patients with the CC genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Sertraline	N.A.	Pain	Patients with the CC genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Venlafaxine	N.A.	Pain	Patients with the CC genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for periorbital edema when treated with imatinib as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk for periorbital edema.		[ 614]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:         11 Drugs in Total
Amitriptyline	N.A.	Depression	Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Depression	Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Depression	Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Antidepressants	N.A.	Pain	Patients with the TT genotype and major depressive disorder who are treated with antidepressants may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Citalopram	N.A.	Pain	Patients with the TT genotype and major depressive disorder who are treated with antidepressants may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Fluvoxamine	N.A.	Pain	Patients with the TT genotype and major depressive disorder who are treated with antidepressants may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Paroxetine	N.A.	Pain	Patients with the TT genotype and major depressive disorder who are treated with antidepressants may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Sertraline	N.A.	Pain	Patients with the TT genotype and major depressive disorder who are treated with antidepressants may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Venlafaxine	N.A.	Pain	Patients with the TT genotype and major depressive disorder who are treated with antidepressants may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.		[ 608]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	The TT genotype was not analyzed, but patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for periorbital edema.		[ 614]
Genetic Polymorphism	rs2235047
Site of GPD	chr7:87509216 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G
Minor Allele Frequency	C=0.1745/874 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:         11 Drugs in Total
Daunorubicin	Drug Info	Neoplasm	Irrelevant to the likelihood of cardiotoxicity in patients (compare with Allele A)		[ 615]
Doxorubicin	Drug Info	Neoplasm	Irrelevant to the likelihood of cardiotoxicity in patients (compare with Allele A)		[ 615]
Anthracyclines And Related Substances	N.A.	Opioid-related Disorders	Allele C is associated with increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele A.		[ 616]
Daunorubicin	N.A.	Cardiotoxicity	Allele C is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele A.		[ 615]
Doxorubicin	N.A.	Cardiotoxicity	Allele C is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele A.		[ 615]
Doxorubicin	N.A.	Cardiotoxicity	Allele C is associated with increased risk of cardiotoxicity when treated with doxorubicin, paclitaxel and trastuzumab in women with Breast Neoplasms as compared to allele A.		[ 617]
Paclitaxel	N.A.	Cardiotoxicity	Allele C is associated with increased risk of cardiotoxicity when treated with doxorubicin, paclitaxel and trastuzumab in women with Breast Neoplasms as compared to allele A.		[ 617]
Trastuzumab	N.A.	Cardiotoxicity	Allele C is associated with increased risk of cardiotoxicity when treated with doxorubicin, paclitaxel and trastuzumab in women with Breast Neoplasms as compared to allele A.		[ 617]
Anthracyclines And Related Substances	N.A.	Neoplasms	Allele C is associated with increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele A.		[ 616]
Anthracyclines And Related Substances	N.A.	Neoplasms	Allele C is not associated with likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele A.		[ 615]
Anthracyclines	N.A.	Neoplasm	Correlated with the increased likelihood of cardiotoxicity in patients (compare with Allele A)		[ 616]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.		[ 616]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the AC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA and decreased likelihood as compared to patients with the CC genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.		[ 616]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Anthracyclines And Related Substances	N.A.	Neoplasms	Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.		[ 616]
Genetic Polymorphism	rs2235067
Site of GPD	chr7:87520606 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.1338/670 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:         12 Drugs in Total
Citalopram	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Amitriptyline	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Venlafaxine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Paroxetine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Amitriptyline	N.A.	Infant	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Citalopram	N.A.	Infant	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Paroxetine	N.A.	Infant	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Venlafaxine	N.A.	Infant	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Amitriptyline	N.A.	Major Depressive Disorder	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.		[ 605]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methadone	N.A.	Diarrhea	Allele C is not associated with dose of methadone in people with Heroin Dependence as compared to allele T.		[ 278]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Amitriptyline	N.A.	Major Depressive Disorder	Patients with the CC genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Patients with the CC genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the CC genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the CC genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Amitriptyline	N.A.	Major Depressive Disorder	Patients with the CT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype and a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Patients with the CT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype and a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the CT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype and a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the CT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype and a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Amitriptyline	N.A.	Major Depressive Disorder	Patients with the TT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Patients with the TT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the TT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the TT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Genetic Polymorphism	rs28401781
Site of GPD	chr7:87519012 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.1474/738 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:         12 Drugs in Total
Citalopram	Drug Info	Major Depressive Disorder	Correlated with the increased drug response in patients (compare with allele C)		[ 618]
Fluoxetine	Drug Info	Major Depressive Disorder	Correlated with the increased drug response in patients (compare with allele C)		[ 618]
Sertraline	Drug Info	Major Depressive Disorder	Correlated with the increased drug response in patients (compare with allele C)		[ 618]
Paroxetine	Drug Info	Major Depressive Disorder	Correlated with the increased drug response in patients (compare with allele C)		[ 618]
Citalopram	N.A.	Adverse Events	Allele T is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.		[ 618]
Fluoxetine	N.A.	Adverse Events	Allele T is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.		[ 618]
Paroxetine	N.A.	Adverse Events	Allele T is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.		[ 618]
Sertraline	N.A.	Adverse Events	Allele T is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.		[ 618]
Citalopram	N.A.	Major Depressive Disorder	Allele T is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.		[ 618]
Fluoxetine	N.A.	Major Depressive Disorder	Allele T is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.		[ 618]
Paroxetine	N.A.	Major Depressive Disorder	Allele T is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.		[ 618]
Sertraline	N.A.	Major Depressive Disorder	Allele T is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.		[ 618]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Citalopram	N.A.	Major Depressive Disorder	Patients with the CC genotype and major depressive disorder may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.		[ 618]
Fluoxetine	N.A.	Major Depressive Disorder	Patients with the CC genotype and major depressive disorder may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.		[ 618]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the CC genotype and major depressive disorder may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.		[ 618]
Sertraline	N.A.	Major Depressive Disorder	Patients with the CC genotype and major depressive disorder may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.		[ 618]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Citalopram	N.A.	Major Depressive Disorder	Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype or may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.		[ 618]
Fluoxetine	N.A.	Major Depressive Disorder	Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype or may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.		[ 618]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype or may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.		[ 618]
Sertraline	N.A.	Major Depressive Disorder	Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype or may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.		[ 618]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Citalopram	N.A.	Major Depressive Disorder	Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.		[ 618]
Fluoxetine	N.A.	Major Depressive Disorder	Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.		[ 618]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.		[ 618]
Sertraline	N.A.	Major Depressive Disorder	Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.		[ 618]
Genetic Polymorphism	rs3213619
Site of GPD	chr7:87600877 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.0543/272 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Atenolol	Drug Info	Hypertension	Correlated with the increased hypercholesterolemia risk in patients (compare with Allele A)		[ 619]
Clopidogrel	N.A.	Drug Toxicity	Allele G is not associated with risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to allele A.		[ 100]
Cyclophosphamide	N.A.	Peripheral Nervous System Diseases	Allele G is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele A.		[ 211]
Epirubicin	N.A.	Peripheral Nervous System Diseases	Allele G is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele A.		[ 211]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Allele G is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele A.		[ 211]
Atenolol	N.A.	Hypercholesterolemia	Allele G is associated with increased risk of Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele A.		[ 619]
Atenolol	N.A.	Hypertension	Allele G is associated with increased risk of Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele A.		[ 619]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Atazanavir	N.A.	Nephrolithiasis	Allele A is not associated with risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele G.		[ 79]
Ritonavir	N.A.	Nephrolithiasis	Allele A is not associated with risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele G.		[ 79]
Tacrolimus	N.A.	Drug Toxicity	Allele A is not associated with adverse events when treated with tacrolimus in children with hematopoietic stem cell transplant as compared to allele G.		[ 35]
Tacrolimus	N.A.	Hypersensitivity	Allele A is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.		[ 527]
Cyclosporine	N.A.	Hypertension	Allele A is not associated with response to cyclosporine in people with Psoriasis as compared to allele G.		[ 118]
Tamoxifen	N.A.	Opioid-related Disorders	Allele A is not associated with increased or decreased recurrence-free survival time when treated with tamoxifen as compared to allele G.		[ 578]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Genotypes AG + GG is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with paclitaxel as compared to genotype AA.		[ 620]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Imatinib	N.A.	Drug Toxicity	Genotype AA is not associated with response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.		[ 343]
Atenolol	N.A.	Hypertension	Patients with the AA genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		[ 619]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Atenolol	N.A.	Hypertension	Patients with the AG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		[ 619]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Atenolol	N.A.	Hypertension	Patients with the GG genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		[ 619]
Genetic Polymorphism	rs3789243
Site of GPD	chr7:87591570 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.4635/2321 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Methadone	N.A.	Diarrhea	Allele G is not associated with dose of methadone in people with Heroin Dependence as compared to allele A.		[ 278]
Methotrexate	N.A.	High On-treatment Platelet Reactivity	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 528]
Antiepileptics	N.A.	Hemorrhage	Allele G is associated with increased risk of drug resistance when treated with antiepileptics in men with Epilepsy.		[ 17]
Antiepileptics	N.A.	Epilepsy	Allele G is associated with increased risk of drug resistance when treated with antiepileptics in men with Epilepsy.		[ 17]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Antiepileptics	N.A.	Drug Resistance	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.		[ 69]
Antiepileptics	N.A.	Epilepsy	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.		[ 69]
Antiepileptics	N.A.	Epilepsy	Irrelevant to the likelihood of drug resistance in patients (compare with Allele G)		[ 69]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Oseltamivir	N.A.	Depression	Genotypes AG + GG are not associated with Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype AA.		[ 359]
Oseltamivir	N.A.	Gastritis	Genotypes AG + GG are not associated with Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype AA.		[ 359]
Oseltamivir	N.A.	Hypersensitivity	Genotypes AG + GG are not associated with Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype AA.		[ 359]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Valproic Acid	N.A.	Gastrointestinal Toxicity	Genotype GG is associated with decreased likelihood of gastrointestinal toxicity when treated with valproic acid in children with Epilepsy as compared to genotypes GT + TT.		[ 542]
Valproic Acid	N.A.	Exanthema	Genotype GG is associated with increased likelihood of Exanthema, Alopecia or Hypersensitivity when treated with valproic acid in children with Epilepsy as compared to genotypes GT + TT.		[ 542]
Valproic Acid	N.A.	Alopecia	Genotype GG is associated with increased likelihood of Exanthema, Alopecia or Hypersensitivity when treated with valproic acid in children with Epilepsy as compared to genotypes GT + TT.		[ 542]
Valproic Acid	N.A.	Hypersensitivity	Genotype GG is associated with increased likelihood of Exanthema, Alopecia or Hypersensitivity when treated with valproic acid in children with Epilepsy as compared to genotypes GT + TT.		[ 542]
Antiepileptics	N.A.	Epilepsy	Male patients with the GG genotype and specifically localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the AA genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics.		[ 69]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Epilepsy	Male patients with the AA genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics.		[ 69]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Epilepsy	Male patients with the AG genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or an increased risk for resistance as compared to patients with the AA genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics.		[ 69]
Genetic Polymorphism	rs4148737
Site of GPD	chr7:87541836 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.3790/1898 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:         26 Drugs in Total
Methotrexate	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with Allele T)		[ 529]
Vincristine	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with Allele T)		[ 529]
Cisplatin	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with Allele T)		[ 529]
Doxorubicin	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with Allele T)		[ 529]
Cyclophosphamide	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with Allele T)		[ 529]
Doxorubicin	Drug Info	Breast Neoplasm	Irrelevant to the drug response in patients (compare with Allele T)		[ 530]
Cyclophosphamide	Drug Info	Breast Neoplasm	Irrelevant to the drug response in patients (compare with Allele T)		[ 530]
Olanzapine	N.A.	Drug Toxicity	Allele C is not associated with exposure to olanzapine in healthy individuals as compared to allele T.		[ 182]
Methotrexate	N.A.	High On-treatment Platelet Reactivity	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.		[ 528]
Cyclophosphamide	N.A.	Neutropenia	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.		[ 530]
Doxorubicin	N.A.	Neutropenia	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.		[ 530]
Cisplatin	N.A.	Opioid-related Disorders	Allele C is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.		[ 529]
Cyclophosphamide	N.A.	Opioid-related Disorders	Allele C is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.		[ 529]
Doxorubicin	N.A.	Opioid-related Disorders	Allele C is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.		[ 529]
Methotrexate	N.A.	Opioid-related Disorders	Allele C is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.		[ 529]
Vincristine	N.A.	Opioid-related Disorders	Allele C is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.		[ 529]
Cisplatin	N.A.	Osteosarcoma	Allele C is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.		[ 529]
Cyclophosphamide	N.A.	Osteosarcoma	Allele C is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.		[ 529]
Doxorubicin	N.A.	Osteosarcoma	Allele C is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.		[ 529]
Methotrexate	N.A.	Osteosarcoma	Allele C is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.		[ 529]
Vincristine	N.A.	Osteosarcoma	Allele C is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.		[ 529]
Cisplatin	N.A.	Osteosarcoma	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.		[ 530]
Cyclophosphamide	N.A.	Osteosarcoma	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.		[ 530]
Doxorubicin	N.A.	Osteosarcoma	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.		[ 530]
Methotrexate	N.A.	Osteosarcoma	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.		[ 530]
Vincristine	N.A.	Osteosarcoma	Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.		[ 530]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antineoplastic Agents	N.A.	Myelosuppression	Genotypes CC + CT is associated with decreased likelihood of Myelosuppression when treated with antineoplastic agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 621]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Cisplatin	N.A.	Osteosarcoma	Patients with the CC genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Cyclophosphamide	N.A.	Osteosarcoma	Patients with the CC genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Doxorubicin	N.A.	Osteosarcoma	Patients with the CC genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Methotrexate	N.A.	Osteosarcoma	Patients with the CC genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Vincristine	N.A.	Osteosarcoma	Patients with the CC genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Cisplatin	N.A.	Osteosarcoma	Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Cyclophosphamide	N.A.	Osteosarcoma	Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Doxorubicin	N.A.	Osteosarcoma	Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Methotrexate	N.A.	Osteosarcoma	Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Vincristine	N.A.	Osteosarcoma	Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Cisplatin	N.A.	Osteosarcoma	Patients with the TT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Cyclophosphamide	N.A.	Osteosarcoma	Patients with the TT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Doxorubicin	N.A.	Osteosarcoma	Patients with the TT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Methotrexate	N.A.	Osteosarcoma	Patients with the TT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Vincristine	N.A.	Osteosarcoma	Patients with the TT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.		[ 529]
Genetic Polymorphism	rs4148739
Site of GPD	chr7:87531733 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.1454/728 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:         43 Drugs in Total
Citalopram	Drug Info	Major Depressive Disorder	Correlated with the increased drug response in patients (compare with Allele T)		[ 618]
Citalopram	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele T)		[ 605]
Amitriptyline	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele T)		[ 605]
Fluoxetine	Drug Info	Major Depressive Disorder	Correlated with the increased drug response in patients (compare with Allele T)		[ 618]
Fluoxetine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele T)		[ 605]
Venlafaxine	Drug Info	Major Depressive Disorder	Correlated with the increased drug response in patients (compare with Allele T)		[ 618]
Venlafaxine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele T)		[ 605]
Sertraline	Drug Info	Major Depressive Disorder	Correlated with the increased drug response in patients (compare with Allele T)		[ 618]
Sertraline	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele T)		[ 605]
Paroxetine	Drug Info	Major Depressive Disorder	Correlated with the increased drug response in patients (compare with Allele T)		[ 618]
Paroxetine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele T)		[ 605]
Citalopram	N.A.	Peripheral Nervous System Diseases	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.		[ 618]
Fluoxetine	N.A.	Peripheral Nervous System Diseases	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.		[ 618]
Paroxetine	N.A.	Peripheral Nervous System Diseases	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.		[ 618]
Sertraline	N.A.	Peripheral Nervous System Diseases	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.		[ 618]
Amitriptyline	N.A.	Exanthema	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Citalopram	N.A.	Exanthema	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Paroxetine	N.A.	Exanthema	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Venlafaxine	N.A.	Exanthema	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Amitriptyline	N.A.	Depression	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Amitriptyline	N.A.	Major Depressive Disorder	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Citalopram	N.A.	Depression	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Fluoxetine	N.A.	Depression	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Fluoxetine	N.A.	Major Depressive Disorder	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Paroxetine	N.A.	Depression	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Sertraline	N.A.	Depression	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Sertraline	N.A.	Major Depressive Disorder	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Venlafaxine	N.A.	Depression	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.		[ 605]
Amitriptyline	N.A.	Depression	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.		[ 618]
Amitriptyline	N.A.	Major Depressive Disorder	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.		[ 618]
Citalopram	N.A.	Depression	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.		[ 618]
Citalopram	N.A.	Major Depressive Disorder	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.		[ 618]
Fluoxetine	N.A.	Depression	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.		[ 618]
Fluoxetine	N.A.	Major Depressive Disorder	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.		[ 618]
Paroxetine	N.A.	Depression	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.		[ 618]
Paroxetine	N.A.	Major Depressive Disorder	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.		[ 618]
Sertraline	N.A.	Depression	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.		[ 618]
Sertraline	N.A.	Major Depressive Disorder	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.		[ 618]
Venlafaxine	N.A.	Depression	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.		[ 618]
Venlafaxine	N.A.	Major Depressive Disorder	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.		[ 618]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:         15 Drugs in Total
Carbamazepine	Drug Info	Epilepsy	Correlated with the decreased drug metabolism in patients (compare with genotype Ct)		[ 547]
Carbamazepine	N.A.	Drug Toxicity	Genotype TT is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to genotype CT.		[ 547]
Amitriptyline	N.A.	Depression	Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Amitriptyline	N.A.	Major Depressive Disorder	Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Citalopram	N.A.	Depression	Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Fluoxetine	N.A.	Depression	Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Fluoxetine	N.A.	Major Depressive Disorder	Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Paroxetine	N.A.	Depression	Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Sertraline	N.A.	Depression	Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Sertraline	N.A.	Major Depressive Disorder	Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Carbamazepine	N.A.	Epilepsy	Genotype TT is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to genotype CT.		[ 547]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:         13 Drugs in Total
Amitriptyline	N.A.	Depression	Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Amitriptyline	N.A.	Major Depressive Disorder	Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Citalopram	N.A.	Depression	Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Fluoxetine	N.A.	Depression	Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Fluoxetine	N.A.	Major Depressive Disorder	Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Paroxetine	N.A.	Depression	Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Sertraline	N.A.	Depression	Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Sertraline	N.A.	Major Depressive Disorder	Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Carbamazepine	N.A.	Epilepsy	No patients with the CC genotype were available for analysis, but patients with the CT genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.		[ 547]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:         13 Drugs in Total
Amitriptyline	N.A.	Depression	Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Amitriptyline	N.A.	Major Depressive Disorder	Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Citalopram	N.A.	Depression	Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Fluoxetine	N.A.	Depression	Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Fluoxetine	N.A.	Major Depressive Disorder	Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Paroxetine	N.A.	Depression	Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Sertraline	N.A.	Depression	Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Sertraline	N.A.	Major Depressive Disorder	Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.		[ 605]
Carbamazepine	N.A.	Epilepsy	Patients with the CT genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.		[ 547]
Genetic Polymorphism	rs4148740
Site of GPD	chr7:87522787 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.1446/724 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:         12 Drugs in Total
Citalopram	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele A)		[ 605]
Amitriptyline	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele A)		[ 605]
Venlafaxine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele A)		[ 605]
Paroxetine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele A)		[ 605]
Amitriptyline	N.A.	Infant	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Citalopram	N.A.	Infant	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Paroxetine	N.A.	Infant	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Venlafaxine	N.A.	Infant	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Amitriptyline	N.A.	Major Depressive Disorder	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Carbamazepine	Drug Info	Epilepsy	Correlated with the increased drug metabolism in patients (compare with genotype AA)		[ 547]
Carbamazepine	N.A.	Drug Toxicity	Genotype AG is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotype AA.		[ 547]
Amitriptyline	N.A.	Major Depressive Disorder	Patients with the AG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype and a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Patients with the AG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype and a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the AG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype and a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the AG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype and a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Carbamazepine	N.A.	Epilepsy	Genotype AG is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotype AA.		[ 547]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Amitriptyline	N.A.	Major Depressive Disorder	Patients with the AA genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Patients with the AA genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the AA genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the AA genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Carbamazepine	N.A.	Epilepsy	Patients with the AA genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.		[ 547]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Amitriptyline	N.A.	Major Depressive Disorder	Patients with the GG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Major Depressive Disorder	Patients with the GG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Major Depressive Disorder	Patients with the GG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Major Depressive Disorder	Patients with the GG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Carbamazepine	N.A.	Epilepsy	No patients with the GG genotype were available for analysis, but patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.		[ 547]
Genetic Polymorphism	rs4728709
Site of GPD	chr7:87604286 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.1769/886 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Vincristine	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased neurotoxicity syndromes risk in patients (compare with allele G)		[ 2]
Vincristine	N.A.	Neurotoxicity Syndromes	Allele A is associated with decreased risk of Neurotoxicity Syndromes when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 2]
Vincristine	N.A.	Acute Lymphoblastic Leukemia	Allele A is associated with decreased risk of Neurotoxicity Syndromes when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 2]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Olanzapine	N.A.	Asthenia	Genotype GG is associated with increased likelihood of Asthenia due to olanzapine in healthy individuals as compared to genotypes AA + AG.		[ 182]
Rivaroxaban	N.A.	Hemorrhage	Genotype GG is not associated with increased likelihood of Hemorrhage when treated with rivaroxaban in people with Atrial Fibrillation as compared to genotype AG.		[ 623]
Rivaroxaban	N.A.	Adverse Events	Genotype GG is associated with increased dose-adjusted trough concentrations of rivaroxaban in people with Atrial Fibrillation as compared to genotype AG.		[ 623]
Vincristine	N.A.	Acute Lymphoblastic Leukemia	Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased risk of grade 1-2 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.		[ 2]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Olanzapine	N.A.	Pain	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele A.		[ 182]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Rivaroxaban	N.A.	Drug Toxicity	Genotypes AA + AG is associated with increased clearance of rivaroxaban in people with Atrial Fibrillation as compared to genotype GG.		[ 623]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Olanzapine	N.A.	Asthenia	Patients with the rs4728709 AA genotype may have a decreased likelihood of developing asthenia when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced asthenia.		[ 182]
Vincristine	N.A.	Acute Lymphoblastic Leukemia	Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 1-2 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.		[ 2]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Olanzapine	N.A.	Asthenia	Patients with the rs4728709 AG genotype may have a decreased likelihood of developing asthenia when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced asthenia.		[ 182]
Vincristine	N.A.	Acute Lymphoblastic Leukemia	Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 1-2 neurotoxicity as compared to patients with the GG genotype or may have an increased risk of grade 1-2 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.		[ 2]
Genetic Polymorphism	rs7787082
Site of GPD	chr7:87527735 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.3778/1892 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:         14 Drugs in Total
Citalopram	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Amitriptyline	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Venlafaxine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Paroxetine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with allele C)		[ 605]
Olanzapine	N.A.	Adverse Events	Allele A is not associated with exposure to olanzapine in healthy individuals as compared to allele G.		[ 182]
Clozapine	N.A.	Peripheral Nervous System Diseases	Allele A is associated with increased clinical benefit to clozapine in people with Schizophrenia or Psychotic Disorder as compared to allele G.		[ 626]
Amitriptyline	N.A.	Exanthema	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele G.		[ 605]
Citalopram	N.A.	Exanthema	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele G.		[ 605]
Paroxetine	N.A.	Exanthema	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele G.		[ 605]
Venlafaxine	N.A.	Exanthema	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele G.		[ 605]
Amitriptyline	N.A.	Depressive Disorder	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele G.		[ 605]
Citalopram	N.A.	Depressive Disorder	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele G.		[ 605]
Paroxetine	N.A.	Depressive Disorder	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele G.		[ 605]
Venlafaxine	N.A.	Depressive Disorder	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele G.		[ 605]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Clozapine	Drug Info	Schizophrenia	Correlated with the decreased drug response in patients (compare with Allele A)		[ 625]
Clozapine	N.A.	Hypersensitivity	Allele G is associated with decreased response to clozapine in people with Schizophrenia as compared to allele A.		[ 625]
Clozapine	N.A.	Schizophrenia	Allele G is associated with decreased response to clozapine in people with Schizophrenia as compared to allele A.		[ 625]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Clozapine	N.A.	Schizophrenia	Patients with the AA genotype and schizophrenia may have an increased response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.		[ 625]
Amitriptyline	N.A.	Depressive Disorder	Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Citalopram	N.A.	Depressive Disorder	Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Paroxetine	N.A.	Depressive Disorder	Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Venlafaxine	N.A.	Depressive Disorder	Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Clozapine	N.A.	Schizophrenia	Patients with the AG genotype and schizophrenia may have an increased response when treated with clozapine as compared to patients with the GG genotype or a decreased response when treated with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.		[ 625]
Amitriptyline	N.A.	Depressive Disorder	Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Citalopram	N.A.	Depressive Disorder	Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Paroxetine	N.A.	Depressive Disorder	Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Venlafaxine	N.A.	Depressive Disorder	Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Clozapine	N.A.	Schizophrenia	Patients with the GG genotype and schizophrenia may have a decreased response when treated with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.		[ 625]
Amitriptyline	N.A.	Depressive Disorder	Patients with the GG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Citalopram	N.A.	Depressive Disorder	Patients with the GG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Paroxetine	N.A.	Depressive Disorder	Patients with the GG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Venlafaxine	N.A.	Depressive Disorder	Patients with the GG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance for remission.		[ 605]
Genetic Polymorphism	rs9282564
Site of GPD	chr7:87600124 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C / T>G
Minor Allele Frequency	C=0.0260/130 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Methadone	Drug Info	Opioid-Related Disorders	Correlated with the decreased drug clearance in patients (compare with Allele T)		[ 1]
Paroxetine	N.A.	Vomiting	Allele C is not associated with plasma concentrations when treated with paroxetine in people with Depressive Disorder, Major as compared to allele T.		[ 77]
Methadone	N.A.	Asthenia	Allele C is associated with decreased concentrations of methadone in people with Opioid-Related Disorders as compared to allele T.		[ 1]
Risperidone	N.A.	Mucositis	Allele C is not associated with clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to allele T.		[ 33]
Methotrexate	N.A.	Dose Reduction	Allele C is associated with increased concentrations of methotrexate in children with as compared to allele T.		[ 629]
Methadone	N.A.	Opioid-related Disorders	Allele C is associated with decreased concentrations of methadone in people with Opioid-Related Disorders as compared to allele T.		[ 1]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Tacrolimus	Drug Info	Kidney Transplantation	Irrelevant to the drug trough concentration in patients (compare with allele C)		[ 527]
Tacrolimus	N.A.	Hypersensitivity	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.		[ 527]
Methadone	N.A.	Hyperprolactinemia	Allele T is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele C.		[ 208]
Tacrolimus	N.A.	Kidney Transplantation	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.		[ 527]
Tacrolimus	N.A.	Lung Transplantation	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.		[ 527]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:         13 Drugs in Total
Tacrolimus	Drug Info	Lung Transplantation	Correlated with the increased drug concentrations in patients (compare with Genotype TT)		[ 458]
Paclitaxel	N.A.	Drug Toxicity	Genotype CT is associated with decreased clearance of paclitaxel.		[ 611]
L-asparagine	N.A.	Neurotoxicity Syndromes	Genotype CT is associated with increased likelihood of Neurotoxicity Syndromes when treated with l-asparagine, prednisone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 629]
Prednisone	N.A.	Neurotoxicity Syndromes	Genotype CT is associated with increased likelihood of Neurotoxicity Syndromes when treated with l-asparagine, prednisone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 629]
Vincristine	N.A.	Neurotoxicity Syndromes	Genotype CT is associated with increased likelihood of Neurotoxicity Syndromes when treated with l-asparagine, prednisone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 629]
Cyclosporine	N.A.	Gingival Overgrowth	Genotype CT is associated with increased concentrations of cyclosporine in people with heart transplantation as compared to genotype TT.		[ 559]
Tacrolimus	N.A.	Mucositis	Genotype CT is associated with increased concentrations of tacrolimus in people with lung transplantation as compared to genotype TT.		[ 458]
Methadone	N.A.	Opioid-related Disorders	Patients with the CT genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.		[ 1]
Tacrolimus	N.A.	Kidney Transplantation	Genotype CT is associated with increased concentrations of tacrolimus in people with lung transplantation as compared to genotype TT.		[ 458]
Tacrolimus	N.A.	Lung Transplantation	Genotype CT is associated with increased concentrations of tacrolimus in people with lung transplantation as compared to genotype TT.		[ 458]
Morphine	N.A.	Hyperlipoproteinemia Type Ii	Children with the CT genotype who are undergoing a tonsillectomy and are treated with morphine may have a longer hospital stay due to respiratory depression as compared to patients with the TT genotype. Other genetic and clinical factors may also influence respiratory depression.		[ 632]
Opioids	N.A.	Death	Patients with opioid dependence and the CT genotype may be at a decreased risk of sudden death when using opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of death when using opioids.		[ 190]
Opioids	N.A.	Opioid-related Disorders	Patients with opioid dependence and the CT genotype may be at a decreased risk of sudden death when using opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of death when using opioids.		[ 190]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:         10 Drugs in Total
Tacrolimus	Drug Info	Kidney Transplantation	Correlated with the decreased drug dose-adjusted trough concentrations in patients (compare with Genotype TT)		[ 629]
Morphine	Drug Info	Neoplasm	Correlated with the increased respiratory insufficiency risk (compare with Genotype TT)		[ 628]
Tacrolimus	N.A.	Transplant Rejection	Genotypes CC + CT is not associated with increased risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotype TT.		[ 87]
Opioids	N.A.	Death	Genotypes CC + CT are associated with decreased risk of Death due to opioids in people with Opioid-Related Disorders as compared to genotype TT.		[ 190]
Tacrolimus	N.A.	Neutropenia	Genotypes CC + CT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype TT.		[ 629]
Morphine	N.A.	Hypoventilation	Genotypes CC + CT is associated with increased risk of Hypoventilation when treated with morphine in children as compared to genotype TT.		[ 628]
Tacrolimus	N.A.	Kidney Transplantation	Genotypes CC + CT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype TT.		[ 629]
Tacrolimus	N.A.	Lung Transplantation	Genotypes CC + CT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype TT.		[ 629]
Morphine	N.A.	Hyperlipoproteinemia Type Ii	Genotypes CC + CT is associated with increased risk of Hypoventilation when treated with morphine in children as compared to genotype TT.		[ 628]
Opioids	N.A.	Opioid-related Disorders	Genotypes CC + CT are associated with decreased risk of Death due to opioids in people with Opioid-Related Disorders as compared to genotype TT.		[ 190]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:         13 Drugs in Total
Prazosin	N.A.	Drug Toxicity	Genotype CC is not associated with decreased clearance of prazosin.		[ 611]
Paclitaxel	N.A.	Drug Toxicity	Genotype CC is associated with decreased clearance of paclitaxel.		[ 611]
Bisantrene	N.A.	Drug Toxicity	Genotype CC is not associated with decreased clearance of bisantrene.		[ 611]
Calcein	N.A.	Drug Toxicity	Genotype CC is not associated with decreased clearance of calcein.		[ 611]
Vinblastine	N.A.	Delayed Graft Function	Genotype CC is not associated with decreased clearance of vinblastine.		[ 611]
Verapamil	N.A.	Thrombocytopenia	Genotype CC is not associated with decreased clearance of verapamil.		[ 611]
Forskolin	N.A.	Thrombocytopenia	Genotype CC is not associated with decreased clearance of forskolin.		[ 611]
Methadone	N.A.	Opioid-related Disorders	Patients with the CC genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.		[ 1]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the CC genotype who have undergone organ transplantation may have decreased concentrations of tacrolimus compared to patients with the TT genotype. Other factors may affect concentration of tacrolimus.		[ 458]
Tacrolimus	N.A.	Lung Transplantation	Patients with the CC genotype who have undergone organ transplantation may have decreased concentrations of tacrolimus compared to patients with the TT genotype. Other factors may affect concentration of tacrolimus.		[ 458]
Morphine	N.A.	Hyperlipoproteinemia Type Ii	Children with the CC genotype who are undergoing a tonsillectomy and are treated with morphine may have a longer hospital stay due to respiratory depression as compared to patients with the TT genotype. Other genetic and clinical factors may also influence respiratory depression.		[ 628]
Opioids	N.A.	Death	Patients with opioid dependence and the CC genotype may be at a decreased risk of sudden death when using opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of death when using opioids.		[ 190]
Opioids	N.A.	Opioid-related Disorders	Patients with opioid dependence and the CC genotype may be at a decreased risk of sudden death when using opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of death when using opioids.		[ 190]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Paclitaxel	N.A.	Neoplasms	Cells with the TT genotype have normal ability to efflux fluorescently labelled paclitaxel.		[ 611]
Methadone	N.A.	Opioid-related Disorders	Patients with the TT genotype who are receiving methadone maintenance therapy may have increased plasma concentrations of methadone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone.		[ 1]
Tacrolimus	N.A.	Kidney Transplantation	Patients with the TT genotype and lung transplantation may have increased concentrations of tacrolimus compared to patients with the CC or CT genotype. Other factors may affect concentration of tacrolimus.		[ 458]
Tacrolimus	N.A.	Lung Transplantation	Patients with the TT genotype and lung transplantation may have increased concentrations of tacrolimus compared to patients with the CC or CT genotype. Other factors may affect concentration of tacrolimus.		[ 458]
Morphine	N.A.	Hyperlipoproteinemia Type Ii	Children with the TT genotype who are undergoing a tonsillectomy and are treated with morphine may have a decreased chance of a prolonged hospital stay due to respiratory depression as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence respiratory depression.		[ 628]
Opioids	N.A.	Death	Patients with opioid dependence and the TT genotype may be at an increased risk of sudden death when using opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect risk of death when using opioids.		[ 190]
Opioids	N.A.	Opioid-related Disorders	Patients with opioid dependence and the TT genotype may be at an increased risk of sudden death when using opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect risk of death when using opioids.		[ 190]
Genetic Polymorphism	rs10248420
Site of GPD	chr7:87535670 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G / A>T
Minor Allele Frequency	G=0.3474/1740 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Clozapine	Drug Info	Schizophrenia	Correlated with the decreased drug response in patients (compare with allele G)		[ 625]
Clozapine	N.A.	Hypersensitivity	Allele A is associated with decreased response to clozapine in people with Schizophrenia as compared to allele G.		[ 625]
Clozapine	N.A.	Schizophrenia	Allele A is associated with decreased response to clozapine in people with Schizophrenia as compared to allele G.		[ 625]
Allele G	Click to Show/Hide the Full List of Affected Drugs:         15 Drugs in Total
Citalopram	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele A)		[ 605]
Amitriptyline	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele A)		[ 605]
Venlafaxine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele A)		[ 605]
Paroxetine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele A)		[ 605]
Olanzapine	N.A.	Somnolence	Allele G is associated with increased likelihood of somnolence due to olanzapine in healthy individuals as compared to allele A.		[ 182]
Olanzapine	N.A.	Arthralgia	Allele G is not associated with exposure to olanzapine in healthy individuals as compared to allele A.		[ 182]
Clozapine	N.A.	Peripheral Nervous System Diseases	Allele G is associated with increased clinical benefit to clozapine in people with Schizophrenia or Psychotic Disorder as compared to allele A.		[ 624]
Amitriptyline	N.A.	Exanthema	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Citalopram	N.A.	Exanthema	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Paroxetine	N.A.	Exanthema	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Venlafaxine	N.A.	Exanthema	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Amitriptyline	N.A.	Depression	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Citalopram	N.A.	Depression	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Paroxetine	N.A.	Depression	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Venlafaxine	N.A.	Depression	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Olanzapine	N.A.	Somnolence	Patients with the rs10248420 AA genotype may have a decreased likelihood of developing somnolence when treated with olanzapine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.		[ 182]
Amitriptyline	N.A.	Depression	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Depression	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Depression	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Clozapine	N.A.	Schizophrenia	Patients with the AA genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.		[ 625]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Olanzapine	N.A.	Somnolence	Patients with the rs10248420 AG genotype may have an increased likelihood of developing somnolence when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.		[ 182]
Amitriptyline	N.A.	Depression	Patients with the AG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Depression	Patients with the AG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Depression	Patients with the AG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the AG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Clozapine	N.A.	Schizophrenia	Patients with the AG genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype, or more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.		[ 625]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Olanzapine	N.A.	Somnolence	Patients with the rs10248420 GG genotype may have an increased likelihood of developing somnolence when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.		[ 182]
Amitriptyline	N.A.	Depression	Patients with the GG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Depression	Patients with the GG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Depression	Patients with the GG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the GG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Clozapine	N.A.	Schizophrenia	Patients with the GG genotype and schizophrenia may be more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.		[ 625]
Genetic Polymorphism	rs10267099
Site of GPD	chr7:87649444 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.1434/718 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Atenolol	Drug Info	Hypertension	Correlated with the increased hypercholesterolemia risk in patients (compare with Allele A)		[ 619]
Methotrexate	N.A.	Hyperprolactinemia	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 528]
Atenolol	N.A.	Hypercholesterolemia	Allele G is associated with increased risk of Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele A.		[ 619]
Atenolol	N.A.	Hypertension	Allele G is associated with increased risk of Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele A.		[ 619]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Atenolol	N.A.	Hypertension	Patients with genotype AA and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		[ 619]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Atenolol	N.A.	Hypertension	Patients with genotype AG and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotype and an increased risk of hypercholesteremia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		[ 619]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Atenolol	N.A.	Hypertension	Patients with genotype GG and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.		[ 619]
Genetic Polymorphism	rs10276036
Site of GPD	chr7:87550882 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	C=0.4323/2165 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Doxorubicin	Drug Info	Breast Neoplasm	Irrelevant to the drug response in patients (compare with Allele T)		[ 530]
Cyclophosphamide	Drug Info	Breast Neoplasm	Irrelevant to the drug response in patients (compare with Allele T)		[ 530]
Cyclophosphamide	N.A.	Neutropenia	Allele A is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.		[ 530]
Doxorubicin	N.A.	Neutropenia	Allele A is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.		[ 530]
Allele C	Click to Show/Hide the Full List of Affected Drugs:         12 Drugs in Total
Methotrexate	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with Allele T)		[ 529]
Vincristine	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with Allele T)		[ 529]
Cisplatin	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with Allele T)		[ 529]
Doxorubicin	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with Allele T)		[ 529]
Cyclophosphamide	Drug Info	Osteosarcoma	Correlated with the increased death risk in patients (compare with Allele T)		[ 529]
Doxorubicin	N.A.	Febrile Neutropenia	Allele C is not associated with likelihood of febrile neutropenia when treated with doxorubicin in women with Breast Neoplasms as compared to allele T.		[ 631]
Methotrexate	N.A.	High On-treatment Platelet Reactivity	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.		[ 528]
Cisplatin	N.A.	Overall Survival	Allele C is associated with increased risk of overall survival when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.		[ 529]
Cyclophosphamide	N.A.	Overall Survival	Allele C is associated with increased risk of overall survival when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.		[ 529]
Doxorubicin	N.A.	Overall Survival	Allele C is associated with increased risk of overall survival when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.		[ 529]
Methotrexate	N.A.	Overall Survival	Allele C is associated with increased risk of overall survival when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.		[ 529]
Vincristine	N.A.	Overall Survival	Allele C is associated with increased risk of overall survival when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.		[ 529]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Nevirapine	N.A.	Drug Hypersensitivity	Genotype TT is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.		[ 631]
Genetic Polymorphism	rs10280101
Site of GPD	chr7:87524269 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G
Minor Allele Frequency	C=0.1446/724 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:         13 Drugs in Total
Citalopram	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele A)		[ 605]
Amitriptyline	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele A)		[ 605]
Venlafaxine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele A)		[ 605]
Paroxetine	Drug Info	Depression	Correlated with the increased likelihood of remission in patients (compare with Allele A)		[ 605]
Olanzapine	N.A.	Hemorrhage	Allele C is not associated with exposure to olanzapine in healthy individuals as compared to allele A.		[ 182]
Amitriptyline	N.A.	Exanthema	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Citalopram	N.A.	Exanthema	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Paroxetine	N.A.	Exanthema	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Venlafaxine	N.A.	Exanthema	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Amitriptyline	N.A.	Depression	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Citalopram	N.A.	Depression	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Paroxetine	N.A.	Depression	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Venlafaxine	N.A.	Depression	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.		[ 605]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Amitriptyline	N.A.	Depression	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Depression	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Depression	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Amitriptyline	N.A.	Depression	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Depression	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Depression	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Amitriptyline	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Citalopram	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Paroxetine	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Venlafaxine	N.A.	Depression	Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine.		[ 605]
Genetic Polymorphism	rs3842
Site of GPD	chr7:87504050 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.1879/941 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:         15 Drugs in Total
Efavirenz	Drug Info	HIV Infection	Correlated with the drug concentrations in patients (compare with Allele T); Correlated with the drug metabolism in patients (compare with Allele T); Irrelevant to the drug concentrations in patients (compare with Allele T)		[ 103], [ 632], [ 633]
Efavirenz	N.A.	Hemorrhage	Allele C is associated with metabolism of efavirenz in people with HIV Infections as compared to allele T.		[ 633]
Lamivudine	N.A.	Drug Hypersensitivity	Allele C is not associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to allele T.		[ 374]
Lopinavir	N.A.	Drug Hypersensitivity	Allele C is not associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to allele T.		[ 374]
Ritonavir	N.A.	Drug Hypersensitivity	Allele C is not associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to allele T.		[ 374]
Zidovudine	N.A.	Drug Hypersensitivity	Allele C is not associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to allele T.		[ 374]
Lumefantrine	N.A.	Death	Allele C is not associated with concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele T.		[ 636]
Efavirenz	N.A.	Cryoglobulinemia	Allele C is not associated with concentrations of efavirenz in children with HIV Infections as compared to allele T.		[ 103]
Dolutegravir	N.A.	Adverse Events	Allele C is not associated with concentrations of dolutegravir in people with HIV Infections as compared to allele T.		[ 107]
Efavirenz	N.A.	Pain, Postoperative	Allele C is not associated with exposure to efavirenz in healthy individuals as compared to allele T.		[ 113]
Efavirenz	N.A.	High On-treatment Platelet Reactivity	Allele C is associated with concentrations of efavirenz in people with HIV Infections as compared to allele T.		[ 632]
Efavirenz	N.A.	HIV Infectious Disease	Allele C is associated with metabolism of efavirenz in people with HIV Infections as compared to allele T.		[ 633]
Efavirenz	N.A.	HIV Infectious Disease	Allele C is not associated with exposure to efavirenz in healthy individuals as compared to allele T.		[ 113]
Efavirenz	N.A.	HIV Infectious Disease	Allele C is not associated with concentrations of efavirenz in children with HIV Infections as compared to allele T.		[ 103]
Efavirenz	N.A.	HIV Infectious Disease	Allele C is associated with concentrations of efavirenz in people with HIV Infections as compared to allele T.		[ 632]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Efavirenz	Drug Info	HIV Infection	Correlated with the increased drug accumulation in patients (compare with Genotype TT); Correlated with the increased drug trough concentration in patients (compare with Genotype TT)		[ 463], [ 636]
Efavirenz	N.A.	Transplant Rejection	Genotypes CC + CT are associated with increased accumulation of drug in PBMCs of efavirenz in people with HIV Infections as compared to genotype TT.		[ 463]
Efavirenz	N.A.	Hypersensitivity	Genotypes CC + CT is associated with increased trough concentration of efavirenz in people with HIV Infections and Tuberculosis as compared to genotype TT.		[ 636]
Efavirenz	N.A.	HIV Infectious Disease	Genotypes CC + CT are associated with increased accumulation of drug in PBMCs of efavirenz in people with HIV Infections as compared to genotype TT.		[ 463]
Efavirenz	N.A.	HIV Infectious Disease	Genotypes CC + CT is associated with increased trough concentration of efavirenz in people with HIV Infections and Tuberculosis as compared to genotype TT.		[ 636]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:         10 Drugs in Total
Olanzapine	N.A.	Cardiac Rhythm Disease	Genotype CC is associated with increased likelihood of Arrhythmias, Cardiac due to olanzapine in healthy individuals as compared to genotypes CT + TT.		[ 182]
Apixaban	N.A.	Hemorrhage	Genotype CC is associated with increased likelihood of Hemorrhage when treated with apixaban, dabigatran, edoxaban or rivaroxaban as compared to genotypes CT + TT.		[ 637]
Dabigatran	N.A.	Hemorrhage	Genotype CC is associated with increased likelihood of Hemorrhage when treated with apixaban, dabigatran, edoxaban or rivaroxaban as compared to genotypes CT + TT.		[ 637]
Edoxaban	N.A.	Hemorrhage	Genotype CC is associated with increased likelihood of Hemorrhage when treated with apixaban, dabigatran, edoxaban or rivaroxaban as compared to genotypes CT + TT.		[ 637]
Rivaroxaban	N.A.	Hemorrhage	Genotype CC is associated with increased likelihood of Hemorrhage when treated with apixaban, dabigatran, edoxaban or rivaroxaban as compared to genotypes CT + TT.		[ 637]
Efavirenz	N.A.	Hemorrhage	Genotype CC is associated with increased exposure to efavirenz in healthy individuals as compared to genotype TT.		[ 638]
Edoxaban	N.A.	Hemorrhage	Genotype CC is associated with increased likelihood of Hemorrhage when treated with edoxaban as compared to genotypes CT + TT.		[ 639]
Rifampin	N.A.	Transplant Rejection	Genotype CC is associated with increased exposure to rifampin in people with Tuberculosis as compared to genotypes CT + TT.		[ 640]
Olanzapine	N.A.	Toxic Liver Disease	Patients with the rs3842 CC genotype may have decreased clearance of olanzapine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs3842 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of olanzapine.		[ 182]
Efavirenz	N.A.	HIV Infectious Disease	Patients with CC genotype, and HIV infection, may have increased exposure to efavirenz compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug.		[ 463]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Atazanavir	N.A.	Nephrolithiasis	Allele T is not associated with risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele C.		[ 79]
Ritonavir	N.A.	Nephrolithiasis	Allele T is not associated with risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele C.		[ 79]
Lumefantrine	N.A.	Neutropenia	Allele T is not associated with response to lumefantrine in women with Malaria and Pregnancy as compared to allele C.		[ 634]
Olanzapine	N.A.	Neurotoxicity Syndromes	Allele T is associated with increased clearance of olanzapine in healthy individuals as compared to allele C.		[ 182]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Tenofovir Alafenamide	N.A.	Progression-free Survival	Genotype CT is associated with increased concentrations of tenofovir alafenamide in people with HIV infectious disease as compared to genotype TT.		[ 640]
Olanzapine	N.A.	Toxic Liver Disease	Patients with the rs3842 CT genotype may have increased clearance of olanzapine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs3842 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of olanzapine.		[ 182]
Olanzapine	N.A.	Cardiac Rhythm Disease	Patients with the rs3842 CT genotype may have a decreased likelihood of developing palpitations when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced palpitations.		[ 182]
Efavirenz	N.A.	HIV Infectious Disease	Patients with the CT genotype, and HIV infection, may have increased exposure to efavirenz compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug.		[ 463]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Olanzapine	N.A.	Toxic Liver Disease	Patients with the rs3842 TT genotype may have increased clearance of olanzapine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs3842 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of olanzapine.		[ 182]
Olanzapine	N.A.	Cardiac Rhythm Disease	Patients with the rs3842 TT genotype may have a decreased likelihood of developing palpitations when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced palpitations.		[ 182]
Efavirenz	N.A.	HIV Infectious Disease	Patients with the TT genotype, and HIV infection, have decreased exposure to efavirenz compared to patients with the CC, or CT genotypes. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug.		[ 463]
Genetic Polymorphism	rs12720066
Site of GPD	chr7:87540386 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C
Minor Allele Frequency	C=0.0212/106 (Global)
Genotypes AC + CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Irinotecan	Drug Info	Colorectal Neoplasm	Correlated with the increased severity of neutropenia in patients (compare with genotype AA)		[ 566]
Irinotecan	N.A.	Neutropenia	Genotypes AC + CC are associated with increased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype AA.		[ 566]
SN-38	N.A.	Pain	Genotypes AC + CC are associated with decreased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA.		[ 566]
Irinotecan	N.A.	Colorectal Neoplasms	Genotypes AC + CC are associated with increased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype AA.		[ 566]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the AA genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AC and CC genotypes when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.		[ 566]
Irinotecan	N.A.	Neutropenia	Patients with the AA genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AC and CC genotypes when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.		[ 566]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the AC genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.		[ 566]
Irinotecan	N.A.	Neutropenia	Patients with the AC genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.		[ 566]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the CC genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.		[ 566]
Irinotecan	N.A.	Neutropenia	Patients with the CC genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.		[ 566]
Genetic Polymorphism	rs4148738
Site of GPD	chr7:87533733 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.3814/1910 (Global)
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Dabigatran	Drug Info	Atrial Fibrillation	Correlated with the decreased drug concentrations in patients (compare with genotype CC)		[ 641]
Apixaban	N.A.	Hemorrhage	Genotypes CT + TT are associated with decreased risk of Hemorrhage when treated with apixaban as compared to genotype CC.		[ 361]
Dabigatran	N.A.	Drug Toxicity	Genotypes CT + TT are associated with decreased concentrations of Dabigatran in people with Atrial Fibrillation as compared to genotype CC.		[ 641]
Dabigatran	N.A.	Atrial Fibrillation	Genotypes CT + TT are associated with decreased concentrations of Dabigatran in people with Atrial Fibrillation as compared to genotype CC.		[ 641]
Apixaban	N.A.	Renal Cell Carcinoma	Genotypes CT + TT are associated with decreased risk of Hemorrhage when treated with apixaban as compared to genotype CC.		[ 361]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:         13 Drugs in Total
Rivaroxaban	N.A.	Hemorrhage	Genotype CC is associated with increased risk of Hemorrhage when treated with rivaroxaban in people with Atrial Fibrillation as compared to genotypes CT + TT.		[ 267]
Rivaroxaban	N.A.	Hemorrhage	Genotype CC is associated with increased concentrations of rivaroxaban in people with Atrial Fibrillation as compared to genotypes CT + TT.		[ 267]
Apixaban	N.A.	Arthralgia	Genotype CC is not associated with trough concentration of apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes CT + TT.		[ 417]
Dabigatran	N.A.	Arthralgia	Genotype CC is not associated with trough concentration of apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes CT + TT.		[ 417]
Edoxaban	N.A.	Arthralgia	Genotype CC is not associated with trough concentration of apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes CT + TT.		[ 417]
Rivaroxaban	N.A.	Arthralgia	Genotype CC is not associated with trough concentration of apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes CT + TT.		[ 417]
Apixaban	N.A.	Hemorrhage	Genotype CC is not associated with risk of Hemorrhage when treated with apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes CT + TT.		[ 417]
Dabigatran	N.A.	Hemorrhage	Genotype CC is not associated with risk of Hemorrhage when treated with apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes CT + TT.		[ 417]
Edoxaban	N.A.	Hemorrhage	Genotype CC is not associated with risk of Hemorrhage when treated with apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes CT + TT.		[ 417]
Rivaroxaban	N.A.	Hemorrhage	Genotype CC is not associated with risk of Hemorrhage when treated with apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes CT + TT.		[ 417]
Rivaroxaban	N.A.	Adverse Events	Genotype CC is associated with increased dose-adjusted trough concentrations of rivaroxaban in people with Atrial Fibrillation as compared to genotypes CT + TT.		[ 622]
Dabigatran	N.A.	Atrial Fibrillation	Patients with genotype CC and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the CT and TT genotypes. Other factors may affect dabigatran plasma concentrations.		[ 641]
Apixaban	N.A.	Renal Cell Carcinoma	Patients with the rs4148738 CC genotype may have increased risk of bleeding when treated with apixaban as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence the toxicity to apixaban.		[ 361]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Rivaroxaban	N.A.	Epistaxis	Genotypes CC + CT is associated with increased likelihood of Epistaxis rivaroxaban in people with Atrial Fibrillation as compared to genotype TT.		[ 510]
Dabigatran	N.A.	Hemorrhage	Genotypes CC + CT is associated with increased likelihood of Hemorrhage when treated with dabigatran in people with Stroke as compared to genotype TT.		[ 643]
Dabigatran	N.A.	Nausea	Genotypes CC + CT is associated with increased concentrations of dabigatran in people with Stroke as compared to genotype TT.		[ 643]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Rivaroxaban	N.A.	Event-free Survival	Genotype CT is associated with increased concentrations of rivaroxaban in people with Atrial Fibrillation as compared to genotype CC.		[ 643]
Dabigatran	N.A.	Atrial Fibrillation	Patients with genotype CT and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the CC genotype. Other factors may affect dabigatran plasma concentrations.		[ 641]
Apixaban	N.A.	Renal Cell Carcinoma	Patients with the rs4148738 CT genotype may have decreased risk of bleeding when treated with apixaban as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to apixaban.		[ 361]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Tacrolimus	N.A.	Hypersensitivity	Allele T is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.		[ 527]
Rivaroxaban	N.A.	Drug-induced Liver Injury	Allele T is associated with decreased concentrations of rivaroxaban in people with Atrial Fibrillation as compared to allele C.		[ 510]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Dabigatran	N.A.	Atrial Fibrillation	Patients with genotype TT and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the CC genotype. Other factors may affect dabigatran plasma concentrations.		[ 641]
Apixaban	N.A.	Renal Cell Carcinoma	Patients with the rs4148738 TT genotype may have decreased risk of bleeding when treated with apixaban as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to apixaban.		[ 361]
Genetic Polymorphism	rs72552784
Site of GPD	chr7:87516598 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Verapamil	N.A.	Drug Toxicity	Genotype TT is not associated with decreased clearance of verapamil.		[ 611]
Vinblastine	N.A.	Drug Toxicity	Genotype TT is not associated with decreased clearance of vinblastine.		[ 611]
Calcein	N.A.	Drug Toxicity	Genotype TT is not associated with decreased clearance of calcein.		[ 611]
Paclitaxel	N.A.	Drug Toxicity	Genotype TT is associated with decreased clearance of paclitaxel.		[ 611]
Bisantrene	N.A.	Drug Toxicity	Genotype TT is not associated with decreased clearance of bisantrene.		[ 611]
Prazosin	N.A.	Drug Toxicity	Genotype TT is not associated with decreased clearance of prazosin.		[ 611]
Forskolin	N.A.	Drug Toxicity	Genotype TT is not associated with decreased clearance of forskolin.		[ 611]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Paclitaxel	N.A.	Drug Toxicity	Genotype CT is associated with decreased clearance of paclitaxel.		[ 611]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Paclitaxel	N.A.	Renal Cell Carcinoma	Cells with the CC genotype have normal ability to efflux fluorescently labelled paclitaxel.		[ 611]
Genetic Polymorphism	rs2235048
Site of GPD	chr7:87509195 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.3952/1979 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Antiepileptics	N.A.	Drug Resistance	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.		[ 69]
Tacrolimus	N.A.	Hypersensitivity	Allele A is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.		[ 527]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Risperidone	N.A.	Peripheral Nervous System Diseases	Genotypes AG + GG are associated with increased response to risperidone in people with Schizophrenia as compared to genotype AA.		[ 485]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	High On-treatment Platelet Reactivity	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 528]
Genetic Polymorphism	rs2520464
Site of GPD	chr7:87571770 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G / C>T
Minor Allele Frequency	C=0.5830/1153 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methadone	N.A.	Diarrhea	Genotype TT is not associated with dose of methadone in people with Heroin Dependence as compared to genotypes CC + CT.		[ 278]
Genetic Polymorphism	rs6949448
Site of GPD	chr7:87512498 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C / T>G
Minor Allele Frequency	T=0.3590/710 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methadone	N.A.	Diarrhea	Allele T is not associated with dose of methadone in people with Heroin Dependence as compared to allele C.		[ 278]
Genetic Polymorphism	rs1186746
Site of GPD	chr7:87504677 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.8130/1608 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Drug Resistance	Allele C is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele T.		[ 69]
Genetic Polymorphism	rs1186745
Site of GPD	chr7:87504631 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A
Minor Allele Frequency	C=0.8900/1761 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Drug Resistance	Allele A is not associated with likelihood of Drug Resistance when treated with antiepileptics in people with Epilepsy as compared to allele C.		[ 69]
Genetic Polymorphism	rs2229107
Site of GPD	chr7:87509343 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>T
Minor Allele Frequency	A=0.9810/1941 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Nevirapine	N.A.	Epistaxis	Allele A is not associated with increased risk of Stevens-Johnson Syndrome/Epidermal Necrolysis, Toxic when treated with nevirapine in people with HIV Infections as compared to allele T.		[ 84]
Phenytoin	N.A.	Osteonecrosis	Allele A is associated with increased plasma drug levels of phenytoin in people with no disease as compared to genotype TT.		[ 21]
Genetic Polymorphism	rs868755
Site of GPD	chr7:87560614 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C / T>G
Minor Allele Frequency	T=0.3190/631 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Drug Toxicity	Genotype TT is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GG + GT.		[ 644]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Imatinib	N.A.	Hypersensitivity	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.		[ 204]
Imatinib	N.A.	Drug Toxicity	Allele T is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.		[ 204]
Imatinib	N.A.	Discontinuation	Allele T is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.		[ 204]
Genetic Polymorphism	rs10280623
Site of GPD	chr7:87573228 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.7960/1575 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Drug Toxicity	Genotype TT is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.		[ 644]
Genetic Polymorphism	rs3747802
Site of GPD	chr7:87713270 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G
Minor Allele Frequency	A=0.9900/1959 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Citalopram	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.		[ 618]
Fluoxetine	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.		[ 618]
Paroxetine	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.		[ 618]
Sertraline	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.		[ 618]
Genetic Polymorphism	rs17327624
Site of GPD	chr7:87587501 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>T
Minor Allele Frequency	G=0.8200/1622 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Cabazitaxel	N.A.	Drug Toxicity	Allele T is associated with increased likelihood of Drug Toxicity when treated with cabazitaxel in people with Neoplasm Metastasis and Prostatic Neoplasms as compared to allele G.		[ 613]
Genetic Polymorphism	rs1202170
Site of GPD	chr7:87565790 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	C=0.4670/924 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Opioids	N.A.	Neurotoxicity Syndromes	Allele C is not associated with dose of opioids in people with Pain as compared to allele T.		[ 109]
Genetic Polymorphism	rs2235013
Site of GPD	chr7:87549310 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	C=0.5250/1038 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Opioids	N.A.	Neurotoxicity Syndromes	Allele C is not associated with dose of opioids in people with Pain as compared to allele T.		[ 109]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Fentanyl	N.A.	Adverse Events	Allele T is not associated with risk of adverse events when treated with fentanyl in people with Neoplasms as compared to allele C.		[ 153]
Genetic Polymorphism	rs2235033
Site of GPD	chr7:87549827 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G / A>T
Minor Allele Frequency	A=0.5250/1038 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Opioids	N.A.	Neurotoxicity Syndromes	Allele A is not associated with dose of opioids in people with Pain as compared to allele G.		[ 109]
Genetic Polymorphism	rs4437575
Site of GPD	chr7:87510000 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.6290/1244 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Opioids	N.A.	Neurotoxicity Syndromes	Allele A is not associated with dose of opioids in people with Pain as compared to allele G.		[ 109]
Genetic Polymorphism	rs7802773
Site of GPD	chr7:87589031 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G / A>T
Minor Allele Frequency	A=0.4620/914 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Opioids	N.A.	Gingival Overgrowth	Allele A is not associated with dose of opioids in people with Pain as compared to allele G.		[ 109]
Genetic Polymorphism	rs13229143
Site of GPD	chr7:87590165 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.6060/1199 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Opioids	N.A.	Gingival Overgrowth	Allele C is not associated with dose of opioids in people with Pain as compared to allele G.		[ 109]
Genetic Polymorphism	rs117937072
Site of GPD	chr7:87535033 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G
Minor Allele Frequency	A=0.9880/1955 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Tacrolimus	N.A.	Hypersensitivity	Allele G is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele A.		[ 527]
Genetic Polymorphism	rs28656907
Site of GPD	chr7:87714706 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.6300/1246 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Imatinib	N.A.	Transplant Rejection	Genotype TT is associated with increased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.		[ 204]
Imatinib	N.A.	Drug Toxicity	Genotype TT is associated with increased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.		[ 204]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Genotype TT is associated with increased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.		[ 204]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Imatinib	N.A.	Drug Toxicity	Allele T is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.		[ 204]
Imatinib	N.A.	Discontinuation	Allele T is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.		[ 204]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Imatinib	N.A.	Drug Toxicity	Patients with the CC genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's imatinib dose requirements.		[ 204]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the CC genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's imatinib dose requirements.		[ 204]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Imatinib	N.A.	Drug Toxicity	Patients with the CT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's imatinib dose requirements.		[ 204]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the CT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's imatinib dose requirements.		[ 204]
Genetic Polymorphism	rs12535512
Site of GPD	chr7:87591018 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.6600/1306 (Global)
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Risperidone	N.A.	Adverse Events	Genotypes CC + CT are not associated with response to risperidone in people with Schizophrenia as compared to genotype TT.		[ 485]
Genetic Polymorphism	rs6961419
Site of GPD	chr7:87542820 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.6150/1217 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Hyperprolactinemia	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.		[ 528]
Genetic Polymorphism	rs6961665
Site of GPD	chr7:87552102 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	C=0.5260/1040 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Hyperprolactinemia	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 528]
Genetic Polymorphism	rs13233308
Site of GPD	chr7:87615644 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.6380/1262 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Hyperprolactinemia	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 528]
Genetic Polymorphism	rs10264990
Site of GPD	chr7:87573299 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G / C>T
Minor Allele Frequency	C=0.2300/455 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Hyperprolactinemia	Allele C is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T.		[ 528]
Genetic Polymorphism	rs2235035
Site of GPD	chr7:87549770 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.7240/1432 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	High On-treatment Platelet Reactivity	Allele A is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele G.		[ 528]
Genetic Polymorphism	rs10808071
Site of GPD	chr7:87511492 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G
Minor Allele Frequency	A=0.8060/1595 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	High On-treatment Platelet Reactivity	Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele A.		[ 528]
Genetic Polymorphism	rs1202171
Site of GPD	chr7:87581729 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.2330/461 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	High On-treatment Platelet Reactivity	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 528]
Genetic Polymorphism	rs10234411
Site of GPD	chr7:87535576 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C / T>G
Minor Allele Frequency	T=0.3700/732 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Carbamazepine	N.A.	Diarrhea	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele T.		[ 18]
Genetic Polymorphism	rs2032588
Site of GPD	chr7:87550127 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.9240/1828 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Opioids	N.A.	Opioid-related Disorders	Allele A is not associated with risk of Opioid-Related Disorders when exposed to opioids as compared to allele G.		[ 377]
Genetic Polymorphism	rs2373586
Site of GPD	chr7:87528267 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G
Minor Allele Frequency	A=0.3220/637 (Global)
Genotypes AC + CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
SN-38	N.A.	Adverse Events	Genotypes AC + CC are not associated with exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA.		[ 566]
References
1	ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006 Dec;80(6):668-81.
2	Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014 Jun;15(8):1105-16.
3	The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther. 2005 Nov;78(5):551-8.
4	Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005 Dec 1;192(11):1931-42.
5	Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis. 2006 Sep 15;43(6):779-82.
6	Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. Pharmacogenomics J. 2017 Oct;17(5):412-418.
7	Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Sci Rep. 2018 May 9;8(1):7342.
8	Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics. 2010 Feb;11(2):163-75.
9	Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease. Eur J Clin Pharmacol. 2017 Jul;73(7):843-854.
10	Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther. 2012 Feb;91(2):257-63.
11	Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite. Eur J Clin Pharmacol. 2017 Dec;73(12):1623-1632.
12	Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol. 2013 May;69(5):1103-12.
13	Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics. 2008 Apr;18(4):299-305.
14	Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin Pharmacol Ther. 2012 Apr;91(4):692-9.
15	Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients. Biochimie. 2010 Sep;92(9):1207-12.
16	ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics. 2006 Jun;7(4):551-61.
17	Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese. Pharmacogenomics. 2009 May;10(5):723-32.
18	Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy. Epilepsy Res. 2015 Nov;117:52-7.
19	Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. PLoS One. 2017 Jul 20;12(7):e0180192.
20	The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. J Clin Lipidol. 2011 Mar-Apr;5(2):91-6.
21	CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86.
22	The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Ther Drug Monit. 2006 Oct;28(5):668-72.
23	Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics. 2011 Sep;12(9):1293-303.
24	CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients. Springerplus. 2015 Oct 23;4:637.
25	Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit. 2012 Dec;34(6):680-5.
26	Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients. Genet Test Mol Biomarkers. 2017 Nov;21(11):663-673.
27	Pharmacogenotyping of CYP3A5 in predicting dose-adjusted trough levels of tacrolimus among Malaysian kidney-transplant patients. Can J Physiol Pharmacol. 2014 Jan;92(1):50-7.
28	CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. Pharmacogenomics. 2014 Feb;15(2):179-88.
29	Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients. Int J Urol. 2016 Jun;23(6):484-90.
30	Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. Eur J Clin Pharmacol. 2013 Sep;69(9):1659-65.
31	MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol. 2004 Nov;58(5):548-53.
32	The impact of genetic polymorphisms on time required to attain the target tacrolimus levels and subsequent pharmacodynamic outcomes in pediatric kidney transplant patients. Saudi J Kidney Dis Transpl. 2014 Mar;25(2):266-77.
33	Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. Clin Pharmacokinet. 2015 Dec;54(12):1259-72.
34	Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects. J Clin Psychopharmacol. 2013 Jun;33(3):289-98.
35	Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. Bone Marrow Transplant. 2011 Jan;46(1):90-7.
36	Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene. 2013 Jan 10;512(2):226-31.
37	Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia. Cancer Chemother Pharmacol. 2017 Oct;80(4):829-839.
38	Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. Oncotarget. 2017 Jun 6;8(23):37761-37772.
39	Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Pharmacogenomics. 2011 Sep;12(9):1269-80.
40	The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study. Basic Clin Pharmacol Toxicol. 2017 Jul;121(1):29-36.
41	Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer Chemother Pharmacol. 2013 Oct;72(4):825-35.
42	Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. Int J Cardiol. 2013 Sep 10;167(6):2882-8.
43	Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol. 2012 May 29;59(22):1928-37.
44	Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. Thromb Haemost. 2013 Apr;109(4):744-54.
45	Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv. 2013 Nov;6(11):1166-75.
46	Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. JACC Cardiovasc Interv. 2010 Jul;3(7):731-41.
47	Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction. Circ Cardiovasc Genet. 2014 Jun;7(3):277-86.
48	The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. Pharmacogenet Genomics. 2014 Apr;24(4):204-10.
49	Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study. J Microbiol Immunol Infect. 2017 Dec;50(6):789-797.
50	Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. Laryngoscope. 2009 Aug;119(8):1484-90.
51	Effects of ABCB1, ABCC2, UGT2B7 and HNF4 genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy. Seizure. 2017 Oct;51:102-106.
52	Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics. 2010 Jan;11(1):23-31.
53	Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006 Sep 15;43(6):783-6.
54	Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. PLoS One. 2017 Oct 16;12(10):e0186200.
55	Lack of association of OPRM1 and ABCB1 single-nucleotide polymorphisms to oxycodone response in postoperative pain. J Clin Pharmacol. 2012 Feb;52(2):234-42.
56	[The Association of Polymorphisms Drug Metabolism and Transport of Imatinib Related Gene with Severe Hematology Adverse Effects in Chronic Myeloid Leukemia Patients]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2025 Apr;33(2):344-351.
57	MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam Clin Pharmacol. 2003 Aug;17(4):463-9.
58	Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5507-12.
59	ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein. Pharmacogenet Genomics. 2013 Jun;23(6):314-23.
60	Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia. Int Immunopharmacol. 2024 May 30;133:112090.
61	Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian J Hum Genet. 2011 May;17 Suppl 1:S32-40.
62	Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-nave HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial. Basic Clin Pharmacol Toxicol. 2011 Dec;109(6):513-20.
63	Pharmacogenetics in modern psychiatry. Psychiatr Danub. 2007 Sep;19(3):231-3.
64	Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation. Clin Ther. 2013 Nov;35(11):1762-9.
65	Opioid-related genetic polymorphisms do not influence postoperative opioid requirement: A prospective observational study. Eur J Anaesthesiol. 2018 Jul;35(7):496-504.
66	Codeine-related deaths: The role of pharmacogenetics and drug interactions. Forensic Sci Int. 2014 Jun;239:50-6.
67	The impact of ABCB1, CYP3A4 and CYP3A5 gene polymorphisms on apixaban trough concentration and bleeding risk in patients with atrial fibrillation. Drug Metab Pers Ther. 2024 Jun 01;39(2):89-97.
68	Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort. Eur J Clin Pharmacol. 2009 Jun;65(6):579-84.
69	The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population. Epilepsy Res. 2007 Feb;73(2):192-8.
70	Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics. 2009 Jun;19(6):429-36.
71	Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res. 2005 Nov 15;11(22):8097-104.
72	CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects. Eur J Clin Pharmacol. 2013 Apr;69(4):799-806.
73	Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology. 2004 Sep 28;63(6):1090-2.
74	Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma. Oncotarget. 2018 Mar 30;9(24):17160-17170.
75	Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis. 2010 Sep 01;202(5):717-22.
76	SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics. 2010 Dec;11(12):1703-13.
77	CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit. 2008 Aug;30(4):474-82.
78	Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations. PLoS One. 2018;13(2):e0192223.
79	Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study. J Antimicrob Chemother. 2014 Dec;69(12):3320-8.
80	Membrane-Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population. J Clin Pharmacol. 2019 Nov;59(11):1471-1476.
81	Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial. Cancer Chemother Pharmacol. 2018 Jan;81(1):183-193.
82	ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients. CNS Neurosci Ther. 2012 Aug;18(8):647-51.
83	Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer. Biomed Pharmacother. 2023 Nov;167:115479.
84	Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. Eur J Clin Pharmacol. 2013 Nov;69(11):1909-16.
85	New genetic variants associated with major adverse cardiovascular events in patients with acute coronary syndromes and treated with clopidogrel and aspirin. Pharmacogenomics J. 2021 Dec;21(6):664-672.
86	Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach. Gene. 2014 Jun 10;543(1):69-75.
87	Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenet Genomics. 2019 Jan;29(1):9-17.
88	Higher frequency of C.3435 of the ABCB1 gene in patients with tramadol dependence disorder. Am J Drug Alcohol Abuse. 2014 Jul;40(4):317-20.
89	The Distribution of the Genotypes of. Genes (Basel). 2023 May 29;14(6).
90	High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. J Antimicrob Chemother. 2014 Jan;69(1):241-5.
91	Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients. Int J Clin Pharmacol Ther. 2016 Mar;54(3):193-9.
92	Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study. J Clin Pharm Ther. 2021 Dec;46(6):1557-1563.
93	Impact of Gastric. Front Pharmacol. 2017;8:670.
94	No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res. 2003 Dec 09;8(12):531-4.
95	OPRM1 c.118A>G Polymorphism and Duration of Morphine Treatment Associated with Morphine Doses and Quality-of-Life in Palliative Cancer Pain Settings. Int J Mol Sci. 2017 Mar 27;18(4).
96	Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. J Clin Pharmacol. 2005 Apr;45(4):411-21.
97	MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr. 2003 Nov 01;34(3):295-8.
98	Influence of CYP450 Enzymes and ABCB1 Polymorphisms on Clopidogrel Response in Moroccan Patients with Acute Coronary Syndromes. Pharmgenomics Pers Med. 2023;16:901-909.
99	Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. J Clin Pharmacol. 2018 Dec;58(12):1550-1556.
100	Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population. PLoS One. 2012;7(6):e39178.
101	Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms. Vascul Pharmacol. 2018 Jul;106:22-27.
102	Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency. Clin Infect Dis. 2010 Jul 01;51(1):101-6.
103	Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin. PLoS One. 2017 Sep 8;12(9):e0181316.
104	ABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohort. PLoS One. 2013;8(1):e55197.
105	Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. Pharmacogenet Genomics. 2014 Jan;24(1):35-42.
106	Epidural analgesia with sufentanil in relation to OPRM1 and ABCB1 polymorphisms. Physiol Res. 2019 Nov 22;68(Suppl 1):S59-S64.
107	High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants. Pharmacogenet Genomics. 2017 Nov;27(11):416-419.
108	ABCB1 Polymorphism Is Associated with Higher Carbamazepine Clearance in Children. Pediatr Rep. 2025 Jan 16;17(1).
109	Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain. 2011 May;152(5):1139-1145.
110	Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos. 2008 Jan;29(1):1-5.
111	Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics. 2016 Feb;17(3):231-40.
112	Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis. 2006 Dec 1;194(11):1481-91.
113	Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers. Pharmacogenomics J. 2020 Apr;20(2):235-245.
114	Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response. J Neurol Sci. 2016 Jul 15;366:149-154.
115	Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients. Chin J Cancer. 2016 Sep 2;35(1):85.
116	Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects. Basic Clin Pharmacol Toxicol. 2019 Mar;124(3):321-329.
117	Effects of OPRM1 and ABCB1 gene polymorphisms on the analgesic effect and dose of sufentanil after thoracoscopic-assisted radical resection of lung cancer. Biosci Rep. 2019 Jan 31;39(1).
118	A pharmacogenetic study of ABCB1 polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population. Pharmacogenomics J. 2014 Dec;14(6):523-5.
119	Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer. Clin Pharmacokinet. 2014 Aug;53(8):741-51.
120	Pharmacokinetics of tramadol is affected by MDR1 polymorphism C3435T. Eur J Clin Pharmacol. 2007 Apr;63(4):419-21.
121	Influence of UGT2B7, OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):423-31.
122	Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res. 2008 Sep;42(11):884-93.
123	Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis. Eur J Clin Pharmacol. 2016 Oct;72(10):1195-1204.
124	Impact of CYP3A4/5 and ABCB1 polymorphisms on tacrolimus exposure and response in pediatric primary nephrotic syndrome. Pharmacogenomics. 2019 Oct;20(15):1071-1083.
125	Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation. Basic Clin Pharmacol Toxicol. 2021 Feb;128(2):297-304.
126	ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide. Pharmacogenomics J. 2020 Apr;20(2):213-219.
127	Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication. Basic Clin Pharmacol Toxicol. 2017 Feb;120(2):199-206.
128	CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment. J Clin Lab Anal. 2018 Jun;32(5):e22369.
129	CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. Thromb Res. 2012 Apr;129(4):441-6.
130	Methadone Dosage and Plasma Levels, SNPs of OPRM1 Gene and Age of First Drug Use Were Associated With Outcomes of Methadone Maintenance Treatment. Front Genet. 2018;9:450.
131	SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma. Pharmacogenomics. 2016 Apr;17(5):463-71.
132	Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients. Pharmacogenet Genomics. 2012 Jun;22(6):399-407.
133	Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. Br J Clin Pharmacol. 2012 Jul;74(1):134-40.
134	Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. Eur J Clin Pharmacol. 2015 Sep;71(9):1059-66.
135	Life-threatening adverse events following therapeutic opioid administration in adults: is pharmacogenetic analysis useful?. Pain Res Manag. 2013;18(3):133-6.
136	Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism. Pharmacogenomics. 2012 Feb;13(3):309-21.
137	CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Ther Drug Monit. 2011 Aug;33(4):417-24.
138	Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T Polymorphisms with Tacrolimus Dose, Serum Concentration, and Biochemical Parameters in Mexican Patients with Kidney Transplant. Genes (Basel). 2024 Apr 16;15(4).
139	Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. Ann Pharmacother. 2010 Nov;44(11):1709-17.
140	ABCB1 c.3435 C>T (rs1045642) as a biomarker for carbamazepine efficacy and toxicity in Algerian patients with epilepsy: initial findings report. Neurogenetics. 2025 Feb 15;26(1):29.
141	Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure. 2006 Jul;15(5):344-7.
142	Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals. Ther Drug Monit. 2012 Apr;34(2):153-9.
143	Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study. Mol Diagn Ther. 2014 Dec;18(6):675-83.
144	ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol. 2013 Oct;131(1):8-14.
145	Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009 Jun 1;48(11):e108-16.
146	Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. Pharmacogenomics J. 2020 Apr;20(2):202-212.
147	Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. Leuk Res. 2010 Feb;34(2):154-9.
148	Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy. Pharmacogenomics J. 2020 Dec;20(6):845-856.
149	Impact of ABCB1 genetic polymorphism on carbamazepine dose requirement among Southern Indian persons with epilepsy. Drug Metab Pers Ther. 2024 Mar 01;39(1):27-34.
150	Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. Clin Genitourin Cancer. 2015 Aug;13(4):350-358.
151	Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. Br J Clin Pharmacol. 2015 Jun;79(6):967-77.
152	The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res. 2008 Sep 30;160(3):308-15.
153	Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl. PLoS One. 2015;10(9):e0137179.
154	Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis. 2007 Jan;13(1):19-23.
155	Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients. Front Pharmacol. 2019;10:206.
156	Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025 Jan;45(1):4-11.
157	A logistic equation to determine the validity of tramadol from related gene polymorphisms and psychological factors. Pharmacogenomics. 2014 Mar;15(4):487-95.
158	Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. Seizure. 2006 Jan;15(1):67-72.
159	Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics. 2012 Jan;13(2):159-69.
160	The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics. 2011 Sep;12(9):1281-91.
161	No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population. Epilepsy Behav. 2009 Jan;14(1):78-82.
162	Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study. Ther Drug Monit. 2007 Jun;29(3):305-12.
163	Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf. 2010 Jan;19(1):75-81.
164	Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease. Eur J Clin Pharmacol. 2015 Sep;71(9):1091-7.
165	Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. Br J Clin Pharmacol. 2008 Aug;66(2):207-14.
166	Multidrug resistance 1 (MDR1) 3435C>T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis. Eur J Clin Pharmacol. 2015 Aug;71(8):959-65.
167	Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer. Pharmacogenomics. 2011 Feb;12(2):205-14.
168	Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. Thromb Res. 2012 Jul;130(1):70-4.
169	Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv. 2011 Dec 1;4(6):585-94.
170	Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. Clin Infect Dis. 2006 Jan 15;42(2):291-5.
171	Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS. 2007 Jan 2;21(1):41-6.
172	Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics. 2007 Mar;8(3):227-35.
173	Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol. 2004 May;57(5):569-75.
174	Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy. Cancer Epidemiol. 2010 Oct;34(5):634-8.
175	Chloride influx in human leucocytes: a triple-isotope technique for the assessment of chloride transporters. Clin Sci (Lond). 1991 Sep;81(3):405-12.
176	Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect Dis. 2013 Jun 4;13:261.
177	ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder. Fundam Clin Pharmacol. 2025 Jun;39(3):e70013.
178	Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. Pharmacogenomics J. 2014 Oct;14(5):457-62.
179	Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer. Cancer Chemother Pharmacol. 2017 Sep;80(3):653-659.
180	Co-Existence of. Balkan J Med Genet. 2023 Dec;26(2):35-40.
181	Tramadol efficacy in patients with postoperative pain in relation to CYP2D6 and MDR1 polymorphisms. Bratisl Lek Listy. 2012;113(3):152-5.
182	Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers. Biomed Pharmacother. 2021 Jan;133:111087.
183	Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics. 2005 Jun;6(4):411-7.
184	Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One. 2008 Apr 02;3(4):e1872.
185	A functional polymorphism in the ATP-Binding Cassette B1 transporter predicts pharmacologic response to combination of nortriptyline and morphine in neuropathic pain patients. Pain. 2020 Mar;161(3):619-629.
186	Pharmacogenomic Approach to SelectingAntiplatelet Therapy in PatientsWith Acute Coronary Syndromes: The PHARMCLO Trial. J Am Coll Cardiol. 2018 May 01;71(17):1869-1877.
187	Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: a study from a south Indian perspective. Pharmacogenomics. 2012 Jul;13(10):1119-27.
188	ABCB1, CYP2B6, and CYP3A4 genetic polymorphisms do not affect methadone maintenance treatment in HCV-positive patients. Arh Hig Rada Toksikol. 2020 Dec 31;71(4):353-358.
189	Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: Does UGT polymorphism affect these drug interactions?. Chem Biol Interact. 2022 Sep 01;364:110042.
190	The ABCB1, rs9282564, AG and TT Genotypes and the COMT, rs4680, AA Genotype are Less Frequent in Deceased Patients with Opioid Addiction than in Living Patients with Opioid Addiction. Basic Clin Pharmacol Toxicol. 2016 Oct;119(4):381-8.
191	Correlation of MDR1 gene polymorphism with propofol combined with remifentanil anesthesia in pediatric tonsillectomy. Oncotarget. 2017 Dec 12;9(29):20294-20303.
192	Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):596-605.
193	Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study. Pharmacogenet Genomics. 2018 Aug;28(8):189-195.
194	Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003 Sep;74(3):245-54.
195	Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Drug Metab Pharmacokinet. 2012;27(4):414-21.
196	Genetic Contribution in Low Back Pain: A Prospective Genetic Association Study. Pain Pract. 2019 Nov;19(8):836-847.
197	Multidrug resistant 1 (MDR1) C3435T and G2677T gene polymorphism: impact on the risk of acute rejection in pediatric kidney transplant recipients. Ital J Pediatr. 2023 May 18;49(1):57.
198	Effects of genetic polymorphisms of OPRM1, ABCB1, CYP3A4/5 on postoperative fentanyl consumption in Korean gynecologic patients. Int J Clin Pharmacol Ther. 2013 May;51(5):383-92.
199	Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021 May;68(5):e28858.
200	Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis. Pharmacogenomics. 2011 May;12(5):713-25.
201	Pharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics. Clin Transl Sci. 2022 Feb;15(2):409-421.
202	A pilot exome sequencing study suggests that germline variants influence methotrexate-induced toxicities in pediatric patients with localized osteosarcoma. Pediatr Blood Cancer. 2023 Jun 20:e30501.
203	Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Invest New Drugs. 2004 Aug;22(3):285-9.
204	Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. Pharmacogenomics J. 2019 Oct;19(5):473-479.
205	Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One. 2011 May 12;6(5):e19527.
206	Influence of (ATP)-Binding Cassette Transporter Subfamily B Member 1 (ABCB1) Gene Polymorphism on the Efficacy of Remifentanil. Med Sci Monit. 2019 Jul 15;25:5258-5262.
207	Polymorphism of the multidrug resistance 1 gene MDR1/ABCB1 C3435T and response to antiepileptic drug treatment in temporal lobe epilepsy. Seizure. 2015 Jan;24:124-6.
208	ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther. 2006 Dec;80(6):682-90.
209	Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol. 2006 Jun;61(6):706-15.
210	Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacogenomics. 2017 Jan;18(1):35-56.
211	Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res. 2014 May 01;20(9):2466-75.
212	Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus. Int J Clin Pharmacol Ther. 2006 Dec;44(12):605-13.
213	Pharmacogenetics of Methadone for Pain Management in Palliative Care. J Pain Symptom Manage. 2022 Jan;63(1):e142-e145.
214	Single nucleotide polymorphisms associated with methotrexate-induced nausea in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2021 Apr 01;19(1):51.
215	Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population. Clin Pharmacol Ther. 2022 Apr;111(4):896-908.
216	Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics. Eur J Pharm Sci. 2017 Mar 01;99:337-342.
217	Possible Genetic Determinants of Response to Phenytoin in a Group of Colombian Patients With Epilepsy. Front Pharmacol. 2020;11:555.
218	Pharmacogenetic study of methadone treatment for heroin addiction: associations between drug-metabolizing gene polymorphisms and treatment efficacy. Pharmacogenet Genomics. 2022 Jan 01;32(1):31-38.
219	Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia. Iran J Basic Med Sci. 2020 Jun;23(6):800-809.
220	ABCB1 Polymorphisms and Cold Pressor Pain Responses: Opioid-Dependent Patients on Methadone Maintenance Therapy. Nurs Res. 2017;66(2):134-144.
221	Influence of Genetic Polymorphisms on the Response to Tramadol, Ibuprofen, and the Combination in Patients With Moderate to Severe Pain After Dental Surgery. Clin Ther. 2021 May;43(5):e86-e102.
222	Association of a polymorphism in MDR1 C3435T with response to antiepileptic drug treatment in ethic Han Chinese children with epilepsy. Zhongguo Dang Dai Er Ke Za Zhi. 2007 Feb;9(1):11-4.
223	Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia. 2005 May;46(5):643-7.
224	Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486-501.
225	ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One. 2012;7(10):e46366.
226	Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites. J Clin Pharm Ther. 2015 Apr;40(2):226-31.
227	C3435T polymorphism of the ABCB1 gene is associated with poor clopidogrel responsiveness in a Mexican population undergoing percutaneous coronary intervention. Thromb Res. 2015 Nov;136(5):894-8.
228	ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics. 2003 Nov;13(11):675-82.
229	The importance of MDR1 gene polymorphisms for tacrolimus dosage. Eur J Pharm Sci. 2016 Feb 15;83:109-13.
230	Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients. Br J Clin Pharmacol. 2014 Aug;78(2):364-72.
231	Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8.
232	Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001 Aug;70(2):189-99.
233	Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis. Pharmacogenomics. 2017 Jan;18(2):175-195.
234	Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients. Br J Clin Pharmacol. 2017 Mar;83(3):562-571.
235	Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting. Anaesthesia. 2010 Oct;65(10):996-1000.
236	Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur J Clin Pharmacol. 2005 Jul;61(5-6):375-9.
237	Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. PLoS One. 2015 Aug 5;10(8):e0134102.
238	Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population. Pharmacogenomics J. 2017 Oct;17(5):471-478.
239	ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol. 2009 Aug;29(4):319-26.
240	Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015 Aug;15(4):372-9.
241	Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics. 2014 Aug;15(11):1479-94.
242	Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010 Oct 16;376(9749):1312-9.
243	Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011 Oct 26;306(16):1765-74.
244	Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009 Jan 22;360(4):363-75.
245	A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenomics J. 2016 Feb;16(1):71-8.
246	Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002 Jan 5;359(9300):30-6.
247	ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affect renal function in patients with rheumatoid arthritis. Clin Chim Acta. 2015 May 20;445:79-84.
248	Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism. Xenobiotica. 2012 Dec;42(12):1248-54.
249	Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. Clin Pharmacokinet. 2016 Dec;55(12):1521-1533.
250	Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011 Nov;12(11):1525-33.
251	Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose. Forensic Sci Int. 2014 May;238:125-32.
252	ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children. Pharmacogenomics. 2014 Jul;15(10):1297-309.
253	Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy? Leuk Lymphoma. 2017 Sep;58(9):1-9.
254	Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther. 2007 Apr;81(4):539-46.
255	Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008 Apr;83(4):559-66.
256	Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males. Pharmacogenomics. 2009 Nov;10(11):1743-51.
257	Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation. PLoS One. 2014 Oct 13;9(10):e109464.
258	Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia. Eur J Clin Pharmacol. 2015 Mar;71(3):293-302.
259	Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies. Pediatr Blood Cancer. 2016 Nov;63(11):1983-9.
260	CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol. 2009 Feb;49(2):196-204.
261	Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study. Pharmacogenomics J. 2017 Oct;17(5):435-440.
262	Efavirenz pharmacogenetics in a cohort of Italian patients. Int J Antimicrob Agents. 2016 Feb;47(2):117-23.
263	Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2003 Jan;73(1):20-30.
264	Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. J Antimicrob Chemother. 2015 Jan;70(1):307-8.
265	A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2002;2(3):191-6.
266	Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy. Support Care Cancer. 2018 May;26(5):1505-1513.
267	Effect of ABCB1 SNP polymorphisms on the plasma concentrations and clinical outcomes of rivaroxaban in Chinese NVAF patients: a population pharmacokinetic-based study. Front Pharmacol. 2025;16:1574949.
268	ABCB1 gene variants, digoxin and risk of sudden cardiac death in a general population. Heart. 2015 Dec;101(24):1973-9.
269	Pharmacogenetic of voriconazole antifungal agent in pediatric patients. Pharmacogenomics. 2018 Jul 01;19(11):913-925.
270	A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011 Nov;57(11):1574-83.
271	Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):474-485.
272	The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Transplant Proc. 2006 Jun;38(5):1290-2.
273	Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. Pharmacol Res. 2016 Sep;111:501-508.
274	Brain/blood ratios of methadone and ABCB1 polymorphisms in methadone-related deaths. Int J Legal Med. 2021 Mar;135(2):473-482.
275	Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide. Int J Mol Sci. 2023 Oct 17;24(20).
276	Impact of CYP2C9, VKORC1, ApoE and ABCB1 polymorphisms on stable warfarin dose requirements in elderly Chinese patients. Pharmacogenomics. 2020 Jan;21(2):101-110.
277	Genetic Variants in the. Genes (Basel). 2024 May 07;15(5).
278	ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet. 2008 Jul 15;17(14):2219-27.
279	Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav. 2007 Aug;11(1):112-7.
280	Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety. Pharmacogenomics. 2017 Nov;18(16):1491-1502.
281	SLCO1B1 and ABCB1 variants synergistically influencethe atorvastatin treatment response in South Indian coronary artery disease patients. Pharmacogenomics. 2022 Aug;23(12):683-694.
282	Polymorphisms of ABCG2, ABCB1 and HNF4 are associated with Lamotrigine trough concentrations in epilepsy patients. Drug Metab Pharmacokinet. 2015 Aug;30(4):282-7.
283	The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogenomics J. 2018 May 22;18(3):422-430.
284	No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther. 2003 Nov;74(5):487-98.
285	ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. Eur J Clin Pharmacol. 2013 Mar;69(3):385-93.
286	Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. Onco Targets Ther. 2016;9:5073-80.
287	Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters. Eur J Clin Pharmacol. 2007 May;63(5):437-49.
288	ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther. 2008 Oct;84(4):457-61.
289	UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res. 2007 Jun 01;13(11):3269-75.
290	Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother. 2009 Nov;64(5):1071-9.
291	Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting. Eur J Vasc Endovasc Surg. 2016 Feb;51(2):175-86.
292	Single-nucleotide polymorphism C3435T in the ABCB1 gene is associated with opioid consumption in postoperative pain. Pain Med. 2013 Dec;14(12):1977-84.
293	Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011 Oct;57(4):612-9.
294	Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation. Br J Clin Pharmacol. 2017 Apr;83(4):863-874.
295	The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. Clin Pharmacokinet. 2016 Sep;55(9):1129-43.
296	Associations between gene polymorphisms and treatment outcomes of methotrexate in patients with juvenile idiopathic arthritis. Pharmacogenomics. 2018 Apr;19(6):529-538.
297	Effect of UGT1A4, UGT2B7, UGT2B15, UGT2B17 and ABC1B polymorphisms on lamotrigine metabolism in Danish patients. Epilepsy Res. 2022 May;182:106897.
298	Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol. 2011 Jul;67(7):693-700.
299	MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol. 2002 May;53(5):526-34.
300	MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol. 2002 Dec;54(6):610-6.
301	MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm Res. 2003 Apr;20(4):552-6.
302	Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty. Pharmacogenomics. 2016 Aug;17(12):1327-38.
303	Association of ABCB1 gene polymorphisms with aspirin or clopidogrel resistance in ischemic stroke: a meta-analysis. Int J Clin Exp Pathol. 2025;18(1):1-11.
304	Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol. 2003 May;22(5):1117-21.
305	Effect of MDR1 C3435T and CYP2C19 genetic polymorphisms on the outcome of Helicobacter pylori eradication treatment in children with gastritis and peptic ulcer, Vietnam. BMC Pediatr. 2024 Jul 19;24(1):464.
306	Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600mg in Treatment-Nave HIV-Infected Patients at 96Weeks: Results of the ENCORE1 Study. Clin Pharmacokinet. 2016 Jul;55(7):861-873.
307	High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004 Jul;14(7):429-40.
308	Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J Clin Psychopharmacol. 2007 Jun;27(3):273-8.
309	Role of MDR1 gene polymorphisms in gingival overgrowth induced by cyclosporine in transplant patients. J Periodontal Res. 2008 Dec;43(6):665-72.
310	Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain. Asian Pac J Cancer Prev. 2013;14(5):2937-43.
311	ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin Pharmacol Ther. 2011 Mar;89(3):422-8.
312	Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012 May;68(5):645-55.
313	Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients. Eur J Clin Pharmacol. 2012 May;68(5):657-69.
314	CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation. Pharmacogenomics. 2018 Jul 01;19(11):895-903.
315	Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer. Pharmacogenomics. 2012 Apr;13(5):615-24.
316	Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008 Apr;99(4):816-23.
317	Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res. 2002 Oct;19(10):1581-5.
318	Prolactin levels: sex differences in the effects of risperidone, 9-hydroxyrisperidone levels, CYP2D6 and ABCB1 variants. Pharmacogenomics. 2018 Jul 01;19(10):815-823.
319	The polygenic implication of clopidogrel responsiveness: Insights from platelet reactivity analysis and next-generation sequencing. PLoS One. 2024;19(7):e0306445.
320	Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis. Cancer Chemother Pharmacol. 2022 Feb;89(2):173-181.
321	Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One. 2011;6(12):e27810.
322	Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer. 2006 Nov;42(17):2893-6.
323	Polymorphisms in the Drug Transporter Gene. Biomedicines. 2023 Sep 11;11(9).
324	Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects. Pharmacol Rep. 2009;61(5):843-50.
325	Genetic polymorphisms in ABCB1 are correlated with the increased risk of atorvastatin-induced muscle side effects: a cross-sectional study. Sci Rep. 2023 Oct 19;13(1):17895.
326	Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma. Pharmacogenomics. 2019 Dec;20(18):1283-1290.
327	Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers. Ther Drug Monit. 2013 Aug;35(4):466-72.
328	An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure. Pharmacogenomics J. 2018 Jan;18(1):153-159.
329	ABCB1 genotype is associated with fentanyl requirements in critically ill children. Pediatr Res. 2017 Jul;82(1):29-35.
330	Involvement of the. Int J Gen Med. 2024;17:1221-1231.
331	Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism. Cancer Sci. 2016 Aug;107(8):1117-23.
332	Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur J Clin Pharmacol. 2014 May;70(5):539-47.
333	Significance of MDR1 gene polymorphism C3435T in predicting drug response in epilepsy. Epilepsy Res. 2014 Feb;108(2):251-6.
334	Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation. Pharmacogenet Genomics. 2014 Sep;24(9):427-35.
335	ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban. Drug Des Devel Ther. 2023;17:2513-2522.
336	Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med. 2009 May;10(5):310-7.
337	Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis. Pharmacogenomics. 2013 Jun;14(8):897-911.
338	ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics. 2010 Dec;11(12):1715-23.
339	The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics. 2001 Jun;11(4):293-8.
340	CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. J Clin Pharmacol. 2011 Nov;51(11):1529-38.
341	Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. Pharmgenomics Pers Med. 2013 Aug 26;6:93-8.
342	The influence of ABCB1 polymorphism C3435T on the pharmacokinetics of silibinin. J Clin Pharm Ther. 2015 Dec;40(6):685-8.
343	Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica. 2013 Feb;98(2):193-200.
344	Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood. 2004 Jan 1;103(1):67-72.
345	Pharmacogenetics and Treatment Response in Narcolepsy Type 1: Relevance of the Polymorphisms of the Drug Transporter Gene ABCB1. Clin Neuropharmacol. 2016 Jan-Feb;39(1):18-23.
346	The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma. Sci Rep. 2016 Feb 2;6:20089.
347	Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017 Feb;15(2):273-283.
348	Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients. Transplantation. 2012 Nov 15;94(9):971-7.
349	Association of ABCB1 C3435T polymorphism with phenobarbital resistance in Thai patients with epilepsy. J Clin Pharm Ther. 2015 Jun;40(3):315-9.
350	Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia. Pharmacogenomics J. 2014 Oct;14(5):452-6.
351	Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients. J Clin Pharmacol. 2013 Nov;53(11):1146-54.
352	Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics. 2008 Apr;18(4):307-15.
353	Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget. 2018 Jan 10;9(10):9114-9136.
354	MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet Genomics. 2008 May;18(5):383-9.
355	Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis. Pharmacotherapy. 2008 Jul;28(7):883-94.
356	Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics. 2011 Dec;12(12):1641-52.
357	The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients. J Hum Genet. 2015 May;60(5):273-6.
358	The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol. 2002 Sep;63(9):765-70.
359	Association study of genetic polymorphisms in proteins involved in oseltamivir transport, metabolism, and interactions with adverse reactions in Mexican patients with acute respiratory diseases. Pharmacogenomics J. 2020 Aug;20(4):613-620.
360	The Influence of C3435T Polymorphism of the ABCB1 Gene on Genetic Susceptibility to Depression and Treatment Response in Polish Population - Preliminary Report. Int J Med Sci. 2015 Nov 20;12(12):974-9.
361	Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users. Clin Pharmacol Ther. 2021 Sep;110(3):768-776.
362	Low N-acetyltransferase 2 activity in isoniazid-associated acute hepatitis requiring liver transplantation. Transpl Int. 2010 Feb;23(2):231-3.
363	Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. Br J Clin Pharmacol. 2009 Sep;68(3):395-401.
364	Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer. 2018 Aug;26(8):2911-2918.
365	The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis. Pain Physician. 2015;18(2):131-52.
366	CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat. 2012 Jul;134(1):401-10.
367	MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001 Oct;18(10):1400-4.
368	Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients. Eur Rev Med Pharmacol Sci. 2016 Jun;20(11):2460-7.
369	Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS One. 2012;7(6):e38150.
370	Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. Pharmacogenet Genomics. 2012 Dec;22(12):887-90.
371	Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2014 Aug;24(8):387-96.
372	Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis. OMICS. 2012 Nov;16(11):589-95.
373	Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet Genomics. 2008 Dec;18(12):1041-9.
374	ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients. J Clin Pharmacol. 2013 Dec;53(12):1286-93.
375	Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer. 2006 May 1;118(9):2195-201.
376	Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period. Eur J Clin Pharmacol. 2011 Aug;67(8):803-13.
377	Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study. PLoS One. 2013 Sep 25;8(9):e75359.
378	Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol. 2009 Feb;20(2):272-7.
379	Relationship between ABCB1 polymorphisms and serum methadone concentration in patients undergoing methadone maintenance therapy (MMT). Am J Drug Alcohol Abuse. 2016 Sep;42(5):587-596.
380	Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients. Am J Kidney Dis. 2018 Mar;71(3):315-326.
381	Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients. PLoS One. 2015 Nov 10;10(11):e0142408.
382	Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia. J Clin Pharm Ther. 2016 Oct;41(5):546-51.
383	Role of CYP3A5 in abnormal clearance of methadone. Ann Pharmacother. 2008 Jun;42(6):893-7.
384	CYP2C19 but not CYP2B6, CYP3A4, CYP3A5, ABCB1, PON1 or P2Y12 genetic polymorphism impacts antiplatelet response after clopidogrel in Koreans. Blood Coagul Fibrinolysis. 2017 Jan;28(1):56-61.
385	Pharmacogenomics and pharmacokinetics of efavirenz 400or 600mg in 184 treatment-naive HIV-infected patients in China. Pharmacogenomics. 2020 Aug;21(13):945-956.
386	The role of MDR1 C3435T gene polymorphism on gingival hyperplasia in Turkish renal transplant patients treated with cyclosporine in the absence of calcium channel blockers. Transplant Proc. 2013;45(6):2233-7.
387	Levofloxacin-induced seizures in a patient without predisposing risk factors: the impact of pharmacogenetics. Eur J Clin Pharmacol. 2013 Aug;69(8):1611-3.
388	Case Report: Low Hematocrit Leading to Tacrolimus Toxicity. Front Pharmacol. 2021;12:717148.
389	Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res. 2011 Feb 01;17(3):620-9.
390	CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy. Pharmacogenomics J. 2016 Jun;16(3):286-92.
391	Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant. Drug Metab Pers Ther. 2017 Mar 01;32(1):49-58.
392	Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010 Jul 10;28(20):3227-33.
393	The Effect of ABCB1 C3435T Polymorphism on Cyclosporine Dose Requirements in Kidney Transplant Recipients: A Meta-Analysis. Basic Clin Pharmacol Toxicol. 2015 Aug;117(2):117-25.
394	An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 2005;5(6):352-8.
395	Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. Pharmacogenomics. 2014;15(15):1867-79.
396	Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 2002 Aug;72(2):209-19.
397	Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. J Clin Pharm Ther. 2017 Dec;42(6):679-688.
398	Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms. Ann Transplant. 2016 Aug 9;21:491-9.
399	Conversion from Prograf to Advagraf in adolescents with stable liver transplants: comparative pharmacokinetics and 1-year follow-up. Liver Transpl. 2013 Oct;19(10):1151-8.
400	The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population. PLoS One. 2017 Mar 30;12(3):e0174511.
401	ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis. Pharmacogenomics J. 2015 Apr;15(2):127-34.
402	Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients. Int J Clin Pharmacol Ther. 2014 Sep;52(9):746-55.
403	Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. Pharmacogenomics J. 2016 Feb;16(1):47-53.
404	Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010 Oct 16;376(9749):1320-8.
405	Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. Pharmacogenomics J. 2012 Apr;12(2):111-8.
406	Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Transplant Proc. 2010 Nov;42(9):3455-8.
407	The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Int J Clin Pharmacol Ther. 2015 Sep;53(9):728-36.
408	Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant. Pharmacogenomics J. 2018 Jan;18(1):180-186.
409	Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms. Transplant Proc. 2017 Jul - Aug;49(6):1492-1498.
410	Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia. J Acquir Immune Defic Syndr. 2015 May 1;69(1):e36-7.
411	Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve gastrectomy. Clin Transplant. 2017 Jun;31(6).
412	Sex Differences in the Blood Concentration of Tacrolimus in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients with CYP3A5*3/*3. Biochem Genet. 2017 Jun;55(3):268-277.
413	CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. Ther Drug Monit. 2010 Oct;32(5):573-8.
414	Pharmacogenetics polygenic response score predicts outcomes in aspirin-treated stroke patients. Front Pharmacol. 2025;16:1519383.
415	Gene Polymorphisms Play an Important Role in the Drug Interaction Between Posaconazole and Tacrolimus in Renal Transplant Patients. Ther Drug Monit. 2025 Jun 01;47(3):330-336.
416	Donor ABCB1 3435 C>T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus. Pharmacogenomics. 2016 Feb;17(3):249-57.
417	Effect of Genotype on the Pharmacokinetics and Bleeding Events of Direct Oral Anticoagulants: A Systematic Review and Meta-analysis. J Clin Pharmacol. 2023 Mar;63(3):277-287.
418	Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 01;45:183-94.
419	Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003 Apr 10;348(15):1442-8.
420	Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther. 2006 Apr;79(4):316-24.
421	Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients. J Clin Pharmacol. 2013 Aug;53(8):827-33.
422	Contrasting ABCB1 pharmacogenetics and psychotropic responses in child and adolescent psychiatry: a case comparison. Pharmacogenomics. 2023 Feb;24(3):131-139.
423	Impact of genetic variants on fentanyl metabolism in major breast surgery patients: a candidate gene association study. Pharmacogenomics. 2024;25(14-15):595-603.
424	Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenet Genomics. 2013 Jun;23(6):293-300.
425	Concurrence of osteonecrosis and steroid myopathy secondary to oral steroid therapy in a patient with ABCB1 gene polymorphisms: A case report. Front Endocrinol (Lausanne). 2022;13:1016687.
426	Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol. 2004 Feb;44(2):135-40.
427	Effects of Single Nucleotide Polymorphisms on Surgical and Postsurgical Opioid Requirements: A Systematic Review and Meta-Analysis. Clin J Pain. 2017 Dec;33(12):1117-1130.
428	Association of Single-Nucleotide Polymorhism C3435T in the ABCB1 Gene with Opioid Sensitivity in Treatment of Postoperative Pain. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2016 Nov 01;37(2-3):73-80.
429	Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. Br J Clin Pharmacol. 2014 Jul;78(1):135-44.
430	Influence of ABCB1 polymorphisms on aripiprazole and dehydroaripiprazole plasma concentrations. Sci Rep. 2025 Jan 09;15(1):1521.
431	Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer. EClinicalMedicine. 2023 May;59:101955.
432	MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J. 2010 Feb;10(1):62-9.
433	Association between. Pharmacogenomics. 2019 Apr;20(5):381-392.
434	Effect of ABCB1 (MDR1) 3435C >T and 2677G >A,T polymorphisms and P-glycoprotein inhibitors on salivary digoxin secretion in congestive heart failure patients. Pharmacol Rep. 2007;59(3):323-9.
435	The Impact of ABCB1 SNPs on Tacrolimus Pharmacokinetics in Liver or Kidney Transplant Recipients: A Meta-analysis. Curr Pharm Des. 2023;29(29):2323-2335.
436	Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2009 Jan;63(1):115-20.
437	Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. Cancer Chemother Pharmacol. 2017 Apr;79(4):767-773.
438	Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers. Pharmacology. 2008;82(3):221-7.
439	Contribution of MDR1 gene polymorphisms on IBD predisposition and response to glucocorticoids in IBD in a Chinese population. J Dig Dis. 2015 Jan;16(1):22-30.
440	Genetic Polymorphisms and Tumoral Mutational Profiles over Survival in Advanced Colorectal Cancer Patients: An Exploratory Study. Curr Oncol. 2024 Jan 03;31(1):274-295.
441	Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting. Clin Ther. 2014 Aug 01;36(8):1242-1252.e2.
442	The influence of COMT and ABCB1 gene polymorphisms on sufentanil analgesic effect for postoperative pain in children with fracture. Medicine (Baltimore). 2024 Apr 26;103(17):e37980.
443	Correlation of MDR1 gene polymorphisms with anesthetic effect of sevoflurane-remifentanil following pediatric tonsillectomy. Medicine (Baltimore). 2017 Jun;96(24):e7002.
444	The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy. Ther Drug Monit. 2010 Oct;32(5):579-85.
445	Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. Br J Clin Pharmacol. 2007 Jan;63(1):53-8.
446	Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015 Jul;16(4):274-81.
447	Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung Cancer. 2016 Mar;93:69-76.
448	Pharmacogenetics of ABCB1, CDA, DCK, GSTT1, GSTM1 and outcomes in a cohort of pediatric acute myeloid leukemia patients from Colombia. Cancer Rep (Hoboken). 2023 Mar;6(3):e1744.
449	Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children. Antimicrob Agents Chemother. 2014;58(1):136-43.
450	Association Between. Front Pharmacol. 2018;9:542.
451	Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations. Ther Drug Monit. 2013 Apr;35(2):270-5.
452	Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin. J Gastroenterol Hepatol. 2009 Feb;24(2):294-8.
453	Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. Gene. 2015 Mar 10;558(2):200-7.
454	Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Thromb Res. 2013 Jul;132(1):81-7.
455	Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness. Medicina (Kaunas). 2014;50(1):19-27.
456	A donor and recipient candidate gene association study of allograft loss in renal transplant recipients receiving a tacrolimus-based regimen. Am J Transplant. 2018 Dec;18(12):2905-2913.
457	The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis. Pharmacogenet Genomics. 2012 Aug;22(8):642-5.
458	Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation. Int J Mol Sci. 2015 Aug 25;16(9):20168-82.
459	Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin Pharmacol Ther. 2011 Oct;90(4):561-7.
460	Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2015 Apr;15(2):109-18.
461	Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis. 2011 Jan 15;203(2):246-57.
462	Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus. Pharmacotherapy. 2017 Sep;37(9):1073-1080.
463	Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics. 2010 Sep;11(9):1223-34.
464	Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug. Br J Clin Pharmacol. 2018 May;84(5):997-1005.
465	Relevance of selected pharmacogenetic polymorphisms to bleeding and thromboembolic risks in Chinese patients taking direct-acting oral anticoagulants. Br J Clin Pharmacol. 2025 May 21.
466	Polymorphism of Drug Transporters, Rather Than Metabolizing Enzymes, Conditions the Pharmacokinetics of Rasagiline. Pharmaceutics. 2022 Sep 21;14(10).
467	CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenet Genomics. 2013 Nov;23(11):627-30.
468	Multiple genetic mutations increase the risk of thrombosis associated with clopidogrel after percutaneous coronary intervention. Pharmacogenomics. 2023 Mar;24(4):227-237.
469	BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen. Cancer Chemother Pharmacol. 2016 Sep;78(3):623-32.
470	Genetic Factors Influencing Warfarin Dose in Han Chinese Population: A Systematic Review and Meta-Analysis of Cohort Studies. Clin Pharmacokinet. 2023 Jun;62(6):819-833.
471	Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy. Drug Metab Pharmacokinet. 2015 Apr;30(2):149-53.
472	Association between ABCB1 C3435 T polymorphism- and methotrexate-related toxicity in pediatric acute lymphoblastic leukemia: a meta-analysis. Hematology. 2025 Dec;30(1):2469373.
473	Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). J Antimicrob Chemother. 2015 Nov;70(11):3096-9.
474	Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. Pharmacogenomics. 2012 Jan;13(1):113-21.
475	Influence of (C1236T and C3435T) Polymorphisms of ABCB1 Gene on Chemotherapy Treatment Outcome and Toxicity in Breast Cancer Patients. Asian Pac J Cancer Prev. 2024 May 01;25(5):1567-1577.
476	The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics. 2012 May;22(5):373-80.
477	A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008 May 01;111(9):4496-9.
478	NeuroPredict: study of the predictive value of ABCB1 genetic polymorphisms and associated clinical factors in chronic chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol. 2024;15:1352939.
479	Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. Br J Clin Pharmacol. 2018 Jun;84(6):1301-1312.
480	Pharmacogenetic markers and macrolide safety in influenza patients: insights from a prospective study. Pharmacogenomics. 2024;25(16-18):661-665.
481	Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia. Pharmacogenomics. 2017 May;18(7):607-611.
482	Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients. Transplantation. 2011 Dec 27;92(12):1342-7.
483	Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA. 2013 May 01;309(17):1821-7.
484	Factors Influencing Mortality in Children with Central Nervous System Tumors: A Cohort Study on Clinical Characteristics and Genetic Markers. Genes (Basel). 2024 Apr 09;15(4).
485	Association of ABCB1 Gene Polymorphisms with Efficacy and Adverse Reaction to Risperidone or Paliperidone in Han Chinese Schizophrenic Patients. Neurosci Bull. 2016 Dec;32(6):547-549.
486	Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection. J Antimicrob Chemother. 2024 Jun 03;79(6):1270-1278.
487	Study on the association between adverse drug reactions to opioids and gene polymorphisms: a case-case-control study. BMC Pharmacol Toxicol. 2023 Nov 21;24(1):64.
488	Population Pharmacokinetics and Hemorrhagic Risk Analysis of Rivaroxaban in Elderly Chinese Patients With Nonvalvular Atrial Fibrillation. J Clin Pharmacol. 2023 Jan;63(1):66-76.
489	Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1. Sci Rep. 2024 Jan 31;14(1):2577.
490	The Effect of Platelet Activity,. Drug Des Devel Ther. 2024;18:109-119.
491	CYP2B6 and ABCB1 genotypes predict methadone plasma exposure among patients on maintenance therapy against opioid addictions in Tanzania. Br J Clin Pharmacol. 2024 Nov;90(11):2823-2836.
492	The association of ABCB1 gene polymorphism with clinical response to carbamazepine monotherapy in patients with epilepsy. Mol Biol Rep. 2024 Jan 25;51(1):191.
493	Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach. AAPS J. 2014 May;16(3):379-91.
494	Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation. Transplant Proc. 2013 Jan-Feb;45(1):137-41.
495	Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function. Exp Ther Med. 2015 Sep;10(3):1149-1156.
496	ATP-binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis. J Gastroenterol Hepatol. 2017 Sep;32(9):1562-1569.
497	Influence of the. Front Pharmacol. 2025;16:1510890.
498	ABCB1 Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta-Analysis Including Results from the CAN-BIND-1 Study. Clin Pharmacol Ther. 2023 Jul;114(1):88-117.
499	ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia. Pharmacogenomics. 2011 Oct;12(10):1493-501.
500	Tacrolimus Concentration Is Effectively Predicted Using Combined Clinical and Genetic Factors in the Perioperative Period of Kidney Transplantation and Associated with Acute Rejection. J Immunol Res. 2022;2022:3129389.
501	Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients. Pharmacogenomics J. 2021 Aug;21(4):491-497.
502	The Pharmacogenetics of Cannabis in the Treatment of Chronic Pain. Genes (Basel). 2022 Oct 11;13(10).
503	Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer. 2012 Apr 01;118(7):1856-67.
504	Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus. Pediatr Nephrol. 2018 Jun;33(6):1045-1055.
505	Contribution of genetic polymorphism in. J Gastrointest Oncol. 2024 Apr 30;15(2):577-584.
506	Variations in Infant CYP2B6 Genotype Associated with the Need for Pharmacological Treatment for Neonatal Abstinence Syndrome in Infants of Methadone-Maintained Opioid-Dependent Mothers. Am J Perinatol. 2017 Jul;34(9):918-921.
507	Influence of genetic variants of opioid-related genes on opioid-induced adverse effects in patients with lung cancer: A STROBE-compliant observational study. Medicine (Baltimore). 2021 Nov 05;100(44):e27565.
508	ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine. Pharmgenomics Pers Med. 2017;10:235-242.
509	A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses. 2012 Oct;28(10):1227-34.
510	Bleeding Events Associated with Rivaroxaban Therapy in Naive Patients with Nonvalvular Atrial Fibrillation: A Longitudinal Study from a Genetic Perspective with INR Follow-Up. Medicina (Kaunas). 2024 Oct 18;60(10).
511	Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. Eur J Clin Pharmacol. 2010 Jul;66(7):681-7.
512	Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. Pharmacogenomics J. 2011 Feb;11(1):35-44.
513	Dolutegravir and Risk of Neuropsychiatric Adverse Events: a Pharmacogenetic Study. J Infect Dis. 2025 Feb 26.
514	ABCB1 Single Nucleotide Polymorphism Genotypes as Predictors of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer. Genet Test Mol Biomarkers. 2021 Jul;25(7):471-477.
515	Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. Eur J Cancer. 2014 Mar;50(4):698-705.
516	Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. PLoS One. 2014;9(9):e107424.
517	Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report. Pharmacogenomics. 2013 Sep;14(12):1389-96.
518	Pharmacogenetics role in the safety of acenocoumarol therapy. Thromb Haemost. 2014 Sep 02;112(3):522-36.
519	Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients. Exp Clin Transplant. 2015 Oct;13(5):441-8.
520	Impact of CYP3A4 and ABCB1 genetic variants on tacrolimus dosing in Greek kidney transplant recipients. Front Pharmacol. 2025;16:1538432.
521	Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors. Drug Metab Pharmacokinet. 2022 Apr;43:100441.
522	Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Pharmacogenomics. 2010 Oct;11(10):1389-402.
523	Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. Br J Clin Pharmacol. 2018 Sep;84(9):2106-2119.
524	CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur Urol. 2015 Oct;68(4):621-9.
525	Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters. Genome Med. 2016 Nov 08;8(1):119.
526	Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: an exploratory pharmacogenetics study. Pharmacogenomics. 2017 Jul;18(10):987-1001.
527	Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. Pharmacogenomics. 2018 Feb;19(3):175-184.
528	A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial. J Clin Pharmacol. 2018 Dec;58(12):1541-1549.
529	Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS One. 2011;6(10):e26091.
530	Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array. Eur J Clin Pharmacol. 2018 Oct;74(10):1291-1298.
531	Population pharmacokinetics and pharmacogenomics of edoxaban in Japanese adults with atrial fibrillation. J Pharm Health Care Sci. 2025 Jun 02;11(1):46.
532	Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects. J Clin Pharm Ther. 2018 Feb;43(1):87-91.
533	Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients. Transl Psychiatry. 2017 Jul 11;7(7):e1170.
534	Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol. 2013 Jan;69(1):53-63.
535	Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters. Pharmacogenomics J. 2017 Jul;17(4):325-330.
536	ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients. Br J Clin Pharmacol. 2008 Aug;66(2):240-6.
537	Role of SLCO1B1, ABCB1, and CHRNA1 gene polymorphisms on the efficacy of rocuronium in Chinese patients. J Clin Pharmacol. 2015 Mar;55(3):261-8.
538	Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients. Pharmacol Res. 2016 Sep;111:877-884.
539	Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia. Pharmacol Res. 2017 Jun;120:138-145.
540	Association between MDR. Gene. 2018 Jun 30;661:78-84.
541	Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome. BMC Pharmacol Toxicol. 2018 Apr 3;19(1):14.
542	Association of ABCB1 Polymorphisms with Efficacy and Adverse Drug Reactions of Valproic Acid in Children with Epilepsy. Pharmaceuticals (Basel). 2023 Oct 30;16(11).
543	Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta Oncol. 2014 Oct;53(10):1413-22.
544	Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam. Biomed Pharmacother. 2022 Nov;155:113747.
545	Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population. Pharmacogenomics J. 2021 Apr;21(2):262-272.
546	Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J. 2010 Oct;10(5):418-30.
547	Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013 Jan;14(1):35-45.
548	Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation. Clin Transplant. 2010;24(6):855-61.
549	Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol. 2008 Apr;35(4):572-9.
550	Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. Cancer Chemother Pharmacol. 2017 Jun;79(6):1179-1186.
551	Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients. Transplant Proc. 2009 Apr;41(3):840-2.
552	Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation. Int J Clin Pract Suppl. 2015 May;(183):53-62.
553	Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients. Transplantation. 2016 Oct;100(10):2129-2137.
554	Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol. Pharmaceutics. 2024 Dec 12;16(12).
555	The association between abcb1 gene polymorphism and clopidogrel response variability in stroke ischemic: a cross sectional study. BMC Neurol. 2024 Jun 24;24(1):216.
556	Pharmacogenetic aspects of efficacy and safety of methotrexate treatment in pediatric acute lymphoblastic leukemia. Drug Metab Pers Ther. 2023 Dec 01;38(4):349-357.
557	Association of ABCB1 C1236T Gene Polymorphisms With the Postoperative Analgesic Effects of Sufentanil and Morphine in Patients With Femoral Fractures. J Perianesth Nurs. 2025 Feb 24.
558	Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile. Pharmaceuticals (Basel). 2024 Aug 07;17(8).
559	Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation. Pharmacogenomics. 2015;16(9):971-9.
560	Investigation of the. Pharmaceuticals (Basel). 2025 Jun 16;18(6).
561	The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. Oncotarget. 2017 Oct 20;8(50):88021-88033.
562	Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol. 2009 Sep 10;27(26):4406-12.
563	Association of ABC Efflux Transporter Genetic Variants and Adverse Drug Reactions and Survival in Patients with Non-Small Lung Cancer. Genes (Basel). 2025 Apr 15;16(4).
564	Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer. 2013 Mar 05;108(4):887-900.
565	Integration of genomics, clinical characteristics and baseline biological profiles to predict the risk of liver injury induced by high-dose methotrexate. Front Pharmacol. 2024;15:1423214.
566	ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J. 2018 Jan;18(1):35-42.
567	Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int. 2008 Sep;21(9):879-91.
568	Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics. 2011 Mar;12(3):365-77.
569	Impact of MDR1 and UGT Gene Polymorphisms on Sodium Valproate Plasma Concentration in Patients with Epilepsy. Clin Lab. 2022 Oct 01;68(10).
570	Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy. Ann Neurol. 2017 Mar;81(3):444-453.
571	Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study. Pharmacogenomics. 2020 Apr;21(5):325-335.
572	Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy. PLoS One. 2015;10(9):e0137660.
573	Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Feb;22(2):268-276.
574	Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J. 2012 Jun;12(3):255-9.
575	Impact of CYP3A5 and MDR-1 gene polymorphisms on the dose and level of tacrolimus among living-donor liver transplanted patients: single center experience. Biomarkers. 2016;21(4):335-41.
576	ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population. BMC Genet. 2016 Jun 13;17(1):79.
577	Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study. PLoS One. 2015 Nov 4;10(11):e0141931.
578	Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010 Mar 10;28(8):1287-93.
579	ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochem Pharmacol. 2009 Jan 1;77(1):66-75.
580	Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention. Eur J Clin Pharmacol. 2017 Sep;73(9):1085-1094.
581	Toxicity and therapy outcome associations in LIG3, SLCO1B3, ABCB1, OPRM1 and GSTP1 in high-grade serous ovarian cancer. Basic Clin Pharmacol Toxicol. 2023 Jun;132(6):521-531.
582	mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):854-9.
583	Analysis of ABCB1 Gene Polymorphisms and Their Impact on Tacrolimus Blood Levels in Kidney Transplant Recipients. Int J Mol Sci. 2024 Oct 12;25(20).
584	Evaluation of the role of metabolizing enzymes and transporter variants in ezetimibe pharmacokinetics. Front Pharmacol. 2024;15:1414059.
585	Effect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study. Drug Alcohol Depend. 2021 Oct 01;227:109025.
586	Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial. Blood Adv. 2023 Jul 25;7(14):3764-3774.
587	ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD. J Clin Psychopharmacol. 2013 Aug;33(4):491-8.
588	Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol. 2009 May;113(2):264-9.
589	Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1310-5.
590	Pharmacogenetics and Pharmacokinetics of Moxifloxacin in MDR-TB Patients in Indonesia: Analysis for. Antibiotics (Basel). 2025 Feb 16;14(2).
591	Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study. Drug Alcohol Depend. 2014 Dec 1;145:185-93.
592	Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenet Genomics. 2013 Oct;23(10):549-57.
593	Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib. Anticancer Drugs. 2017 Jan;28(1):97-103.
594	Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9.
595	Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J Clin Pharm Ther. 2016 Jun;41(3):329-33.
596	Impact of STAT6 Variants on the Response to Proton Pump Inhibitors and Comorbidities in Patients with Eosinophilic Esophagitis. Int J Mol Sci. 2024 Mar 26;25(7).
597	ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin Chem. 2006 May;52(5):893-5.
598	Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib. Eur J Clin Pharmacol. 2022 Aug;78(8):1239-1247.
599	Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. Pharmacogenomics. 2014 Jun;15(9):1207-21.
600	Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients. Mol Biol Rep. 2015 Jan;42(1):105-17.
601	Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. J Antimicrob Chemother. 2014 Nov;69(11):3061-6.
602	ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):398-404.
603	Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis. Pharmacogenomics. 2018 Apr;19(5):383-392.
604	Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol. 2009 Feb;104(2):130-7.
605	Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008 Jan 24;57(2):203-9.
606	Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients. PLoS One. 2014 Nov 5;9(11):e111694.
607	The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis. 2006 Mar;185(1):97-107.
608	ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J. 2013 Aug;13(4):349-53.
609	Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study. J Psychiatr Res. 2016 Feb;73:86-95.
610	Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma. Haematologica. 2015 May;100(5):e204-6.
611	Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol. 2002 Jul;62(1):1-6.
612	ABCB1 1199G>A Polymorphism Impacts Transport Ability of P-gp-Mediated Antipsychotics. DNA Cell Biol. 2018 Apr;37(4):325-329.
613	Single-nucleotide polymorphismassociations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel. Pharmacogenomics. 2022 Jul;23(11):627-638.
614	Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. Pharmacogenomics J. 2018 May 22;18(3):460-466.
615	Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013 Aug;60(8):1375-81.
616	Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012 May 1;30(13):1422-8.
617	Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial. Pharmacogenet Genomics. 2017 Oct;27(10):378-385.
618	ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients. Pharmacogenomics. 2013 Nov;14(14):1723-30.
619	Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. PLoS One. 2013 Oct 7;8(10):e76984.
620	Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance). Cancer Med. 2016 Apr;5(4):631-9.
621	Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study. JCO Precis Oncol. 2023 Mar;7:e2200580.
622	The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation. Hum Genomics. 2023 Jul 07;17(1):59.
623	Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study. Clin Pharmacokinet. 2022 Jun;61(6):881-893.
624	Predictors of clozapine concentration and psychiatric symptoms in patients with schizophrenia. PLoS One. 2025;20(3):e0319037.
625	Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. J Clin Psychopharmacol. 2012 Aug;32(4):441-8.
626	Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma. Oncotarget. 2017 Feb 07;8(6):9388-9398.
627	Pharmacogenetics of pediatric acute lymphoblastic leukemia in Uruguay: adverse events related to induction phase drugs. Front Pharmacol. 2023;14:1278769.
628	Opioid-induced respiratory depression: ABCB1 transporter pharmacogenetics. Pharmacogenomics J. 2015 Apr;15(2):119-26.
629	CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation. Basic Clin Pharmacol Toxicol. 2018 Sep;123(3):320-326.
630	Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients. PLoS One. 2016 Dec 30;11(12):e0168519.
631	Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort in Zimbabwe. Curr HIV Res. 2013 Sep;11(6):481-90.
632	CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure. Pharmacogenomics. 2014 Aug;15(11):1423-35.
633	Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes. PLoS One. 2014 Jan 31;9(1):e86919.
634	Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. Malar J. 2017 Jul 03;16(1):267.
635	CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. Pharmacogenomics. 2016 Apr;17(6):603-13.
636	Association between Genetic Polymorphisms and Bleeding in Patients on Direct Oral Anticoagulants. Pharmaceutics. 2022 Sep 07;14(9).
637	A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol. 2009 Nov;68(5):690-9.
638	Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban. Sci Rep. 2023 Sep 25;13(1):15967.
639	Variability in plasma rifampicin concentrations and role of. Infect Dis (Lond). 2024 Apr;56(4):308-319.
640	High plasma concentration of tenofovir alafenamide in people living with HIV with ABCB1 genetic variants. J Infect Chemother. 2025 Feb;31(2):102541.
641	Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016 Aug;144:1-5.
642	The Effect of ABCB1 and CES1 Polymorphisms on Plasma Levels of Dabigatran and Risk of Hemorrhagic Complications in Ischemic Stroke Patients. American Journal of Therapeutics. 2024 Jul;31(4):e362-e371.
643	Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice. Pharmacogenet Genomics. 2022 Dec 01;32(9):301-307.
644	Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients. Pharmacogenomics. 2016;17(1):25-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.